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Abstract 
Chemokine receptors play a central role in directing leukocytes to various tissues around 
the body by recognising chemotactic cues called chemokines. Upon entry into a tissue, 
infiltrating leukocytes from the blood stream encounter tissue resident cells, and in the 
case of T lymphocytes scan antigen presenting cells (APCs). Following antigen 
recognition, signalling components can be recruited into micro-scale domains at the 
interface of the APC-T cell conjugate, forming a structure known as the immunological 
synapse (IS). The chemokine receptors CCR5 and CXCR4 have been implicated in 
promoting IS formation through their recruitment to the T cell side of human APC-T cell 
interfaces. However, this is based primarily on studies with immortalized cell lines 
transfected with GFP-tagged chemokine receptors and does not take into account what 
happens on the APC side of the IS. Hence, the behaviour of endogenous CXCR4 and 
CCR5 during the formation of IS between primary T cells and APCs needs to be clarified. 
Live cell microscopy and flow cytometry were employed to examine a previously 
uncharacterised macrophage-CD4+ T cell IS, formed in vitro between primary human 
blood isolated T cells and monocyte-derived macrophages (MDMs) pulsed with a 
superantigen (sAg). Under these conditions, MDM-CD4+ T cell conjugates displayed 
elevated T cell intracellular calcium responses. A fraction of these conjugates showed T 
cell receptor capping as well as ICAM1 and relocation of the Golgi apparatus towards the 
cell–cell interface, which suggests that the interactions between MDMs and CD4+ T cells 
lead to the formation of synapses and possibly kinapses.  
Endogenous T cell surface CCR5 and CXCR4 molecules were found to cap at the MDM-
CD4+ T cell IS, albeit infrequently. Yet, intracellular pools of T cell CCR5 receptors were 
consistently reported facing the IS interface and showed partial overlap with a marker of 
the trans-Golgi network, implying that intracellular CCR5 may translocate to the IS as a 
cargo in the Golgi. In contrast, on MDMs, cell surface CCR5 did not accumulate at the IS 
interface. FRAP analysis revealed that CCR5 molecules are relatively mobile at the 
surface of MDMs, and that CCR5 movement is affected by depletion but not sequestration 
of membrane cholesterol. These findings suggested that the non-accumulation of MDM 
CCR5 at the IS interface was not due to the restriction of lateral movement. Importantly, 
this work highlights cell-type differences in the behaviour of endogenous CCR5 receptors. 
This thesis brings new insights into the roles of endogenous chemokine receptors in 
human leukocytes during antigen-dependent interactions and informs future research 
aiming to bridge the gap between mouse and human systems to study immune synapses. 
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Chapter 1: Introduction 
1.1 The Chemokine System 
1.1.1 Nomenclature and grouping 
Chemokine receptors are members of the seven-transmembrane (7TM) receptor 
superfamily of G protein coupled receptors (GPCRs), which function to coordinate 
leukocyte trafficking. The chemokine ligands bound by these receptors are small proteins, 
mostly 70–80 amino acids in length (8–12 kDa), defined by a tertiary structure that is 
stabilised by disulphide bonds between key cysteine residues (Allen et al., 2007; 
Bachelerie et al., 2013). According to the number and position of N-terminal cysteine 
residues each chemokine is assigned to one of four major groups, termed C, CC, CXC 
and CX3C. Chemokine receptor nomenclature is reflective of this since receptors are 
generally restricted to binding chemokines from a particular group (Bachelerie et al., 
2013). For example, the receptor CCR5 binds chemokine ligands belonging to the CC 
group and has been designated the number ‘5’ for identification purposes. To date, 24 
different chemokine receptors have been classified, including six atypical receptors 
(Bachelerie et al., 2013). Yet chemokines are far more numerous, meaning that the 
majority of chemokine receptors are promiscuous with regard to chemokine binding. This 
should not be interpreted as redundancy as even closely-related chemokines can have 
different agonistic effects on receptor function (Rot and von Andrian, 2004). Unrelated to 
their structurally-derived nomenclature, chemokines are also broadly categorised 
according to their function into inflammatory or homeostatic groups, which bind inducible 
or constitutively expressed receptors, respectively (Johnson et al., 2005). Experimentation 
in the present study concerns the inflammatory chemokine receptor CCR5 in particular 
and also the homeostatic chemokine receptor CXCR4. 
1.1.2 Ligand-stimulated initiation of chemokine receptor signalling 
1.1.2.1 Chemokine receptor structure 
Chemokine receptors are proteins of 340–380 amino acids, which exist as 7TM helices 
arranged in a bundle connected by three extracellular loops (ECLs) and three intracellular 
loops (ICLs). The second ICL contains the DRY motif implicated in G protein binding that 
is conserved amongst all but the atypical chemokine receptors (Allen et al., 2007). The N-
terminus is extracellular whilst the C-terminus is intracellular, and in the case of CCR5 
contains cysteine residues, which can be palmitoylated to form an additional loop 
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(Oppermann, 2004) (Fig.1.1). In contrast, a consensus palmitoylation sequence is lacking 
in CXCR4 (Bachelerie et al., 2013). The crystal structures of CCR5 in complex with the 
human immunodeficiency virus (HIV)-entry inhibitor Maraviroc (residues 19–313; 
modifications: C-terminal truncation from F320; 54 residues of rubredoxin inserted into 
ICL3 between R223 and G227; point mutations, C58Y, G163N, A233D and K303E) and 
CXCR4 in complex with small molecule and cyclic peptide antagonists (residues 27–352; 
modifications: 160 residues of T4 lysozyme inserted into ICL3; point mutations, L125W) 
have been determined (Tan et al., 2013; Wu et al., 2010). 
1.1.2.2 Chemokine binding 
Chemokines comprise of an N-terminal region followed by a core domain comprised of an 
N-loop, a 310 helix, a three-stranded β-sheet terminating in a C-terminal α-helix (Allen et 
al., 2007). Initial docking is mediated mostly by ionic interactions of the chemokine core 
domain with the receptor ECLs and N-terminus (Allen et al., 2007; Scholten et al., 2012). 
Distinct residues are critical for binding of different chemokines to ECL regions that often 
overlap, as demonstrated for CCR5 through the generation of systematic point mutations, 
which revealed that different amino acids of ECL2 are responsible for CCL3 and CCL5 
binding (Blanpain et al., 2003). Following the initial docking step, concerted action of the 
receptor N-terminal domain and ECLs coordinate the chemokine N-terminus to interact 
with residues in the receptor transmembrane helical bundle (Allen et al., 2007; Blanpain et 
al., 2003; Scholten et al., 2012). As the intimate positioning implies, the N-terminal region 
of chemokines has been found to be critical in inducing chemokine receptor signalling 
(Allen et al., 2007). This is exemplified by deletion of the first eight N-terminal amino acids 
of CCL5, which ablates chemotaxis and calcium signalling in a monocytic cell line (Gong 
et al., 1996). Furthermore, addition of a methionine residue to the N-terminus of CCL5 
was shown to induce a weak calcium signal and slow internalization, which is consistent 
with partial agonist activity, but led to functional antagonism (Mack et al., 1998; Proudfoot 
et al., 1999). Since then numerous other chemical modifications have been made to the 
N-terminal region of CCL5 to generate more potent functional antagonists (Gaertner et al., 
2008), which highlight how the chemokine N-terminus contributes to the potency and 
regulation of signal transduction.  
Chemokine binding stabilises a conformational arrangement of the transmembrane 
helices of the receptor, which enables signal transduction across the plasma membrane 
(PM) by permitting binding of intracellular machinery such as G proteins or kinases (Berro 
et al., 2013; Springael et al., 2007). However chemokine receptor coupling to G proteins 
can reciprocally influence the chemokine binding. Allosteric binding of different proteins
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Figure 1.1: Schematic of major features of CCR5 and CXCR4. The diagram shows the single 
letter protein codes for the loops as well as the N- and C- terminal segments. Transmembrane 
regions are represented by purple boxes. Palmitoylated cysteine resides are shown bound to the 
membrane with a wavy line. Disulphide bonds are represented by dotted lines. The DRY motif 
responsible for G protein binding is highlighted, as are serine residues that have previously been 
reported to be phosphorylated in the C terminal tails. Adapted and based on diagrams and data 
from previous studies (Alkhatib, 2009; Busillo et al., 2010; Jähnichen et al., 2010). 
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away from the endogenous chemokine binding site contributes to the range of 
conformational arrangements of the receptor (Langmead and Christopoulos, 2014). 
Indeed, G proteins themselves are archetypal allosteric modulators and have been shown 
to modulate the chemokine-binding affinity of CCR5 (Colin et al., 2013). Colin et al. (2013) 
showed a vastly lower affinity of CCR5 for CCL3 when coupled to G proteins locked in 
nucleotide-bound forms by using non-hydrolysable forms of guanosine triphosphate (GTP) 
or pertussis toxin (PTX). Thus within the range of conformational forms available for a 
given chemokine receptor, particular forms can display partiality to chemokine binding 
(Fig. 1.2a).  
1.1.2.3 Initiating downstream responses 
Chemokine-bound receptors become coupled to G proteins that consist of three different 
subunits, designated α, β and γ. The exceptions to this rule are the atypical chemokine 
receptors, which signal via G protein independent mechanisms (Bachelerie et al., 2013).  
Different isoforms of the α-subunits exist and heterotrimeric G proteins are identified by 
the form of Gα that they possess. Use of PTX, which specifically ribosylates the Gαi 
subunit, has led to the finding that chemokine receptors primarily couple to Gi proteins in 
haematopoietic cells (Berro et al., 2013; Thelen and Stein, 2008). Nevertheless coupling 
to G proteins other than Gi may be important in functions related to antigen presentation. 
Coupling of CCR5 to Gq or G11 proteins has been suggested to promote adhesion 
between T cells and antigen presenting cells (APCs) during antigen-dependent 
interactions (Molon et al., 2005). Additionally, G13 dependent trafficking may promote 
CXCR4 heterodimerisation with the T cell receptor (TCR) (Kumar et al., 2011). Aberrant G 
proteins also participate in determining the directionality of cell migration and are triggered 
by HIV binding in order to mediate viral entry and cell-cell fusion (Harmon and Ratner, 
2008; Rot and von Andrian, 2004; Thelen and Stein, 2008). Thus although coupling to Gi 
may be the de facto standard for chemokine receptors, the availability of other types of G 
protein acts to diversify the signalling functions of these receptors. 
Despite the nomenclature focus on the α-subunit, leukocyte migration induced through Gi 
is primarily mediated through the βγ subunits, which dissociate from the stimulus receptor 
and Gαi when the latter binds GTP (Fig. 1.2a). The βγ subunits mediate actin 
polymerisation at the leading edge by initiating a cascade involving phosphatidylinositol 3-
kinase (PI3K), protein kinapse B (PKB) and Rac but also act to trigger calcium signalling 
via interaction with phospholipase C (PLC)-β (Oppermann, 2004; Rot and von Andrian, 
2004). This list is by no means exhaustive and the prevalence of components involved in 
signalling pathways that lead to actin polymerisation is often activation-status or cell type 
dependent (Thelen and Stein, 2008). Ultimately the balance of chemokine-induced 
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Figure 1.2: Turning signalling on or off in response to chemokine. (a) Signalling: Upon binding chemokines, chemokine receptors undergo conformational changes 
permitting heterotrimeric G protein binding. The GDP-bound Gα subunit binds to the DRY motif and coordinates the βγ subunits. It is important to realise that bound 
chemokine has both an on and off rate and in this state the receptor has a low affinity for bound chemokine. When GDP dissociates from the Gα subunit the receptor-G 
protein complex transits into a nucleotide-free state that has high affinity for the bound chemokine. GTP binding instigates a low affinity state that causes the Gα subunit, 
βγ subunits and receptor to dissociate (Chabre et al., 2009; Colin et al., 2013). The βγ subunits activate PI3Ks which generate PIP3. PIP3 acts as a docking site for PKB 
and activates members of the Rac family of small GTPases, both of which are involved in pathways nucleating actin polymerisation at pseudopodia (Rot and von Andrian, 
2004). The GTP bound Gαi subunit acts to inhibit AC activity and the intrinsic GTPase activity of this subunit catalyses hydrolysis of GTP to GDP, in which form the Gα 
subunit re-associates with βγ subunits. (b) Desensitisation: Chemokine-bound receptor has a high affinity for GRK family members which phosphorylate the C-terminal tail 
of the receptor that causes steric inhibition of G protein activation. In turn, phosphorylated receptors have a high affinity for β-arrestin, which prevents further coupling to G 
proteins and act as a scaffold for receptor internalisation (Bennett et al., 2011; Rot and von Andrian, 2004). AC, Adenylate cyclase; GDP, guanosine diphosphate; GRK, G 
protein receptor kinase; GTP, guanosine triphosphate; PI3K, phosphatidylinositol 3-kinase; PIP3, phosphatidylinositol-3,4,5,-trisphosphate; PKB, protein kinase B. 
a 
b 
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signalling pathways acts to coordinate actin treadmilling at the leading edge, which is the 
primary physical mechanism behind leukocyte chemotaxis (Lammermann et al., 2008).   
1.1.3 CCR5 regulation within the plasma membrane 
Two regions of the C-terminal tail of CCR5 are required for CCR5 to reach the PM. The 
first is a string of basic residues (-KHIAKRF-) (Venkatesan et al., 2001), which are located 
N-terminally to the second key region consisting of three cysteine residues (-CKCC-) 
(Oppermann, 2004). These three cysteine residues have been shown to be palmitoylated 
and in the absence of this post-translational modification the expression of CCR5 at the 
PM is vastly reduced. This effect is mediated, in part, by increased receptor degradation 
as CCR5 demonstrates a much shorter half-life when palmitoylation is prevented 
(Percherancier et al., 2001). Furthermore palmitoylation plays a critical role in the mobility 
of CCR5 in the ER, which implies that this lipid modification may also be important in 
conferring lateral mobility of CCR5 at the PM (Blanpain et al., 2001).  
Palmitoylation of integral membrane proteins has been reported to be necessary but not 
sufficient for association with lipid rafts (Levental et al., 2010). In fact, a previous study 
suggested that palmitoylation of CCR5 localises the receptor to lipid rafts (Venkatesan et 
al., 2003). Since certain families of G proteins have been proposed to be enriched in lipid 
rafts (Oh and Schnitzer, 2001), localisation to these dynamic domains may enhance the 
signalling function of CCR5. Indeed although palmitoylation deficient mutants continue to 
bind chemokine ligands with a high affinity and maintain the ability to signal, the duration 
of the functional response is reduced (Blanpain et al., 2001; Venkatesan et al., 2001). 
Perhaps the absence of palmitoylation, which is associated with decreased raft affinity 
(Levental et al., 2010), results in reduced stability of CCR5 clustering into raft signalling 
domains and thus a shortened functional response.  
A parallel stream of evidence exists implicating cholesterol, which is enriched in lipid rafts, 
in CCR5 signalling. In contrast to the palmitoylation deficient CCR5, binding of CCL4 was 
found to be inhibited upon cholesterol extraction (Nguyen and Taub, 2002). This was 
thought to be due to a requirement of membrane cholesterol to enable conformations of 
CCR5 necessary for ligand binding (Signoret et al., 2005). As expected Nguyen and Taub 
(2002) found that calcium signalling after cholesterol extraction was negligible, however 
Cardaba et al (2008) employed a different cholesterol extracting agent and found that 
calcium signalling was reduced but not ablated. Moreover cholesterol extraction prevented 
ligand-induced G protein inhibition of adenylate cyclase (AC) and enabled calcium 
signalling to occur in the presence of PTX (Cardaba et al., 2008). This implies that the 
presence of membrane cholesterol may regulate the interactions of chemokine receptors 
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with G proteins and merits further investigations into the functions of rafts in CCR5 
signalling.  
Recently it has been proposed that the signalling-active conformation of CCR5 is 
associated with cholesterol whereas the signalling-inactive conformation is cholesterol 
independent (Berro et al., 2011). These forms have different affinities for an inhibitor of 
HIV, which is a property related to the G protein coupling ability of the receptors. Non-
resistant strains of HIV preferentially bind the G protein- and cholesterol-independent form 
(Berro et al., 2011; Berro et al., 2013). This is consistent with the lack, or minor effect, of 
preventing palmitoylation on HIV entry and the notion that palmitoylation may promote raft 
coalescence. 
1.1.4 Turning off signalling 
In order to prevent inappropriate stimulation of leukocytes, chemokine-induced signalling 
is terminated by the process of chemokine receptor desensitization. When a particular 
receptor is acted upon directly by an agonist this is termed homologous desensitization 
(Kelly et al., 2008). The C-terminal region of chemokine receptors become phosphorylated 
by a member of the G protein receptor kinase (GRK) family within seconds to minutes of 
chemokine binding (Oppermann, 2004). CCR5 has four serine residues phosphorylated 
but only two are required for β-arrestin binding. Ser337 found to be specifically 
phosphorylated by protein kinase C (PKC), which may represent a negative feedback 
mechanism downstream of PLCβ activation, whilst phosphorylation of Ser349 is GRK 
specific (Oppermann, 2004). CXCR4 has more C-terminal serine phosphorylation sites 
than CCR5 (Busillo et al., 2010). Yet in similarity to CCR5 PKC is also employed to rapidly 
phosphorylate sites (Ser324/5) on this receptor, although these sites may be targeted by the 
ubiquitination machinery their impact upon ligand-induced internalisation of CXCR4 is 
controversial (Busillo et al., 2010; Signoret et al., 1998). The phosphorylated form of the 
receptor has a high affinity for β-arrestin, which binds and targets chemokine receptors for 
internalisation (Fig. 2.1b) (Bennett et al., 2011). Ultimately this results in a decrease of the 
amount of chemokine receptor available at the cell surface for the chemokine to bind. 
Note however that GRK and β-arrestin binding to chemokine receptors also have other 
actions as differential usage has been shown to positively or negatively influence 
downstream signalling events (Busillo et al., 2010; Gurevich and Gurevich, 2008).  
1.1.5 Staging a return: an inside job 
Chemokine receptors internalise predominantly by clathrin or caveolin dependent 
mechanisms. Depending on the cell type and on the duration of stimulus, internalised 
receptors may follow a number of different trafficking pathways (Bennett et al., 2011). 
  
 
23 
 
Specifically, CCR5 undergoes clathrin-dependent internalisation in response to CCL5 
stimulation and resides in recycling endosomes (REs) alongside transferrin receptor (TfR) 
before returning to the PM in a resensitised form (Mack et al., 1998; Signoret et al., 2005; 
Signoret et al., 2000).  During trafficking CCR5 is dephosphorylated but can remain 
chemokine-bound (Signoret et al., 2000), meaning that the receptor may already be in a 
state able to engage G proteins or GRK once more at the PM (Fig. 1.1). Each CCR5 
molecule may be desensitized/ internalised several times before the chemokine 
dissociates or is degraded (Oppermann, 2004; Signoret et al., 2000). However, the 
trafficking pathway is altered upon prolonged treatment of CCL5 or stimulation with an N-
terminally modified form of CCL5 (archaic name: regulated and normal T cell expressed 
and secreted (RANTES)) called Nα-(n-nonanoyl)-des-Ser1-[l-thioproline2, l-α-cyclohexyl-
glycine3] (PSC)-RANTES, which interacts more durably with CCR5 than the native 
chemokine (Escola et al., 2010). Indeed, Escola et al. (2010) reported that CCR5 only 
transiently resides in transferrin-containing REs before continuing to the trans-Golgi 
network (TGN). Under conditions of sustained agonist stimulation return from the TGN to 
the PM is the rate limiting step forming a ‘molecular bottleneck’ for CCR5 (Escola et al., 
2010). 
Although chemokine receptor internalisation is generally considered to be agonist 
dependent, CXCR4 also undergoes constitutive internalisation in similarity to the atypical 
receptor ACKR2 (D6) (Borroni et al., 2010). Both ligand-stimulated and constitutive 
endocytosis are thought to occur through a clathrin-dependent route (Signoret et al., 1997; 
Tarasova et al., 1998). However unlike CCR5, which recycles at a high efficiency, less 
than a third of CXCR4 recycles back to the PM after chemokine stimulation. Instead the 
majority of CXCR4 traffics through endosomal compartments and is sentenced for 
lysosomal degradation mediated through an ubiquitin-dependent process (Borroni et al., 
2010; Tarasova et al., 1998). Juxtaposing the trafficking systems of CCR5 and CXCR4 is 
useful to exemplify the great diversity of internalisation routes and mechanisms adopted 
by chemokine receptors to control expression at the cell surface. 
1.1.6 CCR5 and CXCR4 expression on leukocytes 
1.1.6.1 T cell expression of CCR5 
Lymphocyte expression of CCR5 is often sensitive to antigen experience. For example 
CCR5 is not typically expressed on naïve T cells, which by definition have not 
experienced antigen, but is known to be expressed on effector and memory cells (Bleul et 
al., 1997; Bromley et al., 2008; Groot et al., 2006; Sallusto et al., 2004). Often the 
expression of CCR5 on CD4+ T cells is associated with the T helper (Th)-1 phenotype, 
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which is typified by interferon-γ (IFNγ) production and orchestrates a response to 
intracellular microorganisms (Bromley et al., 2008; Murphy et al., 2011). However CCR5 
has also been found to be expressed alongside other chemokine receptors that are often 
associated with the Th2 phenotype (e.g. CCR4), which is typified by interleukin (IL)-4/    
IL-13 secretion and is involved in immune responses to parasites and in allergy (Bromley 
et al., 2008). Moreover, Th17 cells have also been reported to coexpress CCR5 and 
CCR4 (Lim et al., 2008), which warns against identification of Th subsets based on 
chemokine receptor profiles alone. 
For CD4+ T memory cells, CCR5 expression predominates on the effector memory (TEM) 
cells, which migrate through peripheral tissues and are primed to exert effector function. In 
contrast, central memory (TCM) CD4+ T cells do not express CCR5 and circulate through 
lymphoid tissue in a state that is primed to respond to antigen, after which they 
differentiate into effector cells (Sallusto et al., 2004). Thus CD4+ T cells expressing CCR5 
can predominantly be found in the peripheral tissues. However evidence exists that the 
same is not necessarily the case for CD8+ T cells. In fact, naïve CD8+ T cells were found 
to upregulate CCR5 expression via a mechanism that did not involve triggering the TCR 
and were shown to traffic to lymph nodes (LNs) in a CCR5 dependent manner (Castellino 
et al., 2006). Yet Castellino et al. (2006) also noted the effects of TCR stimulation on 
CCR5 expression in CD4+ and CD8+ T cells, showing that CD4+ T cell CCR5 expression 
was dependent upon TCR engagement and that CCR5 expression levels on CD8+ T cells 
were enhanced in the presence of cognate antigen. Additionally, since CCR5 is expressed 
on both CD8+ TEM and TCM populations (Sallusto et al., 2004) it is likely that CD8+ T cells 
expressing CCR5 may be found in both peripheral and lymphoid sites. In general, T cells 
that express CCR5 have previously undergone antigen-specific activation involving TCR 
signalling. 
One of the cytokines that promotes T cell growth and proliferation, and as such an 
activated phenotype, is IL-2. IL-2 has a reciprocal relationship with CCR5 as it has been 
shown to upregulate CD4+ T cell CCR5 expression in vivo (Bleul et al., 1997; Weissman 
et al., 2000). In turn CCR5 expression increases the production of IL-2 through a positive 
feedback loop (Camargo et al., 2009). This is not to say however that T cell CCR5 is 
expressed under all activation conditions, in fact CCR5 expression levels actually 
decrease upon activation with CD3/CD28 beads in vitro (Richardson et al., 2012). Part of 
this latter phenomenon is mediated by local T cell secretion of CC (β-) chemokines, for 
example CCL3/4/5, which are then able to act in an autocrine fashion to downmodulate 
CCR5 from the cell surface, as described in section 1.1.4. Considered together this 
evidences that CCR5 expression can be enhanced by soluble factors induced in response 
to antigen-dependent signalling (e.g. IL-2), and highlights that chemokine receptor 
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expression in general is tightly regulated by the presence of chemokines in the local 
microenvironment. 
1.1.6.2 T cell expression of CXCR4 
CXCR4 is critical to survival in mice as knockouts of the receptor or its sole ligand 
CXCL12 prove to be lethal (Bachelerie et al., 2013). This receptor has widespread 
functions in haematopoiesis and development, and is thought to be important for T cell 
maturation in the thymus (Murdoch, 2000). CXCR4 is widely expressed on naïve T cells 
(Bleul et al., 1997; Bromley et al., 2008) as well as antigen-experienced T cells such as 
memory, Th1, Th2 and Th17 subsets (Murdoch, 2000; Viola and Luster, 2008). Although 
entry into secondary lymphoid organs is primarily coordinated by CCR7 on naïve T cells, 
memory T cell extravasation into lymphoid organs may involve CXCR4 (Viola and Luster, 
2008). Together this suggests that, in contrast to CCR5, T cells expressing CXCR4 are 
found in both lymphoid and peripheral sites. However, because of the CCR5 expression 
profile the most likely region of CD4+ T cell CXCR4 and CCR5 co-expression is in the 
periphery. Nonetheless, since naïve T cells generally express high levels of CXCR4 it is 
tempting to speculate that the CCR5+ naïve T cells observed by Castellino et al. (2006) 
may undergo antigen-specific engagement whilst co-expressing CCR5 and CXCR4. 
These chemokine receptors have previously been suggested to play a coordinated role in 
promoting adhesion between specific antigen dependent cell-cell junctions (Molon et al., 
2005).  
With regards to CXCR4 expression after TCR engagement, it has been reported that 
CXCR4 promoter usage increases after anti-CD3/CD28 ligation (Moriuchi et al., 1997). 
This corroborates results showing an increase in CXCR4 expression due to T cell 
activation by the mitogen phyohaemaggutinin (PHA) (Bleul et al., 1997). Yet somewhat 
paradoxically, another study found that T cell surface CXCR4 expression decreases 
rapidly upon stimulation with PHA, anti-CD3, or staphylococcal enterotoxin A (SEA) 
(Bermejo et al., 1998). These studies demonstrate that antigen stimulation clearly has the 
capacity to induce changes in CXCR4 expression. Perhaps the differential regulation of 
CXCR4 by mitogen stimulation observed could be explained by differences in cell density 
between the two studies, which may result in different levels of autocrine stimulation by 
cytokines such as IL-2. Indeed, the levels of CXCR4 expression can be regulated by 
increased exposure to cytokines such IL-2, IL-4 and IL-10 and decreased by inflammatory 
cytokines such as IFNγ (Busillo and Benovic, 2007). However this roundup of the 
differential effects of groups of cytokines on CXCR4 may be an oversimplification. As an 
example, IL-10 was reported to increase CXCR4 expression on MDMs (Wang et al., 
2001), but was previously observed to decrease CXCR4 expression on CD4+ T cells 
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(Jinquan et al., 2000). Thus cell-type dependent differences are likely to be of importance 
in determining how CXCR4 expression is regulated by cytokines.  
1.1.6.3 CCR5 and CXCR4 expression on macrophages 
In human tissue, macrophages that are present in numerous different anatomical 
locations, including vaginal macrophages, alveolar macrophages and microglial cells have 
been shown to express CCR5 and CXCR4 (Albright et al., 1999; Opalek et al., 2007; 
Shen et al., 2009). In contrast, very little CCR5 or CXCR4 expression occurs on intestinal 
macrophages, indicating that the expression of CCR5 on macrophages can be regulated 
by the tissue environment (Shen et al., 2009). In support of this idea, when MDMs during 
differentiation, but not after, were exposed to media conditioned by intestinal stromal cells 
the levels of CCR5 were dramatically reduced (Shen et al., 2011).  
With regard to in vitro culture, differentiation of MDMs in the presence of macrophage 
colony-stimulating factor (M-CSF) or granulocyte-macrophage colony stimulating factor 
(GM-CSF) has been reported to increase CCR5 cell surface expression. However, the 
increase is far greater in the presence of M-CSF (Herbein and Varin, 2010; Lee et al., 
1999b). In contrast, culture of MDMs in the presence of GM-CSF has been found to 
reduce CXCR4 levels via an arrestin-dependent mechanism (Lee et al., 1999b; Wang et 
al., 2001). Other factors that can be used for polarisation of MDMs to an M1 or M2 
phenotype have also been demonstrated to have effects on CCR5 and CXCR4 
expression. Treatment of MDMs with lipopolysaccharide (LPS) can induce CCR5 
downmodulation via a chemokine-independent mechanism (Franchin et al., 2000). 
Additionally, whilst IL-10 can increase MDM CXCR4 expression (Wang et al., 2001), it has 
also been reported to decouple CCR5 from signalling on monocytes and dendritic cells 
(DCs), creating a functional decoy receptor of CCR5 in the presence of inflammatory 
stimuli (D'Amico et al., 2000). Altogether current evidence suggests that CCR5 and 
CXCR4 expression on MDMs is also observed on macrophages in vivo and the levels 
may be modulated by soluble factors encountered in pro- and anti-inflammatory 
environments. 
1.1.7 Intracellular accumulation of CCR5 
The sustained presence of chemokines can lead to appearance of intracellular 
accumulations of CCR5 in trafficking compartments (Escola et al., 2010). Corroborating 
this, the relative abundance of the intracellular fraction of CCR5 in peripheral blood CD4+ 
T cells was suggested to be partly dependent upon the presence of cognate chemokines 
in their environment. Despite controversy regarding the presence of an intracellular pool of 
CCR5 in CD4+ T cells and a monocytic cell line (Achour et al., 2009; Guglielmi et al., 
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2011; Pilch-Cooper et al., 2011; Shirvani et al., 2011), this could provide a mechanism to 
rapidly replenish desensitized or degraded receptors at the PM to enable a continued 
response. Thrombin receptors are an example of a GPCR that employs this mechanism; 
the receptors internalised from the PM are replaced with a pool resident in the Golgi 
(Achour et al., 2008).  
The results of Achour et al., (2009) suggest that intracellular pools of CCR5 are located 
within the endoplasmic reticulum (ER) and that interactions with CD4 promote the PM 
expression of CCR5. The potential interaction of CCR5 and CD4 is considered in section 
1.1.10, however it is appropriate here to consider the percentage of cells that Achour et al. 
(2009) found to be CCR5+, and the ensuing debate by several groups. Nearly all (95%) 
CD4+ T cells were suggested to contain internal CCR5 (Achour et al., 2009), which 
exceeds the percentage of cell surface CCR5 in any CD4+ T cell subsets in peripheral 
blood (Lee et al., 1999b). Additionally, increased cell surface expression reported by 
Achour et al. (2009) upon activation with CD3/CD28 beads directly contrasts results of 
Richardson et al. (2012) who demonstrate a decrease in CCR5 using the same method. 
Ultimately, the CCR5 observed by Achour et al., (2009) was proposed to be non-specific 
as the majority of peripheral blood CD4+ T cells did not express CCR5 on either the 
protein or mRNA level (Pilch-Cooper et al., 2011). Thus CD4+ T cells lacking cell surface 
CCR5 do not appear have intracellular pools of CCR5. However for the minority peripheral 
blood CD4+ T cell population expressing surface CCR5, intracellular accumulations of 
CCR5 may contribute a substantial amount to the total cellular CCR5 (Guglielmi et al., 
2011; Pilch-Cooper et al., 2011). Speculatively, including intracellular CCR5 when 
immunolabelling would give higher fluorescence levels of the CCR5+ population and 
better resolution of the positive population in one-colour flow cytometry assays. This may 
explain why Guglielmi et al. (2011) find an increase in the percentage of the CCR5+ 
population upon permeabilisation. As CCR5 was found to recycle rapidly back to the PM, 
50-90% within an hour after removal of chemokine depending on cell-type (Mack et al., 
1998; Signoret et al., 2000), ligand-induced intracellular accumulations may only occur 
upon sustained chemokine stimulation. Alternatively more stable pools may exist or could 
be formed by tethering in the biosynthetic pathway as has been observed for other 
GPCRs (Achour et al., 2008). Overall, intracellular accumulations of CCR5 may occur in a 
subset of CD4+ T cells but considering the specificity issues encountered by Achour et al. 
(2009) the subcellular localisation of any accumulations would need to be readdressed. 
1.1.8 Generation and maintenance of a chemokine gradient  
The notion that chemokines primarily exist in sustained soluble gradients that directly bind 
to cognate receptors on incoming cells is an archaic view that is probably far from reality, 
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especially in vivo. Structurally heterogeneous carbohydrate chains known as 
glycosaminoglycans (GAGs) are ubiquitously expressed by mammalian cells (Allen et al., 
2007). GAGs play a critical role in the formation of chemokine gradients that enable 
directional mobility of cells and recruitment of leukocytes into inflamed tissue. Through 
binding to GAGs, chemokines secreted by a particular cell become locally restricted so 
that an increasing chemokine concentration is apparent in the direction of the source. 
Chemokines bind with a low-affinity to GAGs via electrostatic attraction, and possibly 
other more specific mechanisms (Viola and Luster, 2008). Different chemokines favour 
GAG binding, exemplified by one of the six splice variants of CXCL12 showing preferential 
GAG binding (Bachelerie et al., 2013). In general, chemokines show preferential binding 
to longer GAG sequences. The expression of different families and sulfation patterns of 
GAGs, which influence chemokine binding, are cell-type specific (Allen et al., 2007). 
Moreover, GAGs, which often demonstrate preferential binding of chemokine oligomers, 
may also regulate the balance of chemokine dimers or monomers in different tissues. 
Although chemokine receptors are thought to directly bind chemokine monomers to 
induce migration, both monomers and oligomers of chemokines mediate important roles in 
migration in vivo. (Allen et al., 2007; Bachelerie et al., 2013). Despite a large body of in 
vitro evidence suggesting how chemokine gradients might be formed, their existence has 
only recently been demonstrated in vivo (Weber et al., 2013). 
1.1.9 The purpose of chemokine receptor oligomerisation 
The functional ability of chemokine receptors can be modulated depending on the pool of 
other receptors that are also expressed on the same leukocyte. Hetero- or homo-
multimerisation is able to rapidly modulate the activity, signalling and/or localisation of a 
chemokine receptor in an allosteric manner (Bennett et al., 2011; Chabre et al., 2009). 
Chemokine receptor oligomers may form in the biosynthetic pathway prior to cell surface 
expression where subsequent chemokine binding can act to stabilise or reorganise the 
receptor oligomers that are constitutively formed (Bennett et al., 2011). For example, a 
bioluminescence resonance energy transfer (BRET) study found that CCR5 oligomers 
exist in the ER in human embryonic kidney (HEK)-293 cells transfected with C-terminal 
CCR5-luciferase/CCR5-YFP (Issafras et al., 2002). Notably, neither CCL4 nor CCL5 were 
found to induce higher order oligomerisation of pre-existing CCR5 oligomers, suggesting 
that the pre-formed oligomers are the functional units of CCR5 (Issafras et al., 2002). In 
other situations chemokine binding to CCR5 can be modified as a result of 
heteromerisation with other chemokine receptors. Indeed, CCL4 was found to reduce the 
binding of CCL2 in human CD4+ T blasts co-expressing CCR5 and CCR2b (El-Asmar et 
al., 2005). This effect was proposed to be due to negative binding co-operativity induced 
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by CCR5:CCR2b heterodimer formation, which was shown to occur at equal efficiency to 
homodimer formation in transfected Chinese hamster ovary (CHO) cells (El-Asmar et al., 
2005). Numerous other studies, many involving CXCR4 or CCR5, also show 
oligomerisation of chemokine receptors (reviewed by Bennett et al., 2011), with the 
overarching message that the diversity of chemokine receptor responses are vastly 
increased by the process of oligomerisation. In the next section, the focus is placed on 
those few studies that report the occurrence of chemokine receptor heteromerisation in 
situations of antigen-receptor engagement or in combination with receptors implicated in 
antigen dependent signalling. 
1.1.10 Oligomerisation in APC-T cell interactions 
In Jurkat T cells CXCR4 and green fluorescent protein (GFP) tagged-CCR5 were found to 
heterodimerise, as judged by co-immunoprecipitation (co-IP) and BRET, when stimulated 
by sAg-pulsed B cells. Furthermore in both primary human CD4+ T cells and Jurkat cells, 
the recruitment of CXCR4 to the interface of T cell-B cell conjugates formed in the 
presence of sAg was shown to be dependent upon the expression of GFP-CCR5 
(Contento et al., 2008). Accumulation of either receptor to the Jurkat-B cell interface was 
inhibited by antagonism of the other receptor, leading Contento et al. (2008) to conclude 
that the receptors act co-dependently. The CXCR4:CCR5 heterodimer was suggested to 
have a role in enabling CXCL12-mediated TCR costimulation (Contento et al., 2008), a 
role typically performed by the costimulatory molecule CD28. Since CXCR4 and CCR5 
are primarily expressed on antigen experienced cells in peripheral tissues, one may 
speculate that the formation of a heterodimer acts to lower the threshold for costimulation, 
enabling rapid re-priming and effector responses in inflamed sites. In support of this the 
chemokines CCL3 and CCL5 (inflammatory), but not CXCL12 (homeostatic), were found 
to stabilise constitutively forming CXCR4:CCR5 heterodimers (Isik et al., 2008).  
Additional factors involved in antigen presentation may also play a potential role in 
stabilising CXCR4:CCR5 heterodimers. For example, although CXCR4 and CCR5 
showed colocalisation by microscopy in a fibroblast cell line, the receptors were only 
found to co-IP in the presence of CD4 (Wang et al., 2004). Intriguingly, Achour et al. 
(2009) also suggest that CD4 is able to associate with CCR5 in the ER of transfected 
CHO cells and that this acts to promote CCR5 cell surface expression in a concentration-
dependent manner. Given the role of CD4 in localising lymphocyte-specific protein 
tyrosine kinase (Lck) to the cell-cell interface when TCR is engaged, perhaps CD4 also 
recruits CXCR4:CCR5 in the same platform. Yet CD4 is typically involved at the cell-cell 
interface (Dustin et al., 2010), whilst CCR5 accumulation is not always present at the 
interface of antigen-dependent conjugates (Contento et al., 2008). Thus if CD4 is 
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associated with CCR5, the interaction must be tightly regulated so that CD4 is able to 
mediate its function at the interface without CCR5. A similar argument also applies for 
CXCR4, which has been suggested to heterodimerise with the TCR upon binding CXCL12 
(Kumar et al., 2006). Overall, studies using different cell lines and techniques have 
mounted a body of evidence in support of the formation of combinatorial heterodimers 
between CCR5, CXCR4, CD4 or TCR. Such processes may dictate the switch to G11/q 
signalling, costimulatory capacity, and spatial regulation of these chemokine receptors on 
T cells during antigen-receptor engagement (Molon et al., 2005). 
1.1.11 Chemokine and integrin directed leukocyte migration 
1.1.11.1 Chemokine receptors can influence cell-cell adhesion  
Inside-out signalling from chemokine receptors or TCR can cause integrins, which exist in 
a largely inactive form, to undergo cytoskeletal tethering and concomitant conformational 
changes (Hogg et al., 2011). Evidence suggests that ligand-bound chemokine receptors 
induce integrin extension and ultimately T cell arrest during the process of leukocyte 
extravasation (Shamri et al., 2005). In addition, Bromley and Dustin (2002) showed 
increased T cell-DC conjugate formation in presence of CXCL12, even though high cell-
cell adhesion occurred with or without chemokine in a mechanism insensitive to PTX 
(Bromley and Dustin, 2002). Nevertheless this suggests that chemokines can promote 
cell-cell adhesion but that this effect may be subservient to TCR signalling. Environmental 
factors can also change the cellular interpretation of chemokine receptor-influenced 
adhesion. In particular, a previous report showed that resting T cells rapidly migrate on 
surfaces coated with bound CCL21 via a mechanism independent of integrin interactions 
(Woolf et al., 2007). Yet when Woolf et al. (2007) repeated the same assay under 
conditions of shear flow CCL21 drastically enhanced intercellular adhesion molecule-1 
(ICAM1) dependent adhesion. This supports reports of the integrin-independence of 
mobility observed for leukocytes in LNs but integrin-dependence during extravasation 
(Lammermann et al., 2008). Thus the chemokine receptor interplay with integrins in the 
process of cell-cell interactions cannot simply be extrapolated from the mechanism of 
extravasation and must be studied individually.  
In light of the observations of integrin independent adhesion in tissues, how can the 
chemokine-dependent increase in adhesion reported by Bromley and Dustin (2002) be 
rationalized? The answer comes from looking at the methodology used. Although sheer-
flow was not employed during imaging, conjugates were only imaged after the cells had 
been subjected to sheer-flow wash steps. This may explain why CXCL12 was observed to 
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stabilise interactions but raises questions as to whether the results are physiologically 
relevant to the majority of T cell-DC interactions, which occur in the tissues.  
1.1.11.2 Chemokine-directed movement within tissues 
Irrespective of whether integrins are involved in adhesion in interstitial tissue, chemokines 
still act to influence leukocyte mobility. CCR7 plays the dominant role in directing T cell 
mobility in the LN in response to its ligands, which are secreted by stromal cells (Cahalan 
and Parker, 2008). A lack of CCR7 reduces the speed but not the ‘random walk’ pattern of 
naïve T cell movement in the LN (Mrass et al., 2010). Since the T cells also exhibit a slow 
random walk on glass coverslips this may be a cell-autonomous pattern of behavior 
(Cahalan and Parker, 2008). Thus CCR7 may be important for increased speed of antigen 
sampling that in turn increases the likelihood of recognition of strong agonist peptide-
bound to the major histocompatibility complex (pMHC). Despite the fact that CXCL12 is 
also secreted by stromal cells of the LN, primarily in the medulla, CXCR4 was not found to 
play a role in mediating the mobility of naïve T cells within this site (Asperti-Boursin et al., 
2007). Nonetheless, secretion of other chemokines in the LN may influence T cell mobility 
and show directional migration. In evidence of this, T cell directional bias in the LN has 
been demonstrated in an inflammatory setting, in which CCR5 directs naïve CD8+ T cells 
to DCs that have engaged in antigen-specific interactions with CD4+ T cells (Castellino et 
al., 2006). Thus T cell directionality within interstitial tissue can occur but may be primarily 
instigated by subsets of chemokines expressed in response to infection or inflammation.  
1.2 The Immunological Synapse (IS) 
1.2.1 What is an immunological synapse? 
An immunological synapse (IS) is defined as the specialized junction that occurs when a 
cell of the immune system adheres to another cell, becomes polarised and participates in 
a stable interaction that enables a functional outcome (Dustin, 2009b; Grakoui et al., 
1999). Signalling components, cell surface proteins and lipids become rearranged into 
micrometer scale three-dimensional domains that accumulate to the cell-cell interface 
(Fig. 1.3) (Burack et al., 2002; Dustin, 2009b; Fooksman et al., 2009; Monks et al., 1998). 
Although this definition encompasses many different cell types that can form ISs, the 
present study focuses on interactions between T cells and APCs. Indeed, this group 
shows variation enough in IS formation as there are many different subsets and 
combinations of T cells and APCs, and both cell types contribute to the diversity of 
molecular arrangements at the IS (Dustin et al., 2006; Friedl et al., 2005).  
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Figure 1.3: Organisation of the immunological synapse and kinapse. The diagram shows the dSMAC, pSMAC and cSMAC concentric circles of the IS and indicates 
regions that are similar in the kinapse. The degree of crosshatching indicates the amount of organized actin in each region. The dSMAC is the major region where 
monomeric actin is directed by hydrostatic pressure contributing to the vast actin filament extension in this region that causes the retrograde flow and microclusters of TCR 
that are formed there to be directed inwards towards the cSMAC or uropod. Note the cSMAC is not necessarily equivalent to the uropod, which shows enriched myosin II 
that drives contraction of this region in migrating cells. This diagram is based upon previously reported models (Beemiller and Krummel, 2013; Dustin (2008); Dustin, 
2009b; Kummerow et al., 2009; Yokosuka et al., 2008).  
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The first observations of the IS were made by Kupfer and colleagues using deconvolution 
microscopy to study the interface of fixed murine B–T cell conjugates after 30 min co-
incubation. Cell surface and signalling proteins involved in antigen presentation were 
found to organize into concentric circles, designated supramolecular activation clusters 
(SMACs), at the interface in an antigen-dependent manner (Monks et al., 1998). The 
integrin lymphocyte function-associated antigen (LFA1) occupies the peripheral SMAC 
(pSMAC) around an accumulation of the TCR complex and PKCθ (a T cell specific 
isoform of PKC) in the central SMAC (cSMAC) (Fig. 1.3) (Monks et al., 1998). Soon after, 
Dustin’s group used live T cells and supported planar bilayers to show that the process of 
IS formation is highly dynamic. Initially, LFA1 bound ICAM1 is spread across the T cell- 
bilayer interface and TCR-pMHC molecules reside in an outer circle at the closely-
apposed edges of the T cell- bilayer contact. However, within three minutes the T cell 
organises TCR-pMHC into the centre of the interface whilst LFA1-ICAM1 clusters outside, 
correlating with the cSMAC and pSMAC organisation, respectively, as reported by Monks 
et al. (1998) (Grakoui et al., 1999). Later, the region outside the pSMAC containing the 
bulky phosphatase CD45 became known as the distal SMAC (dSMAC) (Beemiller and 
Krummel, 2013). Rather than simply being a bin for bulky membrane proteins the dSMAC 
is now appreciated as an area of continuous membrane movement associated with rapid 
extension of actin filaments (Dustin et al., 2010). At this point it is prudent to highlight that 
the SMACs are not apparent in all types of IS and their frequency of occurrence in vivo is 
unknown (Dustin et al., 2010; Schubert et al., 2012). Nevertheless the LFA1-ICAM1 
adhesion step was proposed to form a stable anchor-point around which cytoskeletal 
rearrangements occur that drive the central accumulation of TCR-pMHC (Grakoui et al., 
1999). In support of this hypothesis stable APC-T cell engagement is promoted by LFA1 
activation through inside-out signalling after TCR engagement. Also LFA1 or ICAM1 
knockout mice demonstrate compromised CD4+ T cell priming and CD8+ T cell effector 
function and lose the ability to form stable DC- CD8+ T cell conjugates (Hogg et al., 2011; 
Scholer et al., 2008). Thus adhesion is a critical step in IS formation. 
1.2.2 Signalling at the IS  
Antigen recognition is central to IS formation. T cells recognize cognate antigen though 
TCR binding to pMHC, which triggers the T cell signalling cascade detailed below. The 
steps leading to calcium influx across the PM are focused on due to the dependence of 
many activation-induced genes on this process, and as calcium is used as a readout for 
TCR-triggering in later chapters (Kummerow et al., 2009). 
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1.2.2.1 Calcium signalling following antigen receptor engagement 
Each TCR is associated with a total of six CD3 chains (two ε, two ζ, one δ, one γ) that 
contain signalling motifs known as immunoreceptor tyrosine-based activation motifs 
(ITAMs), which together form the TCR complex (Murphy et al., 2011). Upon TCR 
engagement signal transduction is initiated by a currently unclear mechanism, which 
prompts the phosphorylation of the ITAMs by the SRC-family kinases Lck and Fyn (Acuto 
et al., 2008; Kummerow et al., 2009). Constitutive phosphorylation of CD3 ITAMs in 
unstimulated T cells and recognition of self-pMHC resulting in partial CD3ζ ITAM 
phosphorylation both evidence the high native sensitivity of the TCR and overt regulation 
of signal triggering required to score the quality of antigen encountered (Acuto et al., 
2008). This concept is supported by recent in vivo evidence, which clearly demonstrates 
that the T cell elicits a different type of functional behavior in response to high or low 
affinity TCR ligands (Moreau et al., 2012). 
Binding of CD4 to a non-polymorphic region of MHC class II is independent of TCR 
binding and functions to concentrate associated Lck to regions of, rather than to stabilise, 
the TCR-pMHC interaction (Huppa et al., 2010). Through spatially concentrating Lck, CD4 
strengthens signalling and enables downstream calcium mobilisation (Huppa et al., 2010). 
Phosphorylated ITAMs recruit ZAP-70 (ζ-chain-associated protein kinase of 70 kDa), 
which is activated by Lck and subsequently phosphorylates the PM-associated adaptor 
protein linker for activation of T cells (LAT). Phosphorylated-LAT recruits PLCγ, which 
hydrolyses phosphatidylinositol-4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and 
inositol-1,4,5-triphosphate (IP3), the latter of which activates calcium release from ER-
stores (Acuto et al., 2008). The other product, DAG, is thought to be important for the 
recruitment of PKCθ and the microtubule-organising centre (MTOC) to this IS (Griffiths et 
al., 2010; Yokosuka et al., 2008). This entire cascade occurs very quickly as the time 
taken between TCR-pMHC engagement and release of free calcium into the cytosol is 
less than 10 s (Acuto et al., 2008). 
1.2.2.2 Sustained calcium signalling at the cell-cell interface 
IP3 binds to the IP3-receptor in the ER-membrane, which begins to release calcium 
contained within the ER lumen. Note that other signalling molecules also stimulate 
calcium release and these can act in coordination with IP3 to enable sustained calcium 
signalling upon persistent TCR engagement. The decrease in ER-luminal calcium is 
sensed by the cytoplasmic domain of the ER-membrane protein stromal interaction 
molecule 1 (STIM1), which oligomerises and translocates to PM-proximal regions (Hogan 
et al., 2010). PM-proximal STIM1 oligomers recruit the calcium release activated channel 
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(CRAC) ORAI1 and bind directly to stimulate calcium influx over the PM through a 
tetrameric ORAI1 channel (Hogan et al., 2010). Moreover, ORAI1 and STIM1 were shown 
to be rapidly recruited to the human T cell–DC IS making this structure the main site of 
sustained calcium influx (Lioudyno et al., 2008). Indeed, intracellular calcium 
concentrations are higher just beneath the plane of the IS (Lioudyno et al., 2008), but 
because this is buffered by mitochondria translocated to the interface in an LFA-
dependent manner CRAC channels remain open and thus calcium influx is sustained 
(Contento et al., 2010). 
1.2.3 Microclusters as the signalling components of the IS 
In the IS, actin is symmetrically organized and undergoes retrograde flow, which directs 
centripetal movement of TCR-pMHC or LFA1-ICAM1 microclusters newly formed in the 
dSMAC of the IS (Dustin et al., 2010; Varma et al., 2006; Yokosuka et al., 2005). The 
cSMAC was originally assumed to be the signalling module, as it is the region in which 
TCR accumulates (Grakoui et al., 1999; Monks et al., 1998). Yet in response to strong 
stimuli, phosphorylated proteins were not detected at the cSMAC but instead in peripheral 
microclusters (Yokosuka et al., 2005). Additionally, through inhibiting TCR triggering with 
antibodies against pMHC Varma et al. (2006) showed that calcium signalling is rapidly 
inhibited, even though cSMAC formation was not disrupted. Thus the TCR-pMHC 
microclusters in the periphery were implicated as the signalling components of the IS 
since their formation was found to be disrupted using this approach (Varma et al., 2006). 
The current view is that recognition of cognate pMHC causes preformed nanoclusters of 
TCR, and other TCR signalling components such as LAT, to aggregate into microclusters 
(Beemiller and Krummel, 2013). The costimulatory protein CD28 associates with TCR in 
the microclusters and recruits PKCθ (Yokosuka et al., 2008). Signalling components, such 
as LAT, ZAP-70 and Lck interact with TCR microclusters in a transient fashion, which may 
be sufficient for TCR to remain triggered. These interactions may be promoted by a 
localised increased density of cortical actin surrounding TCRs and involvement of lipid 
rafts with actin filaments (Kusumi et al., 2005). The microclusters at the periphery of the IS 
are loosely coupled to a conveyor belt of actin, which alongside association with 
microtubules via dynein, drives them towards cSMAC (Beemiller and Krummel, 2013; 
Dustin et al., 2010; Hashimoto-Tane et al., 2011). Corralled within the cSMAC TCR-pMHC 
microclusters may be divided into clusters of CD28-PKC, which function in a costimulatory 
signalling complex, exclusive from TCR-CD3 clusters, which terminate signalling and are 
targeted for degradation via ubiquitylation (Varma et al., 2006; Yokosuka et al., 2008). The 
relative contributions of these opposing functions have been postulated to enable negative 
regulation of TCR signalling in response to strong stimuli but support weak stimuli by 
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costimulation (Dustin et al., 2010; Yokosuka et al., 2008). Overall, microclusters can be 
imagined as the coloured dots that can form pointillist concentric circles (the SMAC 
modules) and their dynamics contribute to the changing picture of the IS at the cell–cell 
interface over time.  
1.2.4 Functions of the IS 
1.2.4.1 Antigen recognition and sustained signalling 
The IS has been proposed to function as a molecular machine that is able to overcome 
‘barriers’ to sustained TCR engagement (Grakoui et al., 1999). The organization of the IS 
promotes close apposition of the membrane in TCR-pMHC microclusters, which causes 
steric hindrance to larger glycoprotein phosphatases would otherwise inhibit signalling 
(Grakoui et al., 1999; Tybulewicz, 2002). This kinetic segregation model was supported by 
a study in which the extracellular domains of pMHC were elongated, which caused 
reduced signalling efficacy but maintained TCR-pMHC binding affinity (Choudhuri et al., 
2005). In addition the vast reorganization of cortical actin at the IS, with tightly woven 
compartments in the periphery and relatively little in the centre, means that signalling 
molecules recruited to the interface may become corralled in nanoscale regions proximal 
to TCR (Beemiller and Krummel, 2013; Kusumi et al., 2005). Recruitment and 
coalescence of signalling components may also be supported by large-scale stabilisation 
of lipid rafts at the IS (Pike, 2006). Together these structural components of the IS may 
considerably promote the chances of molecular interaction in order to achieve sustained 
signalling. Although other organisations of the IS have been demonstrated (Friedl et al., 
2005), the IS shown on planar bilayers can be viewed as the format that T cell aspires to 
in order to facilitate a high level of sustained signalling. For example the closer proximity 
of mitochondria to the cell-cell interface at the IS promotes sustained calcium influx, 
whereas in mobile antigen-dependent junctions the mitochondria primarily lie at the 
uropod and so calcium influx is less tenable (Kummerow et al., 2009). Thus in this 
capacity the IS functions to organize subcellular components to facilitate high level, 
sustained antigen-dependent signalling. 
1.2.4.2 A vehicle for directed secretion 
One of the proposed functions of the IS is as a vehicle for directed endo- and exocytosis 
(Griffiths et al., 2010). Cytotoxic T lymphocytes (CTLs) perform perhaps the most famed 
example of this function, as only minutes after TCR stimulation they commit the ‘kiss of 
death’ mediated by directed secretion of lytic granules into the IS (Huse et al., 2008). The 
annular pSMAC forms a seal that increases the efficiency of killing the target cell and is 
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thought to help prevent off-target effects on nearby cells (Dustin et al., 2010). The CTL-
target synapse also exhibits a specialized organization, having a secretory domain 
alongside the cSMAC, both of which are surrounded by the pSMAC (Griffiths et al., 2010). 
This type of IS is a good example of how different cell-types can mould the IS organization 
to benefit their function. 
Investigations have previously been made into whether chemokine ligands of CCR5 might 
be directionally secreted by CD4+ or CD8+ T cells (Catalfamo et al., 2004; Huse et al., 
2006). Catalfalmo et al. (2004) found CCL5 present in vesicles of memory and effector 
human CD8 + T cells. Upon interaction with CD3/CD28 beads, vesicles containing CCL5 
were found to localise to the bead–CD8+ T cell interface and were rapidly secreted (> 
50% fluorescence decrease in 30 min) (Catalfamo et al., 2004). In contrast, another study 
observed multidirectional CCL5 and CCL3 secretion from murine CD4+ T cells engaged 
with B cells (Huse et al., 2006). This result did not appear to be due to any technical 
inability to detect directed secretion as Huse et al. (2006) showed directional secretion of 
cytokines such as IL-2, IFNγ and IL-10. The differences may be due to analysis of 
preexistent vesicles containing CCL5 in the CD8+ T cells compared to de novo CCL5 in 
the CD4+ T cells being synthesized in response to TCR engagement (Huse et al., 2006). 
In addition differences between the cell types utilised, including the nature of the APC, B 
cell vs. bead, may contribute to the differences in the directionality of chemokine secretion 
observed. Thus the IS may enable targeted action of cytokines or chemokines upon 
specific cells as a result of antigen recognition, e.g. macrophage activation and 
suppression by IFNγ or IL-10 secreted by Th1 or Th2 cells, respectively (Huse et al., 
2008). Perhaps the IS has evolved as a single machine able to fit numerous different cell 
types and integrate both of the functions considered here, which can be mutually 
beneficial for an appropriate response upon encountering antigen. 
1.2.5 Moving targets: stable and kinetic synapses  
By definition the IS is stable and in support of its existence in vivo, stable DC-T cell 
interactions have been observed to exist in LNs (Dustin et al., 2010). However relatively 
soon after the original description of the IS, T cells were shown to be cumulatively 
activated in an antigen-dependent manner through multiple, dynamic interactions with 
APCs (Underhill et al., 1999). This type of dynamic interaction was also found to be 
relevant in vivo which led to the description of three phases involved in T cell antigen 
recognition: (i) contact initiation, prolonged but discontinuous interactions with multiple 
DCs; (ii) stable interaction, IS formation maintained for hours; (iii) release and swarming 
(Krummel and Cahalan, 2010). The fast integrin-independent mode of leukocyte migration 
through tissues discussed above may predominate in vitro at steady state, but in an 
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inflammatory environment, a slow or stationary integrin-dependent surface contact mode 
might exist (Krummel and Cahalan, 2010). When contact is formed the T-APC conjugate 
can transition between stable (<1 µm/min), slowly mobile (1-2 µm/min), and dynamically 
mobile (1-10 µm/min) junctions in order to cycle through the three possible phases of 
antigen recognition (Friedl et al., 2005). Depending on the quantity of antigen, T cells 
often initiate interactions with APCs in a mobile mode where pMHC is scanned and 
calcium signals are induced upon cognate antigen recognition (Dustin, 2009b; Krummel 
and Cahalan, 2010). This type of mobile contact is referred to as a kinapse (kinetic 
synapse) in order to distinguish it from the stable IS and exhibits a different modular 
arrangement (Dustin, 2009b) (Fig. 1.3).  
Transition between mobile and stable phases implies interchangeability between IS and 
kinapse formations. Mechanically, this has been proposed to be mediated by cytoskeletal 
rearrangements in which the symmetrical ring of actin flowing to the centre of the IS 
becomes destabilised and polarises to one side of the cell (i.e. asymmetric) (Dustin, 
2009b). In the asymmetric state actin flow pushes an edge of the cell forwards, causing 
movement. Yet, TCR microclusters still form at this edge and flow towards F-actin poor 
regions or ‘sinks’ (Beemiller et al., 2012). This indicates that the rules of flow imparted by 
structural features such as actin and lipid rafts may be maintained even when the overall 
arrangement of the IS is skewed or multicentric. After studying the transition between IS 
and kinapse using naïve T cells and planar bilayers Dustin’s group proposed a model in 
which PKCθ disrupts actin assembly causing gaps in the pSMAC actin ring, whereas 
Wiskott-Aldrich syndrome protein (WASp) promotes actin nucleation and reinstates 
symmetry (Dustin, 2009b). Thus differential regulation of signalling molecules such as 
PKC and WASp may be a method by which T cells switch between mobile forms. Notably 
the synapse-to-kinapse decision may also be influenced by signals from chemokines in 
the local microenvironment, which have a hierarchical interplay with TCR engagement 
(Bromley et al., 2000), as discussed in section 1.2.7.  
The initial decision of a cell to engage in stable or mobile interactions may be 
predetermined. For example T cell interaction stability with DCs is inversely correlated to 
activation status but directly correlated with the density of agonist pMHC (Friedl et al., 
2005). Alternatively the decision may relate to the required effector function, for instance 
stable symmetric IS formation may facilitate directional cytokine secretion between B-T 
cells when the T cell secretes cytokines into the tight, enclosed junction (Beemiller and 
Krummel, 2013). Whilst the architecture of the kinapse promotes motility and thus efficient 
scanning and recognition of small numbers of agonist pMHC, it is not efficient for 
polarised secretion, unlike the IS (Dustin, 2009b). Intriguingly, WASp plays a critical role in 
directed secretion of IFNγ by CD4+ T cells, but not multidirectional secretion of 
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chemokines (Morales-Tirado et al., 2004). Considering the role of WASp in promoting 
stable IS formation it is possible that IFNγ may only be able to be secreted when 
cytoskeletal symmetry is achieved. 
In addition to the factors discussed above, whether a synapse or kinapse is formed 
appears to depend, in part, upon the type of APC T cells interact with. In evidence of this, 
the same activated T cell population has been shown to engage in mobile interactions 
with DCs (kinapses) but show stable synapses with B cells (Azar et al., 2010). This is 
consistent with the notion that less stable interactions occur with APCs that have complex 
morphologies and have high cytoskeletal activity (Friedl et al., 2005). Finally, it is 
important to stress that both synapses and kinapses have been shown to evoke antigen-
dependent T cell calcium signals in vivo and only the highest calcium signals result in 
consistently reduced mobility in vitro (Moreau et al., 2012) (Beemiller et al., 2012). In 
general, the synapse and kinapse are interchangeable structures and the decision to exist 
as either form is dependent upon a combination of cell type, activation status, antigen 
density, regulation of signalling and environmental cues. Both should be considered as 
active and physiologically relevant forms of antigen-dependent information exchange. 
1.2.6 Role of APCs in the IS 
Although different APCs are known to influence the formation of the IS (Azar et al., 2010; 
Friedl et al., 2005), the majority of interest in IS formation has been at the T cell side. In 
fact, only a small number of molecular components have been shown to localise to the 
APC side of the IS. One study showed that PIP2 becomes concentrated on the APC side 
of the IS and suggested that this lipid has a role in enabling CTL-mediated lysis 
(Fooksman et al., 2009). Another study found that spinophilin is expressed both in 
neuronal dendrites and DCs and subsequently showed that spinophilin is localised to the 
IS and acts to optimize T cell activation (Bloom et al., 2008). Additionally, by truncating the 
CD80 cytoplasmic domain, the APC was found to be able to modulate the localisation of 
CD80 and the strength of costimulation (Tseng et al., 2005). Such studies highlight that 
the APC is not simply passive with regard to IS formation. Despite recognition that the 
APC cytoskeletal complexity and activation status may also modify the structure of the IS 
(Friedl et al., 2005), very little is known about how APCs may contribute to events at the 
IS.  
1.2.7 The hierarchy of chemokine receptors and TCR signalling 
Certain soluble chemokines (CCL21, CCL19, CXCL10) have been proposed to be able to 
override the ‘stop’ signal that can be issued by TCR engagement and induce T cell 
mobility, an effect which does not occur through stimulation with other chemokines (CCL3, 
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CXCL12) (Bromley et al., 2000). Furthermore, the ‘go’ signal issued by CCL21 is most 
efficient at low concentrations and thus even small differences in the chemokine 
microenvironment may have a significant impact on the stability of IS formation (Dustin, 
2004). Small differences can also be elicited by the differential susceptibility of chemokine 
receptors to desensitisation by bound ligand (Woolf et al., 2007).  Additionally, results 
from our lab indicate that different forms of the same chemokine receptor can be 
preferentially downmodulated. Together, environmental and cell-autonomous mechanisms 
may collectively influence whether a ‘stop’ or ‘go’ signal dominates. 
The intensity of antigen-dependent signalling may also be deterministic to ‘stop’ or ‘go’ 
theory. Intriguingly, CXCL10 signalling via CXCR3 has been demonstrated to result in 
phosphorylation of several signalling components downstream of TCR (LAT, ZAP-70, 
PLCγ) (Dar and Knechtle, 2007). Dar and colleagues observed quite the opposite effect of 
the override of TCR ‘stop’ signals by CXCL10 that was reported by Bromley et al. (2000), 
in that TCR ligation was found to attenuate CXCR3 signalling and chemotaxis (Dar and 
Knechtle, 2007). However, the two studies used different methods of TCR stimulation, one 
involving antibody-induced CD3-crosslinking (Dar and Knechtle, 2007) and the other 
ICAM and pMHC (Bromley et al., 2000). Thus it is possible that CXCL10 signalling was 
not able to overcome the effect of stronger antibody-mediated TCR engagement, which is 
several orders of magnitude greater than that of pMHC (Corse et al., 2011). This suggests 
interplay between the potency of TCR signals alongside a hierarchy of chemokines 
signals. 
1.2.8 Chemokine receptors at the IS: the distraction hypothesis 
GFP-tagged versions of CCR5 and CXCR4 have been shown to localise to the CD4+ T 
cell side of synapses formed with an immortalized B cell line or human monocyte-derived 
DCs (Contento et al., 2008; Molon et al., 2005). The recruitment of transfected GFP-
CCR5 to the interface was inhibited by blocking chemokine binding using anti-CCR5 
(clone: 45531), treatment with a functional antagonist, or blocking secretion from the B 
cells using Monensin A. The recruitment of CXCR4-GFP was blocked by treating with the 
antagonist AMD3100 (Molon et al., 2005). Additionally, T cell migration towards CXCL12 
was reduced in the presence of sAg-pulsed B cells compared to Monensin A treated sAg-
pulsed B cells, indicating that T cells engaged in the IS were less able to migrate towards 
CXCL12 gradients. These results, along with observations that CCR7 did not accumulate 
at the IS and the report by Bromley et al. (2000), led Viola and colleagues to propose the 
distraction hypothesis; certain chemokine receptors (CCR5 and CXCR4) may be recruited 
to the IS in order to prevent distraction from chemokine sources other than the engaged 
APC. This hypothesis appears to explain why CCL3/5 or CXCL12 did not result in a ‘go’ 
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signal in the study by Bromley et al. (2000). However it is important to note that no 
chemokine could be secreted by the APC in the study by Bromley et al. (2000), as the 
‘APC’ was in fact surface-bound ICAM and pMHC. Nevertheless, it is possible that upon 
establishing a CCL3, CCL5 or CXCL12 gradient the Transwell set-up used meant that the 
solid surface mimicked an APC secreting cognate chemokine, thus supporting the 
distraction hypothesis. Despite this in vitro evidence, currently no in vivo evidence exists 
that CD4+ T cells co-expressing CCR5 and CXCR4 recruit these chemokine receptors 
upon synapse formation in the LNs or peripheral tissue sites.  
Another study shows that chemokine receptors may also be involved in IS formation in a 
different type of cell-cell interaction in vitro. CD8+ tumour-infiltrating lymphocyte (TILs) 
clones forming an IS with a lung carcinoma cell line were found to recruit CCR5 to the 
interface (Franciszkiewicz et al., 2009). Accumulation of CCR5 to the IS, but not conjugate 
formation itself, was dependent upon the interaction between TIL integrin CD103 and E-
cadherin expressed on the tumour cell. In the TIL-tumour IS the CD103-E-cadherin 
interaction is comparable to and augments the LFA1-ICAM1 function in adhesion, 
promoting efficient tumour cell lysis and TIL cytokine release (Franciszkiewicz et al., 
2013). In support of the distraction hypothesis, knockdown of E-cadherin resulted in 
enhanced migration of tumour-engaged TILs towards CCL5 in a Transwell assay 
(Franciszkiewicz et al., 2009). Since the tumour cell line also secretes CCL3/4/5 it is 
tempting to speculate that if the authors had also inhibited secretion by tumour cells 
lacking E-cadherin they may have noticed a further enhancement of migration, 
comparable to the results of Molon et al. (2005). Note that, in contrast to a previous study 
in which CXCR4 recruitment to the Jurkat-B cell IS was co-dependently recruited with 
CCR5, TILs despite expressing both CXCR4 and CCR5 showed no accumulation of 
CXCR4 to the TIL-tumour interface (Franciszkiewicz et al., 2009). This suggests that 
chemokine receptor recruitment to the IS may be differentially regulated in different cell 
types.  Nevertheless, common to all these studies are indications that CCR5 can play a 
role in promoting cell-cell adhesion at the IS and that this seems to be mediated by 
recruitment of CCR5 to the cell-cell interface. Overall IS formation alone does not appear 
to be sufficient for chemokine receptor recruitment to the cell-cell interface, but additional 
cues from chemokines, integrins or receptor heterodimerisation promote accumulation to 
the IS (Contento et al., 2008; Franciszkiewicz et al., 2009; Molon et al., 2005). 
 
  
 
42 
 
1.3 Macrophages and the IS 
1.3.1 Macrophage origins and function 
Macrophages are a highly diverse group of mononuclear phagocytes widely expressed 
throughout the body in different tissue environments. The function of macrophages is 
specialized to, and by, the tissue in which they are expressed e.g. phagocytosis and 
antigen presentation in the dermis, elimination of pathogens in the liver, tolerance in the 
intestine, to name a few (Murray and Wynn, 2011). In these environments macrophages 
exist in two major forms, as tissue-resident macrophages and MDMs. Until recently it was 
believed that both forms were replenished by blood monocytes, which begin to 
differentiate to macrophages upon extravasation (Murray and Wynn, 2011). However 
recent evidence in mice has shown that, in contrast to haematopoietic stem cell-derived 
MDMs, tissue-resident macrophages are long-lived, self-renewing cells that are derived 
from the yolk sac with minor contributions from foetal liver monocytes (Schulz et al., 
2012). These tissue-resident macrophages were demonstrated to occupy numerous sites, 
in particular the liver (Kupffer cells) and the brain (microglia) (Schulz et al., 2012). In sites 
of inflammation or injury, blood monocytes become rapidly recruited and differentiate to 
MDMs, which transiently contribute to the tissue macrophage compartment (Zigmond and 
Jung, 2013). As an exception to this rule, monocytes are constitutively recruited to 
maintain a consistent population of CX3CR1
+ macrophages in the gut, although this is 
potentially caused by tonic inflammation in response to the environment (Zigmond and 
Jung, 2013).  
Monocyte recruitment occurs early on after tissue inflammation and is followed by 
differentiation and activation of macrophages, then conversion to suppressor cells and 
finally restoration homeostasis in the tissue (Murray and Wynn, 2011). The monocytes 
that give rise to both CX3CR1
+ gut macrophages and MDMs can be identified based on 
the expression of myeloid marker of the lymphocyte antigen 6C (Ly6C+) (Zigmond and 
Jung, 2013). Typically, high expression of Ly6C is indicative of the ‘inflammatory 
monocyte’ subset, which in humans is designated by the CD14hiCD16- monocyte 
phenotype (Gordon and Taylor, 2005; Murray and Wynn, 2011). Both human and murine 
inflammatory monocytes express CCR2, which plays a key role in directing monocytes to 
inflammatory sites (Gordon and Taylor, 2005). Although there are phenotypic similarities, 
the lack of Ly6C in humans highlights a general problem; a number of the identifiers of 
monocyte or macrophage subsets in mice are absent or differentially expressed in 
humans cells (e.g. Ly6C, F4/80, Ym1, Fizz1) (Murray and Wynn, 2011). Nevertheless, the 
origins of different macrophage compartments and the principals of recruitment during 
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inflammation are likely to apply to humans. However the findings of Geissmann and 
colleagues imply that macrophages generated from monocytes or bone marrow in vitro 
may never be able to completely recapitulate the phenotype of tissue-resident 
macrophages present at steady state in vivo (Schulz et al., 2012). 
1.3.2 Macrophages: plastic fantastic 
Macrophages demonstrate a high degree of plasticity and integrate many different signals 
that define their position within a vast possible spectrum of immunosuppressive to pro-
inflammatory functional phenotypes (Sica and Mantovani, 2012). It is unclear whether the 
differential macrophage phenotypes that promote inflammation and subsequent resolution 
result from newly recruited macrophages or repolarisation of macrophages in situ. Either 
way, macrophages become educated by the tissue environment, sensing tissue damage 
or the presence of pathogens and interacting with T cells, both directly and via reciprocal 
cytokine secretion (Biswas and Mantovani, 2010; Sica and Mantovani, 2012). 
Macrophages are broadly classified into two groups according to their activation state, 
namely classically activated (M1) and alternatively activated (M2) (Biswas and Mantovani, 
2010). Macrophages become polarised towards an M1 phenotype upon recognition of 
bacterial stimuli such as LPS, subsequent recruitment and activation of Th1 cells, which in 
turn secrete IFNγ and elicit full macrophage activation (Fig. 1.4). Typically M1 
macrophages have been associated with expression of inflammatory cytokines, enhanced 
production of reactive oxygen species, efficient antigen presentation and upregulation of 
the costimulatory molecules CD80/86 (Biswas and Mantovani, 2010; Sica and Mantovani, 
2012). M1 macrophages play a role in containing intracellular bacteria, protozoa (such as 
Leishmania major at the site of infection) and mediating anti-tumoural responses (Murray 
and Wynn, 2011).  
Macrophages polarised towards an M2 phenotype promote Th2 responses, become 
immunoregulatory, exhibit changes in metabolic substrate preference, demonstrate an 
enhanced phagocytic capability and an increased expression of scavenger receptors 
(Biswas and Mantovani, 2010). Three subdivisions of M2 cells have been specified, 
namely M2a, M2b and M2c, which are defined according to the cytokines and complexes 
they are exposed to during differentiation in vitro (Fig. 1.4). Note that macrophages 
polarised towards M2b and M2c cells are sometimes collectively referred to as ‘M2-like’ 
cells (Biswas and Mantovani, 2010). M2a macrophages are polarised by the Th2 
cytokines IL-4 and/or IL-13 and like M2b macrophages, which are differentiated in the 
presence of immune complexes and LPS, promote Th2 activation and responses 
(Mantovani et al., 2004). In contrast, M2c macrophages have a deactivated phenotype,
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Figure 1.4: Macrophage polarisation and chemokine profiles. The diagram shows the factors that are used to influence the differentiation and activation of 
macrophages in vitro. The four types of polarised macrophage demonstrate chemokine and cytokine expression patterns that dictate their roles in directing different arms 
of the immune response. This figure is based on previous reports (Biswas and Mantovani, 2010; Gordon, 2003; Mantovani et al., 2004; Rey-Giraud et al., 2012). GM-CSF, 
granulocyte-macrophage colony stimulating factor; IFNγ, interferon-γ; LPS, lipopolysaccharide; M-CSF, macrophage-colony stimulating factor. 
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are primarily involved in immunosuppression and tissue remodeling and extensively 
downregulate MHC class II (Mantovani et al., 2004). Thus, M2c macrophages would not 
be expected to interact with CD4+ T cells in an antigen-specific manner that would lead to 
IS formation. M1 and M2 polarised macrophages have different chemokine expression 
repertoires (Mantovani et al., 2004), which not only promote the recruitment of different 
lymphocytes but may also potentially influence their antigen-specific interactions in the 
tissue. According to the two-signal activation model, recent lymphocyte immigrants would 
engage pMHC present on the APC (macrophage or DC) and in turn receive a cytokine 
signal from that APC that induces T cell activation (Martinez et al., 2009). This notion is 
consistent with the systems view of the immune system, in which T cells that have 
undergone previous antigen-recognition and expansion in the LN can be restimulated by 
APCs resident in the target tissue (Gerard et al., 2013). As an example of this type of 
activation, IFNγ secretion by Th1 cells may be induced following antigen-specific 
engagement with M1 macrophages secreting IL-12 (Martinez et al., 2009). Speculatively, 
the M1 macrophage secretion of CCL3/4/5 may enhance macrophage-Th1 cell adhesion 
according to the distraction hypothesis or even substitute as a costimlatory signal, as 
previously observed in IS formation between T-B cells (Contento et al., 2008; Molon et al., 
2005). The notion of enhanced adhesion is particularly appealing considering IFNγ can be 
directionally secreted by T cells and that the IS may act as a vehicle for directed secretion 
(Huse et al., 2006). Yet in spite of this, current in vitro and in vivo data suggest that CD4+ 
T cell interactions with macrophages in vivo are often dynamic, see section 1.3.4. 
Nevertheless, this highlights that the M1 or M2 polarisation and the resulting chemokine 
and cytokine profile may affect the stability or occurrence of a macrophage-T cell IS. 
1.3.3 Practicalities of generating human MDMs 
There is a general lack of consensus as to the method by which human MDMs are 
generated. Serum, or the lack of, has been shown to affect the functional activity of MDMs 
(Rey-Giraud et al., 2012). In addition, foetal calf serum (FCS) is thought to contain 
numerous undefined factors that can activate signalling pathways able to initiate changes 
in cell morphology and adhesion (Rey-Giraud et al., 2012). The presence of these factors 
can be batch-dependent. Typically, M-CSF or GM-CSF are often used to polarise 
macrophages to M2 or M1 phenotypes in vitro, respectively, alongside the aforementioned 
cytokines (e.g. IL-4, IL-13 and IFNγ) and bacterial products such as LPS (Foucher et al., 
2013; Jaguin et al., 2013; Martinez et al., 2006; Rey-Giraud et al., 2012). M-CSF in 
particular is often added to promote survival, although its addition can be rationalized by 
evidence that M-CSF is constitutively expressed in vivo (Hamilton and Achuthan, 2013). 
Use of different combinations of these factors may be a source of disparity between M1 
and M2 polarised MDMs prepared in different studies.  
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1.3.4 Evidence for macrophage-CD4+ T cell interactions in vivo  
IS formation is thought to occur between effector CD4+ T cells and macrophages in the 
tissue environment (Dustin et al., 2001b). In vitro, synapse or kinapse formed between 
murine macrophages and CD4+ T cells have been shown to be highly dynamic (Underhill 
et al., 1999). However direct visualization of this type of IS and whether typical markers 
accumulate to the cell-cell interface has not yet been demonstrated in human cells or in 
vivo. Nevertheless, a recent study in mice has indicated that macrophages and DCs are 
implicated in the local restimulation of primed CD4+ T cells in atherosclerotic lesions 
(Koltsova et al., 2012). In turn, the CD4+ T cells secrete proinflammatory cytokines 
enhancing lipid uptake (Koltsova et al., 2012), which amongst other T cell responses 
drives atherosclerotic plaque formation and disease progression (Libby et al., 2013). In 
humans, approximately two-thirds of T cells present in atherosclerotic plaques are CD4+ 
with the majority possessing an activated effector-memory phenotype (Libby et al., 2013). 
Despite the accumulation of CD4+ T cells into a macrophage-rich pathological location 
and indication that the direct interactions of these cell types has a functional outcome for 
disease progression, little is known about antigen-dependent macrophage–CD4+ T cell 
interactions in peripheral tissues. 
CD4+ Th1 cells also play a key role in interacting with macrophages infected with 
mycobacteria in order to contain the infection (Murphy et al., 2011). However the level of 
mycobacterial-antigen presentation in granulomas (collections of macrophages) is only 
able to induce arrest and directed cytokine secretion in a small fraction of the total 
antigen-specific CD4+ T cells infiltrating the tissue (Egen et al., 2011). The authors 
suggest functional limitation of antigen presentation within the granuloma and generalise 
that there is insufficient antigen at sites of infection to support effector T cell responses in 
this region (Egen et al., 2011). 
Antigen presentation to CD4+ T cells by macrophages infected with L. major in peripheral 
tissue (cutaneous) sites was shown to have a highly diverse nature (Filipe-Santos et al., 
2009). Some CD4+ T cells exhibited transient, short-lived contacts whilst only a subset 
were shown to form longer lived (≥ 30 min), stable interactions with infected cells. It is 
notable that for the majority of stable interactions only one CD4+ T cell formed a 
conjugate with each infected macrophage (Filipe-Santos et al., 2009). This contrasts, the 
multiple CD4+ T cells to one macrophage previously observed in vitro (Underhill et al., 
1999). In similarity to Egen et al. (2011) spatial heterogeneity in the efficiency of antigen 
presentation was observed in which a small number of T cell were observed to arrest at 
particular ‘hotspots’ in the infection site. Interestingly both antigen-specific and activated 
polyclonal CD4+ T cells were able to enter the site of infection with the same efficiency, 
although only the former were observed to pattern to areas of infected macrophages 
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within the cutaneous lesion (Filipe-Santos et al., 2009). In general the in vivo data tends to 
support the in vitro concept that the macrophage–CD4+ T cell interaction in tissues 
involves kinapse-type interactions and that synapses can occur but are limited by antigen 
availability. 
The details and dynamics of the IS were developed through examining the interactions 
between T cells and planar bilayers, B cells or DCs. These interactions have been 
investigated using both murine and human cells in vitro and in vivo. Murine systems have 
previously been used to study the formation and dynamics of the macrophage-CD4+ T 
cell IS, yet very little, if any, work has been done in human cells. With regards to CCR5, 
this chemokine receptor has been implicated in IS formation between a number of cell 
types however its role in the macrophage–CD4+ T cell IS has not yet been established. 
This study examines the formation of a macrophage–CD4+ T cell IS in vitro using human 
cells and investigates the role of CCR5 with particular focus on the macrophage side of 
this interaction. 
1.4 Research aims 
 
 
 To develop an in vitro system using primary human MDMs and CD4+ T cells to 
characterise the formation of productive MDM-CD4+ T cell interactions leading to 
IS formation 
 
 To determine whether endogenously expressed CCR5 and CXCR4 are recruited 
to the MDM-CD4+ T cell IS 
 
 To explore factors that may impact the lateral mobility of endogenous CCR5 on the 
MDM membrane 
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Chapter 2: Methods 
2.1 Isolation of primary human cells 
2.1.1 Isolation of monocytes by adherence 
Prior to commencing isolation, all media and solutions were equilibrated to room 
temperature (RT) for a minimum of 2 h and, for each donor, five 14.5 cm dishes (Greiner 
bio-one, Kremsmuenster, Austria) were coated with gelatin (Sigma Aldrich, Gillingham, 
UK) and left to dry during this period. Details of the composition of solutions used in this 
study can be found in Table 2.1. Single donor leukocyte aphaeresis cones (NHS Blood 
and Transport Service, UK) were drained into a tube containing 10 ml phosphate buffered 
saline (PBS) before residual cells were washed from the cone using 35 ml PBS. The 
volume was made up to 50 ml with PBS after removing two aliquots: 11 ml for CD4+ T cell 
isolation and 200 µl for comparison of the purity of CD4+ T cell isolation. The remaining 
volume of PBS diluted blood was distributed into three tubes containing 14 ml of 
Lymphoprep (Axis Shield, Oslo, Norway) by gently layering over the top of the density 
separation media. Tubes were centrifuged at 2000 rpm for 34 min (swing-out rotor, 
acceleration “5” and no brake). The peripheral blood mononuclear cell (PBMC) layer was 
removed using a Pasteur pipette and dispensed into a single 50 ml tube containing 10 ml 
PBS. PBMCs were washed twice in 35 ml PBS at 1050 rpm, then 2 – 4 times in 35 ml 
HBSS without Ca2+ or Mg2+ at 1100 rpm, both steps using gentle acceleration (“7”) and 
braking (“6”) during centrifugation. PBMCs were resuspended in 35 ml of RPMI without 
serum (nsRPMI), a cell-count taken using a haemocytometer (a mean of 6.5 x 108 ± 3.5 x 
108 PBMCs), then washed into 25 ml 5% (v/v) FCS-RPMI and dispensed over the gelatin-
coated plates before adding 10 ml 5% (v/v) FCS-RPMI v/v to each plate. Cells were 
incubated for 2 h at 37 °C, 5% CO2 before non-adherent cells were removed and each 
plate washed vigorously a minimum of 4 times with 7 ml 5% (v/v) FCS-RPMI. Adherent 
cells were detached in 10% (v/v) FCS-RPMI using a cell scraper (Sarstedt, Nümbrecht, 
Germany), washed once, counted (on average 5.3 x 107 ± 2.5 x 107 monocytes) and 
aliquoted into 10 cm plates (TPP, Trasadingen, Switzerland), 7 ml/plate at a density of 0.7 
– 1.0 x 106 monocytes/ml.  
2.1.2 Isolation of CD4+ T cells 
CD4+ T cells were isolated from total blood using the RosetteSep human CD4+ T cell 
enrichment cocktail (Stemcell Technologies, Grenoble, France) according to the 
manufacturer’s instructions. Briefly, 0.5 ml RosetteSep human CD4+ T cell enrichment 
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Name Composition 
Cell Culture 
nsRPMI 
(RPMI without serum) 
500 ml RPMI 1640 (without L-glutamine), 2 mM L-glutamine, 100 U/ml 
Penicillin, 100 µg/ml Streptomycin, 12.5 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES).  
5% (v/v) FCS-RPMI As for nsRPMI, plus 25 ml PAA gold FCS (PAA Laboratories GmbH) 
10% (v/v) FCS-RPMI 
As for nsRPMI, plus 50 ml PAA gold FCS (PAA Laboratories GmbH) 
Note: HyClone
TM
 FCS (Thermo Fisher Scientific Inc.) was used for cells 
lines e.g. CHO-K1 
5% (v/v) huAB-RPMI As for nsRPMI, plus 25 ml human AB serum (PAA Laboratories GmbH) 
10% (v/v) MEM eagle 
500 ml Minimal essential media (MEM) eagle, alpha modification (Sigma-
Aldrich), 2 mM  L-glutamine, 100 U/ml Penicillin, 100 µg/ml Streptomycin, 
12.5 mM HEPES, 50 ml Hyclone
TM
 FCS. 
MC5 Hybridoma 
media 
DMEM with 4.5 g/L glucose, 2 mM L-glutamine, 1 x HT supplements,        
1 mM sodium pyruvate, 100 U/ml Penicillin, 100 µg/ml Streptomycin 
PBS 500 ml ddH20, PBS tablet (Life Technologies Ltd.). Autoclaved 
Immunolabeling Solutions 
Binding Media (BM) 
10 ml 10x RPMI 1640 without carbonate or glutamine (Sigma-Aldrich),    
90 ml ddH20, 0.2% (w/v) BSA, 10 mM HEPES. 
FACS buffer PBS, 1% (v/v) FCS, 0.05% (w/v) Sodium Azide 
Quench solution 
(NH4Cl) 
50 mM NH4Cl in FACS buffer 
Other Solutions 
Binding Buffer 20 mM Sodium Phosphate, pH 7.0 
Elution Buffer 0.1 M Sodium Citrate, pH 3.0 
 
Table 2.1: Composition and abbreviations of solutions used. All reagents are from Gibco® Life 
Technologies unless stated otherwise. Before use all FCS was decomplemented by heating at 56 
°C for 30 min. 
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cocktail was added to 11 ml of blood, mixed and incubated for 20 min at RT. The sample 
was diluted 1:1 with 2% (v/v) FCS-PBS then gently layered over 15 ml Lymphoprep and 
centrifuged for 20 min at 1200 x g with no brake. CD4+ T cells were removed from the 
interface as described for the buffy coat in section 2.1.1, washed twice in 35 ml 2% (v/v) 
FCS-PBS, counted using a haemocytometer (on average 4.6 x 107 ± 2.5 x 107 CD4+ T 
cells), washed once with 35 ml 10% (v/v) FCS-RPMI and finally resuspended in 10% (v/v) 
FCS-RPMI at 2 x 106 cells/ml. A summary cartoon of separation and differentiation is 
shown in Fig. 2.1a. 
2.2 Cell culture and differentiation conditions 
2.2.1 Generating monocyte-derived macrophages 
From the day of isolation (day 0), monocytes were cultured in 10% (v/v) FCS-RPMI for 48 
h before media was replaced with 10% (v/v) FCS-RPMI supplemented with 50 ng/ml M-
CSF (Peprotek, NJ, USA). During differentiation to MDMs, media was changed every 2 – 
3 d as indicated (Fig. 2.1b). M1-polarised MDMs were also cultured in 10% (v/v) FCS-
RPMI but instead of adding M-CSF, GM-CSF (R&D Systems, Abingdon, UK) was added 
on day 1 then 50 ng/ml IFNγ (Sigma-Aldrich) and 10 ng/ml LPS (Sigma-Aldrich) were 
added from day 5 onwards (Fig. 2.1b). All MDMs were harvested using cell scrapers. 
2.2.2 Culture of CD4+ T cells 
CD4+ T cells were cultured overnight in 10% (v/v) FCS-RPMI before adding 5 µg/ml 
phytohaemagglutinin-M (PHA; Sigma-Aldrich) for 3 d. After stimulation, cells were cultured 
in 10% (v/v) FCS-RPMI supplemented with 10 U/ml IL-2 (Peprotek) in T75 flasks for the 
remaining duration of the culture, replenishing media every 2 – 3 d (Fig. 2.1b). 
Alternatively, after overnight culture CD4+ T cells were adjusted to a density of 1 x 106 
cells/ml, transferred to 24-well plates (Sigma-Aldrich) (1 ml/well), and to each well 25 µl of 
washed human T-activator CD3/CD28 Dynabeads® (Invitrogen, Paisley, UK) was added 
alongside 30 U/ml IL-2. These T cells were counted every 48 h using a haemocytometer 
and were split 1:1 when counts exceeded 2 x 106 cells/ml, after taking into account loss of 
media volume by weighing the 24-well plate. In all cases CD3/CD28 activated cells were 
magnetically separated before use according to the guidelines supplied from Invitrogen. 
2.2.3 Culture of cell lines 
DHFR-deficient CHO cells stably transfected with human CCR5 (CHO-CCR5) (Mack et 
al., 1998) were cultured in 10% (v/v) FCS-MEM eagle,  modification (Sigma-Aldrich) in 
10 cm dishes (BD Biosciences) until 80-90% confluency, then detached with 10 mM 
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Figure 2.1: Timeline for culture of primary cells. Monocytes isolated on day 0 are cultured to 
generate MDMs which are conditioned in M-CSF or GM-CSF. The timeline also shows the stages 
at which PHA and IL-2 are added in order to generate PHA-activated CD4+ T cells. The full circle 
(coloured accordingly) indicates the day on which media is replaced, which is not necessarily 
concomitant with the addition of growth factors or cytokines. 
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ethylenediamintetraacetic acid (EDTA) in PBS and split 1:30. CHO-K1 cells, kindly 
provided by Prof PM Kaye  (University of York, York, UK), were cultured in an identical 
manner but using 10% (v/v) FCS-RPMI. Daudi cells, kindly provided by Dr G Doody 
(University of Leeds, Leeds, UK), were cultured in T75 flasks using 10% (v/v) FCS-RPMI 
and viability was assessed routinely by staining aliquots 1:1 v/v with 0.4% (w/v) trypan 
blue solution (Sigma-Aldrich). Daudi cells were maintained at 0.5 – 2.0 x 106 viable 
cells/ml and passaged by centrifuging for 5 min, 180 x g, resuspending in fresh media. 
2.2.4 Cryopreservation of cells 
Cells were centrifuged at 250 x g, 5 min then resuspended in PAA gold FCS (PAA 
Laboratories GmbH, Pasching, Austria), typically at a density of 2 x 107 cells/ml and 
aliquoted into NuncTM cryovials (Thermo Fisher Scientific Inc.) before adding 20% (v/v) 
dimethyl sulphoxide (DMSO; Sigma-Aldrich) in FCS at a 1:1 ratio, inverting the vial to mix 
and transferring to a Mr. FrostyTM freezing container (Thermo Fisher Scientific Inc.) 
precooled to 4 °C. This was stored at -80 °C for 24 h before vials were transferred to liquid 
nitrogen for long-term storage. Note that PBMCs and any non-adherent cells (monocyte-
depleted PBMCs) were cryo-preserved at higher final densities, ~5 x 107 and 1 x 108, 
respectively. Vials were thawed rapidly in a 37 °C water-bath until only a small crystal of 
ice remained before adding an equal volume of pre-warmed media dropwise to the vial 
over ~30 s. The entire contents of the vial were then transferred to a tube containing 20 ml 
media (at 37 °C) and cells were washed once more with media before incubation at 37 °C, 
5% CO2. 
2.3 Purification and coupling of the anti-CCR5 mAb MC5 
The monoclonal antibody (mAb) MC5 was produced by a hybridoma grown in MC5 
hybridoma media (see Table 2.1) from which supernatant was collected by centrifugation 
at 300 x g, 5 min to remove cells, then frozen at -80°C. Once 500 ml of the hybridoma 
supernatant had been collected the volume was mixed 1:1 with Binding Buffer in a 1L 
sterile conical flask. A 1 ml HiTrapTM rProtein A FF column (GE Healthcare Life Sciences, 
Buckinghamshire, UK) was used to purify the antibody according to the manufacturers 
instructions. Briefly, the column was regenerated by running 15 ml Elution Buffer through, 
then equilibrated with 20 ml Binding Buffer before the supernatant:Binding Buffer solution 
was run through the column at 0.9 ml/min using a peristaltic pump. The column was 
washed with 15 ml Binding Buffer, then MC5 was eluted with Elution Buffer into 1 ml 
aliquots containing 100 µl 1M Tris-HCl (pH 9.0). Aliquots with A280 > 0.6 were combined 
and dialyzed into PBS using Snakeskin MWCO 3.5K (Pierce Biotechnology, IL, USA). The 
concentration was determined to be 5.4 mg/ml using the Bradford assay.  
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The MC5 antibody was fluorescently coupled using the DyLight488 kit or DyLight650 
microscale kit (Pierce Biotechnology) according to the manufacturer’s instructions 
(instruction sheet 1897.10; www.thermoscientific.com/pierce). For the DyLight488 kit a 
number of modifications were made in order to achieve a dye:protein (D:P) molar ratio of 
approx. 3. Specifically, 620 µl MC5 was mixed with 49.6 µl 0.67 M borate buffer and 
subsequently 600 µl (3 mg antibody) of this mixture was incubated with the vial of 
DyLight488. Each spin column was packed with an increased amount of resin (300 µl) in 
order to accommodate the increased volume (300 µl) of MC5-DyLight488 solution that was 
loaded. The absorbance at 280 nm and 493 nm was measured using NanoDrop 
spectrophotometer (Thermo Fisher Scientific Inc.) in order to estimate the resulting 
concentration and D:P ratio. 
2.4 Immunolabelling techniques for flow cytometry 
Antibodies were acquired from the following sources as indicated in Table 2.2. 
2.4.1 Standard flow cytometry immunolabelling method: 
characterisation of cells 
On day 1 and day 9 of culture monocytes/MDMs, detached by scraping, and CD4+ T cells 
were counted and aliquoted into a Corning® U-bottomed 96-well plate (Thermo Fisher 
Scientific) at 1 x 105 cells/well. The plate was centrifuged at 300 x g, 3 min, 4 °C to pellet 
cells; centrifugation conditions were kept constant until cells were fixed, after which cells 
were centrifuged at 19 °C. Supernatant was flicked off and the cell pellets resuspended in 
50 µl/well 30 µg/ml immunoglobulin G (IgG) human serum (huIgG; Sigma-Aldrich) made 
up in binding media (BM) and incubated for 30 min at 4 °C. Cells were centrifuged and the 
Fc-receptor (FcR) block discarded before resuspending pellets in 50 µl/well 5 µg/ml 
primary antibody solutions made up in BM and incubating for 90 min at 4 °C. Wells 
containing monocytes/MDMs were incubated with antibodies against CD3, CD4, CD11b, 
CD14, CD16, CD19, CD68, CD83, human leukocyte antigen-DR (HLA-DR) and CCR5 
(MC5, CTC5, 2D7). T cells were incubated with antibodies directed against the underlined 
markers and additionally CD8, CD25 and CD45RO (Table 2.2). After incubation, cells 
were washed three times in 250 µl/well BM at 4 °C then resuspended in 200 µl/well cold 
3% (w/v) paraformaldehyde (PFA: Polysciences Inc., PA, USA) made up in PBS and fixed 
for 20 min at RT. Fixative was removed and cells were washed and incubated for 20 min 
in quench solution, centrifuged then resuspended in 50 µl/well of 4 µg/ml goat anti-mouse 
(GAM)- R-phycoerythrin (PE) secondary antibody solution and incubated for 60 min. Cells 
were washed three times with 250 µl/well FACS buffer then analysed on a FACSArrayTM.
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Primary Antibodies 
Specificity Clone Isotype Source 
Catalogue 
Number 
CD3 UCHT1 IgG1 Biolegend 300402 
CD3 OKT3 IgG2a Biolegend 317304 
CD4 RPA-T4 IgG1 Biolegend 300502 
CD8 RPA-T8 IgG1 Biolegend 301002 
CD11b ICRF44 IgG1 eBioscience 14-0118-82 
CD14 UCHM1 IgG2a AbDSerotec MCA596GA 
CD16 eBioCB16 IgG1 eBioscience 14-0168-80 
CD19 HIB19 IgG1 eBioscience 14-0199-82 
CD25 BC29 IgG1 eBioscience 14-0259-82 
CD45RO UCHL1 IgG2a eBioscience 14-0457-82 
CD68 Y1-82A IgG2b BD Pharmingen 556059 
CD80 2D10 IgG1 Biolegend 305201 
CD83 HB15e IgG1 BD Pharmingen 556854 
CD163 GHI/61 IgG1 Biolegend 333602 
GM130 35/GM130 IgG1 BD Biosciences 610822 
HLA-DR L243 IgG2a Biolegend 307612 
LPBA 6C4 IgG1 Echelon Z-LBPA 
TfR H68.4 IgG1 Invitrogen 13-6890 
TGN46* TGOLN2 IgG AbD Serotec AHP500 
Antibodies Against Chemokine Receptors 
CCR5 45531 IgG2b R&D Systems MAB182 
CCR5 2D7 IgG2a BD Pharmingen 555991 
CCR5 CTC5 IgG1 R&D Systems MAB1802 
CCR5 MC5 IgG2a Produced in-house 
pS
349
 CCR5 EII/19 IgG1 Biolegend 321602 
CXCR4 12G5 IgG2a Kind gift from Prof. Q Sattentau 
Isotype Control Antibodies 
IgG2a κ IsoControl
488
 eBM2a IgG2a eBioscience 53-4724-80 
IgG2a κ IsoControl eBM2a IgG2a eBioscience 14-4724-85 
IgG1 κ IsoControl P3.6.2.8.1 IgG1 eBioscience 14-4714-85 
Secondary Antibodies 
Specificity Name Host Fragment Source 
Catalogue 
Number 
Mouse IgG GAM-Fab
488
 Goat Fab 
Jackson 
ImmunoResearch 
115-547-003 
Mouse IgG GAM
488
 Goat F(ab')2 Invitrogen A11017 
Mouse IgG GAM
594
 Goat F(ab')2 Invitrogen A11020 
Mouse IgG SAM
PE
 Sheep Whole IgG Sigma-Aldrich P8547 
Sheep IgG DAS
488
 Donkey Whole IgG Invitrogen A11015 
Mouse IgG1 GAM-IgG1
488
 Goat Whole IgG Invitrogen A21121 
Mouse 
IgG2a 
GAM-IgG2a
647
 Goat Whole IgG Invitrogen A21241 
Table 2.2: Details and sources of antibodies 
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Bioanalyser flow cytometer (BD Biosciences). All steps after fixation were carried out at 
RT and with shaking during incubations 
2.4.2 Immunolabelling MDMs for CD80 and CD163 expression 
MDMs generated by culture with GM-CSF or M-CSF (Fig. 2.1b) were harvested on day 8 
of culture and aliquoted at 1 x 105 cells/well into U-bottomed 96-well plates. MDMs to be 
labelled with anti-CD163 were fixed immediately in 200 µl/well 3% (w/v) PFA (in PBS) for 
20 min at RT. Cells were washed and incubated in 250µl/well quench solution for 20 min, 
FcR-blocked with 50 µl/well 30 µg/ml huIgG for 30 min, centrifuged, then resuspended in 
50 µl/well 5 µg/ml anti-CD163 or IgG1 isotype control primary antibody solutions and 
incubated for 60 min.  Cells were washed three times then resuspended in 50 µl/well 4 
µg/ml GAM-IgG1488 secondary antibody solution, incubated for 60 min, then washed three 
more times. All antibody solutions prepared, and wash steps performed (250 µl/well) are 
in FACS buffer and all incubations involve shaking. 
MDMs to be labelled with anti-CD80 were labelled live. Cells were FcR-blocked in 50 
µl/well 30 µg/ml huIgG in BM for 25 min, centrifuged, and FcR-blocking solution discarded 
before the cell pellets were resuspended in 100 µl/well 5 µg/ml anti-CD80 or IgG1 isotype 
control made up in BM and incubated for 20 min. The cells were washed three times in 
250 µl/well BM then resuspended in 100 µl/well 4 µg/ml GAM-IgG1488 made up in BM and 
incubated for 20 min. Subsequently, cells were washed twice with PBS before the cell 
pellets were resuspended in 200 µl/well violet live/dead fixable dye (Life Technologies 
Ltd., Paisley, UK) at 1:1000 in PBS (stock: 50 µl DMSO added to 1 vial of lyophilized dye) 
and incubated for 30 min. After washing cells twice in PBS, 200 µl/well ice-cold 3% (w/v) 
PFA was added to each well and cells were fixed at RT for 20 min. The plate was washed 
once with FACS buffer and samples were kept at 4 °C until analysis. All centrifugation was 
carried out at 300 x g, 3 min and cells were kept at 4 °C with shaking during incubations at 
all times, unless stated otherwise. All samples were analysed using a CyAnTM ADP 
Analyser flow cytometer (Beckman Coulter Ltd., High Wycombe, UK). 
2.4.3 Competition binding assay 
MDMs (day 9) were treated in accordance with the method detailed in section 2.4.1, but 
with the following solutions in place of the primary antibody. To MDMs 50 µl/well of a 
solution of 15 µg/ml MC5488 alone or with 0.1, 1.0, 5.0 or 15.0 µg/ml MC5 was added. A 
control well containing 15 µg/ml IgG2a488 isotype control was also included. After fixation, 
cells were analysed using a CyAnTM ADP Analyser flow cytometer. Background-corrected 
Median Fluorescence Intensity (MFI) values were calculated by subtracting the 
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fluorescence intensity of the isotype control, and results were expressed as a percentage 
of the MFI value at 15 µg/ml MC5488 alone. 
2.4.4 Titrations 
MDMs (day 9-11 of culture) were detached by scraping, resuspended at 2 x 106 cells/ml in 
BM containing 30 µg/ml huIgG and incubated for 30 min, 4 °C. During this incubation a U-
bottomed 96-well plate was prepared containing 12.5 µl/well MC5, CTC5, 2D7, IgG1 or 
IgG2a isotype controls in separate wells that had been double-diluted to cover a 
concentration range of 0.2-50 µg/ml. FcR-blocked MDMs (or CHO-CCR5 cells) were 
resuspended at 8 x 106 cells/ml in BM containing 10 µg/ml huIgG and aliquoted over the 
prepared 96-well plate at 12.5 µl/well, giving a final concentration range of 0.1-25 µg/ml. 
Cells were incubated for 90 min, 4 °C before 200 µl BM was added and cells were 
washed three times in 250 µl BM then fixed in 200 µl/well 3% PFA (w/v in PBS) for 20 
min, RT. After washing and 20 min incubation in 200 µl/well quench solution, cells were 
resuspended in 50 µl/well 4 µg/ml GAM647 in FACS buffer and incubated for 60 min. 
Finally, cells were washed three times in FACS buffer and analysed by flow cytometry. 
After acquisition the concentration-matched isotype control MFI was subtracted from the 
MFI reading of each specific antibody. 
A similar method was used for titration of MC5488 (D:P ratio, 5.4) and MC5 followed by 
GAM-Fab488 but with the following amendments. MC5488 and IgG2a488 isotype control or 
MC5 and IgG2a isotype control were double diluted to give a final concentration range of 
0.006-100 µg/ml after 1:1 v/v addition of 20 µl/well FcR-blocked MDMs (at 5 x 106 
cells/ml). In line with the fluorescence recovery after photobleaching (FRAP) 
immunolabelling procedure MC5488 and IgG2a488 were incubated for 90 min, during which 
time MC5 and IgG2a were incubated for 60 min, washed then incubated with 50 µl/well 4 
µg/ml GAM-Fab488 for 30 min. MDMs labelled using either method were then washed and 
analysed live on a CyAn ADP flow cytometer, adding 4',6-diamidino-2-phenylindole, 
dihydrochloride (DAPI; Invitrogen) at a final concentration of 5 µg/ml prior to analysis to 
enable live/dead exclusion. All steps were performed at 4 °C. 
2.4.5 Testing MC5 dissociation 
MDMs (day 8/9 of culture) were aliquoted (1x 105 cells/well) into U-bottomed 96-well 
plates, centrifuged at 300 x g for 3 min then resuspended in 25 µl/well 30 µg/ml huIgG in 
BM. Cells were incubated for 30 min before the addition of 25 µl/well 10 µg/ml MC5 or 
IgG2a isotype control in BM and a further incubation for 60 min. After washing three times  
with 250 µl/well BM, cells were resuspended in 100 µl/well 4 µg/ml GAM-Fab488 in BM and 
incubated for 30 min. Cells were washed as before and each well transferred into an 
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individual tube on ice. At this point half of the samples were fixed at 4 °C in 200 µl 3 % 
PFA (w/v in PBS) for 20 min, washed then incubated for 20 min in 200 µl quench solution. 
Note, all steps prior to this were carried out at 16 °C. The total volume was made up to 
300 µl/tube with BM before samples were either incubated on ice or plunged into a 37 °C 
water bath for 0, 15 or 30 min. Immediately after incubation 700 µl ice-cold BM or 4.3% 
PFA (w/v in PBS) was added to samples that had, or had not, been fixed, respectively. 
Note that for one donor MDMs were not fixed at this point but were washed in BM and 
incubated once again with 100 µl 4 µg/ml GAM-Fab488 for 30 min, then washed and fixed. 
After 20 min incubation samples were washed into FACS buffer and kept on ice until 
analysis using a CyAnTM ADP Analyser flow cytometer. The same procedure was carried 
out for CHO-CCR5 cells but without FcR-blocking steps. 
General note: when immunolabelling primary cells all antibody solutions were 
supplemented with 5 µg/ml huIgG. All flow cytometry analysis was performed using FloJo 
(TreeStar, OR, USA). 
2.5 Lymphocyte proliferation assay 
2.5.1 CFDA-SE labelling PBMCs 
PBMCs were thawed, as detailed in section 2.2.4, counted using a haemocytometer and 
the cell density adjusted to 1 x 107 PBMCs/ml. A solution of 1.68 µM Vybrant® 
carboxyfluorescein diacetate N-succinimidyl ester (CFDA-SE) (Life Technologies Ltd.) in 
PBS was made from a 10 mM CFDA-SE stock solution in DMSO and added 1:1 v/v to the 
PBMCs, mixed by pipetting and incubated at 37 °C, 5% CO2 for 15 min. Labelled PBMCs 
were centrifuged at 400 x g, 5 min, the supernatant aspirated and the pellet resuspended 
in 2 ml 10% (v/v) FCS-RPMI, in which cells were incubated for a minimum of 30 min at 37 
°C, 5% CO2. Subsequently, cells were washed three times in 5% (v/v) huAB-RPMI to 
remove all traces of FCS then cultured overnight in a 10 cm dish (TPP). Labelled PBMCs 
were removed by scraping, counted, and the density adjusted to 2 x 106 cells/ml before 
pipetting 100 µl aliquots into a sterile Corning® U-bottomed 96-well plate (Thermo Fisher 
Scientific Inc.).  100 µl 5% (v/v) huAB-RPMI, alone or supplemented with stimulants, was 
added to triplicate wells of PBMCs in order to achieve final concentrations of 2.5 µg/ml 
PHA, 1:20000 Imject® Alum (Pierce Biotechnology) and 1:1000 Revaxis® (Sanofi-Pasteur 
MSD), a kind gift from Prof. C Lacey (University of York, York, UK). During CFDA-SE 
labelling all solutions had been pre-equilibrated to 37 °C. Finally the 96-well plate was 
incubated for 5 days at 37 °C, 5% CO2. 
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2.5.2 Live/dead staining, fixation and immunolabelling of cells for flow 
cytometry 
Post-incubation CFDA-SE labelled PBMCs were washed twice in PBS involving 
centrifugation at 300 x g, 3 min at RT (centrifugation and temperature are constant for all 
remaining steps), then cell pellets were resuspended in 200 µl/well violet live/dead fixable 
dye (Invitrogen) at 1:1000 in PBS and incubated for 30 min. After this, cells were washed 
twice with PBS then fixed in 250 µl/well 3.7% PFA (w/v in PBS) for 20 min, then 
immunolabelled with CD3 (OKT3) or IgG2a isotype control followed by GAM647 secondary 
antibody according to the method detailed for CD163 in section 2.4.2. Cells were analysed 
using a CyAnTM ADP Analyser flow cytometer. 
2.6 Purification and transfection of CCR5-GFP DNA 
2.6.1 Plasmid DNA: sources and purification 
The N-terminal GFP-CCR5 plasmid (Gomez-Mouton et al., 2004) and the C-terminal 
CCR5-GFP sequence (Hüttenrauch et al., 2005) subcloned into pcDNA3.1(+) were kind 
gifts from Prof. M. Marsh. Plasmids were transformed by heat shock for 70 s, 42 °C into 
chemically competent DH5α and selected for by resistance to Ampicillin (100 µg/ml) or 
Kanamycin (50 µg/ml), as appropriate. Single colonies were picked and grown in Luria-
Bertani broth overnight before being harvested for Midi or Maxi prep plasmid purification 
(QIAGEN Ltd., Manchester, UK) according to the manufacturer’s instructions. The DNA 
concentration was assessed by Nanodrop A260 reading and adjusted to 1 µg/µl in Tris-
EDTA buffer (QIAGEN Ltd.) before storage at -20 °C. 
2.6.2 Transient transfection into MDMs and CHO-K1 cells 
MDMs were transfected on day 8 using the Amaxa® Human Macrophage Nucleofector Kit 
(Lonza Group Ltd., Basel, Switzerland) according to the manufacturers protocol. Briefly, 
MDMs were detached using 2.2 ml/plate 0.25% (w/v) Trypsin-EDTA (Life Technologies 
Ltd.) for 25 min at RT, washed in 10% (v/v) FCS-RPMI, counted and adjusted to ~0.5 x 
105 MDMs/tube. MDMs were then resuspended in Nucleofector solution and nucleofected 
on program Y-10 in the presence of 5 µg either CCR5-GFP or GFP-CCR5 plasmid DNA. 
Immediately, MDMs were transferred into 0.5 ml 10% (v/v) FCS-RPMI and split between 
two collagen-coated coverslip glass-bottomed dishes (MatTek Corporation, MA, USA) to 
adhere for 20 min at 37 °C, 5% CO2 before adding 2 ml 10% (v/v) FCS RPMI 
supplemented with 50 ng/ml M-CSF to each dish and culturing for 48 h prior to FRAP. 
Notably, the transfection efficiency was very low as fewer than 20 CCR5-GFP+ cells were 
found on each dish. 
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CHO-K1 cells were transfected using a lipid-based reagent called GeneCellinTM 
(BioCellChallenge, Paris, France), according to the manufacturer’s protocol. In short, 24 h 
prior to transfection CHO-K1 cells were seeded onto collagen-coated coverslip glass-
bottomed dishes at 5 x 104 cells/dish in a volume of 2 ml 10% (v/v) FCS-RPMI. In a 
polypropylene tube, 2 µg GFP-CCR5 or CCR5-GFP was diluted in 200 µl nsRPMI before 
adding 8 µl GeneCellinTM, vortexing and incubating for 15 min at RT. The solution was 
pipetted dropwise onto the CHO-K1 cells then incubated for 48 h at 37 °C, 5% CO2 before 
FRAP was performed.  
2.7 Coverslip coatings 
To generate poly-D-lysine (PDL) coated coverslips a solution of 100 µg/ml PDL (70-150 
kDa; from Poly-D-lysine hydrobromide (Sigma-Aldrich)) was pooled onto either 10 mm 
#1.5 coverslips (Agar Scientific, Stansted, UK) or the centre of 25 mm #1.0 coverslips 
(SLS, East Riding, UK), which had been washed with 100% ethanol and air-dried, and 
was incubated for 30 min, RT. Excess PDL solution was removed and coverslips were 
washed extensively with sterile water and air-dried before use. 
35 mm uncoated, PDL or collagen coated coverglass-bottomed dishes (#1.5) were 
obtained from MatTek Corporation. For polyethylenimine (PEI) coating, uncoated dishes 
were washed in 100% ethanol then air-dried before pooling over 300 µl 1% (w/v) PEI 
solution and incubating for 10 min. Excess PEI was removed and dishes were washed 
with 95% ethanol, air-dried then incubated with 300 µl 0.1% (w/v) glutaraldehyde for 30 
min. Dishes were washed extensively with sterile water and allowed to dry.  
2.8 Immunolabelling for FRAP 
2.8.1 Indirect immunolabelling procedure 
MDMs were detached using cell scrapers on day 8, counted and seeded onto collagen-
coated coverglass-bottomed dishes in 250 µl 10% (v/v) FCS-RPMI at 1.5 x 105 
MDMs/dish. Cells were allowed to adhere to the glass for 20 min at 37 °C, 5% CO2 before 
2 ml 10% (v/v) FCS-RPMI, supplemented with 50 ng/ml M-CSF, was added to each dish 
and incubation at 37 °C, 5% CO2 for 24 h followed. For experiments with CHO-CCR5 
cells, cells were seeded at the same density 24 h prior to immunolablelling. On day 9, 
media was decanted and blotted away with filter paper then MDMs were FcR-blocked for 
30 min with 100 µl 30 µg/ml Fc-fragment huIgG (Bethyl Laboratories Inc., TX, USA) made 
up in BM. After this, 100 µl MC5 at 10 µg/ml in BM was added to the MDMs, which were 
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then incubated for 60 min further. Antibody solutions were discarded and MDMs washed 
three times in 1 ml/dish BM, incubating for 2 min/wash. Excess BM was blotted away and 
MDMs were incubated for 30 min in 200 µl 4 µg/ml GAM-Fab488, made up in BM 
supplemented with 5 µg/ml Fc-fragment huIgG, prior to washing three times as described 
previously. All immunolabelling steps were carried out at 16 °C and preceded addition of 2 
ml pre-warmed phenol-red free RPMI and transfer to the 37 °C stage incubator on the 
confocal microscope. Samples were incubated on the stage for 20 min prior to 
commencing FRAP. The final imaging conditions are described in section 5.2.6 and 
accompanying figures. Under these conditions cells were imaged at 3 s intervals for 20 
cycles, bleached, imaged for a further 20 cycles, then the interval switched to 10 s for the 
remaining 32 cycles. 
2.8.2 Direct immunolabelling procedure 
MDMs were seeded onto PEI, PDL or collagen-coated dishes, where indicated, and FcR 
blocked as described in section 2.8.1. Subsequently, FcR-block was removed and MDMs 
were incubated with 100 µl 20 µg/ml MC5488 (D:P ratio, 5.4) in BM containing 5 µg/ml 
huIgG for 90 min, 16 °C. Cells were washed three times with BM before addition of 2 ml 
pre-warmed  10% (v/v) FCS-RPMI, transfer to the 37 °C stage incubator and 
commencement of FRAP after a short period of incubation (~5 min) to equalize 
temperature inhomogeneity between the sample and the objective (Plan-Apochromat 
63x/1.20 water immersion). For directly labelled MDMs, imaging conditions for PEI 
[Bleach: 100% laser power, 15 iterations, 8.70 x 3.43 µm region of interest (ROI). 
Acquisition: 1.7% laser power, 1.58 µs pixel dwell, 44.90 x 44.90 µm field of view, 51 µm 
pinhole,12 bit, no line average, 3 s interval, 121 cycles, bleach after 15 cycles] were 
similar to collagen/PDL/CyGel but with the following modifications [Bleach: 26% laser 
power, 20 iterations, 13.05 x 5.14 µm ROI. Acquisition: 2.55 µs pixel dwell, 67.34 x 67.34 
µm field of view, bleach after 20 cycles]. 
All FRAP data was acquired using a Zeiss LSM 780 Axio Observer.Z1 invert confocal 
microscope (Carl Zeiss Ltd., Cambridge, UK) at 37 °C with a supply of 5% CO2 mixed with 
atmospheric air to prevent acidification of the media. Zen 2010 software (Carl Zeiss Ltd.) 
was used for acquisition and export of the intensity data for each timepoint in the bleach, 
decay and background ROIs drawn. 
2.8.3 Labelling with DiO 
MDMs were seeded in dishes as described in section 2.8.1 and on day 9, media was 
removed and MDMs were washed with PBS. PBS was removed before 100 µl of a 5 µM 
VybrantTM DiO Cell Labelling Solution (Life Technologies Ltd.) made up in PBS, was 
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pooled over the cells and incubated for 3 min at 37 °C. Excess dye was aspirated and 
MDMs were washed three times in 2 ml 10% (v/v) FCS-RPMI, 10 min incubation per 
wash, before phenol-red free RPMI was added and FRAP was performed. All solutions 
and incubation steps for this protocol were at 37 °C. 
2.8.4 Mounting in CyGel 
Imaging in CyGelTM (BioStatus, Shepshed, UK) was performed on uncoated coverglass-
bottomed dishes. CyGelTM was prepared according to the manufacturer’s instructions and 
250 µl was pooled over the cells on the coverglass of the dish whilst on ice. Dishes were 
equilibrated to 37 °C for 20 min prior to FRAP. 
2.9 Analytical techniques for FRAP 
2.9.1 Single normalisation 
FRAP bleach and decay ROIs were normalised using the FRAPcalc plugin developed by 
Dr. Kota Miura (EMBL, Heidelburg, Germany) for IGOR Pro (WaveMetrics Inc., OR, USA). 
Relevant equations from the FRAPcalc manual are presented below. For further 
information and definitions consult the online manual: http://cmci.embl.de/documents/ 
frapmanu. 
Each FRAP curve was loaded individually and a single exponential model was selected 
from the dropdown list in the ‘FitPanel’ window. The ‘Back Multi’ tickbox was checked 
before running the program. Using the data browser, single normalised decay 
(‘bkgAvg_norm’; equation 1) and bleach (‘FRAP_norm’; equation 2) values that had been 
calculated were exported into a table. 
Equation 1: Idecay-norm(t) = (Idecay(t) - Ibkgd(t)*(Ibleach-pre/ Idecay-pre))/ (Ibleach-pre - Ibleach t=0) 
Equation 2: Ibleach-norm(t) = (Ibleach(t) – Ibleach t=0)/ (Ibleach-pre - Ibleach t=0) 
Idecay-norm(t) is the normalised decay value, Idecay(t) is the intensity value of the decay ROI, 
Ibkgd(t) is the intensity value of the background ROI,  Ibleach-norm(t) is the normalised bleach 
value, all at a particular timepoint (t). Ibleach-pre
 is the mean value of all bleach ROI 
intensities, individually subtracted for background ROI intensities, which occur before the 
bleachpoint. Idecay-pre is similar but is calculated using decay ROI intensities. Ibleach t=0
 is the 
intensity of the bleach ROI at the bleachpoint (i.e. when t=0). 
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2.9.2 Double normalisation 
The FRAPcalc plugin was run selecting the single exponential model from the dropdown 
list and the ‘Phair’ tickbox. The double normalised bleach curve (equation 3) was exported 
from the list in the data browser. Values were then spread over the full range (equation 4) 
in Microsoft Excel. 
Equation 3: Ifrap-norm(t) = (Idecay-pre/ Idecay(t) – Ibkgd(t)) * (Ibleach(t) – Ibkgd(t)/ Ibleach-pre) 
Equation 4: Ifrap-spread (t) = (Ifrap-norm(t) - Ifrap-norm t=0)/ (Ifrap-norm-pre - Ifrap-norm t=0) 
Ifrap-norm(t) is the double normalised decay value, Ifrap-spread (t) is the double normalised 
decay value spread over the full range (0 – 1), all at a particular timepoint (t). Ifrap-norm t=0 is 
the double normalised intensity of the bleach ROI at t=0, Ifrap-norm-pre is the mean value of all 
double normalised bleach ROI values that occur before the bleachpoint. 
2.9.3 Fitting normalised FRAP curves 
Individual normalised bleach or decay curves for each donor were compiled and the mean 
± standard deviation (SD) from the bleachpoint onwards was plotted. The single 
normalised decay curve for each donor was fitted with a single exponential decay 
(equation 5), whilst single and double normalised bleach curves were fitted with an 
exponential rise to maximum (equation 6). The regression curves (solid lines) for each 
donor are plotted, along with 95% prediction bands (dotted lines), and a plot of the mean 
residuals of the fit. The t1/2 and mobile fraction values calculated alongside the regression 
of double normalised data were tabulated. For the mean single normalised curve and the 
mean 1-decay curve (generated by subtracting a value of 1 from all values comprising the 
decay curve) the area under each curve was calculated and tabulated. All these 
procedures were performed using GraphPad Prism 5 (GraphPad Softward Inc., CA, USA). 
Equation 5: Idecay-fit(t) = Adecay e
τ
decay
t + y0 decay 
Equation 6: Ifrap(t) = y0 + Ae
-τt 
Where y0 is the intensity value when time is zero, A is the difference between the plateau 
(intensity value at infinity time) and the y0 value, τ is the time constant. 
Additionally, FRAP curves were fitted individually using the FRAPcalc plugin, selecting the 
single exponential model from the dropdown list and the ‘Phair’ tickbox. This meant that 
each FRAP curve was double normalised (equation 3) then fitted with a single exponential 
rise to maximum (equation 6). Q-values for each fit were recorded. Mobile fraction and t1/2 
values from fits with residuals that passed D’Agostinos test for normality were plotted in 
GraphPad Prism 5. 
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2.9.4 Linear regression analysis of early post-bleach time-points  
FRAP was performed on live or fixed MDMs that had been indirectly labelled with MC5 
followed by Fab488, as described in section 2.8.1. Intensity data from bleach and decay 
ROIs for the first 10 cycles (30 s) acquired immediately after the bleachpoint (t0) were 
imported into MATLAB (Mathworks, MA, USA). Linear regression was performed by 
calling the polyfit function and the gradient of the fit, residuals, and the R2 value were 
exported. The runs test was performed on the residuals and the gradients were plotted in 
GraphPad Prism 5. 
2.10 Drug treatments 
2.10.1 Disrupting cholesterol 
On day 7, MDMs were seeded onto coverslip glass-bottomed dishes (1.5 x 105 
MDMs/dish) or plated at 1.6 x 106 cells/well in 6 well plates then incubated for 24 h to 
allow the cells to adhere. Subsequently, MDMs were washed in nsRPMI then treated (at 
37 °C, 5% CO2) with the cholesterol-disrupting drugs methyl-β-cyclodextrin (MβCD), filipin 
III, and U18666A (all from Sigma-Aldrich) or with appropriate controls, as indicated in 
Table 2.3. MDMs in dishes were immunolabelled as described in section 2.8.1 then 
subjected to FRAP. MDMs treated in sterile Corning® 6-well plates (Themo Fisher 
Scientific Inc.) were detached by scraping, aliquoted across a U-bottomed 96-well plate 
and immunolabelled for CCR5 (mAbs: MC5, 2D7 and 45531) or respective isotype 
controls according to the method detailed in section 2.4.1. 
Drug Stock Conc. 
Final 
Conc. 
Incubation Control 
Dilution Time (h) Media 
MβCD 
38 mM in 
ddH20 
10 mM 1 
nsRPMI 
(+ 1:38 10x PBS) 
5:19 PBS 
Filipin III 
1 mg/ml in  
Ethanol 
5 µg/ml 0.25 nsRPMI 
1:200 
Ethanol 
U18666A 
10 mg/ml in 
ddH20 
1 µg/ml 16 
10% (v/v)       
FCS-RPMI 
1:1000 
ddH20 
Table 2.3: Agents used to disrupt membrane cholesterol. 
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2.10.2 Downmodulation or antagonism of cell surface CCR5 on MDMs 
MDMs (day 7/8) were seeded at 1 x 105/well into 24-well plates containing 10 mm 
coverslips and allowed to adhere for 24 h prior to treatment. 
CCR5 downmodulation: MDMs adhered to coverslips were treated with 0.5 ml/well 100nM 
PSC-RANTES, a kind gift from Prof. O. Hartley (University of Geneva, Geneva, 
Switzerland), in 10% (v/v) FCS-RPMI for 16 h at 37 °C, 5% CO2. After incubation, MDMs 
were washed three times with 10% (v/v) FCS-RPMI, coverslips were transferred to new 
wells then spiked or not with sAg for conjugate formation and immunolabelling as detailed 
in section 2.11.  
CCR5 antagonism: MDMs adhered to coverslips were treated with sAg cocktail or left 
untreated, as described in section 2.11.1. For the final hour of sAg pulsing 0.5 ml/well 
800nM TAK-779 (Ref #: ARP968: Centre of AIDS Reagents, NIBSC, Potters Bar, UK) in 
10% (v/v) FCS-RPMI was added to give a final concentration of 400 nM TAK-779 in 1ml. 
After treatment, MDMs were washed three times in 10% (v/v) FCS-RPMI, transferred to 
new wells then resuspended in 250 µl 10% (v/v) FCS-RPMI before proceeding with to co-
incubate MDMs with CD4+ T cells.  
2.11 Imaging fixed MDM-CD4+ T cell conjugates 
2.11.1 Conjugate formation 
MDMs (day 7/8) were detached using cell scrapers, counted, then aliquoted at 2 x 105 
MDMs/well into 24-well plates containing sterile 10 mm coverslips and allowed to adhere 
for a minimum of 24 h at 37 °C, 5% CO2. On days 9-11 of culture media MDMs were 
pulsed with 0.5 ml/well sAg in 10% (v/v) FCS-RPMI for 2 h; either 1 µg/ml staphylococcal 
enterotoxin E (SEE) (Toxin Technology Inc., FL, USA) alone or a 1 µg/ml SEA, 
staphylococcal enterotoxin B (SEB) (Sigma-Aldrich) and SEE sAg cocktail, as indicated. 
Unpulsed controls were treated with 0.5 ml/well 10% (v/v) FCS-RPMI alone for the same 
duration. After treatment, media was aspirated and MDMs were washed in 1 ml/well 10% 
(v/v) FCS-RPMI and resuspended in 250 µl 10% (v/v) FCS-RPMI. Autologous CD4+ T 
cells were adjusted to 1.6 x 106 cells/ml and added at 250 µL/well to the MDMs in the 24-
well plate giving a T cell: MDM ratio of 2:1. The plate was centrifuged at 100 x g for 1 min 
then incubated for 30 min at 37 °C, 5% CO2. Immediately after incubation, media was 
aspirated and 0.5 ml/well 3% PFA (w/v in PBS) was added. Cells were fixed for 20 min, 
washed, then incubated in quench solution for 20 min before proceeding to 
immunolabelling. Note that prior to fixation all solutions were used at 37 °C. 
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2.11.2 Immunolabelling fixed conjugates: intact 
Fixed conjugates were FcR blocked with 250 µl/well 30 µg/ml huIgG in 1% (v/v) FCS-PBS 
for 30 min. The blocking solution was aspirated and 250 µl/well 5 µg/ml UCHT1 plus 5 
µg/ml MC5 in 1% (v/v) FCS-PBS was added. An isotype control was always run in 
parallel, which was a solution of 5 µg/ml IgG1 plus 5 µg/ml IgG2a isotype control 
antibodies in 1% (v/v) FCS-PBS. Cells were incubated in primary antibody solutions for 60 
min then washed three times in 1 ml/well 1% (v/v) FCS-PBS, incubating for 5 min/wash, 
before adding 250 µl/well 4 µg/ml GAM-IgG1488 with 4 µg/ml GAM-IgG2a647 in 1% (v/v) 
FCS-PBS. Cells were incubated for 60 min in the secondary antibody solution, washed 
three times and stained for 5 min with 0.5 ml/well 1 µg/ml DAPI in PBS. Coverslips were 
mounted in Mowiol on Superfrost® Plus glass slides (Thermo Fisher Scientific Inc.) and 
set by incubating overnight. Slides were stored at -20 °C or imaged the day after 
immunolabelling. Conjugates were imaged with a Zeiss LSM710 Axio Observer.Z1 invert 
confocal microscope running Zen 2009 software (Carl Zeiss Ltd.) set up with gains and 
laser powers that gave no signal in the isotype control samples. The specificity of isotype-
specific secondary antibodies was routinely checked by using an IgG2a primary antibody 
(e.g. MC5 or OKT3) with the GAM-IgG1488 secondary and an IgG1 primary antibody (e.g. 
CTC5 or UCHT1) with the GAM-IgG2a647 secondary. Note that all primary and secondary 
antibody solutions were supplemented with 5 µg/ml huIgG. Immunolabelling steps were 
performed at RT and incubations involved slow side-to-side shaking at 50 rpm.  
2.11.3 Immunolabelling fixed conjugates: permeabilised 
MDM-CD4+ T cell conjugates were labelled and mounted as described in section 2.11.2 
but all blocking, wash and antibody solutions also contained 0.05% (w/v) saponin, made 
up from a 5% (w/v) stock of Saponin from Quillaja bark (Sigma-Aldrich), until the final 
staining step with DAPI. 
2.11.4 Image processing 
Scale bars were added and image intensities were adjusted, in order to optimise visibility 
when printed, using Adobe Photoshop CS3. No fluorescence was visible in associated 
isotype control images after identical adjustments were made. Volocity v 6.0 (PerkinElmer, 
MA, USA) was used for all 3D reconstructions of z-stacks. All maximum intensity 
projections and orthogonal sections were created using ImageJ (NIH, MD, USA). 
   
66 
 
2.12 Analysing MDM-CD4+ T cell conjugate formation by 
flow cytometry 
2.12.1 PKH26 labelling MDMs 
MDMs (day 8 of culture) were detached using a cell scraper and washed twice in 15 ml 
nsRPMI, centrifuging at 400 x g for 5 min. Cells were counted and 5 x 105 MDMs were 
aliquoted into a well of a 6 well plate for unlabeled controls. After centrifugation all nsRPMI 
was aspirated according to the manufacturer’s instructions and the MDM pellet was gently 
resuspended in Diluent C (Sigma-Aldrich) to give a density of 2.5 x 106 MDMs/ml, before 
dividing into polypropylene tubes in 1 ml aliquots. A 4 µM PKH26 (Sigma-Aldrich) solution 
was prepared in Diluent C, added 1:1 v/v to the aliquoted MDMs and immediately mixed. 
MDMs were incubated in the PKH26 solution for 5 min at RT, and mixed by inversion half 
way through the incubation. To each tube 2 ml of FCS was added to stop the labelling 
reaction, cells were incubated for 1 min then centrifuged for 10 min at 400 x g. The 
supernatant was aspirated, MDMs resuspended in 10% (v/v) FCS-RPMI, then transferred 
to a new tube and washed twice more in 10% (v/v) FCS-RPMI to ensure removal of any 
unbound dye. PKH26-labelled MDMs were counted then aliquoted across a 6-well plate at 
0.5 – 1 x 106 cells/well in 10% (v/v)FCS-RPMI supplemented with 50 ng/ml M-CSF. 
2.12.2 Labelling CD4+ T cells with DiD 
A 50 µM dilution of VybrantTM DiD Cell Labelling Solution (Life technologies Ltd.) was 
prepared in ethanol in a glass vial. CD4+ T cells were resuspended at 1 x 106 cells/ml in 
nsRPMI at 37 °C. Note that a minimum of 2 x 106 cells were left in culture for unlabeled 
control samples. CD4+ T cells were labelled with 250 nM DiD, incubating in a 37°C water 
bath for 5 min. Labelled CD4+ T cells were centrifuged at 400 x g for 5 min, the 
supernatant was aspirated and the cells were washed three times in 10 ml 10% (v/v) FCS-
RPMI. Cell density was adjusted to 4 x 105 cells/ml in 10% (v/v) FCS-RPMI and T cells 
were incubated for 10 min (minimum) at 37 °C, 5% CO2 prior to loading with a calcium 
sensitive dye. 
2.12.3 Labelling CD4+ T cells with fluo-2leakres 
From a stock solution of fluo-2leakres/AM (TEFlabs Inc., TX, USA) at 3.8 mM in DMSO, a 
3.0 µM solution was made in 10% (v/v) FCS-RPMI, which was used to label all T cells 
from a particular donor. For each ml of DiD-loaded CD4+ T cells, 110 µl of 3.0 µM fluo-
2leakres/AM was added and cells were subsequently incubated at 37 °C, 5% CO2 for 30 
min. After incubation cells were washed twice in 10% (v/v) FCS-RPMI and resuspended at 
the same density as the sAg-pulsed MDMs to give a 1:1 CD4+ T cell: MDM ratio. Note 
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also that CD4+ T cells at 4 x 105 cells/ml that had not been loaded with DiD were labelled 
with fluo2leakres/AM as controls. In experiments using fluo-8/AM (AAT Bioquest Inc., CA, 
USA) the same procedure was followed, except that a stock solution of 5 mM was 
prepared in DMSO and 110 µl of a 1.7 µM stock was added per ml of T cells. 
2.12.4 Superantigen pulsing and cell conjugation 
PKH26-labelled MDMs (day 10) were detached from one well of the 6-well plate using a 
cell scraper. MDMs were counted to ascertain the density at which DiD+ fluo-2+ CD4+ T 
cells need to be resuspended, and divided evenly across five tubes compatible for use 
with a CyAnTM ADP Analyser flow cytometer. In samples where MDMs were pulsed with 
SEE prior to co-incubation, SEE was added to these tubes at a final concentration of 1 
µg/ml at 0.5 ml/tube. MDMs were incubated with SEE for 2 h at 37 °C with 5% CO2, 
mixing every 30 min to limit attachment. All samples were washed in 10% (v/v) FCS-RPMI 
then resuspended in 225 µl/tube 10% (v/v)FCS-RPMI. Quickly, 225 µl of autologous 
DiD+fluo-2+ CD4+ T cells were added to each tube to give a 1:1 CD4+ T cell: MDM ratio 
and cells were centrifuged at 100 x g for 1 min to initiate attachment. Immediately 
afterwards (time zero, t0), one of the tubes was briefly vortexed then analysed using the 
flow cytometer whilst the remaining four tubes were incubated in a water bath at 37 °C for 
5, 15, 30 or 45 min then analysed. Before analysis, DAPI was added at a final 
concentration of 5 µg/ml so that dead cells could be excluded. Furthermore, all samples 
were analysed twice, the second time adding 30 µl of 10 µg/ml ionomycin (Sigma-Aldrich) 
to a 270 µl sample. Care was taken to maintain the temperature of solutions at 37 °C 
throughout. In certain samples, MDMs were not pulsed with SEE or, alternatively, 50 µl 10 
µg/ml SEE solution was added at t0 instead of pre-treating MDMs. 20000 DAPI
- PKH26+ 
events were acquired for each sample. Seven compensation controls of MDMs and CD4+ 
T cells, labelled as detailed in Table 2.4, were run for each donor and compensation was 
performed post-acquisition using FloJo (TreeStar). The parameter of ‘conjugate formation 
(%)’ was the frequency of PKH26+DiD+ events within the DAPI- (live) parent population. 
The ‘calcium signal relative to ionomycin (%)’ was calculated by expressing the 
fluorescence value of the DAPI-PKH26+PW100 (pulse width ≥ 100) DiD+ gate from the 
primary analysis of the sample as a percentage of the fluorescence in the same gate upon 
secondary analysis of the sample (i.e. after the addition of ionomycin). 
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 Compensation Control 
Dye A B C D E F G 
PKH26        
DiD        
Fluo-2leakres        
Table 2.4: Compensation controls for live calcium flow cytometry assay 
2.13 Live calcium imaging of MDM-CD4+ T cell interaction 
2.13.1 CFDA-SE labelling MDMs 
MDMs (day 7/8) were detached using a cell scraper, washed twice in PBS at 37 °C, then 
adjusted to a density of 1 x 107 cells/ml and labelled with Vybrant® CFDA-SE (Life 
Technologies Ltd.) as described in section 2.5.1. After the wash steps MDMs were 
resuspended at 2 x 106 cells/ml and a 100 µl drop was pooled over the centre of a 25 mm 
glass coverslip that had been coated with PDL in the centre, as described in section 2.7. 
MDMs were allowed to adhere for 1 h at 37 °C, 5% CO2, before adding 2 ml 10% (v/v) 
FCS-RPMI supplemented with 50 ng/ml M-CSF and returning to the incubator. Note that 
Daudi cells did not need to be CFDA-SE labelled due to changes in the microscope 
hardware enabling brightfield images to be acquired instead. Daudi cells were seeded at 2 
x 105 cells/coverslip onto 25 mm glass coverslips with a PDL-coated centre for 1 h prior to 
sAg-pulsing. MDMs (day 9/10) or Daudi were pulsed with 2 ml/well 1 µg/ml sAg-cocktail or 
SEE in 10% (v/v) FCS-RPMI for 2 h at 37 °C, 5% CO2. Unpulsed controls were treated 
with 2 ml/well 10% (v/v) FCS-RPMI alone. All coverslips were washed once before loading 
into the perfusion chamber.  
2.13.2 Fura-2/AM loading of CD4+ T cells 
CD4+ T cells were adjusted to a density of 2 x 107 cells/ml in 10% (v/v) FCS-RPMI.  A 10 
µM solution of fura-2/AM (Biotium Inc., CA, USA) in 10% (v/v) FCS-RPMI, prepared from 
a 5 mM stock in DMSO, was mixed 1:1 v/v with the T cells and incubated in a water bath 
at 37 °C for 30 min. Cells were washed twice with 10% (v/v) FCS-RPMI, centrifuging at 
300 x g for 5 min, then resuspended at 1 x 106 cells/ml in phenol-red free RPMI and 
incubated at RT for 30 min until use. 
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2.13.3 Performing live calcium imaging 
A Nikon Eclipse TE200 wide-field fluorescence microscope (Nikon Instruments Europe 
BV, Amsterdam, Netherlands) fitted with a mercury lamp, an OptiScanTM II filterwheel 
controller (Prior Scientific, Cambridge, UK) and a Rolera-XR Fast 1394 camera (Q-
Imaging, BC, Canada) was preheated to 37 °C. High vacuum grease (Dow Corning, MI, 
USA) was applied as a thin film on both sides of an RC-21BRFS perfusion chamber 
(Warner Instruments, CT, USA). All input and output tubing was filled with phenol-red free 
RPMI and the ends of tube were stoppered using bulldog clips. Excess media was blotted 
away from the coverslip seeded with sAg-pulsed or unpulsed APCs. The area outside of 
the PDL-coated centre was dried with lint-free tissue. The coverslip was applied onto the 
perfusion chamber insert and pressed down to ensure a tight seal with the grease. Phenol 
red free media (240 µl) was pooled into the central reservation on top of the coverslip 
before another 25 mm coverslip was placed on top, again pressure was applied to ensure 
a tight seal with the grease. The perfusion chamber was loaded into the P-2 platform 
(Warner Instruments), which was screwed in place before securing it onto the microscope 
stage. The loaded perfusion chamber was left for 10 min to equilibrate to temperature. 
During this time 1 ml of fura-2 labelled T cells were loaded into a 1 ml syringe, which was 
attached to the input tubing leading to the perfusion chamber. The syringe was fitted into a 
custom-built syringe pump, which was built based on a design originally devised by Dr. G. 
Chistol (University of California, Berkeley), and equilibrated for 10 min. Finally, the output 
tubing from the syringe pump was connected to a peristaltic pump. 
After focusing on a field of view of macrophages in the centre of the perfusion chamber, 
the fura-2 loaded T cells were injected into the chamber at ~ 33 µl/s. The peristaltic pump 
was run simultaneously so that excess media running through the perfusion chamber was 
removed. Immediately, imaging was initiated: every 10 s, for a total of 1200 s, the sample 
was excited with a mercury lamp passed sequentially through 340 nm, 380 nm and 
485/20 nm filters. Images were acquired through a green emission filter using SimplePCI 
(Hamamatsu Corporation, PA, USA) imaging software. After setup of the technique, 
exposure times were kept constant when imaging cells from different donors. 
2.13.4 Processing calcium image-sequences 
ImageJ was used to process the calcium image-sequences. T cells were manually tracked 
using the MTrackJ plugin, selecting a circular point size of 20 pixels (px). The same tracks 
were applied over 340 nm and 380 nm image-sequences and measurements of intensity, 
time, and position for each track were exported into Excel. The 340 nm intensity values 
were divided by the corresponding 380 nm intensity values to give the 340:380 ratio for 
each time point making up the total track of a T cell. All tracks spanning < 300 s were 
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excluded from further analysis. A function was written in MATLAB to automatically 
generate panels of ‘340:380 ratio’ vs. ‘time’ plots for every tracked T cell in an image-
sequence. These plots were used for the visual classification of calcium profiles according 
to the criteria detailed in section 3.2.8.  
The maximum 340:380 value for each tracked T cell was also calculated in Microsoft 
Excel. Since the original tracks were saved, each tracked T cell could be linked to its 
corresponding max. 340:380 value using the track ID. This enabled the track line on the 
image-sequence to be colour-coded according to the max. 340:380 value. Tracks with a 
max. 340:380 value < 0.5 were coloured green. Tracks with a max. 340:380 value ≥ 1.0 
were coloured red. The remaining tracks were coloured white. For visual presentation the 
ratio image-sequence was generated by applying the 340 nm and 380 nm channel image-
sequences to the RatioPlus plugin available for ImageJ. The brightness and contrast of 
the resulting image was set to span between 0.5 and 2.0 before applying a ’16 colours’ 
look-up table (LUT) to the image-sequence. Colour-coded tracks were overlaid onto this 
image. 
2.13.5 Piecewise linear regression and principal component analysis 
The track data table was formatted so each row represented a single track and each 
column contained the 340:380 ratios for each image frame of that track. A separate 
datasheet was formatted identically but containing the time information of the tracks. 
These datasheets were the input files used for a c-script ‘plr2.c’ (Appendix 1) written by 
Dr J. Wilson (University of York, York, UK). The script performs piecewise linear 
regression and exports a list of 18 parameters to describe the fit for each track. This 
process was repeated for all image-sequences acquired (+/sAg) for each donor to 
generate a large datasheet where rows represented individual tracks and columns the 
piecewise linear regression parameters. Only thirteen of the parameters were taken 
forward. The datasheet was imported into MATLAB and all parameters were standardised 
using the zscore function before performing principal component analysis using the 
princomp function. The eigenvalues of each principal component were plotted in a bar 
chart known as the scree plot. The proportion of variance for each component was 
calculated: eigenvalue of each principal component/ sum of eigenvalues for all principal 
components. Kaiser’s criterion was used do decide the number of meaningful principal 
components. Scores plots of all of the principal components fulfilling this criterion were 
generated in order to identify separate clusters between samples in the presence or 
absence of sAg. 
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2.14 Correlative calcium imaging 
CFDA-SE labelled MDMs (section 2.13.1) were seeded onto collagen-coated coverslip 
glass bottomed dishes as described earlier. On day 10, MDMs were pulsed with 2 ml 1 
µg/ml SEA/SEB/SEE in 10% (v/v) FCS-RPMI for 2 h. The sAg cocktail was removed and 
dishes were marked with tape, so that the same field of view could be easily relocated. To 
each dish 0.5 ml phenol-red free media at 37 °C was added and cells were incubated for 
10 min on the stage of the Nikon Eclipse TE200 wide-field fluorescence microscope, 
which had been equilibrated to 37 °C. Imaging was immediately initiated after pipetting in 
0.5 ml of fura-2 labelled T cells, and performed as described in section 2.13.3 but for 1800 
s. Subsequently, imaging media was aspirated and cells were fixed for 20 min in 2 ml of 
3% PFA (w/v in PBS). The fixative was removed and cells were washed, incubated in 
quench solution for 20 min, then incubated overnight in FACS buffer at 4 °C. Cells were 
permeabilised and blocked in 1 ml/dish of 30 µg/ml huIgG for 30 min, then incubated for 
60 min with 250 µl 5 µg/ml OKT3. Cells were washed three times, incubated for 45 min 
with 250 µl of 4 µg/ml GAM594, then washed three more times. Samples were mounted 
using a drop of Mowiol and laying a 10 mm coverslip on top. All antibody solutions and 
washes were performed using 1% (v/v) FCS-PBS with 0.05% (w/v) saponin. The original 
field-of-view was located using the mark and z-stacks of all CD3+ T cells within the field 
were acquired on the LSM710 confocal microscope. The position of each z-stack was 
drawn on the final field-of-view image (t = 1800 s) that had been acquired before cells 
were fixed, creating a map correlating the calcium signal of a given T cell with its 
distribution of CD3. 
2.15 Statistics 
Paired or unpaired two tailed Students t-tests were performed after testing data for 
normality using D’Agostinos test. Data that did not pass the test for normality at first were 
log-transformed and, if this resulted in normal distribution of the data, were then compared 
using a t-test. Data that were not normally distributed were compared using Wilcoxon 
matched pairs (paired data) or Mann-Whitney U test (unpaired data). Unpaired t-tests 
were only performed after checking for equal variance using F test; if unequal variance 
was found but data was normally distributed an Unpaired t-test with Welch’s correction 
was used. Where three or more samples were compared a one-way analysis of variance 
(ANOVA) was used, followed by Tukey’s post-test to identify differences between 
samples. Fishers exact test was performed using the GraphPad online calculator 
(http://graphpad.com/quickcalcs/ contingency1/). Unless stated otherwise, all statistical 
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comparison was performed using GraphPad Prism 5. A P<0.05 was considered to be 
significant and values given in text are mean ± SD. 
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Chapter 3: Investigating the 
formation of antigen-dependent 
MDM-CD4+ T cell conjugates 
3.1 Introduction 
TCR recognition of cognate pMHC leads to a concentration of signalling components at 
the cell-cell interface that enables the T cell to increase the signalling kinetics of the 
antigen-dependent cell-cell contact formed (Krummel and Cahalan, 2010). The signalling 
components are recruited to this region, spatially organized and dynamically regulated as 
part of the IS or kinapse (see section 1.2).  
The micro-scale organization of components of the IS can vary according to the type of 
antigen presenting cell (APC) or effector involved (Friedl et al., 2005). One example is that 
the classical concentric circle structure observed at the B cell- T cell IS can differ in DC- T 
cell conjugates, which instead show a multicentric pattern of TCR accumulation (Dustin et 
al., 2006). Furthermore, APC cytoskeletal complexity, antigen frequency and quality, and 
the structure of the environment (e.g. 2D vs. 3D) all impact on whether stable or more 
dynamic interactions are undertaken (Friedl et al., 2005). In particular, antigen-dependent 
interactions involving macrophages have often been shown to be highly dynamic. 
3.1.1 Macrophage-CD4+ T cell interactions: occurrence and dynamics 
Despite the fact that macrophages have a spectrum of activation and polarisation states, 
MHC class II expression is retained on the majority of these states enabling antigen to be 
scanned by infiltrating CD4+ T cells (Biswas and Mantovani, 2010). Antigen-dependent 
interactions of macrophages with CD4+ T cells forms an important aspect of cell-mediated 
immunity that can result in macrophage activation (Murphy et al., 2011). Macrophage 
activation is important for the control of phagosome-dwelling pathogens, such as 
Mycobacterium tuberculosis (Murray, 1999) and L. major (Meier et al., 2003), and plays a 
role in non-infectious diseases, such as atherosclerosis (Libby et al., 2013). Recent in vivo 
evidence, discussed in section 1.3.4, has demonstrated a role for antigen-dependent 
macrophage-CD4+ T cell interaction in the aforementioned diseases within peripheral 
tissues (Egen et al., 2011; Filipe-Santos et al., 2009; Koltsova et al., 2012). Together 
these studies have shown that CD4+ T cell arrest on macrophages can occur, albeit at 
low frequency, which suggests that IS formation can take place between these cell types 
in vivo.  
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Several in vitro studies have also examined the role of antigen-dependent signalling 
between macrophages and CD4+ T cells using murine cells. Using fixed cell imaging of 
ovalbumin peptide (OVA)-pulsed murine macrophages and CD4+ T cells, Meier et al. 
(2003) identified IS formation by reorganisation of the MTOC to the cell-cell interface. 
Reorganisation of the MTOC was not found to be dependent upon CD28 costimulatory 
signalling, which is consistent with the fact that, so far, no costimulatory role has been 
confirmed for CD28 in effector T cell function (Chen and Flies, 2013; Meier et al., 2003). A 
different study imaged live murine T cells with GFP, under the control of a promoter region 
responsive to nuclear factor of activated T cells (NFAT), stably incorporated into the 
chromosomal DNA (Underhill et al., 1999). In response to antigen recognition via TCR, 
which triggers a signalling cascade involving translocation of NFAT into the nucleus, GFP 
becomes expressed. Using this method, Underhill et al. (1999) showed that interactions 
between macrophages and CD4+ T cells were highly dynamic, which was not apparent in 
the study by Meier et al., (2003). In response to OVA-pulsed macrophages, CD4+ T cells 
were observed to have an initial stable interaction followed by crawling across the surface 
of the macrophages (Underhill et al., 1999). T cells hopped from one macrophage to 
another sequentially in order to become activated (GFP+) (Underhill et al., 1999). There is 
potential that the human macrophage-CD4+ T cell IS is equally dynamic and that antigen-
dependent signalling is predominantly associated with a kinapse-type organization. Thus 
by simply looking for the concentric circles of TCR and ICAM that are only found in certain 
types of synapse, many of the antigen-dependent signalling events may be ignored. The 
chosen approach must be able to detect a shared signal in order to acknowledge all types 
of T cell response to antigen.  
3.1.2 A readout for productive macrophage-CD4+ T cell signalling 
3.1.2.1 Calcium reports on antigen-dependent signalling 
Calcium is a ubiquitous second messenger. Increases in cytoplasmic calcium are 
triggered by a myriad of upstream receptors (e.g. GPCRs and FcR) and calcium, in turn, 
has the capability to interact with thousands of proteins downstream (Clapham, 2007). In 
T cells the degree of activation is closely linked to the level of cytosolic calcium (Wülfing 
and Davis, 1998) through a series of carefully characterised events (Hogan et al., 2010). 
For decades TCR recognition of cognate peptide antigen presented in the context of MHC 
class II has been known to induce a rapid rise in T cell intracellular calcium levels (Dustin, 
2009a). Furthermore, the subtleties of T cell calcium signalling have been studied in 
relation to formation of the IS. Elevation in intracellular calcium occurs prior to cSMAC 
formation (Grakoui et al., 1999) and correlates with the lifetime of TCR microcluster 
formation and residency at the IS periphery prior to reaching the cSMAC (Varma et al., 
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2006). Indeed, the events are so closely linked that intracellular calcium signalling has 
been utilised as an immediate indicator of IS formation (Revy et al., 2001). Moreover 
calcium signalling is one of the descriptors of similarity between immunological synapses 
and classical neural synapses, from which the IS was named (Dustin, 2009b; Krummel 
and Cahalan, 2010). 
3.1.2.2 Calcium signalling may distinguish mobile and stable interactions 
Calcium signalling is an appropriate readout of antigen-receptor engagement but evidence 
also exists that the quality of signalling may reflect different modes of APC-T cell 
interactions. In a signalling model suggested by Kummerow et al. (2009), low levels of 
calcium signalling, resulting from low levels of IP3 and partial store depletion, are 
associated with kinapse formation. On the other hand, high sustained calcium signals are 
linked with stable synapse formation (Kummerow et al., 2009). On the basis of this model 
one may speculate that the mobile interactions, described by Underhill et al. (1999), are 
associated with low, intermittent intracellular calcium rises in T cells. Indeed, this type of 
signalling is known to result in the selective activation of NFAT (Dolmetsch et al., 1997). 
Furthermore, a report by Moreau et al. (2012) showed that both kinapse- and synapse-
type interactions exist in vivo and both exhibit calcium signalling. Although no direct 
comparison of the calcium profiles was performed, they showed that the strongest TCR 
signals gave rise to synapses, whilst lesser TCR signals indicated kinapse formation. 
Working alongside this is evidence that differential calcium profiles are observed in 
response to agonist or partial-agonist peptides (Wülfing et al., 1997) and that cSMAC 
formation is dependent upon agonist quality (Dustin et al., 2010). Considered together this 
suggests that certain signatures of calcium signalling initiated downstream of TCR binding 
to different quality agonists might have the potential to identify different types of 
synapse/kinapse formation. Indeed, in a departure from the classical view that TCR-
triggered calcium signalling equates to arrest, a new school of thought is emerging that 
considers T cell mobility as inversely proportional to the level of calcium signalling 
(Beemiller and Krummel, 2013; Moreau et al., 2012). 
Thus, the present study used reporters of T cell intracellular calcium as a readout of 
productive human MDM-CD4+ T cell conjugate formation. Encompassed within this 
readout is antigen-dependent signalling in the form of both synapses and kinapses, which 
is useful as the nature of antigen-dependent MDM-CD4+ T cell interactions is unknown. 
3.1.3 Tools to analyse calcium signalling 
A wide range of fluorescent indicators, which bind to calcium, exist to study changes in 
intracellular calcium levels (Takahashi et al., 1999). The present study used fura-2 and 
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fluo-2 in order to study calcium signalling by wide-field fluorescence microscopy and flow 
cytometry, respectively. Fura-2 undergoes a decrease in its absorption wavelength upon 
binding calcium (363 to 335 nm) (Takahashi et al., 1999); therefore sequential excitation 
at 340 and 380 nm in the absence of calcium results in greater emission (500 nm) for 380 
nm compared to 340 nm, but vice versa in the presence of calcium. Fura-2 is classed as a 
ratiometric dye since the ratio of fluorescence for excitation at 340:380 nm can be 
calculated to give an accurate estimation of the increase/decrease in calcium. This acts to 
correct for total concentration, uneven loading and leakage of the dye, but also 
aquisitional photobleaching (Takahashi et al., 1999). This final correction is critical for a 
microscopy-based technique in which aquisitional photobleaching can be rife. In contrast, 
fluo-2 is a non-ratiometric indicator and, similarly to related indicators such as fluo-3, 
demonstrates vastly increased emission intensity upon binding calcium (Takahashi et al., 
1999). Fluo-2 is an effective indicator for use in standard flow cytometry assays as it is 
excited at 488 nm. Although photobleaching is not a major concern in cytometry assays, 
fluo-2 loading or leakage has to be carefully monitored as these factors cannot be 
corrected for in the same way as they can for fura-2. 
3.1.4 Forming an IS in primary human cells 
3.1.4.1 Generating antigen-specific T cells 
The first step in forming an MDM-CD4+ T cell interaction that has the potential for IS 
formation is to generate CD4+ T cells with TCRs specific to a particular antigen presented 
in the context of MHC class II on autologous APCs. Typically this would involve 
immunization of a subject with an antigen, which induces a primary immune response or 
recalls a previous immune response and, after a short period, cells can be harvested from 
tissue or peripheral blood (Murphy et al., 2011). Upon culturing harvested cells with the 
same antigen in vitro, proliferation of antigen-specific T cells will occur and can be 
measured using CFDA-SE dilution or incorporation of 3H-thymidine (Mariotti and Nisini, 
2009). Antigen is added to autologous MDMs and is processed and presented in the 
context of MHC. Pure populations of antigen-specific T cells, obtained by repeated 
expansion or cell-sorting, can then be co-incubated with MDMs presenting cognate 
antigen and IS formation can be monitored. 
3.1.4.2 Use of superantigen 
sAg acts to crosslink MHC class II to a subset of TCR-Vβ regions through a binding 
mechanism that also involves CD28 and occurs outside of the MHC class II peptide-
binding groove (Krakauer, 2013). A key difference between sAg and peptide antigen is in 
the requirement for processing. Macrophages receiving particular endogenous or 
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exogenous signals can have reduced ability to process peptide antigen (Gordon, 2003). 
However only if the macrophage MHC class II cell surface expression is also changed 
would the sAg show any difference in the ability to crosslink to TCR. Another difference 
between peptide antigen and sAg is that a particular TCR is specific for peptide-MHC, 
whereas many different TCRs sharing the same Vβ family are bound by sAg-MHC. 
Furthermore, the majority of sAgs bind several different Vβ families (Table 3.1). The result 
is that each sAg is able to stimulate 2-20% of all T cells, a much greater frequency than 
the number of antigen specific T cells in the same population (Murphy et al., 2011). Note 
that the sAg, staphylococcal enterotoxin E (SEE), recognizes many of the Vβ families 
commonly found in human peripheral blood lymphocyte (PBLs), from which the T cells in 
the present study were derived (Table 3.1). Overall, sAg facilitates in vitro studies of IS 
formation by effectively overcoming the requirement to generate large numbers of 
antigen-specific CD4+ T cells. 
This chapter focuses on forming productive MDM-CD4+ T cell conjugates. Cell surface 
markers reporting on the phenotype of MDMs and activation of CD4+ T cells are 
evaluated. Conjugate formation and calcium signalling are analysed by flow cytometry and 
microscopy techniques. A classification system has also been devised in order to assess 
the quality of the calcium signal. 
  
 TCR Vβ region usage Reference 
sAgs 
(SEA/SEB/SEE) 
3, 3, 5.1, 6.1-3, 8, 11, 12, 14, 15, 17, 18, 20 
(Murphy et al., 
2011) 
Peripheral 
blood 
lymphocytes 
6.2 > 6.1 > 5.1 > 8 > 2 = 13.1 = 13.2 > 4 = 5.2 >7 = 17 
(remaining <4 % relative distribution) 
(Ochsenreither et 
al., 2008) 
4, 5, 6, 8, 13 (frequent); 1, 9, 15 (infrequent) 
(not all Vβs examined) 
(Geursen et al., 
1993) 
 
Table 3.1: TCR-Vβ regions recognised by various superantigens (sAgs) and their prevalence 
in peripheral blood lymphocytes. 
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3.2 Results 
3.2.1 Attempt to recall T cells with Revaxis 
In the present study no medical history was supplied with the peripheral blood leukocyte 
cones received from the NHS. In addition, when using this source of cells, no opportunity 
was available to immunize patients prior to collecting blood. Therefore any attempt to 
expand antigen-specific CD4+ T cells from this source of cells required recall with an 
antigen that had previously been experienced by a large percentage of the UK population. 
As tetanus immunisations have occurred across the UK since 1961 (Adeboye and 
Sangowawa, 2002), this made tetanus toxoid (TT) a likely candidate for antigen recall. 
Thus, a vaccine for diptheria, tetanus and poliomyelitis (DTP), marketed as Revaxis 
(which amongst other antigens contains TT) was used at a 1 : 1000 dilution in culture with 
PBMCs to recall DTP-specific CD4+ T cells. Revaxis is alum-adsorbed and, therefore, 
alum at a concentration matched for the aluminum content of Revaxis was used as a 
negative control for proliferation.  
The PBMCs were isolated as described in section 2.1.1, labelled with CFDA-SE then 
cultured with Revaxis, alum or PHA for 5 days as detailed in section 2.5.1. After 
incubation, cells were immunolabelled for CD3 (OKT3) and stained with a live/dead dye, 
before analysis by flow cytometry. The representative colour density dot-pots illustrate that 
only live cells were included within the analysis and that, within this population, the vast 
majority of the cells were CD3+ (Fig. 3.1). An additional gate was drawn to determine the 
percentage of divided cells (CFDA-SE low). Little or no division is visible in plots of 
PBMCs stimulated with either alum or Revaxis, compared to PHA in which the majority of 
cells have lower CFDA-SE associated fluorescence indicative of cell division (Fig. 3.1). 
The graph shows the percentage of divided cells obtained for all donors tested, with no 
significant difference in division between alum and Revaxis indicating that this method is 
inefficient in the recall of DTP-specific T cells from the general UK blood donor population. 
Despite the fact that T cell lines can be made with only one or two antigen-specific T cells, 
this process requires a ready source of feeder cells, which would necessitate generation 
of an autologous Epstein-Bar virus (EBV)-B cell line or the addition of autologous PBMCs 
every 20–30 days (Mariotti and Nisini, 2009). Unfortunately, both processes use valuable 
autologous PBMCs from which MDMs are isolated and would, therefore, vastly limit the 
number of assays that could be performed before a new line would have to be generated. 
As an alternative approach, sAg was chosen to study the formation of MDM–CD4+ T cell 
conjugates.
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Figure 3.1: Recall of human antigen-specific T cells using Revaxis. PBMCs (n=5) were thawed 
and labelled with 0.84 µM CFDA-SE at a density of 1 x 10
7
 cells/mL according to the protocol 
described in section 2.5.1. After 24 h incubation at 37°C, 5% CO2, labelled PBMCs were 
transferred to a 96-well plate at 2 x 10
5
 cells/well in 200 µL medium and 1:20000 Imject Alum, 
1:1000 Revaxis or 2.5 µg/mL PHA was added. Cells were incubated for 5 days before FcR-
blocking, immunolabelling live with CD3 (OKT3) or IgG2a isotype control, followed by a fixable 
live/dead dye. PBMCs were then fixed, quenched and labelled with GAM-647 secondary antibody. 
Representative colour density plots are shown to illustrate gating strategy and cell division. The 
graph shows the percentage of divided cells for each donor and the difference between stimulation 
agents was compared using ANOVA followed by Tukey’s test. ns, not significant; ***, P < 0.001. 
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3.2.2 Monocyte and MDM cell surface markers 
In order to indicate the phenotype and purity of cells isolated by adherence to gelatin, 
adherent cells were tested after overnight culture (monocytes; day 1) and again after 
differentiation to MDMs in M-CSF (MDMs; day 9). On either day the surface of live cells 
was stained with a panel of primary mAbs against CD3, CD4, CD11b, CD14, CD16, 
CD19, CD68, HLA-DR and CCR5 (three clones: 2D7, MC5 and CTC5) before fixation and 
labelling with GAM-PE secondary as detailed in section 2.4.1. 
3.2.2.1 Markers of adherence isolated myeloid cells 
CD11b is an integrin involved in cell–cell and cell–extracellular matrix (ECM) adhesion 
and is highly expressed on cells of myeloid lineage in humans (Dziennis et al., 1995). 
CD11b was expressed by the majority (82 ± 9%) of isolated adherent cells and MDMs 
differentiated from them (86 ± 9%), indicating that these cells are myeloid (Fig. 3.2). 
Additionally, the percentage of cells expressing CD68 at the cell surface increased upon 
differentiation to MDMs (Fig. 3.2), consistent with a previous report showing an increase 
in CD68 expression between monocytes and MDMs (Rey-Giraud et al., 2012). CD68 is a 
transmembrane glycoprotein, expressed in endosomal compartments and, to a lesser 
extent, at the PM. It is often used as a selective marker for monocytes and macrophages, 
although CD68 can be detected in other cell types (Gottfried et al., 2008). This provides 
supporting evidence of the monocyte/macrophage phenotype of adherence-isolated cells.   
Another marker that predominates on monocytes and macrophages is CD14, which acts 
in concert with toll-like receptor-4 for pathogen recognition (Murphy et al., 2011). The 
percentage of CD14+ cells in the MDM population (81 ± 10%) was significantly higher 
than that of monocytes (66 ± 12%) (Fig. 3.2). Previously it has been reported that in 
healthy donors up to 25% of monocytes may be CD14- (Steinbach and Thiele, 1994), 
which may have contributed to the fraction of CD14- cells observed in the present study. 
This fraction may be also be populated by T cells (CD3+) or B cells (CD19+), although 
these were washed away over culture so that they represented only 2 ± 2% and 4 ± 2% 
after 9 days (Fig. 3.2). Additionally, the expression of CD83, a mature DC marker, 
remained low over the duration of culture (Fig. 3.2) evidencing that DCs were not isolated 
or expanded during differentiation. Together with the markers described above this 
indicated that, after 9 days of culture, the majority of cells were MDMs. 
3.2.2.2 The polarisation of M-CSF conditioned MDMs 
The percentage of cells expressing the IgG-specific FcγRIII receptor (CD16) was 
significantly increased upon differentiation of monocytes (17 ± 9%) to MDMs (71 ± 12%)
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Figure 3.2: Cell surface markers of monocytes and MDMs isolated and differentiated from human peripheral blood. Samples of monocytes or MDMs were 
harvested and immunolabelled for the indicated marker and with the relevant isotype controls according to the method detailed in section 2.4.1 on day 1, prior to 
differentiation with M-CSF, and day 9, after differentiation. Representative histograms for monocytes and MDMs are shown overlaid on the relevant isotype control (shaded 
grey). Gates to estimate the percentage of positive cells were set using the relevant isotype control (grey) for each marker (black) according to side-scattered light (SSC) 
and fluorescence, as illustrated in the gating strategy. Bar charts show the percentage of positive cells on monocytes and MDMs of paired donors for each marker (mean ± 
SD). Statistical comparison was carried out as indicated: 
 a
, Paired Student’s t-test;
 b
, Wilcoxon matched-pairs test. ***, P<0.001; *, P<0.05; ns, non-significant. 
8
1
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(Fig. 3.2). Increased CD16 expression has been associated with both M1 and M2 
phenotypes (Mantovani et al., 2004; Rey-Giraud et al., 2012). Importantly, HLA-DR 
expression levels were maintained over culture (Fig. 3.2), which was crucial for the MDMs 
to be able to form the IS but also excluded the M2c MDM phenotype, which does not 
express MHC class II. For further assessment of the degree of MDM polarisation, the 
expression levels of the CD80 and CD163 cell surface markers on the M-CSF conditioned 
MDMs were compared to those on the GM-CSF conditioned MDMs. MDMs were cultured 
with M-CSF or GM-CSF, as detailed in section 2.2.1, then immunolabelled live for CD80 
and a fixable live/dead dye. Alternatively, MDMs were fixed and then immunolabelled for 
CD163 according to the method detailed in section 2.4.2. Cells were analysed by flow 
cytometry and M-CSF conditioned MDMs were found to express lower levels of the 
costimulatory ligand CD80 but higher levels of the scavenger receptor CD163 than GM-
CSF conditioned MDMs (Fig. 3.3). Overall this suggests that the M-CSF conditioned 
MDMs were polarised towards an M2 phenotype. 
3.2.2.3 Expression of CCR5 on MDMs 
A subpopulation of monocytes was shown to express cell surface CCR5 when detected 
with mAbs directed against three different epitopes (MC5, 26 ± 15%; 2D7, 21 ± 15%; 
CTC5, 31 ± 28%). After differentiation the percentage of cells expressing CCR5 
significantly increased (MC5, 67 ± 21%; 2D7, 52 ± 25%; CTC5, 68 ± 23%). Moreover, 
when gating only on CCR5+ cells the MFI for CTC5 was significantly higher on MDMs 
compared to monocytes; there was no significant difference on MDMs compared to 
monocytes for 2D7 and MC5 (Fig. 3.4). Note that comparison of the MFI of the entire 
population (ungated) also showed a significant increase in MC5 (P = 0.0162) and CTC5 
(P = 0.0012) levels over differentiation (Wilcoxon matched pairs; data not shown) 
supporting previous work in our laboratory (Signoret lab, unpublished data). Furthermore, 
these results corroborate other reports which have shown increased CCR5 expression 
upon differentiation of monocytes to MDMs (Lee et al., 1999b; Naif et al., 1998). Overall 
this shows that, under the differentiation conditions of the present study, an increase in 
the percentage of CCR5+ cells has the greatest impact on the increase in CCR5 
fluorescence. 
Achour et al. (2009) suggested a relationship between CD4 and CCR5 expression at the 
PM, therefore the expression of CD4 on MDMs was also examined. A significant increase 
was apparent in the percentage of CD4+ cells in the MDM (69 ± 18%) population 
compared to monocytes (6 ± 5%) (Fig. 3.2). Notably, Lee et al. (1999b) also observed an 
increase in cell surface levels of CD4 and CCR5 after 6-7 days compared to 0–1 days of 
culture in M-CSF. Although both CD4 and CCR5 were significantly upregulated on MDMs, 
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Figure 3.3: Expression of CD80 and CD163 by M-CSF vs. GM-CSF conditioned MDMs. MDMs 
were cultured in the presence of M-CSF or GM-CSF/IFNγ/LPS for 8 days. Cells were 
immunolabelled live for CD80 and also with a live/dead marker dye. Alternatively MDMs were fixed 
and immunolabelled for CD163, as detailed in section 2.4.2. For CD80, gates were set on live 
(fluorescence
low
) FSC/SSC
high
 events as illustrated. Histograms show the expression levels of 
CD80 (n=2) or CD163 (n=3). The plot shows the percentage of cells in the positive gate (indicated 
on histograms) for CD163 for all donors. 
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Figure 3.4: CCR5 expression on monocytes and MDMs. Samples of monocytes or MDMs were 
harvested and immunolabelled with the indicated CCR5 mAb or the relevant isotype control, 
according to the method detailed in section 2.4.1, on day 1 prior to differentiation with M-CSF, and 
day 9 after differentiation. Representative histograms for monocytes and MDMs are shown overlaid 
on the relevant isotype control (shaded grey). Positive cells were gated as previously described 
(Fig. 3.2). Bar charts show the percentage of positive cells for each CCR5 epitope on monocytes 
and MDMs from matched donors. Table shows the number of donors and the median fluorescence 
intensity values (MFI) of cells within the positive gate. Statistical comparison was carried out as 
indicated: 
a
, Paired Student’s t-test; 
b
, Wilcoxon matched-pairs test. ***, P<0.001. 
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investigation of any relationship between these proteins is beyond the scope of the 
present study. 
3.2.3 Cell surface markers of differentially activated CD4+ T cells 
Autologous CD4+ T cells were isolated alongside monocytes and activated by stimulation 
with PHA and recombinant IL-2 or CD3/CD28 beads according to the methods detailed in 
section 2.2.2. PHA is a non-specific mitogen that induces T cell activation by an unclear 
mechanism. CD3/CD28 beads directly engage antigen and costimulatory receptors, 
activating T cells in a mechanism more akin to physiological antigen presentation (Duarte 
et al., 2002). These different modes of activation were performed in order to investigate 
whether the frequency of MDM-CD4+ T cell IS formation could be increased by using T 
cells with differing activation statuses. 
The CD4+ T cell purity was checked after every isolation by dual indirect immunolabelling 
for CD3 (OKT3) and CD4 (RPA-T4) co-expression and a mean purity of 96% CD3+CD4+ 
cells was determined (Fig. 3.5). Neither PHA/IL-2 nor CD3/CD28 activation resulted in a 
significant increase in the percentage of CD8+ or CD19+ cells, both of which remained 
minimal, nor was there a significant decrease in the percentage of CD4+ cells. 
Conversely, the percentage of CD14+ cells increased significantly using the CD3/CD28 
activation method. Nevertheless, the majority of cells after activation remained 
CD3+CD4+. 
Since T cell activation following antigen encounter induces expression of the IL-2α chain 
(CD25), which confers a higher affinity for IL-2 (Murphy et al., 2011), the expression of 
CD25 was assessed as a measure of activation. The proportion of isolated CD4+ T cells 
expressing CD25 (< 5%) was significantly increased by both the PHA/IL-2 and CD3/CD28 
activation protocols, albeit to different extents (21 ± 6% and 84 ± 4%, respectively) (Fig. 
3.5). Furthermore, CD3/CD28 activation, but not PHA/IL-2 activation, resulted in a 
significant increase in the percentage of cells expressing HLA-DR (Fig. 3.5), which is also 
upregulated upon T cell activation (Murphy et al., 2011). Both activation methods resulted 
in an increased percentage of cells expressing CD45RO (Fig. 3.5), which is the low 
molecular weight isoform of CD45 that becomes expressed after the T cell encounters 
antigen (Hamann et al., 1996). Although this increase was only significant for PHA/IL-2 
stimulated cells, the CD3/CD28 activated cells showed an increase relative to 
unstimulated cells for every donor. Together these results show that both methods 
resulted in CD4+ T cell activation, but that using CD3/CD28 beads results in more 
pronounced activation. 
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Figure 3.5: Cell surface markers of CD4+ T cells before and after stimulation with PHA/IL-2 or CD3/CD28 beads. The purity of CD4+ T cell isolations was assessed 
on day 1 by dual labelling with OKT3 and RPA-T4 or respective isotype controls. Samples of CD4+ T cells were harvested and immunolabelled with the indicated mAb 
directed against the indicated epitope or relevant isotype control, as detailed in section 2.4.1, on day 1 prior to activation in culture with PHA/IL-2 or CD3/CD28 beads, and 
on day 9 after activation. Representative histograms for days 1 and 9 are shown overlaid on the relevant isotype control (shaded grey). The percentage of positive cells for 
each marker was determined by setting gates above the isotype control as previously illustrated (Fig. 3.2). Bar charts show the percentage of positive cells for each marker 
on days 1 and 9 (mean ± SD). Statistical comparison was carried out as indicated:
a
, Paired Student’s t-test;
 b
, Wilcoxon matched-pairs test. ***, P<0.001; **, P<0.01; *, 
P<0.05; ns, non-significant. 
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3.2.4 CCR5 expression on activated T cells 
CCR5 cell surface expression before and after CD3/CD28 or PHA/IL-2 activation was 
measured by flow cytometry using the mAbs MC5, 2D7 and CTC5. For both MC5 and 
2D7, a decrease in the percentage of CCR5+ cells was apparent after activation by either 
method, although the effect was more pronounced after CD3/CD28 activation where the 
decrease showed significance (Fig. 3.6a). This result corroborates evidence from 
Richardson et al. (2012) who showed that CCR5 cell surface (and mRNA) levels were 
reduced to a greater extent by CD3/CD28 stimulation than PHA/IL-2 stimulation. Opposite 
to the reduction in CCR5 cell surface expression observed using MC5 and 2D7, the 
percentage of CTC5+ cells significantly increased on CD3/CD28 stimulated T cells and, 
within CTC5+ gates, the expression levels of CTC5 were increased after PHA/IL-2 or 
CD3/CD28 activation (Fig. 3.6a). To determine the cause of this, PHA/IL-2-activated T 
cells were dual labelled with a live/dead marker and either MC5 or CTC5 followed by 
GAM647. The CTC5hi population was discovered to be composed of dead cells, which was 
not the case for MC5+ cells (Fig. 3.6b). This result indicates that the discrepancy between 
different mAbs in the level of cell surface staining after activation was due to the 
emergence of dead cells that label CTC5hi, which are not present on day 1 (Fig. 3.6a, 
histograms). Thus, the CTC5hi population was excluded from analysis in flow cytometry 
experiments for the remainder of this study. 
3.2.5 Flow cytometric analysis of MDM-CD4+ T cell conjugate 
formation 
As well as being useful in determining the expression of markers in fixed cell populations, 
flow cytometry can be used to follow more transient events in live cells such as calcium 
signalling. The capacity of flow cytometry to rapidly analyse tens-of-thousands of cells 
labelled with several coloured dyes makes it particularly suitable for analysing 
heterogeneous MDM-CD4+ T cell co-culture samples. This, in turn, enables effective 
reporting of the frequency of stable conjugate formation and the calcium signalling that 
occurs within this subpopulation of conjugates (Burchiel et al., 2000). 
3.2.5.1 Measuring conjugate frequency and calcium signalling 
MDMs and CD4+ T cells were labelled with lipophilic membrane dyes PKH26 and DiD, 
respectively, according to the protocol detailed in section 2.12. This allowed clear 
identification of each separate population in co-culture and monitoring of the frequency of 
MDM-CD4+ T cell conjugates formed over the period of co-culture (Fig. 3.7). In addition, 
DiD+ CD4+ T cells were loaded with a calcium sensitive dye before being added to 
PKH26+ MDMs at 37 °C, immediately centrifuged to synchronize the initiation of MDM-
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Figure 3.6: Activation of human CD4+ T cells with CD3/CD28 beads results in a decrease in 
cell surface CCR5. (a) Samples of CD4+ T cells were harvested and immunolabelled with the 
indicated anti-CCR5 mAb or relevant isotype controls, as detailed in section 2.4.1, on day 1 prior to 
activation in culture with PHA/IL-2 or CD3/CD28 beads, and day 9 after activation. Representative 
graphs for days 1 and 9 are shown overlaid on the relevant isotype control (shaded grey). The box 
plots show the percentage of positive cells (+ve gate), as identified by gating all events above the 
isotype control, for days 1 and 9. Statistical comparison performed using a paired Student’s t-test. 
**, P<0.01; *, P<0.05; ns, non-significant. Table shows the number of donors and the median 
fluorescence intensity (MFI) values of cells within the +ve gate. Statistical comparison was carried 
out as appropriate: 
a
, Wilcoxon matched-pairs test ;
b
, Paired Student’s t-test (after Log(Y) 
transform);
c
, Paired Student’s t-test. (b) Charts show PHA-activated CD4+ T cells that were FcR-
blocked, labelled live with the indicated antibody and a fixable live/dead dye, fixed, quenched and 
labelled with a secondary GAM
647
 In one condition, CD4+ T cells were heat-killed by treating at 
56°C 30 min prior to labelling. The red box indicates the CTC5
hi
 dead population. 
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Figure 3.7: Diagram of flow cytometry method for measuring calcium signalling. Cartoon 
diagram summarising the method used to analyse formation of productive MDM-CD4+ T cell 
conjugates and the gate used to determine the percentage of conjugates formed, accompanying 
description in section 3.2.5.1.  
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CD4+ T cell interactions and then either analysed immediately (0 min) or after being 
maintained at 37 °C for various intervals (5, 15, 30, 45 min). At each interval DAPI was 
added to the co-culture sample immediately prior to analysis to identify live/dead cells; 
DAPI transits the membrane of dead cells more rapidly than live cells. After primary 
acquisition, ionomycin was added to the same sample before analysing it again 
(secondary acquisition). Further details of this protocol can be found in section 2.12.4. 
Compensation was performed post-acquisition before gating on live MDMs DAPI-, 
PKH26+, which were measured over a predefined event-width (pulse width ≥ 100 (PW100); 
estimated MDM-CD4+ T cell width based on the pulse width of MDMs and CD4+ T cells 
alone) and were conjugated to CD4+ T cells (DiD+) (Fig. 3.8a). The fluorescence intensity 
of the calcium signal of events within the DAPI-PKH26+PW100DiD+ gate was exported and, 
for each interval, the MFI of the primary acquisition was expressed as a percentage of the 
MFI upon secondary acquisition, referred to herein as the ‘calcium signal relative to 
ionomycin (%)’. 
3.2.5.2 Calcium dye leakage impacts prolonged analysis 
Previously, the calcium dye fluo-8 has been used in a flow cytometry method in our 
laboratory to study the calcium signalling of monocytes for up to 300 s in response to 
CCL2, CCL5 and lipoteichoic acid (Fox et al., 2011). On the basis of this assay fluo-8 was 
initially used to study calcium signalling in APC-CD4+ T cell conjugates at various 
intervals within a 45 min co-culture period at 37 °C. A higher intracellular calcium signal 
was detected in conjugates formed with SEE-pulsed MDMs at the 5 min time-point relative 
to conjugates formed in the absence of antigen. At 45 min the fluorescence levels of 
conjugates formed in SEE-pulsed and no antigen samples were remarkably similar, 
appearing to indicate that sAg-dependent calcium signalling had been abolished by this 
time. However, when ionomycin was added to the same sample no increase in 
fluorescence was observed (Fig. 3.8b) showing that it was, in fact, the ability to detect the 
calcium signal that had been abolished. This is consistent with the concept that different 
calcium indicators have different leakage propensities in different cell types (Takahashi et 
al., 1999). To combat leakage, cells can be treated with probenecid or, alternatively, a 
number of leak-resistant forms of calcium dyes exist which can be used in place of the 
traditional dyes (Takahashi et al., 1999). Therefore, a leak-resistant version of fluo-8 
called fluo-2leakres (note: fluo-2 and fluo-8 are pseudonyms for the same indicator) was 
loaded alongside fluo-8 into CD4+ T cells from the same donor at final concentrations of 
0.30 and 0.17 µM, respectively. The loss of fluorescence over time was compared directly 
over 45 min. In both the absence and presence of calcium released by ionomycin 
treatment, the MFI of fluo-2leakres showed far greater stability over time than that of fluo-8 
(Fig. 3.8b). Moreover, when fluo-2leakres was used in the MDM-CD4+ T cell conjugate
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Figure 3.8: Leakage of calcium sensitive dyes. (a) Gating strategy employed to measure CD4+ 
T cell intracellular calcium level MFI when interacting with MDMs. (b) Leakage of fluo-8 compared 
to fluo-2leakres calcium dyes. Histograms of CD4+ T cells interacting with MDMs gated as indicated 
in (a) showing the ability of the different dyes to detect a change in fluorescence intensity (i.e. 
calcium signalling) after 5 or 45 min incubation at 37 °C in the presence of SEE or after addition of 
1 µg/mL ionomycin. Graph shows leakage of fluo-8 (black lines/symbols) compared to fluo-2leakres 
(red lines/symbols) as a loss in MFI from CD4+ T cells of the same donor in the absence of MDMs 
in the presence (open circles) or absence (filled circles) of ionomycin. 
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assay, the conjugates formed in the presence of sAg showed higher fluorescence 
intensities than those formed in the absence of antigen at both 5 and 45 min (Fig. 3.8b). 
3.2.5.3 Effect of sAg on MDM-CD4+ T cell conjugate frequency and signalling 
Conjugates formed between PHA-activated CD4+ T cells and MDMs pulsed with SEE 
prior to co-incubation were of a similar frequency to those formed in the absence of 
antigen (45 min: 8 ± 2% and 8 ± 3%, respectively) (Fig. 3.9). No change in the frequency 
or kinetics of conjugate formation (45 min: 7 ± 1%) was observed when SEE was added to 
the MDM-CD4+ T cell co-cultures at the 0 min interval instead of pre-treating the MDMs. 
Similarly, the frequency of conjugates formed between CD3/CD28 activated CD4+ T cells 
and MDMs after adding SEE was not increased compared to conjugates formed in the 
absence of antigen (45 min:  9 ± 2% and 11 ± 0%, respectively). As a positive control for 
conjugate formation, CD4+ T cells were labelled/opsonized with whole IgG anti-CD3 
(OKT3), which may be bound by MDMs expressing CD16 (see section 3.2.2). As 
expected anti-CD3 coated T cells showed a significant increase in the frequency of 
conjugates formed over time, evidenced by mean values at all time-intervals from 5 min 
onwards having mutually exclusive 95% confidence intervals (CI) compared to untreated 
controls. Overall, upon addition of SEE MDM-CD4+ T cell conjugate frequency remained 
low and was comparable to the frequency of conjugates formed in the absence of antigen. 
Certainly, the measure of conjugate frequency in this instance provided little evidence for 
the potential of stable IS formation occurring upon the addition of SEE. 
To determine whether addition of sAg has any effect upon the potential of MDMs and 
CD4+ T cells to form synapses, the levels of intracellular calcium in T cells forming 
conjugates was studied. High calcium levels are an early indicator of the T cell response 
that is maintained over the course of antigen-dependent interactions between B- T cell 
conjugates (Huppa et al., 2003). The flow cytometry method was demonstrated to be able 
to detect the expected increase in intracellular CD4+ T cell calcium levels, which occurred 
due to Fc-crosslinking of anti-CD3 labelled T cells in MDM-CD4+ T cell conjugates. The 
intracellular calcium signal for CD4+ T cells forming conjugates with MDMs in the 
presence of SEE was high in comparison to the basal signal of conjugates formed in the 
absence of antigen (Fig. 3.9). For all conditions the intracellular calcium level peaked at 
the 5 min interval and did not return to the baseline level of conjugates formed in the 
absence of antigen over the time-course of analysis. When MDMs were pulsed with SEE 
or when CD4+ T cells were labelled with OKT3 prior to co-incubation, the calcium signal 
was relatively high at the initial 0 min time interval, compared to when SEE was added at 
the start of co-incubation. This shows that CD4+ T cell calcium influx upon TCR ligation or 
crosslinking through conjugate formation with MDMs occurs rapidly after conjugate 
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Figure 3.9: Analysing the formation of MDM-CD4+ T cell conjugates by flow cytometry. Upper graphs show the percentage of conjugates formed over time in the 
presence (coloured line) or absence (black line) of SEE. SEE was either incubated with MDMs for 2 h prior to co-incubation with CD4+ T cells or added at t = 0 (i.e. during 
co-incubation). The latter condition was completed for CD4+ T cells activated with PHA or with CD3/CD28 beads. As a positive control αCD3-coated CD4+ T cells were 
used to form conjugates with MDMs. Lower graphs show the intracellular calcium level in CD4+ T cells engaged in conjugates with MDMs as a fraction of the maximum 
calcium mobilisation by subsequent treatment of the same sample with 1 µg/mL ionomycin. Graphs show mean of donors (n=3); error bars, SD. 
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formation, faster than the time taken for centrifugation and initiation of sample acquisition 
(typically < 2 min). In comparison, the cases where SEE was added at 0 min showed a 
delayed rise in intracellular calcium, which can be explained by the time taken for the SEE 
to diffuse in solution and bind MHC class II and TCR (Fig. 3.9). Both the PHA/IL-2 and 
CD3/CD28 activated CD4+ T cells showed similar patterns of calcium signalling and, 
although they exhibited marginally different kinetics of conjugate formation relative to 
respective no antigen controls, neither showed greater than 10% conjugate formation. 
Therefore only the PHA/IL-2 activated CD4+ T cells were used for the remainder of the 
investigation into MDM-CD4+ T cell IS formation. Overall, sAg-dependent calcium 
signalling decreased marginally after the 5 min interval but then plateaued and was 
maintained above baseline levels for the duration of co-culture. In fact, the level of CD4+ T 
cell intracellular calcium signalling within MDM-CD4+ T cell conjugates was maintained to 
a greater extent with SEE than for conjugates formed with anti-CD3 coated CD4+ T cells. 
Thus, the addition of SEE enabled the MDM-CD4+ T cell conjugates to engage in 
sustained, sAg-dependent calcium signalling akin to that associated with IS formation 
(Huppa et al., 2003). 
3.2.6 Live cell imaging of productive MDM-CD4+ T cell conjugates 
Live cell microscopy of calcium signalling enables single cells to be followed over time, a 
parameter which is not possible using flow cytometry (Takahashi et al., 1999). In addition, 
in order to visualize IS markers and whether chemokine receptors accumulate at the 
interface of MDM-CD4+ T cell conjugates engaged in sAg-dependent signalling, an 
imaging-based approach must be adopted. Therefore a time-lapse fluorescence 
microscopy technique was developed to image intracellular CD4+ T cell calcium 
responses to sAg-pulsed or unpulsed MDMs (Fig. 3.10). Briefly, MDMs labelled with 
CFDA-SE were seeded onto PDL-coated coverslips, treated with SEE, a cocktail of 
SEA/SEB/SEE sAg or medium alone, then loaded into a perfusion chamber.  Autologous 
CD4+ T cells (1 x 106 cells) that had been loaded with fura-2/AM were injected into the 
perfusion chamber containing adherent MDMs at a controlled rate. Imaging was initiated 
immediately after injection and images were acquired every 10 s for a total of 1200 s (20 
min) (Fig. 3.10a). A similar procedure was also performed for Daudi-CD4+ T cell 
conjugates and further details of the protocol can be found in section 2.13. After CD4+ T 
cells were tracked, time-lapse images were processed as detailed in section 2.13.4. In 
these images CD4+ T cells with elevated intracellular calcium levels are represented by 
colour according to the intensity of the calcium rise. Tracks of the T cells are overlaid onto 
the image (Fig. 3.10b). An increased signal upon excitation at 340 nm compared to 380 
nm (i.e. higher 340:380 ratio) indicates a rise in intracellular calcium levels. 
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Figure 3.10: Live calcium imaging of MDM-CD4+ T cell interactions. (a) Cartoon diagram of the 
method used to image CD4+ T cell calcium signalling events when interacting with sAg-pulsed or 
unpulsed MDMs as described in section 3.2.6.(b) Final frame of the time sequence for each donor 
(n = 3) showing the entire field of view, representative of three time sequences. Images were 
processed to depict calcium flux of CD4+ T cells (coloured according to the intensity of calcium rise 
according to a 340:380 ratio using the indicated scale) interacting with MDMs (grey). CD4+ T cells 
were tracked using MTrackJ and tracks were colour coded according to the maximum 340:380 
ratio experienced over time (green tracks, <0.5; white tracks, ≥ 0.5 and < 1.0; red tracks, ≥1.0). 
Scale bars, 50 µm. 
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Representative images of the final time-frame for each donor (n=3) illustrate that more 
CD4+ T cells with higher intracellular calcium intensities (cells coloured: yellow/red) were 
present in sAg-pulsed samples (+ sAg) compared  to untreated controls (no antigen) (Fig. 
3.10b; supplemental movies 1-6). The rise in intracellular calcium appeared to occur 
when CD4+ T cells were in close proximity to an MDM (i.e. forming signalling conjugates), 
supporting the results of the flow cytometry technique. Moreover, a greater number of 
tracked CD4+ T cells reached a high 340:380 ratio (≥ 1.0) over the duration of imaging 
(tracks colored red) in samples with sAg compared to no antigen controls (Fig. 3.10b). 
Note also that, compared to untreated controls, more CD4+ T cell tracks with a maximum 
340:380 ratio < 0.5 (tracks coloured green) occurred in the presence of sAg (Fig. 3.10b). 
This effect is unlikely to be due to changes in CD4+ T cell number as this was kept 
constant. Rather, it may be related to sAg-treatment inducing flattened MDMs to become 
more rounded, so reducing the overall coverage of MDMs on the coverslip and 
opportunities for transient tethering. 
During set-up and optimisation of the imaging protocol MDMs were pulsed with SEE alone 
before being exposed to T cells, in keeping with the flow cytometry protocol (Fig. 3.11). 
However, the two donors imaged with SEE-pulsed MDMs showed different results: ‘Donor 
A’ showed very few T cells with a higher calcium signal compared to no antigen controls 
and statistical significance of the population in the opposite direction than expected (i.e. 
higher maximum 340:380 ratio in the absence of antigen) (Fig. 3.11); ‘Donor B’ gave a 
number of T cells with higher calcium signal compared to no antigen controls and 
indicated a significant increase in the maximum 340:380 ratio upon sAg-treatment (Fig. 
3.11). In an effort to try and improve the number of conjugates forming and consistency 
between donors, MDMs were pulsed with a cocktail of sAg (SEA/SEB/SEE) as used by 
Contento et al. (2008). SEE vs. sAg cocktail treatment was not directly compared in the 
same donors, therefore the benefit of SEA and SEB addition is unclear. Nevertheless, the 
three donors treated with the sAg cocktail gave consistently higher calcium responses 
when pulsed with sAg, which was not the case for one of the donors pulsed with SEE only 
(Fig. 3.11). Therefore the sAg cocktail was carried forward and used for the remainder of 
the study. 
The difference observed in CD4+ T cell intracellular calcium levels between conjugates 
formed with sAg-treated and untreated MDMs was quantified by extracting the maximum 
340:380 ratio for each tracked cell. For each donor, maximum 340:380 values were 
compiled from CD4+ T cells tracked in three separate movies when MDMs were treated, 
or not, with sAg. Two of the three donors tested showed significantly increased maximum 
calcium signal experienced by CD4+ T cells in the presence of sAg-treated MDM 
compared to untreated MDMs (Fig. 3.11; Mann-Whitney U test). Clearly, the number of 
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Figure 3.11: Analysis of MDM-CD4+ T cell conjugate formation by live microscopy. Fura-2 
loaded CD4+ T cells were perfused over autologous MDMs or Daudi cells that were untreated (no 
Ag) or pulsed with sAg, specifically SEE alone or a cocktail of SEA/SEB/SEE at 1 µg/mL for 2 h. 
Intracellular calcium levels were imaged by fluorescence microscopy then CD4+ T cells were 
tracked and the maximum 340:380 ratio (calcium level) for each CD4+ T cell was calculated. For 
each of Donors A–G, the scatter graphs show the maximum 340:380 ratios in the presence and 
absence of sAg, with statistical comparison according to the Mann-Whitney U-test. For Donors C-
G, which were imaged under identical conditions, the set of bar graphs show the percentage of 
cells above a cut-off value (maximum 340:380 ≥ 1.0) in the presence or absence of sAg and these 
proportions were statistically compared using Fisher’s exact test. 
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responding cells and the level of intracellular calcium was highly variable between 
different donors. Nevertheless, for each donor a small population of CD4+ T cells showed 
a higher level of calcium signalling in the presence of sAg-pulsed MDMs compared to 
untreated MDMs. For this reason the effect of treating with sAg on the proportion of cells 
with a maximum 340:380 ratio ≥ 1.0 was compared using Fisher’s Exact Test, as used by 
Kallikourdis et al. (2013). This analysis showed that the proportion of CD4+ T cells with 
higher calcium intensities (maximum 340:380 ratio ≥ 1.0) was significantly greater in the 
presence of sAg-treated compared to untreated MDMs (Fig. 3.11, Donors C-E). 
To determine whether IS formation with MDMs was the cause of the limited frequency of T 
cells undergoing high calcium signals the present study also explored the T cell 
intracellular calcium response to B cells, which have been ubiquitously used in studies of 
IS formation. The frequency of CD4+ T cells that responded to sAg-pulsed B cells (Daudi 
cell line) by exhibiting a high rise in intracellular calcium was lower than that observed for 
MDMs pulsed with antigen. Despite this, the proportion of CD4+ T cells with maximum 
340:380 ratios ≥ 1.0 was significantly greater in the presence of sAg-pulsed Daudi 
compared to no antigen controls (Fig. 3.11). Interestingly, in the absence of antigen 
Daudi-CD4+ T cell interactions appeared to result in a lower percentage of cells exhibiting 
intermediate calcium responses. Due to the smaller size of Daudi cells compared to 
MDMs this may simply reflect a reduced cell-cell surface area available for ‘scanning’-
associated calcium signals. Altogether these results show that a high intracellular calcium 
level is apparent in a small number of CD4+ T cells that engage MDMs. Although the 
frequency of these responses is low, this is also reflected through the previous 
observations in the flow cytometry based analysis, and the response frequency does not 
appear to be limited by the MDM cell type. 
3.2.7 sAg changes the quality of calcium signalling in conjugates  
Calcium signalling is not simply a digital on/off switch but rather an analogue system in 
which differences in amplitude and duration of the calcium signal result in differential 
cellular responses (Dolmetsch et al., 1997). Therefore it is important not only to consider 
the high-point of responses (e.g. maximum 340:380 ratio) but also the nature of the 
intracellular calcium signalling both before and after this point. To this end the levels of 
intracellular calcium for each individual CD4+ T cell in every time-sequence were plotted 
over time in an effort to identify patterns. 
A sample of intracellular calcium profiles of CD4+ T cells that exhibited a maximum 
340:380 ratio ≥ 1.0 in the presence of sAg-pulsed or unpulsed MDMs are shown 
alongside their corresponding cropped time-sequence images (Fig. 3.12). These images 
reiterate that high calcium signalling occurred when the CD4+ T cell was in close proximity 
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to MDMs (i.e forming conjugates) rather than occurring further afield whilst appended to 
other CD4+ T cells. Side-by-side inspection of each image time-sequence and calcium 
profile illustrates that high levels of intracellular calcium, even when transient, did not 
occur when the T cell was moving rapidly (Fig. 3.12; supplemental movies 7-12). The 
bottom ‘no antigen’ profile is an excellent example of this as nodules on the track that 
were formed when the cell was less mobile can be seen to coincide with transient rises in 
calcium (Fig. 3.12). A similar relationship is exemplified in the top ‘plus sAg’ profile in 
which the T cell was seen to crawl along the surface of the MDM, maintaining a low 
intracellular calcium signal prior to a sharp increase that coincided with arrest of 
movement. However, arrest of cell movement did not necessarily equate to an increase in 
intracellular calcium as tracks of T cells that did not show an increase in intracellular 
calcium (maximum 340:380 < 0.5) often migrated quickly at the start of imaging then 
arrested (green tracks: Fig. 3.10b). This was simply because T cells were injected at a 
controlled rate but the rate of flow was not maintained. Moreover, no significant difference 
in the meandering index (total straight-line displacement from the track origin (µm) / length 
of track (µm)) of tracks with a maximum 340:380 ratio ≥ 1.0 compared to tracks with a 
maximum 340:380 ratio < 0.5 was found within the sAg-pulsed time-sequence. Therefore, 
whilst a rise in intracellular calcium appeared to coincide with arrest of migration, in this 
experimental setting an arrest in migration did not necessarily identify a CD4+ T cell that 
was signalling. 
CD4+ T cells that had been grouped into the category of ‘maximum 340:380 ratio ≥ 1.0’ 
and were interacting interacting with sAg-pulsed or unpulsed MDMs showed differently 
shaped intracellular calcium profiles with respect to each other. When interacting with 
sAg-pulsed MDMs a number of CD4+ T cells underwent a high-amplitude, sharp initial rise 
in intracellular calcium, which was maintained, often at a slightly lower level, over the 
imaging time-frame (Fig. 3.12). In contrast, CD4+ T cells interacting with unpulsed MDMs 
did not appear able to recapitulate this profile but, instead, followed sharp rises in 
intracellular calcium with a decrease to baseline levels (i.e. the 340:380 ratio for each 
track prior to the rise) over the time-frame of imaging (20 min) (Fig. 3.12). In general this 
suggests that the high calcium signals exhibited by CD4+ T cells in the absence of sAg 
were more transient than the high calcium signals in the presence of sAg. 
3.2.8 Qualitative classification of CD4+ T cell calcium profiles 
Visual comparison of all the calcium profiles with a maximum 340:380 ratio ≥ 1.0 
demonstrates that, in the absence of antigen, none of the profiles showed the high 
amplitude and duration of calcium that were evident in a sizeable proportion of the profiles 
formed in the presence of sAg (Fig. 3.13). In order to assess whether the presence of sAg  
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Figure 3.12: Arrest in CD4+ T cell mobility coincides with the onset of sustained calcium 
signalling.  Example intracellular calcium profile of a CD4+ T cell identified to have a maximum 
340:380 ratio ≥ 1.0 in the presence or absence of sAg. Corresponding image stills at regular 
intervals over the time-course are shown for each CD4+ T cell (colour coded to relate with intensity 
of the 340:380 ratio according to the indicated scale) interacting with MDMs (white cells). The track 
taken by the corresponding CD4+ T cell is highlighted in red. Scale bar, 10 µm.  
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Figure 3.13: Calcium profiles from cells reaching a maximum 340:380 ratio ≥ 1.0.  Profiles were grouped into four categories: (i) flat, no rise or sharp spikes above 
baseline (not depicted in the figure as 340:380 < 1.0); (ii) transient, a rise in calcium followed by one or more returns to baseline over the course of analysis; (iii) low, a rise 
in calcium that did not return to baseline and did not fulfil the acceptance criteria of the high group; (iv) high, initial rise above a 340:380 ratio of 1.5 and sustained above a 
340:380 ratio of 1.0 or alternatively an initial rise above 340:380 ratio of 2.0. Black lines, plus sAg. Red lines, no antigen. 
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also affected the proportions of transient or lower level calcium profiles occurring across 
the population, every calcium profile was qualitatively classified into one of four groups: (i) 
flat, no rise or sharp spikes above baseline; (ii) transient, a rise in calcium followed by one 
or more returns to baseline over the course of analysis; (iii) low, a rise in calcium that did 
not return to baseline and did not fulfil the acceptance criteria of the high group; (iv) high, 
initial rise above a 340:380 ratio of 1.5 and sustained above a 340:380 ratio of 1.0 or 
alternatively an initial rise above 340:380 ratio of 2.0 (Fig. 3.14). This classification 
method indicates that, even in the presence of sAg-pulsed MDMs, the majority of CD4+ T 
cells exhibited no change in intracellular calcium levels (group:’flat’). Nevertheless, a 
greater percentage of non-responders were present when MDMs were untreated (72 ± 
14%) compared to sAg-pulsed MDMs (63 ± 11%). As noted above, the small percentage 
(5 ± 3%) of CD4+ T cells that responded with ‘high’ group profiles were exclusive to the 
sAg-treatment group. In addition, the proportion of CD4+ T cells undergoing sustained 
signalling at a low level more than doubled when interacting with sAg-pulsed MDMs (13 ± 
5%) in comparison to unpulsed MDMs (5 ± 3%). This indicates that different 
subpopulations within the CD4+ T cell MDM milieu responded in distinct ways to the same 
sAg cocktail, resulting in different levels of calcium signalling. The percentage of CD4+ T 
cells with transient calcium profiles was relatively similar when interacting with sAg-pulsed 
(19 ± 7%) and untreated MDMs (23 ± 11%) (Fig. 3.14). The slightly reduced percentage 
of transient profiles in the presence of sAg together with the expansion of the ‘high’ and 
‘low’ populations suggests that sAg acts to stabilise otherwise transient TCR-MHC 
scanning events. 
3.2.9 Towards an automated classification strategy for calcium profiles 
The qualitative classification procedure gave indications that an increased proportion of 
CD4+ T cells responded to sAg-pulsed MDMs with subtle rises in calcium compared to 
unpulsed MDMs. However, calcium profiles in both the ‘high’ and ‘low’ groups still showed 
substantial intragroup variation; some profiles having a sharp rise and others taking 
longer, some with high signals that decreased rapidly followed by a signal maintained at 
only a fraction of the initial rise, whilst others maintained the level of the initial rise or 
showed a gradual decrease. Further sub-grouping of like-by-like profiles (according to 
similarity of these features and delineation of the responses with or without sAg-treatment) 
by means of quantitative visual classification is extremely unlikely to yield meaningful or 
accurate comparisons. Thus, attempts were made to describe the curves in an automated 
fashion (i.e. without human-error of visual classification) using computational 
mathematics. One of these methods involved performing piecewise linear regression on 
each calcium profile to approximate/simplify each curve. A collaboration was initiated with 
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Figure 3.14: Qualitative classification of calcium profiles. Representative examples of calcium 
profiles visually classified into four groups (flat, transient, low or high) according to the criteria 
detailed in section 3.2.8. Pie charts showing the percentage of CD4+ T cell calcium profiles that fell 
into each group when interacting with unpulsed or sAg-pulsed MDMs. 
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Dr J. Wilson (University of York, York, UK) who wrote a c-script program (Appendix 1) 
that was able to fit each calcium profile with one to three linear segments. Segments were 
fitted in order to minimize the total R2 value and eighteen parameters (Fig. 3.15) for each 
prolife were extracted to describe the fitted segments. Thus, calcium profiles could be 
analysed in a high-throughput manner and translated into a series of parameters that 
described the basic curve shape.  
A function was written in MATLAB, which enabled parameters extracted using the linear 
piecewise regression curve to be reconstructed into linear segments and overlaid on the 
relevant raw calcium profiles in an array of individual subplots. Visual inspection of these 
revealed that the three segment linear regression appeared able to represent the major 
increases and decreases of the curves (Fig. 3.15). Indeed, this was reinforced by the R2 
values of the fitted profiles being similar to each other (0.79 ± 0.09). Thus, the segments 
fitted appeared to be reasonable approximations of the general shape of the calcium 
profiles. 
Principal component analysis (PCA) was applied to the list of parameters, which had first 
been z-score normalised, in order to identify whether the combination of all of the 
parameters was able to discriminate between CD4+ T cell calcium profiles in the presence 
or absence of sAg. This type of analysis reduces the dimensionality of multiparametric 
data by finding the axes/directions within the data that give rise to the greatest variance 
(Jolliffe, 2002). The direction that describes the greatest variance is the first principal 
component, the direction describing the next greatest variance is the second principal 
component, and so on (Ringner, 2008). Only principal components with variance > 1 were 
considered. This cut-off was chosen according to Kaiser’s rule, which stipulates that any 
principal component with variance ≤ 1 contains less information than the original 
parameters and, therefore, should be excluded (Jolliffe, 2002). Calcium profiles 
designated as ‘flat’ according to the visual classification of the data were removed prior to 
data analysis. Note also that five of the original parameters were not included in the 
analysis; the time-dependent parameters (iv, vii-x) are arbitrary because the time of cell-
cell interactions was not synchronized. The scree plot shows that the first five principal 
components fulfilled Kaiser’s criteria and together these components comprised 77% of 
the total variance of the data (Fig. 3.15). However, it can be argued that only the first two 
components will be useful as these occur prior to the elbow of the plot, which can be used 
as an alternative cut-off feature (Jolliffe, 2002). Nevertheless, scores for all combinations 
of the first five principal components were plotted against each other. Plots for the first 
three components are shown as examples. None of the plots showed separate clusters 
that corresponded to the CD4+ T cell calcium profiles interacting with either sAg-pulsed or 
unpulsed MDMs (Fig. 3.15). Therefore, using this method of analysis, even the low-onset 
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Figure 3.15: Quantitative classification using piecewise linear regression of calcium 
profiles. Examples of piecewise linear regression (red lines) overlaid onto calcium profiles (blue 
lines) where one, two or three linear sections are fitted.     indicates the position of the breakpoints 
between fitted linear segments. Parameters extracted from the piecewise linear regression are 
stated; those in grey were excluded from further analysis. Principal component analysis was 
performed on the remaining 13 parameters and the relative contribution of all PCs is shown in the 
scree plot. PC scores plots of all combinations of the first three PCs illustrate that sAg (●) and no 
antigen (●) groups do not form separate clusters. PC, principal component. 
 *     
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intensity calcium profiles of the unpulsed cells could not be separated from the high-onset 
calcium profiles of the sAg-pulsed cells. Certainly, differences exist in the calcium profiles 
as evidenced by the visual classification system (Fig. 3.13 & 3.14), however these 
differences, or distinct groups of calcium profiles, are not evident using the above 
piecewise linear regression coupled with PCA. 
3.3 Discussion 
3.3.1 MDM cell surface markers and phenotype 
The cell surface markers tested indicate that the population of cells, isolated by adherence 
and differentiated in M-CSF, were myeloid (CD11b+) and not populated by mature DCs 
(CD83+) or contaminated by large numbers of B cells (CD19+) or T cells (CD3+) (Fig. 
3.2). Due to the absence of an adopted standard and the fact that subtle changes in 
culture conditions can alter MDM functional activity, the present study examined the 
expression of certain cell surface markers in order to determine the phenotype of the 
MDMs generated. A higher expression of CD14 has been shown to be associated with 
M2-polarised macrophages relative to M1 (Mantovani et al., 2002; Rey-Giraud et al., 
2012). However the present study was concerned with comparing the expression of 
MDMs relative to monocytes at the start of culture. Under similar culture conditions Rey-
Giraud et al. (2012) reported vastly increased CD14 fluorescence levels on M2 MDMs 
relative to monocytes, opposite to the decrease in fluorescence intensity observed in the 
present study (Fig. 3.2; histograms). Perhaps this difference stems from the analysis of 
monocytes after overnight culture in the present study, which has been reported to result 
in up- or down-regulation of other cell surface markers on monocytes. Indeed, the lack of 
CD4 observed on monocytes (Fig. 3.2) may be due to the transient cell surface 
downregulation of CD4 compared to freshly-isolated monocytes, which has been 
previously noted (Graziani-Bowering and Filion, 2000; Naif et al., 1998). Conversely, HLA-
DR expression increases after overnight culture of monocytes (Andreesen et al., 1990; 
Graziani-Bowering and Filion, 2000). Evidently, placing monocytes into culture can rapidly 
alter their cell surface phenotype; thus attention should be paid to the time-point of 
immunophenotyping for comparison of expression between monocytes and MDMs.  
In contrast to CD14, a large increase in CD16 expression levels was observed on MDMs 
(Fig. 3.2; histograms). However, the change in CD16 expression is controversial: a 
previous study associated it with M2 polarised MDMs (Rey-Giraud et al., 2012), and 
another with M1 (Mantovani et al., 2004). The expression of HLA-DR indicates that MDMs 
have the capability to bind and elicit the function of the sAg (Krakauer, 2013), but also 
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indicates that the MDMs do not adopt a deactivated (M2c) phenotype (Herbein and Varin, 
2010). Based on CD14, CD16 and HLA-DR expression levels alone it is unclear whether 
the MDMs may be more M1 or M2 polarised. Therefore, CD80 and CD163 expression 
levels on M-CSF and GM-CSF differentiated MDMs were also compared (Fig. 3.3). The 
M-CSF MDM population had a higher percentage CD163 expression and a lower CD80 
expression, consistent with the observations of other studies (Foucher et al., 2013; Rey-
Giraud et al., 2012). Taken together these results indicate that our MDMs presented a 
more M2-polarised phenotype.  
Culture in the presence of M-CSF is generally known to produce M2-polarised MDMs, 
although these can be skewed typically to secrete M1 inflammatory cytokines using LPS 
or M1 conditioned media (Rey-Giraud et al., 2012). This is a reminder that the M1 and M2 
states represent extremes of a functional continuum (Mantovani et al., 2013) and, 
therefore, the ideal way to phenotype MDMs is to discern the functional state by 
assessing cell-associated markers, metabolic substrate preference and, most critically, 
cytokine secretion (Mantovani et al., 2002). Thus, the limited selection of cell-surface 
markers tested in the present study only give a simplistic view of which end of the 
continuum the MDMs generated may exist. More would need to be done to fully 
characterise the M1 or M2 phenotype. 
3.3.2 CCR5 expression is dependent on cell type and activation 
CCR5 is expressed on a significantly greater percentage of the MDMs compared to 
monocytes (Fig. 3.4). This observation is consistent with a report by Lee et al. (1999b) 
showing that the average number of 2D7 binding sites increases during differentiation of 
MDMs, and also with the suggestion that M-CSF increases CCR5 expression on MDMs to 
facilitate HIV entry (Herbein and Varin, 2010). 
The CD3/CD28 activated CD4+ T cells clearly represent a more homogenously activated 
population than the PHA/IL-2 activated CD4+ T cells. However, the CD3/CD28 activation 
method is concomitant with CCR5 downregulation, which has been reported to be caused 
by increased β-chemokine production and loss of the quiescence-associated transcription 
factor, Kruppel like factor 2 (KLF-2) (Richardson et al., 2012). Despite differential CCR5 
cell surface expression, a small population was consistently detected as CCR5+ when 
labelling with CTC5 after activation. This population was composed of late 
apoptotic/necrotic cells as it stained positive with a live/dead dye (Fig. 3.6). Since CTC5 
recognizes the N-terminal region of CCR5 and is also able to recognize denatured CCR5 
(Lee et al., 1999a), there is a case for CTC5 recognizing a form of CCR5 that is made 
accessible upon cell death. Although a subject of controversy (Pilch-Cooper et al., 2011), 
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CCR5 may exist in intracellular pools in some CD4+ T cells (Achour et al., 2009; Guglielmi 
et al., 2011). Whilst it is possible that necrotic degradation processes (lysosome rupture, 
protease activation, PM rupture) could result in denatured or incomplete intracellular 
CCR5 being released from the T cell that might be recognised by CTC5, MC5 is also able 
to recognise a very similar linear epitope on CCR5 (Blanpain et al., 2002). Thus because 
the CCR5hi population in question is only recognised by CTC5 and not MC5, the most 
likely explanation for this result is that the CTC5 mAb is demonstrating non-specific 
binding to the dead cells within the sample. In general, this demonstrates that live/dead 
exclusion can be useful in phenotyping cells for CCR5 using CTC5 and that care is 
required when drawing conclusions using a single mAb. 
Unlike CD3/CD28 activation, a subpopulation of PHA/IL-2 activated cells express cell 
surface CCR5 after activation (Fig. 3.6). Considering that neither PHA/IL-2 nor the 
CD3/CD28 activated T cells showed higher frequencies of IS formation (Fig. 3.9), the 
PHA/IL-2 activated T cells are advantageous as the contribution of endogenous CCR5 on 
the T cell side of the IS can also be studied using this population. In future studies, 
considering the interplay between CCR5 and IL-2 (Camargo et al., 2009), it would be 
useful to determine the concentration of IL-2 that confers maximal CCR5 expression 
through the PHA/IL-2 activation method in order to increase the chance of imaging a 
CCR5+ T cell forming a synapse. 
3.3.3 T cell recall using Revaxis: a problem of concentration 
The inability to recall DTP-specific T cells from PBMCs using Revaxis (Fig. 3.1) may 
indicate a lack of recent immune challenge by DTP antigens in the donors tested. 
Furthermore, lack of proliferation to Revaxis was still observed when measured with 3H-
thymidine incorporation instead of CFDA-SE, which is known to be toxic at high 
concentrations and, thus, can lead to aberrant proliferative function (Parish et al., 2009). 
Additionally, no increase in proliferation was detected over a dilution range of Revaxis 
from 1:125 to 1:4000 that was tested for two donors. The optimal dilution of Revaxis 
(1:1000) had previously been determined by Dr. A. Itano (Tempero Pharmaceuticals, 
USA) and colleagues who were able to recall DTP-specific T cells successfully. However, 
if the donor cohort used in their study had recently received a booster vaccination then the 
chances of recalling antigen-specific T cells using this method would be much higher 
(Mariotti and Nisini, 2009). Another study used Revaxis (1:250 dilution) as a positive 
control for IL-17 production in response to a recall antigen, however an enzyme-linked 
immunospot assay was used and, therefore, this report did not directly examine whether 
any proliferative response actually occurred (Nogueira et al., 2010).  
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Even after immunization, the frequency of TT specific T cells that can be stimulated to 
proliferate is 1:10000 (Murphy et al., 2011). The success rate of isolating antigen-specific 
T cells from donors which have not been vaccinated in the past few years or have never 
received vaccination is low or near-zero (Mariotti and Nisini, 2009). Nevertheless, strong 
evidence exists that, even 10 years after vaccination, TT is able to induce a proliferative 
response in memory T cells in vitro (Sallusto et al., 1999). Perhaps influences of 
experimental procedures, such as the decrease in proliferative response to TT obtained 
when using PBMCs frozen in FCS compared to freshly-isolated PBMCs (Disis et al., 
2006), may go some way to explaining the lack of proliferation in response to Revaxis in 
the present study. However, the main problem with using Revaxis may be that, even at 
1:125 dilution, the quantity of TT is low (≥ 0.16 Lf U/ml TT) compared to a report showing 
that 13-52% of the PBMC population had undergone division after treatment with 2 Lf 
U/ml TT (Zaunders et al., 2009). The possibility still exists that a low dilution of Revaxis 
(e.g. 1:10) may be able to recall DTP-specific T cells in unprimed donors. However, the 
potential effects due to higher concentrations of alum and excipients, such as 
formaldehyde, would need to be carefully controlled.  
3.3.4 Diverse potential of sAgs in CD4+ T cell stimulation 
The use of sAg effectively overcomes the need to generate antigen-specific CD4+ T cells 
in order to form conjugates with MDMs in which the TCR and MHC class II molecules are 
engaged. There are, however, several important considerations when using sAg instead 
of conventional peptide antigen presented by MHC class II. The differences may bear 
relation to the frequency of conjugate formation (Fig. 3.9) and the spread of calcium 
profiles observed (Fig. 3.14). Yet sAgs bear some similarity (Omoe et al., 2010) to the 
way in which different peptide-MHC complexes give rise to different affinities for the same 
TCR which, in turn, has an effect on T cell function, calcium signalling and IS formation 
(Morris and Allen, 2012). This was evidenced by studies showing that the different binding 
affinity of SEA and SEAS206P (SEA with a single point mutation) to TCR was the 
discriminating factor between preferential expansion of T cells expressing Vβ3 compared 
to Vβ11 and vice versa, respectively (Omoe et al., 2010). Working on this principle the 
level of different T cell responses measured by intracellular calcium levels across a 
polyclonal population stimulated by single sAgs would be expected to exhibit differences. 
The sAg-cocktail (SEA/SEB/SEE), however enables 11 (Murphy et al., 2011) of the 25 
known functional TCR-Vβ families (Brewer and Ericson, 2005) to be engaged, with Vβ3 
being bound by both SEA and SEB (Table 3.1). As each interaction has a potentially 
different affinity this effect may contribute, in part, to the variation in the range of calcium 
profiles seen in our experiments (Fig. 3.13).  
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The majority of CD4+ T cells do not form conjugates or exhibit any detectable elevation in 
intracellular calcium in either the presence or absence of sAg (Fig. 3.9 & 3.11). Several 
approaches were used to investigate the ability of the MDMs and CD4+ T cells to form 
productive conjugates: (i) pulsing with a sAg-cocktail instead of SEE only; (ii) substituting 
MDMs with B cells (Daudi) as APCs; (iii) using CD3/CD28-activated CD4+ T cells instead 
of PHA-activated CD4+ T cells.  
More T cells in the samples pulsed with sAg-cocktail, as opposed to samples pulsed with 
SEE-only, showed a calcium increase above untreated controls (Fig. 3.11). Thus, using a 
number of sAgs together appeared to potentiate their effects. This indicates that a limiting 
factor for the number of conjugates responding may be the correspondence between Vβ 
profiles of the donors and the target Vβ families of the sAgs. TCR-Vβ usage in individuals 
is known to vary (Ochsenreither et al., 2008), reflected by the difference in the percentage 
of cells experiencing high calcium levels between each donor (Fig. 3.11). Despite this, 
existing literature suggests that, on average, the Vβ chains of highest frequency within the 
PBL population are those targeted by the sAg cocktail, in particular SEE (Table 3.1). This 
indicates that, in PBLs, the cumulative expression of Vβs that are recognized by the sAg-
cocktail is unlikely to be the limiting factor for inducing conjugate formation or calcium 
signalling. However, as activation protocols can polarise Vβ expression profiles (Geursen 
et al., 1993), the profiles of PHA/IL-2 activated CD4+ T cells would need to be measured 
directly to determine whether relative Vβ expression changed substantially over the 
course of culture. 
Conjugate number may also be affected by the ability of certain macrophages to present 
antigen. Certainly, macrophages are not as efficient as DCs in presenting antigen to naïve 
T cells (Zigmond and Jung, 2013). Yet naïve T cells were not in abundance at the time of 
conjugate formation in the present study. This was indicated by the upregulation of 
activation markers on both PHA and CD3/CD28 activated CD4+ T cell populations, along 
with the high percentage of cells expressing CD45RO, which is suggestive of an 
effector/memory cell phenotype. The ability of macrophages to be able to present antigen 
to effector CD4+ T cells has been demonstrated in vivo (Filipe-Santos et al., 2009; 
Koltsova et al., 2012; Morris et al., 2013). Nevertheless, under certain activation states 
macrophages are not efficient at antigen presentation and can suppress T cell function 
and proliferation (Hoves et al., 2006). However, in the present study when MDMs were 
substituted by B cells, the percentage of CD4+ T cells with a 340:380 ratio ≥ 1.0 did not 
increase (Fig. 3.11). Thus, the large percentage of non-responding CD4+ T cells in the 
presence of sAg did not appear to be due to the cell type engaged in the synapse nor the 
ability of MDMs to form productive conjugates with CD4+ T cells.  
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The flow cytometry method (Fig. 3.9) showed that, after 45 min, fewer than 10% of 
conjugates formed between MDMs and PHA/IL-2 activated CD4+ T cells. However, this 
population of PHA/IL-2 activated CD4+ T cells had a low activation status, indicated by the 
low percentage of cells expressing CD25 or HLA-DR and the reduced levels of CD45RO 
over culture (Fig. 3.5). Since a previous report showed that T cell activation status can 
impact on the dynamics of interactions with APCs (Azar et al., 2010), conjugate formation 
with CD3/CD28-activated CD4+ T cells was tested. Generally the CD3/CD28 activated T 
cells had a higher activation status, shown by a greater percentage of cells expressing 
CD25 or HLA-DR with respect to PHA/IL-2 activated CD4+ T cells. However, as with the 
PHA/IL-2 activated CD4+ T cells, MDM conjugate formation with CD3/CD28 activated 
CD4+ T cells did not exceed 10%. Therefore, the low number of conjugates formed was 
not limited by the low activation status of the PHA/IL-2 activated CD4+ T cell population. 
In addition, the low frequency of conjugates did not appear to be dictated by the APC type 
and was unlikely to be due to a lack of SEA/SEB/SEE-bound TCR-Vβ regions in the CD4+ 
T cell population. 
3.3.5 Analysis of MDM-CD4+ T cell conjugates by flow cytometry 
One other study (Rethi et al., 2002), has looked at T cell intracellular calcium signalling in 
conjugate formation over an extended time-course by flow cytometry. Rethi et al. (2002) 
examined calcium signalling at various time points over 180 min between co-cultured 
murine B cell and fluo-3 loaded T cell hybridomas. The results showed that intracellular 
calcium levels were increased in the presence of antigen-loaded B cells, with calcium 
levels peaking at ~40 min and then declining through to 180 min (Rethi et al., 2002). The 
fact that an increase in calcium was measured in the presence of antigen supports the 
results of the present study (Fig. 3.9). The differences in kinetics may be due to Rethi et 
al. (2002) using B cells instead of macrophages, gating on all fluo-3 loaded T cells rather 
than on conjugates only, or having no prior centrifugation step, which they suggest may 
“promote induction of the calcium signal” (Rethi et al., 2002). The present study used a 
much lower centrifugation speed than those tested by Rethi et al. (2002) (100 x g cf. 2000 
x g) but, nevertheless, we accept that the calcium peak seen at ~5 min is more of a 
reflection of synchronized contact initiation in the presence of sAg, which becomes more 
asynchronous across the population over time. Thus, of all the aforementioned factors 
that may impact on the recorded kinetic, the difference is most likely due to the 
synchronized contact initiation employed compared to the asynchronous co-sedimentation 
utilised by Rethi et al. (2002). Nevertheless, the present study further supports the 
considerable evidence showing a rapid rise in intracellular calcium downstream of TCR 
ligation (Kummerow et al., 2009). 
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The method presented here has several beneficial aspects compared to the protocol used 
by Rethi et al. (2002). Only conjugates formed from the two separate populations were 
gated on, thus excluding any calcium signalling arising from events that may have 
occurred between calcium dye-loaded T cells only. Additionally, the fluo-2leakres was shown 
to have minimal leakage (Fig. 3.8), which has previously been reported as a problem 
when using fluo-3 in lymphocytes (Takahashi et al., 1999), therefore minimizing any 
artefactual reductions in the intracellular calcium levels measured over a long period that 
are simply due to dye leakage. Furthermore, pulse width gating helps to select for events 
involving two or more cells. For future optimization the protocol could make use of an 
intracellular dye instead of DiD, which may reduce the dye transfer that could occur by 
intercellular exchange of PM fragments (trogocytosis). 
Overall the flow cytometry protocol showed that MDM-CD4+ T cell conjugates occurred at 
a similar frequency when pulsed with sAg compared to unpulsed conjugates. Importantly, 
a sharp rise in T cell intracellular calcium levels occurred for sAg-pulsed MDM-CD4+ T 
cell conjugates, but not for MDM-CD4+ T cell conjugates in the absence of sAg (Fig. 3.9). 
Moreover, live cell imaging studies supported observations of the cytometry protocol in 
illustrating that a small, but significantly greater, proportion of CD4+ T cells exhibited high 
levels of intracellular calcium upon interaction with MDMs pulsed with sAg compared to 
untreated MDMs (Fig. 3.11). This shows that productive MDM-CD4+ T conjugates were 
formed in the presence of sAg, which indicates that concurrent synapse and/or kinapse 
formation was likely to be occurring. 
3.3.6 Apparent arrest of CD4+ T cells upon calcium onset  
In the present study CD4+ T cells were found to arrest coincidentally with the onset of 
high intracellular calcium levels (340:380 ≥ 1) (Fig. 3.10b & 3.12). This appears to 
contrast with seminal work conducted by Underhill et al. (1999) who demonstrated that 
mobile murine T cells were able to be activated by macrophages. Critically, imaging was 
conducted over a much longer period of time (180 min) than in the present study (20 min). 
As cell-cell interactions can interconvert between immobile and crawling states (Friedl et 
al., 2005), it is possible that imaging for longer than 20 min may capture T cells in a 
mobile state that still maintains calcium signalling. Furthermore, Underhill et al. (1999) 
may have been looking more at kinapses than synapses as NFAT only requires a low 
level of intermittent calcium signalling in order to be selectively activated (Dolmetsch et al., 
1997). In the present study, the sudden rise of calcium amongst T cells that exhibited 
‘high’ profiles coincided with apparent arrest, which may classically reflect a synapse. Yet 
many other T cells exhibited ‘low’ calcium profiles, which if imaged for longer may be 
detected to be slowly-mobile and thus correlate with the observations of Underhill et al. 
  
 
113 
 
(1999). To identify such kinapses the imaging technique needs to be able to differentiate 
between stable (< 1 µm/min) and slowly-mobile (1-2 µm/min) states (Friedl et al., 2005). 
Thus, whilst the current low-resolution (0.92 µm/pixel) technique combined with manual 
tracking can report on larger-scale movements, such as dynamic crawling (1-10 µm/min) 
(Friedl et al., 2005), the difference between stable or slowly-mobile states would only be a 
change in a single pixel over a minute. In the future, imaging with the same hardware 
would require a higher magnification and automated cell tracking that uses shape to 
discern the T cell centroid. This set-up may be able to distinguish the differences between 
the stable and slowly-mobile states, though the compromise would be that the numbers of 
responders with 340:380 ≥ 1.0 per field would be very low. 
3.3.7 Grouping calcium profiles to find a signature for IS formation 
Most of the intracellular calcium profiles were flat but, where increases in calcium were 
apparent, the profiles were incredibly variable with regard to intensity and duration (Fig. 
3.13). Using a reductionist system, different profiles and numbers of responding cells were 
previously observed to depend upon subtle differences in sequence and concentration of 
peptide that the APCs were pulsed with (Wülfing et al., 1997). This suggests, therefore, 
that using a variety of sAgs which preferentially bind different TCR-Vβ regions contributed 
to the variation in calcium profiles in the present study. Additionally, Wülfing et al. (1997) 
showed that low or high concentrations of agonist resulted in ~95% of T cells responding 
with a sustained singular onset signal. However, a similar percentage of cells responded 
to a partial agonist, which at a high concentration maintained the proliferative capacity, 
although the calcium profile was a singular onset signal that decreased slowly over time 
(Wülfing et al., 1997). Remarkably, in the present study the majority of calcium profiles 
with maximum 340:380 ≥ 1.0 in the presence of sAg showed a slowly decreasing signal 
after the initial onset. It is, therefore, tempting to speculate that the resulting response may 
also be associated with proliferative capacity, which is known to require calcium signalling 
to be sustained over a time-course of hours (Hogan et al., 2010). Certainly, the results of 
the flow cytometry study showed that calcium signalling in conjugates occurred for at least 
45 min. This, combined with the observation that the percentage of cells classified as 
‘transient’ did not increase upon addition of sAg, suggests that long-term calcium 
signalling may be taking place. However, although this may lead to effector function, the 
function is not necessarily proliferation but, perhaps, cytokine production, which also 
requires long-term calcium signalling (Hogan et al., 2010). Nonetheless, in the absence of 
sAg the majority of non-‘flat’ calcium profiles were ‘transient’ and expected to relate to the 
ubiquitous use of calcium downstream of numerous receptors, including GPCRs 
(Clapham, 2007). Indeed, our laboratory has previously demonstrated that transient rises 
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of a similar duration occur in monocytes in response to chemokine stimulation (Fox et al., 
2011). 
Classification of calcium profiles has the potential to enable identification of different types 
of synapse or kinapse. The first step in classification was to identify whether differences 
could be detected in the wide range of different calcium profiles apparent in the presence 
or absence of sAg (Fig. 3.13). The qualitative classification system indicated that only a 
small percentage of CD4+ T cells displayed some kind of sustained (i.e. classes: ‘low’ and 
‘high’) response in the absence of sAg, whereas a larger proportion were engaged in 
sustained signalling in the presence of sAg (Fig. 3.14). This suggests that the addition of 
sAg enabled MDMs and CD4+ T cells to engage in productive conjugates with sustained 
calcium signalling downstream of TCR ligation. Since the sustained response was formed 
from a range of low to high amplitude calcium profiles, these may represent a mix of 
synapses and kinapses according to the model suggested by Kummerow et al. (2009). In 
particular, the high level signals were exclusive to interactions dependent upon sAg. 
These strong calcium signals may be associated with stable IS formation, supported by 
evidence of close CD4+ T cell apposition to MDMs and arrest coinciding with calcium 
onset of ‘high’ profiles (Fig. 3.12). 
Unfortunately, the computational methods intended to further subgroup similar calcium 
profiles were unable to even resolve the difference between calcium profiles of CD4+ T 
cells with or without sAg. Visual inspection indicated this lack of difference was unlikely to 
originate from oversimplification of the data using the piecewise linear regression as the 
segments tended to reflect the general shape of the calcium profiles (Fig. 3.15). However, 
it may be that any differences in the ‘jumps’ between sections, which effectively report on 
the amplitude of the onset, only translate to a small degree of the overall variation when 
considered together with the other parameters. Thus, the principal components that 
dominate may not necessarily be those that were selected as dominant variables for the 
visual classification system (e.g. calcium onset amplitude). In several calcium profiles 
linear segments were observed to be fitted to the onset in order to minimize R2, giving a 
steep positive gradient. Without modifying the c-script to restrict the fitting of sections with 
steep positive gradients it remains unclear whether these types of segment may give rise 
to systematic artefacts within the parameters. Systematic artefacts are known to 
contribute to variation and, thus, have the potential to dominate the principal components 
(Ringner, 2008). Nevertheless, the parameters extracted from the current piecewise linear 
regression analysis were unable to describe the evident visual differences between non-
‘flat’ calcium profiles of CD4+ T cells in the presence or absence of sAg.  
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Recently, a method has been described where a high cell density tracking function was 
coupled to fluorescence signal processing and was subsequently presented as a heat 
map of cell number over time (Salles et al., 2013). Rather than grouping the highly 
variable calcium profiles to identify which profile types in antigen-pulsed samples also 
existed in unpulsed samples, Salles et al. (2013) used unstimulated cells as a background 
in order to set a threshold that identified peptide-specific activation. However, the 
threshold was set using fluorescence intensity parameters of the calcium profile which 
could lead to misrepresentation of the antigen-dependent response. For example this 
system would not detect whether the presence of antigen resulted in an increased 
frequency of a subset of calcium profiles lying just below the response threshold that are 
identical to a subset in the absence of antigen. Nevertheless, the one-look overview in the 
method presented by Salles et al. (2013) speeds up many of the time-consuming aspects 
of analysing APC-T cell calcium responses. Indeed, similar methods employing 
automated high-density tracking that are able to report on parameters, such as cell shape, 
will facilitate future work in the field and, perhaps, enable calcium profiles with similar 
features to be successfully grouped by automated approaches. 
The results presented in this chapter demonstrate that a limited number of conjugates 
form between primary human CD4+ T cells and MDMs in the presence and absence of 
sAg. The low frequency of productive conjugates does not appear to be limited by the 
APC type nor was it increased by using differentially activated T cells. Imaging studies 
revealed that the calcium profiles of interacting T cells show a wide range of amplitudes 
and durations, which may reflect different mechanisms of antigen-dependent signalling. 
Crucially, T cells engaged in conjugates only exhibited high, sustained levels of 
intracellular calcium in the presence of sAg, which is suggestive of MDM-CD4+ T cell IS 
formation. Therefore, despite its limitations, we decided to use MDM-CD4+ T cell 
conjugates formed in the presence of sAg to assess the role of CCR5 at the IS. 
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Chapter 4: Chemokine receptors at 
the MDM-CD4+ T cell IS 
4.1 Introduction 
4.1.1 Chemokine receptors and IS formation 
Chemokines play a role in priming cells into a signalling-ready state for antigen-receptor 
engagement (Contento et al., 2010). Indeed, in the presence of chemoattractants 
leukocytes adopt a polarised morphology where the uropod of the cell is largely pulled 
along by the protrusive flow of F-actin at the leading edge of the cell (Lammermann et al., 
2008). This polarised morphology promotes TCR sensitization at the leading edge, 
possibly by enhancing the proximity of TCR to signalling components and/or through 
actin-flow mediated disruption of low affinity TCR-MHC interactions at the cell-cell 
interface (Beemiller and Krummel, 2010; Tybulewicz, 2002). Additionally, it has been 
proposed that T cell chemokine receptors crosstalk with the integrin LFA1 to direct 
mitochondrial translocation to the interface with an APC and through doing so set up the T 
cell in a signalling-ready state (Contento et al., 2010). Although integrins are not 
necessary for mobility within a tissue (Lammermann et al., 2008), such crosstalk 
interactions with chemokine receptors may reveal a more subtle role for integrins in 
regulating the dynamics of APC-T cell interactions. Generally, these mechanisms of 
chemokine-induced cell polarisation, which aid TCR signalling or cognate antigen 
recognition could lead to an enhanced frequency of IS formation. 
4.1.2 Chemokine receptor distribution at the IS 
Chemokine receptor signalling has been suggested to influence whether a T cell decides 
to ‘stop’ or ‘go’ in the context of TCR engagement (Bromley et al., 2000). One of the ways 
in which chemokine receptors may regulate this decision is according to the ‘distraction 
hypothesis’. Indeed,  GFP-CCR5 and CXCR4-GFP, when overexpressed in T cells, have 
been shown to be recruited to the T cell side of the human B cell-CD4+ T cell or DC-CD4+ 
T cell IS (Contento et al., 2008; Molon et al., 2005). However since CCR7 did not become 
localised to the interface this is consistent with the proposed hierarchy of chemokine 
receptor and TCR signalling (Bromley et al., 2000; Molon et al., 2005). Furthermore, 
CXCR4 and CCR5 were found to be recruited to the IS in a co-dependent manner 
mediated by APC-secreted chemokines; this was suggested to involve CXCR4:CCR5 
heterodimerisation. Hidden at the APC- T cell interface, these receptors were 
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hypothesised to prevent distraction and promote T cell adhesion rather than chemotaxis 
by signalling through Gq/11 (Contento et al., 2008; Molon et al., 2005). Notably, these 
studies did not consider chemokine receptor expression on the APC cell side nor did they 
show whether differences in localisation still occur with endogenously expressed 
receptors. Although CD8+ T cells expressing CCR5 have been suggested to be involved 
in IS formation at the LN and peripheral sites (Castellino et al., 2006; Franciszkiewicz et 
al., 2009), CD4+ T cells expressing CCR5 would be expected to predominate in peripheral 
sites, since they are primarily of activated or effector memory phenotype (Bleul et al., 
1997; Sallusto et al., 2004). As macrophages are also present at peripheral sites and 
interact with CD4+ T cells in a number of diseases, discussed in section 1.3.4, it seems 
relevant to determine whether CCR5 and CXCR4 are also involved in the productive 
MDM-CD4+ T cell interaction demonstrated in chapter 3. 
4.1.3 MDMs expressing cell surface CCR5 
The results from chapter 3 show that MDMs generated in the present study express 
CCR5, in similarity to macrophages found in certain tissues in vivo (Shen et al., 2009). 
Thus these MDMs can be used as a model to investigate whether endogenous CCR5 
may also localise on the APC side of the IS. In previous studies both GM-CSF and M-CSF 
conditioned MDMs have been shown to express CCR5 (Lee et al., 1999b). However their 
different polarisation towards M1 or M2 phenotypes, respectively (Rey-Giraud et al., 2012) 
can potentially have implications for IS formation. Indeed, M1 macrophages are often 
associated with more efficient antigen presentation and higher levels of costimulatory 
molecules than M2-polarised macrophages (Biswas and Mantovani, 2010). Consequently 
it is important to determine whether these factors translate to more frequent IS formation. 
M-CSF and GM-CSF are cytokines that act to regulate myeloid cell number, survival and 
differentiation (Hamilton and Achuthan, 2013). Each binds to a different receptor and 
exhibits a different pattern of expression; M-CSF being ubiquitous and consistently 
expressed, in contrast to GM-CSF expression, which is normally upregulated in response 
to injury or infection (Hamilton and Achuthan, 2013). In general, M-CSF exclusively 
promotes macrophage differentiation and survival whereas GM-CSF is much more 
promiscuous, also acting on DCs, neutrophils and eosinophils (Hamilton and Achuthan, 
2013). Together these findings constitute a reason for the addition of M-CSF to 
macrophage cultures in vitro in an effort to keep them in their ‘normal state’. Polarising 
macrophages with GM-CSF and M-CSF generates macrophages with similar but not 
identical features to M1 or M2 macrophages, which are polarised by exposure to LPS and 
IFNγ or IL-4 and IL-13, respectively (Gordon, 2003; Hamilton and Achuthan, 2013). In 
appreciation of this, the present study uses GM-CSF alongside LPS and IFNγ in order to 
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recreate as many of the inflammatory stimuli that may lead to M1 polarised MDMs as 
possible. 
4.1.4 Visualising MDM-CD4+ T cell IS formation 
CD4+ T cells form conjugates with sAg-pulsed MDMs, which in turn triggers a rise in T cell 
intracellular calcium levels, as demonstrated in chapter 3. One of the advantages of using 
calcium as a readout of productive MDM-CD4+ T cell conjugate formation was the ability 
to report on all types of antigen-dependent engagement. However productive conjugate 
formation does not necessarily equate to the accumulation of proteins at the MDM-CD4+ 
T cell interface. This is evidenced by the lack of large-scale molecular clustering in T cells 
forming kinapses compared to synapses (Azar et al., 2010). Thus a marker must be used 
to select for signalling MDM-CD4+ T cell conjugates that form an IS. 
In the original description of the IS, antibodies directed against CD3, PKCθ, Lck and fyn, 
or talin and LFA1 were used to mark the cSMAC and pSMAC, respectively (Monks et al., 
1998). In addition the MTOC or the Golgi, which is coordinated to the IS by the MTOC, 
become distributed to the APC- T cell interface upon IS formation (Griffiths et al., 2010). 
However although the MTOC can be used to identify IS formation, in 33% of conjugates it 
has been seen to localise within the third of the T cell proximal to the APC simply by 
chance (Meier et al., 2003). Considering the low frequency of MDM-CD4+ T cell 
conjugates undergoing high calcium signals, this high background level of MTOC 
alignment would not reliably report on IS formation. With regards to potential markers on 
the APC side, cognate ligands of antigen-presentation machinery such as MHC class II 
and ICAM1 have been shown to accumulate (Grakoui et al., 1999; Monks et al., 1998). 
Additionally the APC has been reported to coordinate the accumulation of spinophilin and 
PIP2 to the IS (Bloom et al., 2008; Fooksman et al., 2009). 
The pSMAC of the IS is similar to the lamella observed in the kinapse, since both modules 
are enriched in actin, which undergoes continuous treadmilling (Dustin, 2009b). 
Furthermore both modules are enriched in LFA1 and talin, meaning that synapses and 
kinapses alike would show accumulations of these markers to the APC- T cell interface. 
However the LFA1/talin/actin would show different distributions at the synapse compared 
to the kinapse; a critical difference between these structures is that the pSMAC exhibits 
radial symmetry whilst the kinapse lamella does not (Dustin, 2009b). Note that Monks et 
al. (1998) observed a high percentage of total LFA1 accumulating to the IS, demonstrating 
that it is potentially a useful marker. Nevertheless the cSMAC has been proposed to be 
the most unique module of the IS with no equivalent in the kinapse (Dustin, 2009b). On 
this basis markers associated with the cSMAC are the most effective descriptors of IS 
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formation. Indeed, CD3 and markers against other components of the TCR complex as 
well as PKCθ have been widely used to mark IS formation and remain distributed at the IS 
for over 30 min, making them suitable candidates for the present study (Grakoui et al., 
1999; Revy et al., 2001; Yokosuka et al., 2005). 
This chapter investigates whether productive MDM-CD4+ T cell conjugates formed in the 
presence of sAg result in IS formation. Immunofluorescence microscopy is used to 
investigate the localisation of IS components and whether the frequency of IS formation 
changes with MDM polarisation. The contribution of cell surface CCR5 on the 
macrophage side of the MDM-CD4+ T cell IS is explored as well as the localisation of 
CCR5 and CXCR4 on the T cell side. 
4.2 Results 
4.2.1 CD3 capping marks MDM-CD4+ T cell IS formation 
4.2.1.1 Relationship of CD3 capping with CD4+ T cell intracellular calcium 
CD3 was selected from the potential markers to identify IS formation for several reasons:               
(i) other studies have used CD3 as a marker for IS formation, including the original 
description of the IS by Kupfer and colleagues; (ii) mAb clones of different isotopes are 
available enabling indirect immunolabelling with chemokine receptor mAbs using isotype-
specific secondary antibodies; (iii) mAbs raised against CD3 are inexpensive. Another 
potential marker for the IS is PKCθ, yet despite attempting several different fixation and 
permeabilisation strategies no signal was obtained from immunolabelling MDM-CD4+ T 
cell conjugates using anti-PKCθ mAb C-18 (Santa Cruz Biotechnology, TX, USA). In 
contrast, CD3 accumulation was visible in a small percentage of sAg-pulsed MDM-CD4+ 
T cell conjugates, thus it was the preferred marker to identify IS formation in the present 
study. 
Initially, T cells were labelled with an anti-CD3 Fab fragment digested from whole IgG 
OKT3 in an attempt to visualise accumulation of CD3 in live T cells loaded with the Fura-
2/AM calcium indicator. Analytical gels confirmed that the CD3-Fab fragments generated 
were pure and of the correct size. However when T cells were indirectly labelled with 
CD3-Fab followed by Fab488, a very low fluorescence signal above the levels of control T 
cells labelled with Fab488 secondary was identified by flow cytometry. Furthermore, no 
specific signal for these cells was able to be detected by wide-field fluorescence 
microscopy. Using whole IgG was not a viable alternative since T cells labelled with OKT3 
and co-incubated with MDMs demonstrate enhanced conjugate formation and calcium 
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signalling (Fig. 3.9). In general, coating T cells with any whole IgG antibody would 
effectively opsonise them for interactions with the high affinity IgG receptor (CD16), which 
was previously shown to be upregulated on the MDMs used in the present study (Fig. 
3.2). 
As an alternative approach a correlative imaging technique was used to investigate the 
extent of CD3 accumulation in relation to CD4+ T cell calcium signalling. Glass-bottomed 
dishes were set up so that a central reference point could be easily relocated on different 
microscopes. Practically this meant that a small triangular piece of autoclave tape was 
fixed to the outside base of a glass-bottomed dish, which contained adherent MDMs that 
had been pulsed, or not, with sAg. The tape was positioned so that one of the corners of 
the triangle pointed to the centre of the dish. Dishes that had been marked in this way 
were placed on the microscope stage so that the triangle was located at three o’clock 
relative to the eyepiece. The field of view was then positioned so that the tip of the triangle 
corner was just visible on the middle right of an image acquired using the camera. Fura-2-
loaded CD4+ T cells were pipetted onto the MDMs and conjugate formation was imaged 
live for 30 min. Cells were then immediately fixed, permeabilised, and immunolabelled for 
CD3 (OKT3). Guided by the mark, the original field of view was relocated on a confocal 
microscope and z-stacks of all remaining CD3+ T cells in this field were acquired. The 
position of each confocal z-stack was marked on the final field of view acquired during live 
calcium imaging. This process created a map linking each T cell labelled with CD3 to the 
calcium signalling that T cell had undergone prior to fixation. 
Orthogonal views of the CD3 distribution on each T cell clearly show that CD3 can 
accumulate to the MDM-CD4+ T cell interface. Furthermore, the corresponding calcium 
profiles of each T cell indicate that the accumulation of CD3 appears to correlate to 
existence of a rise in intracellular calcium (Fig. 4.1a). The apparent relationship was 
tested by (i) visually classifying each CD4+ T cell calcium profile into ‘high’, ‘low’, 
‘transient’ and ‘flat’ groups, according to the criteria described in section 3.2.8, and (ii) 
measuring the level of CD3 fluorescence at the interface compared with the rest of the 
CD4+ T cell. This measure was achieved by tracing the PM outline of the CD4+ T cell at 
the interface with the MDM in the appropriate orthogonal view in ImageJ (Fig. 4.1b). The 
position of the interface was determined using brightfield images acquired during the z-
stack. The mean fluorescence across the trace at the interface was then divided by the 
mean fluorescence of the traced outline of the remaining PM (i.e. not at the interface). 
Results show that the ratio of CD3 at the interface is significantly higher for CD4+ T cells 
that have calcium profiles categorised as ‘high’ when compared to others (Fig. 4.1b). 
Further, the ‘low’ group also shows significantly more accumulation of CD3 compared with 
the ‘flat’ group. Notice however that many CD4+ T cells in the ‘low’ group show equal 
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Figure 4.1: CD3 accumulation at the MDM-CD4+ T cell interface correlates with intracellular 
calcium rise. (a) The intracellular calcium rise in CD4+ T cells interacting with sAg-pulsed MDMs 
was imaged, cells were immediately fixed, permeabilised and immunolabelled for CD3 followed by 
GAM
594
. Images show CD3 labelling on individual CD4+ T cells in orthogonal views and the 
correlating intracellular calcium profile. The dashed red line indicates the edge of the MDM in the 
brightfield image. (b) Quantification of CD3 capping (intensity of CD3 capping at the interface 
divided by CD3 intensity of the T cell membrane not at interface; line width, 10 px) from all T cells 
from 4 donors grouped according to visually classification of calcium profiles. Statistical comparison 
using ANOVA followed by Tukey post-test. Pie chart shows relative proportion calcium profile 
groups of CD3+ T cells in field of view after immunolabelling. Error bars, mean ± SD. *, P < 0.05; 
**, P < 0.01; ***, P < 0.001. Scale bars, 5 µm. 
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amounts of CD3 accumulation to the ‘flat’ or ‘transient’ group. It is possible that lack of 
CD3 accumulation alongside concomitant calcium signalling in these cells may indicate 
kinapse instead of synapse formation. 
Overall this result shows that IS-formation and high calcium signalling are associated in 
CD4+ T cells engaged with sAg-pulsed MDMs. With regard to the T cells that remain on 
the coverslip after fixation and immunolabelling, a greater percentage were found to have 
‘high’ or ‘low’ profiles compared to when the cells were imaged live (Fig. 4.1b & Fig. 
3.14). This is most likely to be due to the wash steps performed during immunolabelling, 
which may have removed many of the T cells that were not strongly adhered to MDMs. T 
cells that are not adhered to MDMs cannot engage their TCRs with sAg-bound MHC and 
therefore may undergo lower levels of calcium signalling than adherent T cells. Thus the 
immunolabelling procedure enriches for the types of stable adhesion and high levels of 
calcium signalling that are associated with IS formation. In general, the correlative 
technique confirms the utility of CD3 as a marker and the occurrence of IS formation 
between sAg-pulsed MDM-CD4+ T cell conjugates. 
4.2.1.2 CD3 accumulation with M-CSF vs. GM-CSF conditioned MDMs 
The MDMs forming synapses in the present study showed indications of M2 polarisation; 
however, M1 macrophages are typically associated with more efficient antigen 
presentation (Biswas and Mantovani, 2010). Therefore investigations were made into 
whether CD3 capping, indicative of IS formation, may be limited by the MDM polarisation. 
MDMs were conditioned with M-CSF, or GM-CSF, LPS and IFNγ according to the method 
detailed in section 2.2.1 and seeded onto coverslips. Conjugates were formed between 
sAg-pulsed MDMs and autologous CD4+ T cells, then fixed and immunolabelled for CD3 
(UCHT1). Using a wide-field fluorescence microscope the frequency of IS formation was 
counted via the eyepiece. Note that both DAPI and CD3 images were captured to provide 
a digital record of observations (images not shown). Results show that more CD3 capping 
was apparent in the presence of M-CSF compared with GM-CSF conditioned MDMs (Fig. 
4.2a). Thus IS formation is not limited by the polarity of M-CSF conditioned MDMs that are 
used throughout the present study. Furthermore, MDM-CD4+ T cell conjugates were 
immunolabelled for the M2-marker CD163 alongside CD3, according to the method 
detailed in section 2.11.2. Images show that CD3 capping can occur in T cells engaged 
with CD163+ cells (Fig. 4.2b). This provides further evidence that IS formation is due to 
direct CD4+ T cell interaction with M2-polarised MDMs rather than with other cell types 
(e.g. contaminating B cells). Additionally, MDM-CD4+ T cell conjugates labelled for ICAM1 
and CD3 (UCHT1) revealed that CD3 capping is concomitant with ICAM1 accumulation to 
the MDM-side of the interface (Fig. 4.2c). Generally, this demonstrates that hallmark IS 
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Figure 4.2: Hallmarks of IS formation between CD4+ T cells and M-CSF conditioned MDMs. 
(a) MDMs were cultured with M-CSF or GM-CSF/LPS/IFNγ as described in section 2.2.1 and 
seeded onto coverslips on day 7 at 2 x 10
5
 cell/coverslip. After a further 72 h in culture MDMs 
pulsed with sAg cocktail for 2 h and coincubated with autologous CD4+ T cells for 30 min. 
Conjugates were immediately fixed and immunolabelled for CD3 (UCHT1) followed by GAM
488
 
secondary antibody, stained with DAPI and imaged by fluorescence microscopy. Bar chart shows 
the number of synapses (according to CD3 capping), counted in 30 fields of view for six coverslips 
from two donors, formed between CD4+ T cells and either M-CSF or GM-CSF conditioned MDMs 
(mean ± SD). (b) Representative images (20 images, n = 2) of CD3-capping with CD163+ MDMs. 
Conjugates were formed between sAg pulsed M-CSF-cultured MDM and CD4+ T cells, fixed and 
immunolabelled for CD3 (OKT3) and CD163 followed by GAM-IgG1
488
 and GAM-IgG2a
647
 
secondary antibodies. (c) Images showing sAg-pulsed or unpulsed MDM-CD4+ T cell 
immunolabelled for CD3 (UCHT1) and ICAM1 as described for (b). Yellow arrows indicates IS 
formation according to CD3 capping. Scale bars, 10 µm 
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markers such as CD3 and ICAM1 accumulate to the interface, in line with other types of 
synapse, and that synapse formation is not constrained by the M2 polarisation of MDMs.  
4.2.2 MDM cell surface CCR5 distribution upon IS formation 
To determine whether the distribution of endogenous CCR5 on the MDM PM changes 
upon IS formation, MDM-CD4+ T cell conjugates were formed, fixed and immunolabelled 
for CCR5 and CD3 according to the method detailed in section 2.11.2. No change in the 
cell-surface distribution of CCR5 (MC5) on MDMs was apparent upon IS-formation with 
CD4+ T cells when pulsed with sAg compared to unpulsed controls (Fig. 4.3a). The MDM 
membrane was traced to test whether a slight decrease, that is not detectable by eye, 
may occur in CCR5 levels at the IS (Fig. 4.3b). Using the trace, the median fluorescence 
value of CCR5 across the membrane was determined and then subtracted from every 
individual fluorescence intensity value in the trace. These values were plotted when the 
same trace detected regions of intensity in the CD3 channel, i.e. at the MDM-CD4+ T cell 
interface. Finally the distance across each MDM-CD4+ T cell interface was normalised to 
an arbitrary value of 100 to aid comparison. Still, no difference in the fluorescence 
intensity was detected at the interface between MDMs and CD4+ T cells either with or 
without sAg (Fig. 4.3c).  
A recent study from our lab identified a functionally distinct pool of CCR5 on MDMs 
(Signoret lab, unpublished data). These receptors are specifically recognised by the mAb 
CTC5 and label discrete areas of the PM. We co-labelled MDM-CD4+ T cell conjugates 
with CTC5 and OKT3 and found that regions of CTC5 capping were not located opposite 
to CD3, but rather were apparent at the sides or opposite the position of IS formation (Fig. 
4.4). Overall, the current evidence suggests that the distribution of CCR5 on the cell 
surface of MDMs is unaffected upon IS formation with CD4+ T cells. 
4.2.3 Removal or inhibition of MDM cell surface CCR5 on IS formation 
Despite the fact that MDM cell surface CCR5 is not accumulated to or excluded from the 
MDM-CD4+ T cell IS, we examined whether MDM cell surface CCR5 may play any other 
essential role in IS formation. Ligand-induced downmodulation is a well-characterised 
mechanism of chemokine receptor regulation, particularly with regard to CCR5 (Mack et 
al., 1998; Signoret et al., 2004; Signoret et al., 2005; Signoret et al., 2000; Signoret et al., 
1998). The reduction in cell surface expression of CCR5 upon pulsing cells with native 
ligands, such as CCL5, is only transient. However synthetically modified forms of CCL5 
induce a more robust and prolonged reduction in cell surface levels (Escola et al., 2010). 
Specifically, PSC-RANTES has a more durable association with CCR5 and treatment with 
this N-terminally modified form of CCL5 results in long-term sequestration in the TGN,
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Figure 4.3: MDM CCR5 does not cap opposite CD3. (a) Representative images of MDMs pulsed 
+/- sAg and incubated with 1:2 with autologous CD4+ T cells (30 min), fixed then immunolabelled 
for CCR5 (MC5) and CD3 (UCHT1) followed by GAM-IgG1
488
 and GAM-IgG2a
647
. (b) Diagram 
illustrating how MDM cell surface fluorescence at the is quantified at the interface. Yellow line 
shows an example of the 10 px wide line drawn around the MDM PM over which the fluorescence 
intensities of CD3 and CCR5 are measured (middle plots). The median value (black dotted line) for 
CD3 and CCR5 intensities is calculated and subtracted (right plots). The interface is designated as 
the intensity at which median-subtracted CD3 fluorescence exceeds 10 (yellow box). The original 
line distance spanned by this box (x) is normalised across a range of 0-100 and designated the 
interface distance (c) Average trace of CD3 and CCR5 intensity, subtracted for median MDM cell 
surface fluorescence value, at the MDM-CD4+ T cell interface (mean ± 95% CI for 15 conjugates) 
formed +/- sAg. Scale bars, 10 µm. 
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Figure 4.4:  The CTC5-bound form of CCR5 does not localise to the MDM-CD4+ T cell IS. 
MDMs were pulsed with sAg then coincubated with autologous CD4+ T cells (30 min), fixed and 
immunolabelled for CD3 (OKT3) and CCR5 (CTC5) followed by GAM-IgG1
488
 and GAM-IgG2a
647
 
secondary antibodies. Images are representative of 2 donors. Yellow arrow indicates IS formation. 
Scale bar, 10 µm 
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even after inhibition of PM CCR5 signalling (Escola et al., 2010). In addition, overnight-
treatment of MDMs with PSC-RANTES was found to reduce cell surface CCR5 levels by 
more than 90% when labelling with MC5 (Signoret lab, unpublished data). Thus, MDMs on 
glass coverslips were treated with 100 nM PSC-RANTES or in media alone for 16 h.  
These MDMs were pulsed with sAg and then co-incubated with CD4+ T cells, fixed and 
immunofluorescently labelled for CCR5 (MC5) and CD3 (UCHT1), as detailed in section 
4.2.2. MDMs on control coverslips, to which CD4+ T cells were not added, showed vastly-
depleted CCR5 cell surface levels after treatment with PSC-RANTES compared to 
treatment with media alone (Fig. 4.5a; left panels). Note that PSC-RANTES was washed 
away 2.5 h prior to fixation, thus the continued absence of CCR5 at the cell surface 
corroborates evidence that downmodulation with PSC-RANTES results in long-term 
intracellular sequestration of CCR5 (Escola et al., 2010). Nevertheless, IS formation was 
observed despite CCR5 depletion from the MDM cell surface (Fig. 4.5a). This indicates 
that the presence of CCR5 on the MDM cell surface is not essential for MDM-CD4+ T cell 
IS formation. 
In an alternative approach MDMs were treated with TAK-779, a small, non-peptide 
inhibitor of chemokine binding and downstream signalling of CCR5 (Baba et al., 1999). 
MDMs were incubated with 400 nM TAK-779 or media for 1 h in the course of pulsing with 
sAg. MDMs-CD4+ T cell conjugates were formed, fixed and immunolabelled as detailed 
for PSC-RANTES treated cells. Despite TAK-779 treatment CD4+ T cells demonstrated 
capping of CD3 to the MDM-CD4+T cell interface, indicative of IS formation (Fig. 4.5b). 
This indicates that signalling downstream of MDM cell surface CCR5 is not required for 
MDM-CD4+ T cell IS formation. 
4.2.4 CXCR4 at the CD4+ T cell side of the IS 
When overexpressed, CXCR4-GFP has been demonstrated to accumulate on the CD4+ T 
cell side of the B cell- CD4+ T cell IS (Contento et al., 2008). Since the majority of PHA/ 
IL-2 activated T cells express cell surface CXCR4 (Bleul et al., 1997), we decided to 
determine whether endogenous CXCR4 might localise to the T cell side of the MDM-
CD4+ T cell IS. IS formation and immunolabelling of intact cells was performed as 
described in section 2.11.2, but using primary antibodies raised against CXCR4 (12G5) 
and CD3 (UCHT1). Representative images show that in sAg-pulsed MDM-CD4+ T cell 
conjugates forming the IS, endogenous CD4+ T cell CXCR4 can become enriched at the 
cell-cell interface (Fig. 4.6a). Furthermore, the images illustrate that little or no CXCR4 
was detectable on any MDMs, therefore this enrichment is unlikely to be an artefact of 
fluorescence from the macrophage cell side of the IS.  
  
 
128 
 
a
CCR5 MC5 CD3 CCR5 CD3 CCR5 CD3 CCR5 CCR5
CD3 CCR5 CD3 CCR5 CD3 CCR5 CD3 CCR5 CD3 CCR5
Media
TAK-779
b
Media
PSC-RANTES
CD3 CD3 CCR5 CD3 CCR5
CCR5
CCR5
CCR5 CCR5
CD3
CD3
MDMs + CD4+ T cells
MDMs + CD4+ T cellsMDMs alone
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5:  Decreasing or antagonising MDM cell surface CCR5 does not prevent IS 
formation. (a) MDMs were treated with 100nM PSC-RANTES or media alone for 16 h before 
pulsing with sAg and coincubating with autologous CD4+ T cells. During pulsing and coincubation 
MDMs only (left panels) were kept in media. All samples were immediately fixed and 
immunolabelled for CD3 (UCHT1) and CCR5 (MC5) according to the method detailed in section 
2.11.2. (b) MDMs were pulsed with sAg and either 400 nM TAK-779 or media alone for the final 60 
min of incubation. MDMs were coincubated with autologous CD4+ T cells, fixed and 
immunolabelled as described in (a). Coloured fields of view show merged CD3, CCR5 and DAPI 
fluorescence representative of two donors. Scale bar, 20 µm. Single channel images, zoomed on a 
region of IS formation in the merged image above, are also shown Scale bar, 10 µm. Yellow arrow 
indicates IS formation.  
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Figure 4.6:  CXCR4 accumulation to the MDM-CD4+ T cell IS. (a) Conjugates were formed 
between CD4+ T cells and sAg-pulsed or unpulsed MDMs for 30 min, fixed and then 
immunolabelled for CXCR4 and CD3 followed by isotype specific secondary fluorophores. 
Representative images of CXCR4 accumulation at the interface between MDMs and T cells are 
presented. Scale bar, 10 µm. (b) Graphs show fluorescence quantification of the T cell membrane 
as described in section 4.2.1.1. Each symbol represents an individual T cell from a total of 2 donors 
when interacting with MDMs had been pulsed with (+sAg: 34 cells) or without sAg (no Ag: 36 cells). 
Red line geometric MFI. ***, P< 0.001 (Student’s unpaired t-test). Cells with accumulation > 2 SD 
above the mean no Ag fluorescence value (2.02), sAg = 24%, noAg = 8%. 
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In order to compare the level of CXCR4 and CD3 accumulation at the IS relative to 
conjugates formed in the absence of antigen the ratio of fluorescence at the interface 
compared to the rest of the T cell was calculated, as described in section 4.2.1 (Fig. 
4.1b). Results show that the mean accumulation of CD3 at the cell-cell interface is over 
four-fold greater in the presence of sAg-pulsed MDMs compared to unpulsed controls (4.8 
± 2.7 and 1.1 ± 0.3, respectively). In contrast, the mean enrichment of CXCR4 at the IS is 
less than two-fold of that observed in the absence of antigen (1.6 ± 0.5 and 1.2 ± 0.4, 
respectively) (Fig. 4.6b). Thus, although both CD3 and CXCR4 show significantly greater 
accumulation on CD4+ T cells upon IS formation compared to conjugates formed in the 
absence of antigen, the accumulation of CXCR4 to the interface is more modest (Fig. 
4.6a & b). Additionally, the no antigen control interface ratio mean plus two SDs was used 
as a value to designate greater-than-normal accumulation of either CXCR4 or CD3 to the 
conjugate interface. Values calculated in this way are referred to as ‘cut-off’ values 
throughout the rest of this study. 
The percentage of T cells showing CXCR4 accumulation above the cut-off value was 24% 
in the presence of sAg, compared to 8% of cells in the absence of antigen. In contrast, 
100% of cells lie above the cut-off value for CD3. Thus only a quarter of T cells show 
levels of CXCR4 accumulation at the interface that are greater than those observed in 
conjugates forming in the absence of IS formation.  Moreover, the level of CXCR4 that 
accumulates at the IS is only marginal in comparison to CD3. 
4.2.5 CCR5 at the CD4+ T cell side of the IS 
4.2.5.1 Accumulation of CD4+ T cell surface CCR5 
Since CXCR4 accumulation has been reported to be directed by CCR5 on the CD4+ T 
cell side of the B cell-CD4+ T cell IS (Contento et al., 2008), we also investigated whether 
CCR5 may accumulate on the T cell side of the MDM-CD4+ T cell IS. In section 4.2.2, 
fixed MDM-CD4+ T cell conjugates were immunolabelled for CCR5 and CD3 to examine 
the MDM side of the IS; however, the role of CCR5 on the T cell side may have been 
overlooked. This is due to the low percentage T cells per coverslip that demonstrate CD3 
capping combined with the fact that only 12 ± 9 % of PHA/IL-2 activated CD4+ T cells are 
CCR5+ (Fig. 3.6). Thus the chances of observing synapse formation involving a CCR5+ T 
cell are very low. Nevertheless, fixed MDM-CD4+ T cell conjugates were immunolabelled 
intact with CCR5 and CD3, as described in section 4.2.2. Conjugates involving CD4+ T 
cells expressing CCR5 were imaged by confocal microscopy. Representative images 
indicate that CD4+ T cell CCR5 accumulation can occur alongside CD3 capping at the IS, 
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although often very little, if any, enrichment of CCR5 at the MDM-CD4+ T cell interface is 
observed (Fig. 4.7a). 
Even though MDMs express cell surface CCR5, no change in the levels of MDM CCR5 at 
the MDM-CD4+ T cell interface was detected compared to conjugates formed in the 
absence of antigen (Fig. 4.2). Based upon this evidence, any enrichment of CCR5 
detected at synapses formed between MDMs and CCR5+ CD4+ T cells can be expected 
to be due to the T cell. Furthermore, by using the interface: rest of T cell ratio (as used for 
CXCR4 fluorescence quantification in section 4.2.4) contributions of MDM CCR5 can be 
controlled for by comparing accumulation at the IS to conjugates formed between CCR5+ 
CD4+ T cells and unpulsed MDMs. The ratio of CCR5 enrichment at the interface of 
MDM-CD4+ T cells forming synapses is significantly greater than that of conjugates 
formed in the absence of antigen (Fig. 4.7b). In similarity to CXCR4, the mean 
accumulation ratio of CD4+ T cell CCR5 in synapses is less than two-fold that of 
conjugates formed in the absence of antigen (1.7 ± 0.8 and 1.1 ± 0.3, respectively). Again, 
CCR5 accumulation is modest in comparison to CD3, which showed five-fold greater 
levels at the IS than in conjugates formed in the absence of antigen (5.2 ± 2.3 and 0.9 ± 
0.3, respectively). Interestingly, 48% of CD4+ T cells engaged in synapses, versus 4% 
CD4+ T cells in conjugates formed in the absence of antigen, showed a level of CCR5 
enrichment above the no antigen CCR5 cut-off value. Overall this shows that endogenous 
T cell CCR5 can be accumulated to the MDM-CD4+ T cell IS, corroborating GFP-CCR5 
accumulation observed in other synapses (Contento et al., 2008; Molon et al., 2005). 
However as only half of the CCR5+ T cells showed CCR5 accumulation at the IS, there is 
an indication that certain synapses formed within the heterogeneous population of primary 
cells possess the features required for CCR5 accumulation, whilst others do not. 
4.2.5.2 Localisation of CCR5 on permeabilised CD4+ T cells 
To begin to determine whether cell surface CCR5 localisation at the IS may be regulated 
by internalisation at the interface, the presence and localisation of intracellular CCR5 in 
CD4+ T cells forming synapses was investigated. MDM-CD4+ T cell conjugates were 
fixed, permeabilised and immunolabelled for CD3 (UCHT1) and CCR5 (MC5) according to 
the method detailed in section 2.11.3. Images show accumulations of CCR5 on the CD4+ 
T cell side of the IS for conjugates formed with both sAg-pulsed and unpulsed MDMs (Fig. 
4.8a). Thus CD4+ T cells appear to have intracellular accumulations of CCR5, only 
accessible upon permeabilisation, which localise to the cell-cell interface irrespective of IS 
formation. The interface ratio approach, used above to quantify CD3, CCR5 and CXCR4 
accumulation to the IS, is not appropriate here as the 10 px lines drawn around the 
membrane will not include the intracellular fluorescence. For this reason an alternative
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Figure 4.7: CCR5 accumulation to the MDM-CD4+ T cell IS for cells immunolabelled when 
intact. (a) Conjugates were formed between CD4+ T cells and sAg-pulsed or unpulsed MDMs for 
30 min, fixed and then immunolabelled for CCR5 and CD3 followed by isotype specific secondary 
fluorophores as detailed in section 2.11.2. Representative images of CCR5 accumulation at the 
interface between MDMs and T cells are presented. Scale bar, 10 µm. (b) Graphs show 
fluorescence quantification of the T cell membrane, as described in section 4.2.1.1, of CCR5/CD3 
labelled MDM-CD4+ T cell conjugates. Each symbol represents an individual T cell from a total of 2 
donors when interacting with MDMs had been pulsed with (+sAg: 21 cells) or without sAg (no Ag: 
24 cells). Red line shows geometric mean. **, P<0.01; ***, P<0.001 (Student’s unpaired t-test). 
Cells with accumulation > 2 SD above the mean no Ag fluorescence value (1.70), sAg = 48%, 
noAg = 4%. 
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Figure 4.8: CCR5 accumulation to the MDM-CD4+ T cell IS for cells immunolabelled when 
permeablised. (a) Conjugates were formed between CD4+ T cells and sAg-pulsed or unpulsed 
MDMs for 30 min, fixed, permeabilised and then immunolabelled for CCR5 and CD3 followed by 
isotype specific secondary fluorophores as detailed in section 2.11.3. Representative images of 
CCR5 accumulation at the interface between MDMs and T cells from 2 donors. (b) Example of 
ROIs drawn and calculations involved in the quantification process, accompanying description in 
section 4.2.5.2. Graphs show the polarisation of CCR5 (crosses) or CD3 (filled circles) observed in 
each T cell analysed in conjugates formed with (n=23) or without (n=28) sAg from D2013006 and 
D2013007 using this fluorescence quantification method. 
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quantification method was adopted using four 50x50 px ROIs positioned on the T cell: one 
at the interface, one on the opposite side of the interface termed ‘away’, and one on either 
side of the interacting T cell termed ‘side (a)’ and ‘side (b)’ (Fig. 4.8b). The ROIs span 
some of the intracellular space enabling both internal and membrane fluorescence to be 
measured. Each ROI is expressed as a percentage of the total fluorescence of all four 
ROIs. Subsequently, by subtracting the percentage of fluorescence in the ‘away’ ROI from 
the ‘interface’ ROI a measure of front-to-back CCR5 polarity is obtained. Similarly, a 
measure of side-to-side CCR5 polarity is gained by subtracting the percentage of 
fluorescence of ‘side (b)’ from ‘side (a)’ (Fig. 4.8b). For each T cell the side-to-side and 
front-to-back polarity values can be plotted as x and y values giving a graphical 
representation of CCR5 distribution compiled for each cell measured. Such an approach 
is effective because in the absence of antigen, CD3 can be seen to be distributed about 
the axis intersection but upon addition of sAg the cells show polarity of CD3 towards the 
direction of the interface, as expected (Fig. 4.8b). The same CD4+ T cells also show 
increased CCR5 polarity towards the interface when engaged with sAg-pulsed compared 
to unpulsed MDMs. Indeed CCR5 front-to-back polarity for CD4+ T cells conjugated with 
sAg-pulsed MDMs was significantly greater compared to conjugates formed with unpulsed 
MDM (P<0.001; t-test with Welch’s correction). Further, after all plus or minus signs had 
been removed from the data (as designation of side (a) or (b) ROIs was arbitrary) CCR5 
side-to-side polarity in CD4+ T cells engaged with sAg-pulsed MDMs was found to be 
significantly less than in conjugates formed with unpulsed MDMs (P<0.05; Mann-Whitney 
U-test). This demonstrates that CCR5 becomes more equally distributed across either 
side of the cell upon IS formation. Together these results indicate that CCR5, both 
intracellular and cell surface, accumulates towards the centre of the MDM-CD4+ T cell 
interface upon IS formation. Notice that the +sAg CCR5 graph indicates that in the 
presence of sAg-pulsed MDMs all measured cells show a degree of polarisation towards 
the interface. Yet this measure of polarity is partially due to fluorescence from the MDM, 
which is also labelled with CCR5. Additionally, not all CCR5 should be thought of as 
actively polarising to the interface upon IS formation. This is evident as in the absence of 
antigen a number of CD4+ T cells already show CCR5 polarised towards the interface 
rather than being more evenly distributed and surrounding the axis origin, as is the case 
for CD3 (Fig. 4.8b). In general, intracellular CCR5 can be observed at the cell-cell 
interface in the absence of IS formation, however far more cells demonstrate CCR5 
polarisation to the cell-cell interface after IS formation. Thus the ability to visualise 
intracellular CCR5 can contribute to whether or not CCR5 accumulation is observed on 
the T cell side of the MDM-CD4+ T cell IS. 
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5.2.6 Colocalisation of intracellular CCR5 with TGN and TfR 
It remains unclear whether accumulation of CCR5 is truly internal or whether cell surface 
epitopes, otherwise inaccessible to antibody, are revealed by permeabilisation. To 
investigate this, MDM-CD4+ T cell conjugates were colabelled with CCR5 (MC5) and a 
marker directed against an integral membrane protein of the TGN (TGN46), according to 
the method detailed in section 2.11.3. Z-stacks of sAg-pulsed or unpulsed conjugates 
were acquired. Confocal sections zoomed on the region of CD4+ T cell TGN staining 
showed that TGN46 partially colocalised with CCR5 in conjugates formed in both the 
presence and absence of sAg (Fig. 4.9.1a). This suggests that the CCR5 revealed by 
permeabilisation is at least partly intracellular. 
In an effort to investigate whether the increased CCR5 accumulation at the MDM-CD4+ T 
cell interface formed with sAg-pulsed MDMs may be caused by alterations in trafficking of 
CCR5 conjugates were immunolabelled for TfR and CCR5. TfR is a marker for clathrin 
mediated endocytosis and the RE route that is followed by CCR5 during ligand-induced 
internalisation (Signoret et al., 2005). Speculatively, CCR5 may show a higher level of 
overlap with TfR if the rate of internalisation is increased at the IS. Yet, no change in the 
colocalisation of CCR5 with TfR was evident in conjugates formed in the presence of sAg 
(Fig. 4.9.1b).  CCR5 colocalisation with TfR appeared to be less widespread than with the 
TGN. Overall, this suggests that the increase in CCR5 fluorescence at the IS when 
permeabilised is not caused by increased trafficking to the RE compartment. Thus it 
remains unclear as to whether the localisation of CCR5 in permeabilised cells at the IS is 
due to active internalisation of CCR5 at the IS or passive redistribution of intracellular 
pools of CCR5. In relation to the latter point, immunolabelling of sAg-pulsed and unpulsed 
MDM-CD4+ T cell conjugates for both GM130 and CD3 was carried out and z-stacks were 
acquired. Whilst no global change in the distribution of the MDM Golgi was observed, the 
T cell Golgi accumulated to the cell-cell interface preferentially in IS-forming conjugates 
(Fig. 4.9.2). Localisation of T cell Golgi to the IS is well-documented and results from 
association of the Golgi with the MTOC via motor protein attachments (Griffiths et al., 
2010). Since a fraction of internal CCR5 appears to be colocalised with the TGN in both 
the presence and absence of sAg, Golgi polarisation to the IS is likely to contribute to 
CCR5 enrichment at the IS. 
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Figure 4.9.1:  Colocalisation of TGN or TfR with CCR5. MDM-CD4+ T cell conjugates were 
formed, fixed and immunolablelled for (a) TGN and CCR5 followed by anti-sheep
488
 and GAM-
IgG2a
647
 or (b) TfR and CCR5 followed by GAM-IgG1
488
 and GAM-IgG2a
647
 secondary antibodies 
according to the method detailed in section 2.11.3. Three examples of CCR5+ conjugates formed 
+/- sAg are shown, which are representative of z-stacks acquired from two or three donors. For 
each example individual slices of the z-stack are shown over the region of CCR5 intracellular 
accumulation at the MDM-CD4+ T cell interface. Within these slices the dotted box indicates the 
region where TGN or TfR and CCR5 are shown as separate greyscale images. Scale bar, 5 µm. 
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Figure 4.9.2: The Golgi redistributes to the T cell side of the MDM-CD4+ T cell IS. Conjugates 
were formed between CD4+ T cells and sAg-pulsed or unpulsed MDMs for 30 min prior to fixation 
and indirect immunolabelling for Golgi (GM130) and CD3 (OKT3) followed by GAM-IgG1
488
 and 
GAM-IgG2a
647
 according to the method described in section 2.11.3. Confocal Z-stacks were 
acquired to judge the position of the Golgi at the cell-cell interface. Images show max. intensity 
projections and a brightfield slice from the stack. 3D reconstructions were used to determine the 
region of cell-cell contact. Yellow and cyan dotted outline indicate the extent of MDM and T cell 
volumes, respectively. Black arrow indicates the position of the interface. The bar chart indicates 
the percentage of MDM-CD4+ T cell conjugates to which the Golgi localises to the cell-cell 
interface in the presence or absence of sAg (mean ± SD). Scale bar, 10 µm. 
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4.3 Discussion 
4.3.1 Implications of defining IS formation by CD3 capping 
CD3 accumulation to the interface was found to be significantly greater when calcium 
signalling was high (Fig. 4.1). This corroborates the concept that the higher, more 
sustained calcium profiles of CD4+ T cells engaging sAg-pulsed compared to unpulsed 
MDMs (section 3)  are associated with spatial reorganization of TCR-CD3 to the cell-cell 
interface, a hallmark of IS formation (Monks et al., 1998). Yet observe that some of the 
‘low’ calcium profiles also accumulate CD3 (IS formation) whilst others do not, which may 
indicate kinapse formation. This highlights that in using CD3 capping as a selection 
criterion, certain other antigen-dependent conjugates become excluded from the analysis. 
The link between CD3 capping and calcium signalling was expected, due to the link 
between calcium signalling regulation and IS formation (Kummerow et al., 2009) In 
addition, correlation between CD3-capping and calcium flux has previously been used to 
demonstrate IS formation (Revy et al., 2001). In the present study, the correlative assay 
confirmed that capping of CD3 to the cell-cell interface is an appropriate marker to identify 
fixed MDM-CD4+ T cell conjugates forming synapses. This was an essential step in order 
to be able to select for the rare events of IS formation within the plethora of cell-cell 
interactions, so that the localisation of chemokine receptors and other proteins could be 
investigated. Moreover, bilayer studies have demonstrated that the central accumulation 
of CD3 at the IS interface begins only several minutes after initial calcium flux and 
remains present for 30-60 min (Yokosuka et al., 2005). Thus, although the duration of cell-
cell contact may differ in the present study, selecting synapses by the presence of CD3 at 
the interface encompasses both nascent and longstanding synapses. However this may 
have implications for the frequency of cells in which CCR5 or CXCR4 are found to be 
present at the IS opposite to CD3, as CCR5 and CXCR4 may be recruited to IS for a 
shorter duration than CD3. Such transient localisation has been observed for PKCα 
(Gharbi et al., 2013) and for CD4, which initially accumulates to the cSMAC but shortly 
becomes redistributed to the pSMAC (Krummel et al., 2000). Note, however that Molon et 
al. (2005) reported that in synapses formed between Jurkat cells and B cells or DCs, 
GFP-CCR5 remained localised at the interface for at least 30 min. 
4.3.2 IS formation with M1/M2 polarised MDMs 
In order to determine whether the capacity to form an IS is affected by polarising MDMs 
towards an M1 or M2 phenotype, synapses were formed with MDMs, which had been 
cultured in GM-CSF/LPS/IFNγ or M-CSF, respectively. A greater number of synapses 
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were formed with M2 compared to M1 polarised MDMs (Fig. 4.2). Initially, this result 
appears paradoxical as M1-polarised MDMs are associated with more efficient antigen 
presentation, as judged by apparently higher levels of CD80 in comparison to M2 MDMs, 
shown in section 3.2.2.2 (Biswas and Mantovani, 2010; Martinez et al., 2009). However, 
this difference may not affect the ability to form an IS. The absence of functional CD80 is 
neither essential for, nor reduces the frequency of synapse formation and would only 
affect the area and density of TCR-MHC accumulated to the interface (Choi and 
Schwartz, 2011; Wetzel et al., 2002). Additionally the difference in synapse number is not 
likely to be caused by an inability of sAg to bind to either M1 or M2 MDMs. This is 
because the M2 cells used here still express CD80, albeit at lower levels than the M1 
cells, as well as MHC class II and so fulfil the requirements of sAgs in order to contact the 
full range of Vβ regions (Lando et al., 1996). Instead, perhaps the differences are caused 
by the relative abundance of different T cell phenotypes (e.g. Th1 and Th2 cells) within the 
population of PHA/IL-2 cells. M2 MDMs are known to preferentially secrete Th2-linked 
chemokines so a greater number of synapses may be formed if more T cells in the 
population express cognate chemokine receptors. However, apart from CCR5 the 
chemokine receptor expression profile of the CD4+ T cell population is unknown, as is the 
chemokine secretion pattern of the MDMs that are utilised in the present study. 
4.3.3 Differential CCR5 accumulation to the IS 
The MDM side of the IS is relatively unexplored in comparison to the T cell side. The 
accumulation of several APC markers to the IS is coordinated by their cognate receptors 
on the T cell, as evidenced by studies with planar bilayers (Grakoui et al., 1999). For this 
reason the accumulation of ICAM1 on the MDM side of the IS (Fig. 4.2) observed in the 
present study is thought to be nucleated by the engaged CD4+ T cell. Nevertheless this 
does not mean that the APC is passive in the synapse, as demonstrated by the fact that 
CD80 and the APC cytoskeleton may modulate the organisation of the IS (Friedl et al., 
2005; Tseng et al., 2005). Moreover, some components that are localised to one side of 
the synapse are not necessarily reflected on the other. An example of this is the evidence 
presented in this chapter showing that CCR5 does not accumulate to the MDM side of the 
MDM-CD4+ T cell synapse (Fig. 4.3) but can accumulate to the T cell side (Fig. 4.7).  
Previous research suggests that IS formation alone is not sufficient to prompt CCR5 
accumulation to the interface, but another trigger is required (Contento et al., 2008; 
Franciszkiewicz et al., 2009; Molon et al., 2005). For CD4+ T cells engaged in synapses 
with DCs or B cells, this trigger has been suggested to exist in the form of cognate 
chemokines secreted by the APC (Molon et al., 2005). If CD4+ T cell CCR5 in the present 
study is indeed brought to the IS via a mechanism dependent upon APC secretion of 
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cognate chemokines, why is MDM CCR5 not also recruited to the interface? Two theories 
are evident: (i) MDMs secrete CCL3/4/5 uniformly so autocrine signalling does not induce 
CCR5 polarisation; (ii) CCR5 is not coupled to the same regulatory machinery on MDMs 
as in T cells.  
The first theory is perhaps the simplest explanation. Although directional secretion of 
chemokine across the IS by T cells can occur (Catalfamo et al., 2004), directionality is 
often cell-type or activation-status specific (Huse et al., 2008). Multi-directional distribution 
of chemokine would aid recruitment of relevant T cells in a given microenvironment (Huse 
et al., 2008) and therefore may speculatively be the dominant secretion pattern for APCs. 
This means that MDM CCR5 would be exposed to an equal level of autocrine chemokine 
all around the cell. In contrast, the T cell would sense a gradient and migrate towards the 
APC, a mechanism which has been shown to polarise the cellular CCR5 distribution in 
other situations such as chemotaxis (Gomez-Mouton et al., 2004). 
Regarding the latter theory, the susceptibility of distinct conformational forms of CCR5 to 
undergo ligand induced down-modulation has demonstrated the differential regulation of 
CCR5 between monocytes/MDMs and T cells (Signoret lab, unpublished data). 
Additionally, Moore and colleagues have identified conformations of CCR5 that are 
dependent upon the availability of cholesterol in order to signal (Berro et al., 2011). Also, 
CCR5 signalling via G proteins in specific microdomains is known to be stabilised by the 
presence of membrane cholesterol (Cardaba et al., 2008), which may be present at 
different quantities/distributions in T cells compared to MDMs. Indeed, differences are 
apparent even within the same cell type, evidenced by the fact that lipid rafts become 
enlarged and associate with more signalling components in activated compared to resting 
T cells (Tuosto et al., 2001). Taken together with the evidence that T cell CCR5 
redistribution towards anti-CD4 coated beads is cholesterol dependent (Nguyen et al., 
2005), accumulation of MDM CCR5 to the IS may be limited to a particular conformational 
form. However, no evidence was found to support the recruitment of an alternative form of 
CCR5 to the IS on the MDM side since neither MC5 nor CTC5 mAbs, which identify 
different pools of CCR5 that are susceptible or not to ligand induced down-modulation, 
demonstrated any accumulation towards the IS (Fig. 4.3 & 4.4). Nevertheless the different 
components of the cellular background, such as the absence of Lck and the reduced 
levels of CD4 on MDMs (Lee et al., 1999b; Pelchen-Matthews et al., 1998), may 
contribute to why accumulation of CCR5 is observed on the T cell side but not the MDM 
side of the IS. This variation may be due to differences in chemokine receptor cross-talk 
pathways between cell-types (Bennett et al., 2011). 
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Notably, one study found evidence for crosstalk between MHC class II and β-chemokine 
receptors. Specifically, sAg-treatment of monocytes resulted in rapid down-modulation of 
the receptors for CCL3 and CCL4 as well as the inhibition of calcium mobilisation in 
response to these chemokines (Rahimpour et al., 1999). Thus sAg-pulsing of MDMs may 
induce CCR5 unresponsiveness, which in turn could influence recruitment of CCR5 to the 
IS. Despite this, no decrease in CCR5 expression on sAg-treated MDMs was evident by 
immunofluorescence microscopy (Fig. 4.3) demonstrating that the observations of 
Rahimpour et al. (1999) may not apply to MDMs.  
Efforts were made to determine whether CCR5 could be involved in a signalling capacity 
at the IS. Numerous attempts were made to detect phosphorylation of CCR5 on 
chemokine-treated MDMs by immunofluorescence using CCR5 antibodies that 
preferentially bind CCR5 phosphorylated at either Ser337 or Ser349. CCR5 phosphorylation 
in response to exogenous CCL5 treatment was successfully detected using an anti-CCR5 
phosho-Ser349 mAb (clone: E11/19) on CHO-CCR5 cells, confirming previous results on 
these cells and on monocytes (Fox et al., 2011; Signoret et al., 2004). However no 
increase in CCR5 phosphorylation was detected when MDMs were treated and 
immunolabelled in the same way. Interestingly, even after MDMs were treated overnight 
with amino-oxypentane RANTES (100 nM) and focal regions of internalised CCR5 were 
evident, no E11/19 staining could be detected. Altogether this indicates a lack of 
sensitivity of detection of E11/19 on MDMs, possibly as a result of MDM cell size; even 
though CCR5+ monocytes and MDMs express similar levels of CCR5 by flow cytometry 
(Fig. 3.4) the MDMs are much larger when adhered to coverslips and therefore the 
fluorescence signal per unit area is less.  
Inhibition of cell surface CCR5 signalling (using TAK-779) or drastic reduction in cell 
surface CCR5 expression (by treatment with PSC-RANTES) did not prove to influence 
MDM-CD4+ T cell IS formation (Fig. 4.5). Whether the same is true when CCR5 functions 
are inhibited on CD4+ T cells is currently unknown. Although Contento et al. (2008) 
treated T cells with CCL5 or TAK-779, the authors did not assess whether there was an 
inhibitory effect on IS formation or conjugate number. Perhaps the effect of PSC-RANTES 
or TAK-779 treatment would be much more subtle. Indeed, rather than being essential or 
not for IS formation, CCR5 may affect the number or dynamics of synapses formed. 
Bearing in mind that previous reports have shown that the IS still forms on planar bilayers 
or with naïve T cells, which typically do not express CCR5 (Bromley and Dustin, 2002; 
Grakoui et al., 1999), the assessment of more subtle features of IS formation may be 
worthwhile considering in future investigations. 
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4.3.3.1 CCR5 at the CD4+ T cell side of the IS 
The evidence presented here builds upon previous studies, which demonstrate that GFP-
CCR5 accumulates to the B cell- CD4+ T cell or DC- Jurkat IS (Contento et al., 2008; 
Molon et al., 2005), by showing that primary MDM-CD4+ T cell synapses can also localise 
endogenous CCR5 on the T cell side (Fig. 4.7). However, this is not a complete 
localisation of CCR5 to the IS, in contrast to the depiction of GFP-CCR5 on CD4+ T cells 
in previous studies (Contento et al., 2008; Molon et al., 2005). This raises issues 
regarding the interpretation of why CCR5 may localise to the IS. A study examining the 
hierarchy of chemokine- and TCR-stimulated signalling showed that soluble CCL3 is not 
able to induce T cell migration when the TCR is engaged (Bromley et al., 2000). This 
gives rise to the distraction hypothesis, which might account for why certain chemokine 
receptors such as CCR5 can be localised at the IS (Molon et al., 2005). Yet in the present 
study the average accumulation ratio shows less than a two-fold increase in the levels of 
CCR5 at the synapse compared to the rest of the cell. This means that a substantial 
amount of receptor remains spread over the rest of the cell. In addition, the surface area 
of the cell-cell interface is typically less than the remainder of the cell, which implies that 
the amount of CCR5 spread over the rest of the cell is, if anything, underestimated by the 
accumulation ratio. Together, these factors indicate that a significant amount of CCR5 is 
still positioned across the rest of the T cell, which could bind ‘distracting’ chemokine 
ligands.  
Less than half of the CCR5+ CD4+ T cells that engaged in synapses with MDMs showed 
a level of CCR5 accumulation above that typically expected in the absence of antigen 
(according to the cut-off ratio) (Fig. 4.7). Molon et al. (2005) previously showed that CCR5 
accumulation to the Jurkat-B cell IS is dependent upon chemokine secretion by the B cell 
and the ability of T cell surface CCR5 to bind this chemokine. Based on this premise, the 
results of the present study might perhaps imply that only a subset of MDMs are secreting 
CCR5 ligands. Indeed this is not unprecedented, as M1 or M2 polarised MDMs are known 
to have different chemokine secretion profiles, with M1 macrophages preferentially 
secreting chemokines that are bound by CCR5 (Mantovani et al., 2004). Although the 
MDMs used in the present study are more M2 than M1, given the immense plasticity of 
macrophages the population used here may have features of both phenotypes or 
represent a heterogenous mix of these cells. Indeed evidence for the latter is apparent 
from images illustrating that a range of levels of the M2 marker, CD163, exist across the 
population (Fig. 4.2 & Fig. 3.3). Speculatively, the CD163low MDMs might demonstrate 
more secretion of M1-linked chemokines than the CD163high MDMs. Since synapses can 
be formed with both CD163low and CD163high MDMs (Fig. 4.2), the potential differences in 
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Figure 4.10: Summary of chemokine receptor recruitment to the IS. (Box 1) MDM cell surface 
CCR5 does not accumulate to the IS. On the CD4+ T cell no cell surface CCR5, but intracellular 
CCR5 can accumulate to the cell-cell interface in some T cells in the absence of IS formation. 
Upon IS formation intracellular CCR5 generally shows polarity to the cell-cell interface. Also, some 
T cells show cell surface CCR5 recruitment to the IS. One explanation may be multidirectional 
secretion of chemokine by some MDMs but not others in the heterogeneous MDM population. (Box 
2) Diagram summary of previous work by Contento et al. (2008) showing CXCR4-CCR5 co 
dependently accumulate to the IS. (Box 3) Accumulation of CXCR4 to the MDM-CD4+T cell IS on 
T cells lacking cell surface CCR5. Conjugates formed between CD3/CD28 activated CD4+ T cells 
and sAg-pulsed MDMs (30 min), fixed and immunolabelled for CD3 (UCHT1) and CXCR4 (12G5) 
followed by GAM-IgG1
488
 and GAM-IgG2a
647
 secondary antibodies. Images representative of a 
single donor. Plot shows quantification of CXCR4 accumulation at the IS. Scale bar, 10 µm 
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secretion of CCR5 ligands by these subsets might explain whether or not CCR5 localises 
to the MDM-CD4+ T cell synapse (Fig. 4.10). Notably, different expression of E-cadherin, 
the ligand of CD103, is also apparent on M1 and M2 MDMs (Sica and Mantovani, 2012). 
Thus these differences may also be apparent if CD103 was found to trigger CCR5 to the 
MDM-CD4+ T cell IS, as it does in TIL-tumour synapses (Franciszkiewicz et al., 2009). 
4.3.3.2 Intracellular T cell CCR5 redistributes to the cell-cell interface 
Immunolabelling after permeabilisation reveals intracellular epitopes of endogenous 
CCR5 which polarise towards the IS. Moreover, intracellular CCR5 can also localise to the 
MDM-CD4+ T cell interface in the absence of sAg (Fig. 4.8a). This is reflected by the 
distribution of the CCR5-fluorescence quantification, which shows a skew towards the 
interface ROI even in the absence of sAg (Fig. 4.8b). Whilst the fluorescence of MDM 
CCR5 will also contribute to this interface-skewed baseline distribution, as measured by 
the fluorescence quantification method, images indicate that the level of CCR5 
fluorescence associated with the T cell is generally dominant. Thus the quantification still 
primarily reflects the distribution of T cell CCR5 towards the interface. Despite these 
technical aspects, there is an increase in the levels of CCR5 polarisation towards the cell-
cell interface upon the addition of antigen (Fig. 4.8b). Indeed the majority of conjugates 
demonstrate CCR5 polarisation to the IS, which is in contrast to the lower percentage of 
intact T cells showing cell surface CCR5 accumulation to the IS. 
Permeabilisation enables detection of total cellular CCR5 meaning that this approach is 
most comparable to studies that have utilised CCR5 tagged with GFP, which identifies 
both cell surface and internal CCR5 (Contento et al., 2008; Molon et al., 2005). Even 
though the authors of these studies claimed to have omitted non-PM fluorescence from 
their analysis, they did not exclude the possibility that the GFP-CCR5 observed might 
reside in intracellular compartments that are tightly apposed to the PM. Indeed the Golgi is 
an example of such a compartment; the constituent stacks have previously been shown to 
contact the PM at the IS (Stinchcombe et al., 2006). Together with the results of the 
present study, which shows that CCR5 localisation to the IS is more apparent after 
permeabilisation (Fig. 4.8), this indicates that the localisation of cell-surface CCR5 to the 
synapse may have been overestimated in previous studies utilising GFP-CCR5 (Contento 
et al., 2008; Molon et al., 2005).  
The present study indicates that both cell surface and intracellular CCR5 can accumulate 
to the MDM-CD4+ T cell IS on the T cell side. However, the mechanisms involved in 
recruiting CCR5 in these different cellular locations are likely to be different as APC-
secreted chemokines cannot access any CCR5 resident inside the T cell. Perhaps an 
  
 
145 
 
alternative mechanism may involve the Golgi, which we found to preferentially localise to 
the cell-cell interface upon IS formation, consistent with previous reports (Fig. 4.9.2) 
(Griffiths et al., 2010; Stinchcombe et al., 2006). Since the intracellular CCR5 shows 
partial colocalisation with the TGN (Fig. 4.9.1a) it is possible that the intracellular pool of 
CCR5 becomes redistributed to the IS as a passenger in the Golgi. 
Due to the partial colocalisation with the TGN, the internal CCR5 identified in the present 
study is not thought to be the same intracellular pool of CCR5 previously identified in the 
ER of T cells (Achour et al., 2009). CCR5 has been shown to accumulate in the TGN of 
primary human T cells in response to prolonged treatment with CCL5 (Escola et al., 
2010), but also to TfR+ REs in CHO-CCR5 cells (Mueller et al., 2002; Signoret et al., 
2000). However CCR5 colocalisation with TfR (Fig. 4.9.1b) appeared to occur to a lesser 
extent than the TGN, although perhaps this reflects previous observations that upon 
prolonged CCL5-treatment residence in the TfR+ compartment is transient (Escola et al., 
2010). It is currently unknown whether this intracellular pool of CCR5 may be caused by 
internalisation of cell surface CCR5 or receptor in the biosynthetic pathway. However 
internalisation and recycling via REs and/or TGN trafficking compartments that have been 
implicated in the trafficking of CCR5 and are known to polarise to the IS, may represent a 
mechanism by which CCR5 becomes localised to the plane of the IS. This type of 
mechanism is not unheard of, as redirection of REs to the IS has been shown to 
contribute to TCR accumulation at the cell-cell interface (Das et al., 2004). 
Finally, no change in CCR5 colocalisation with either the TGN or TfR was apparent in 
conjugates pulsed with sAg (Fig. 4.9.1), suggesting that CCR5 trafficking through these 
compartments is not influenced by the IS. However one major limitation of this observation 
is that these may not represent bone fide synapses, as identified using CD3 in all other 
sections of the present study. This is because conjugates forming ‘synapses’ were 
selected based on the localisation of RE and trans-Golgi markers to the interface, since 
these compartments are known to accumulate to the IS (Das et al., 2004; Griffiths et al., 
2010). Yet accumulation of the Golgi to the cell-cell interface is also apparent in the 
absence of antigen, albeit to a lesser degree, thus the sAg-pulsed conjugates observed 
with organelle markers are purposefully not referred to as synapses (Fig. 4.9.2).  
4.3.4 CXCR4 localisation and T cell activation  
CXCR4 was also shown to be localised to the MDM-CD4+ T cell IS. In similarity to that 
observed for CCR5 the level of recruitment to the IS was marginal. Fewer T cells (24%) 
were found to express CXCR4 levels at the IS above the levels in conjugates in the 
absence of antigen. A previous report suggests that CXCR4 forms heterodimers with 
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CCR5, which accumulate at the B cell-T cell IS in a mechanism dependent upon the 
presence of CCR5 and cognate ligands secreted by the APC (Contento et al., 2008). 
However, when we formed the MDM-CD4+ T cell IS using T cells that had been activated 
with CD3/CD28 beads, expressing little or no cell surface CCR5 (Fig. 3.6), CXCR4 
accumulated to the IS (Fig. 4.10: Box 3). Thus, in the absence of CCR5 there appears to 
be potential for CXCR4 to be brought to the IS via other processes. Indeed, CXCR4 has 
been suggested to heterodimerise with the TCR complex in order to mediate signalling 
functions via ITAM domains in response to CXCL12 (Kumar et al., 2006). Another study 
has also found CXCR4 transactivation of the TCR, although via more classical TCR-
signalling mechanism involving ITAM phosphorylation mediated Lck linked via an adaptor 
protein (Patrussi et al., 2007). Yet it is unknown whether MDMs in the present study would 
represent a source of CXCL12. Nevertheless, a previous report found that CXCR4 capped 
in response to anti-CD4 beads via a mechanism dependent on Lck and lipid rafts (Nguyen 
et al., 2005) providing further evidence for CXCR4 redistribution with signalling 
components that are known to be recruited to the IS. 
In summary, endogenous CCR5 was not seen to accumulate to the macrophage side of 
the MDM-CD4+ T cell IS. In contrast, endogenous CCR5 and CXCR4 were able to 
accumulate to the T cell side of this IS, as shown for other types of synapses (Contento et 
al., 2008; Franciszkiewicz et al., 2009; Molon et al., 2005). This may indicate differential 
exposure to chemokine gradients or receptor regulation on the T cells and MDMs. 
Furthermore the intracellular CCR5 in the T cells, which partially colocalised with the TGN, 
polarised to the MDM-CD4+ T cell interface upon IS formation. However the role of this 
intracellular CCR5 is unclear regarding its contribution to cell surface CCR5 at the IS. 
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Chapter 5: Investigating the mobility 
of plasma membrane CCR5 in MDMs 
5.1 Introduction 
5.1.1 Current working models of plasma membrane organisation 
Study of the mobility of the transmembrane protein, CCR5, in the plasma membrane (PM) 
calls for an understanding of the environment within which such proteins exist. The PM is 
a bilayer organisation of phospholipids in which hydrophobic fatty acid tails are butted 
together and hidden from the aqueous environment by counterpart polar head groups 
(Cooper, 2000). There is a preferential association of different phospholipids with either 
leaflet of the PM, e.g. phosphatidylcholine and sphingomyelin with the outer leaflet, and 
phosphatidylethanolamine, phosphatidylserine, and phosphatidylinositol with the inner 
leaflet (Cooper, 2000). Embedded within this lipid bilayer are different types of membrane 
protein: (i) integral (e.g. transmembrane proteins such as CCR5), (ii) peripheral (e.g. 
PLC), (iii) lipid anchored (e.g. G proteins). These proteins are arranged in an amphipathic 
fashion within the lipid matrix; an organisation that was initially considered a two-
dimensional arrangement of proteins within a viscous fluid, according to the ‘fluid mosaic’ 
model (Singer and Nicolson, 1972).  
5.1.1.1 The inclusion and reinvention of lipid rafts 
The ‘fluid mosaic’ model was soon found to be incomplete following the discovery that the 
lipid bilayer can undergo phase separation into both liquid-ordered and liquid-disordered 
domains (Pike, 2009; Simons and Vaz, 2004). Before the end of the 20th  
Century these domains had become termed lipid rafts and were described as detergent 
insoluble collections of laterally-associated sphingolipids packed with cholesterol and 
located within the PM. The ‘lipid raft hypothesis’ formally proposed and described the 
existence of the two domains and suggested that they might act to concentrate receptors, 
thereby promoting appropriate interactions and enhancing signalling efficiency (Simons 
and Ikonen, 1997). In the last decade, the traditional view of lipid rafts has been 
refashioned as many of the original techniques used to demonstrate their existence (e.g. 
detergent extraction, mechanical disruption, Shiga toxin or cholera toxin labelling) 
intrinsically disrupt their native organisation (Lingwood and Simons, 2010). The definition 
of lipid rafts as “small (10-200 nm) heterogeneous, highly dynamic, sterol- and 
sphingolipid-enriched domains that compartmentalise cellular processes” much more 
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accurately describes the nature of these lipid entities (Pike, 2006). Indeed, at steady state 
in unstimulated cells rafts are thought to exist as short-lived transiently-forming nanoscale 
sterol- and sphingolipid clusters (Lingwood and Simons, 2010). These lipid entities exist in 
an energy state that is on the tipping-point of stable raft formation (Kusumi et al., 2005) 
that can occur on coalescence by actin remodelling or receptor oligomerisation, such as 
occurs during IS formation (Lingwood and Simons, 2010). 
Two partially related hypotheses, the protein islands theory and the picket-fence model, 
have supplemented the original lipid-based models by considering the influence of the 
cortical cytoskeleton upon membrane compartmentalisation. The protein islands theory 
suggests that membrane-associated proteins and cholesterol accumulate into 
cytoskeletal-rich regions, which are surrounded by a sea of protein-free PM (Lillemeier et 
al., 2006). Lillemeier et al. (2006) used protein chimeras, which are normally organised 
into mutually exclusive raft and non-raft regions, to show that after activation these 
proteins can become amalgamated. It was proposed that oligomerisation and other 
interactions of proteins and lipids from different islands occur as a result of hop diffusion 
(Lillemeier et al., 2006). Hop diffusion was shown to occur by single fluorescent molecule 
video imaging (SFVI) of fluorescent lipid and describes the event of a PM component (e.g. 
a protein) crossing over the boundary between two adjacent compartments of the PM, 
within which the component is temporarily corralled. It is a key concept of the picket-fence 
model (Kusumi et al., 2005).  
5.1.1.2 A picket-fence model of the plasma membrane 
The picket-fence model is based on observations from techniques such as single particle 
tracking (SPT) and SFVI as well as FRAP. SPT and SFVI enable analysis of the 
molecular dynamics of the PM in scales of less than 100 nm, whereas FRAP is designed 
to analyse dynamics over scales greater than several hundred nanometers (Kusumi et al., 
2005). In the picket-fence model the cortical actin cytoskeleton compartmentalises the PM 
by forming a ‘fence’ that is anchored through both leaflets of the PM by transmembrane 
protein fence posts or ‘pickets’ (Kusumi et al., 2005). Proteins and lipids are thus 
temporarily corralled and experience hop diffusion at varying rates depending on the 
density of the cortical actin meshwork and number of transmembrane protein pickets 
linked to the actin fences at any given moment (Kusumi et al., 2005). The underlying 
meshwork has been visualised and the compartment sizes that have been observed 
support concomitant hop diffusion rates, thereby providing direct evidence to support the 
picket-fence model (Morone et al., 2006). 
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The complexities of the PM have meant that model systems are often employed to study 
particular aspects of membrane biology. Model bilayers, composed from just two or three 
lipid species rather than hundreds in a typical cell membrane, have demonstrated the 
existence of lipid-lipid immiscibility founding the underlying principle of raft formation 
(Simons and Vaz, 2004). Despite their usefulness, concatenation of different models can 
sometimes lead to misinterpretation due to a lack of understanding of the technical 
constraints of each system. A good example of this is the pocketed distribution of 
cholesterol shown by Lillemeier et al. (2006), which appears to contradict a later study 
suggesting that the majority of the PM exists in a liquid-ordered phase (Levental et al., 
2009). However, whilst one study used EM to visualise ripped membrane sheets and the 
accompanying cortical cytoskeleton of T cells (Lillemeier et al., 2006), the other used giant 
PM vesicles, which are intrinsically devoid of a functional cortical cytoskeleton (Levental et 
al., 2009). The latter system lacks the machinery to limit or concentrate cholesterol to 
particular regions of the PM, which may account for the difference in results. Thus, 
although reductionist models have their use, it is important to consider the protein or lipid 
of interest in the context of its native membrane complete with an intact cytoskeleton. 
5.1.2 GPCRs: flexible signal transducers within the plasma membrane 
The organisation of the PM forms a complex type of chessboard on which thousands of 
transmembrane protein pieces play. Inherent to each piece are structural properties that 
influence the functional outcome, or type of move it is able to make. Whilst numerous 
growth factor and cytokine receptors require dimerization to switch on downstream 
signalling events, the 7TM structure of GPCRs enables receptors to act as conformational 
switches (Thelen, 2001). Indeed, the interactions between transmembrane helices of 
CCR5 are thought to contribute to a range of active conformations that may influence 
downstream signal transduction (Springael et al., 2007). Despite a seemingly intrinsic 
structural ability to signal as monomers, the capacity of CCR5, as well as GPCRs in 
general, to signal as monomers, dimers or oligomers has been a subject of intense debate 
(Gurevich and Gurevich, 2008; Hernanz-Falcón et al., 2005; Lemay et al., 2005). 
Application of advanced imaging techniques, such as SFVI, has recently provided visual 
evidence that the chemoattractant GPCR N-formyl peptide receptor exists in an 
equilibrium of rapid monomer-dimer formation and dissociation (Kasai et al., 2011). This 
supplements the idea that any given GPCR can exist in a number of oligomeric states 
(Gurevich and Gurevich, 2008). Indeed, CCR5 has been shown to form homodimers and 
heterodimers with C5aR (Hüttenrauch et al., 2005), CXCR4 (Contento et al., 2008) or 
CCR2b (El-Asmar et al., 2005). Evidently the process of receptor multimerisation requires 
that at least one of the receptors involved has a degree of mobility within the PM. FRAP is 
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one of the ways that this level of mobility can be analysed in an undisturbed state (Phair et 
al., 2004). Photometric data from the steady-state can then be compared to FRAP in the 
presence of drug/ligand treatment; these data can then be used to discern whether the 
receptor of interest is immobile in order to determine the nature of tethering or inform 
about the occurrence of multimerisation. 
5.1.3 Principles of fluorescence recovery after photobleaching (FRAP) 
FRAP is a technique that involves irreversible bleaching and the subsequent 
measurement of fluorescence in a small region of interest (ROI) over a period of time 
(Ishikawa-Ankerhold et al., 2012). This technique is used to determine the mean mobility 
of many individual molecules within that small ROI (Klein and Waharte, 2010). Repeat 
images of the same field of view are recorded using a low laser power at given intervals 
over a defined period of time. Within this field of view several regions are drawn from 
which intensity values are extracted that enable normalised curves to be calculated 
according to the equations detailed in section 2.9 (Fig. 5.1). 
5.1.4 Presentation of FRAP curves and data 
In the present study FRAP curves are shown as the mean (± SD) of all normalised curves 
from an individual donor at each time-point (t). These single and double normalised mean 
curves are fitted with an appropriate single exponential equation, as described in section 
2.9.3. Mobile fraction and t1/2 values derived from regression of double normalised curves 
are presented in tables below the FRAP graphs. To aid visual comparison an overall 
mean curve was generated from the mean double normalised FRAP curves for each 
donor acquired under identical experimental conditions, with ± SD values propagated 
according to √([var1+var2+…+ varn]/n). 
Each FRAP curve was also fitted individually with a single exponential rise to maximum 
after double normalisation. The t1/2 and mobile fractions were derived only from the fitted 
curves that met the Gaussian assumptions of regression; curves were excluded on failure 
of residuals to pass D’Agostinos test for normality. Any t1/2 values derived from 
extrapolated mobile fraction values were excluded. Mobile fractions >1.5 were also 
excluded on the basis that the original measurement of pre-bleach fluorescence was likely 
to be inaccurate in these instances. Upon fulfilment of these criteria t1/2 and mobile fraction 
values derived from individual FRAP curves from different donors were pooled before 
being graphed and statistically compared with values from other treatment conditions. 
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Figure 5.1: Summary of the performance of FRAP and extraction of photometric data.               
(a) CCR5 is immunofluorescently labelled according to the technique detailed in section 2.8.1. A 
small region of fluorescence is bleached with a high-powered laser pulse. Recovery of 
fluorescence into the bleached region is analysed over time. (b) Imaged  fields of view showing the 
three regions of interest (ROIs) used to extract photometric data: (i) the bleach (Ibleach(t)) ROI is the 
region in which bleaching occurs at t = 0; (ii) the decay (Idecay(t)) ROI is drawn on another cell, 
where possible, and acts as a reference for loss of fluorescence during FRAP; (iii) the background 
(Ibkgd(t)) ROI is used to measure background non-cell-associated fluorescence. Note that as only a 
very small amount of the total cell intensity is bleached, no ROI was drawn to calculate the ‘gap-
ratio’ which accounts for a significant drop in fluorescence in other studies (Phair et al., 2004) (c) 
Plot showing the fluorescence intensity at every time-point in each of the three ROIs. Notice that a 
number of images are taken prior to bleaching (-63 – 0 s: 20 cycles) to determine the mean level of 
fluorescence in bleach and decay ROIs, from which the Ibleach-pre and Idecay-pre values are derived, 
respectively. The intensity value measured immediately after bleaching (y0 bleach) is the final 
parameter required for the normalisation transformations detailed in section 2.9. 
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5.1.5 CCR5 in the plasma membrane 
The mobility of CCR5 within the PM has been studied with particular interest because of 
its implications with regard to HIV infection. Receptor mobility of CCR5 and CD4 facilitates 
sequential interactions with HIV envelope proteins that are required for viral binding and 
entry (Rawat et al., 2008). CCR5 mobility has been studied by FRAP on several 
occasions in different cell lines but never at endogenous expression levels in primary 
cells. FRAP studies of HIV-fusion permissive and non-permissive cells indicate that, for 
both cell types, CCR5-GFP has a similar mobility and exists almost entirely as a mobile 
fraction in the PM (Rawat et al., 2008). CCR5-GFP was also reported to be highly mobile 
in the PM of transfected human osteosarcoma (HOS) cells, with 100% recovery seen 
within 90 s (Steffens and Hope, 2004). Recovery was dramatically reduced on cholesterol 
depletion, which the authors suggested may indicate a possible role for lipid rafts in 
mediating the membrane mobility of CCR5 (Steffens and Hope, 2004). Another FRAP 
study, using U373-MAGI cells transfected with CCR5-YFP, reported 84% recovery within 
8 min (480 s) (Nakata et al., 2010). Although this study also noted the presence of a 
greater immobile fraction after cholesterol depletion, the speed of recovery in untreated 
cells was markedly slower than that reported by Steffens and Hope (2004). This disparity 
highlights the importance of performing FRAP on CCR5 in a more physiologically relevant 
cell type as the percentage and timeframe of recovery are likely to be different again. 
In this chapter the mobility of endogenous CCR5 is investigated in primary human MDMs 
using FRAP. The recovery of CCR5 is compared to the steady-state mobility of CCR5 in 
stably transfected CHO-CCR5 cells and to MDMs transiently transfected with GFP-CCR5 
constructs. The effect of cholesterol depletion on the mobility of endogenous CCR5 in 
MDMs is also examined and discussed. 
5.2 Methodological Developments 
5.2.1 Selecting a suitable antibody to study CCR5 mobility 
The binding properties of three monoclonal antibodies (mAbs) that recognise distinct 
extracellular epitopes of CCR5 (MC5, 2D7 and CTC5) were tested by titration on MDMs 
and CHO-CCR5 cells (Fig. 5.2a). Comparison of the half maximal concentration (½Bmax) 
shows that functional binding affinity of the three clones differs significantly on MDMs but 
not on CHO-CCR5 cells (Fig. 5.2b). On MDMs the binding affinity of CTC5 is much lower 
than that of MC5 and 2D7. This builds on the finding of a previous study reporting that 
CTC5 has a lower affinity than 2D7 when these mAbs were titrated across human CD4+ T 
cells and U87-CD4-CCR5 cells (Berro et al., 2011). In fact, the high ½Bmax value, which 
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Figure 5.2: Comparison of binding properties of three anti-CCR5 monoclonal antibodies to 
MDMs and CHO-CCR5 cells. (a) The anti-CCR5 clones MC5, 2D7, and CTC5 were titrated across 
MDMs and CHO-CCR5 cells and values were normalised to the maximal concentration (25 µg/mL). 
Graphs show mean ± SD of MDM (n=3) and CHO-CCR5 (n=4) titrations performed on separate 
days. (b) Table showing ½Bmax values (µg/mL) calculated for each antibody clone from normalised 
titration data fitted with a one-site ligand binding regression (Y=Bmax*X/[Kd+X]). One-way (MDM) or 
repeated-measures (CHO-CCR5) ANOVA tests were performed followed by Tukey post-test. (c) 
The mean expression level of 2D7 and CTC5 relative to MC5 (red line) at the maximum 
concentration titrated (25 µg/mL) is shown for both matched donor MDM and CHO-CCR5 cells. (d) 
Schematic representation of the extracellular epitopes of CCR5 bound by the mAbs MC5, CTC5, 
2D7 and 45531. 
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indicates the low affinity of CTC5 binding, is likely underestimated in the present study as 
binding saturation was not achieved across the titrated concentration range.  
At the highest concentration used for titration (25 µg/mL), the relative level of CTC5 bound 
was greater than that of MC5 and 2D7 on MDMs (CTC5>MC5>2D7; Fig. 5.2c). Although 
this indicates a greater epitope availability, the low affinity of CTC5 infers a lower binding 
stability rendering it inferior to MC5 and 2D7 as a tool to study CCR5 mobility by FRAP.
Berro et al. (2011) showed that, for human CD4+ T cells and U87-CD4-CCR5 cells, 
maximal CTC5 binding was greater than that of 2D7. In contrast to this and my previous 
results on MDMs, the present study found the relative binding level of CTC5 on CHO-
CCR5 cells to be lower compared to MC5 and 2D7 (Fig. 5.2c). Taken together this 
suggests that the different CCR5 antigenic determinants may be influenced by the cell-
type in which CCR5 is expressed (Signoret lab, unpublished data). As MC5 binds at a 
greater level and interferes less with the chemokine binding and signalling of CCR5 
(Blanpain et al., 2002) it is a superior tool to analyse the native properties of CCR5 on live 
cells. The mAb clones tested here, as well as others used in this chapter, were previously 
mapped to epitopes on CCR5 (Blanpain et al., 2002) and their positions are illustrated in 
Fig. 5.2d. 
5.2.2 Testing adherence of MDMs to different coverslip coatings  
5.2.2.1 FRAP of MDMs on PEI-coated coverslips  
MDMs that were seeded onto PEI-coated coverslips and labelled with MC5488 were 
subjected to FRAP under initial imaging conditions, as described in section 2.8.2. Single 
normalised bleach curves for each donor (Fig. 5.3.1a) showed a similar mean recovery 
curve. This was despite vast differences in the individual FRAP curves recorded for each 
cell, which are reflected in wide standard deviation (SD) error bars even at time intervals 
close to the bleach point. In contrast, mean decay curves showed divergence between 
donors, with one donor having much greater decay than the other (Fig. 5.3.1a). Thus, 
since double normalisation calculations account for decay, the double normalised mean 
recovery profiles (Fig. 5.3.1a) for each donor diverged after this process. The regression 
curve of the double normalised data was associated with wide 95% prediction bands, the 
lower of which lay below a normalised fluorescence value of zero for both donors over the 
entire time series. This means that fluorescence intensity measurements may be less than 
the initial bleach value and indicates an immense degree of variation between individual 
FRAP curves. Nevertheless, the mean half-time (t1/2) and mobile fraction values for cells 
from each donor can be estimated from the regression curve (Fig. 5.3.1a). On MDMs 
seeded on PEI-coated coverslips the mean t1/2 was 77 s and was associated with similar
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Figure 5.3.1: Investigating seeding MDMs on PEI- or collagen-coated coverslips to minimise 
cell movement. (a) Single normalised FRAP curves showing bleach and decay curves acquired 
for MDMs seeded on PEI-coated coverslips. Two donors (○ D2011004, ○ D2011005) were 
assayed under identical imaging conditions (see section 2.8.2). The normalised fluorescence value 
at the final time-frame is shown on the decay graph (mean ± SD). Decay was accounted for to yield 
double normalised FRAP curves as described in section 2.9.2. Data show the mean ± SD error 
bars for each donor overlaid with appropriate regression curves (solid lines) associated with 95% 
prediction bands (dotted lines) and mean residual values for each fit, which are plotted above. The 
table shows t1/2, mobile fraction and R
2
 values calculated from the double normalised regression 
curve. (b) Representative bright-field images of MDMs seeded on PEI- and collagen-coated 
coverslips. Using the first time-frame of FRAP the cross-sectional cell area (cell size) was 
estimated. Graph shows mean ± SD values from 10 cells for each donor (n=3) from MDMs seeded 
on PEI and collagen statistically compared using an unpaired Student’s t-test. Scale bars, 10 µm. *, 
p < 0.05. CI, confidence interval.  
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CIs for both donors. However, the calculated mobile fraction was markedly different for 
each donor with recovery values of 49% and 63% lying within mutually exclusive 95% CIs. 
Together this indicates that a slow mobile fraction of CCR5 exists on the cell surface of 
MDMs. Considering the experimental error, more accurate description of the speed and 
level of CCR5 mobility was not appropriate. For this reason efforts were made to 
investigate and improve the experimental conditions. 
5.2.2.2 The morphology of MDMs is influenced by PEI 
The PEI-coating was originally used with the ideal view that this cationic polymer would 
promote adhesion and, therefore, reduce cell drift across the field of view. Global cell drift 
causes variation in the recovery curve as the cell membrane moves out of the bleach ROI. 
PEI has previously been described in promoting cell attachment of PC-12 and HEK-293 
cells with an efficacy comparable to more classical coatings, such as collagen and PDL 
(Vancha et al., 2004). Although PEI has also been successfully used as an attachment 
factor in other culture systems (Khanam et al., 2007; Ruardij et al., 2003), in the present 
study it was noticed that the MDMs adhering to this cationic polymer exhibited aberrant 
morphologies. Bright-field images of bleached MDMs from each donor (n=3) are provided 
to visually represent the difference in morphology seen between cells seeded on PEI vs. 
collagen-coated coverslips (Fig. 5.3.1b). The cross-sectional areas of MDMs, seeded on 
PEI or collagen-coated coverslips and bleached during FRAP were compared and the 
MDMs adhered to PEI were found to be significantly smaller than when adhered to 
collagen (Fig. 5.3.1b). This indicated that MDMs seeded on PEI-coated coverslips did not 
spread and attach as well as those seeded on collagen, therefore the PEI protocol was 
discontinued. 
5.2.2.3 FRAP of MDMs on collagen, PDL or in CyGel  
FRAP was performed on cells from the same donor in order to investigate whether MDMs 
seeded on collagen- or PDL-coated coverslips, or when embedded in a thermoreversible 
hydrogel (marketed as CyGel), gave more reliable results than seen with PEI. FRAP of 
MDMs seeded on collagen or PDL yielded recovery curves of a similar profile to the 
original FRAP curves observed on PEI (Fig. 5.3.2a). For collagen the lower 95% 
prediction band lay above zero at later time-points (Fig. 5.3.2a), unlike for the double 
normalised recovery on PEI (Fig. 5.3.1a). This indicates that on collagen the recovery 
curves exhibited less variation than on PEI, perhaps due to the improved cell attachment 
on collagen as demonstrated above. The mobile fraction and/or t1/2 values for collagen 
and PDL showed some difference to those for PEI; in several cases these differences 
were significant as determined by having mutually exclusive 95% CIs. Yet considering that  
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Figure 5.3.2: Investigating seeding MDMs on PDL- or collagen-coated coverslips or in CyGel 
to minimise cell movement. Double normalised FRAP curves for cells from the same donor 
seeded on collagen (filled circles), PDL (unfilled circles) or embedded in CyGel (crosses) and 
assayed under identical imaging conditions. For CyGel, where fewer than five traces were 
acquired, each replicate is shown, otherwise mean ± SD is plotted. A regression curve (solid line), 
95% prediction bands (dotted line), and plot of mean residuals is shown. Mean t1/2 and mobile 
fraction values (lower and upper 95% confidence intervals in parentheses) are indicated in red. (b) 
Cartoon of the process used to measure level of cell drift as a mean change in intensity. Briefly, 
FRAP time-sequences of MC5
488
-labelled MDMs seeded on PDL, collagen or in CyGel were 
acquired. In ImageJ the time-sequence was thresholded so that MC5
488 
and cellular 
autofluorescence highlighted the MDMs. In the first frame circular ROIs were drawn around the 
MDMs to occlude their signal. The same ROIs were applied across the entire time-sequence so 
that only if the MDM drifted from its original position would an increase in intensity be detected. 
Graph shows the mean ± SD change in intensity as a measure of drift of MDMs (n = 1) seeded on 
collagen, PDL or embedded in CyGel over the time-frame of FRAP (frame interval, 3 s).  
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FRAP curves from only a single donor were tested and minor changes in the imaging 
technique had been made, it was inappropriate to extrapolate these small differences into 
general patterns. When MDMs were embedded in CyGel, regression of the recovery was 
associated with much tighter prediction bands and a flatter profile compared to PEI, 
collagen or PDL (Fig. 5.3.2a). This may stem from the CyGel physically restricting the cell 
from any global movement (supplemental movies 13 & 14). Further, the effects of CyGel 
on the fluidity of the membrane and on the antibody used to label the MDMs were unclear. 
CyGel was, therefore, deemed not appropriate for use when analysing the recovery of 
antibody-labelled CCR5 on MDMs.  
5.2.2.4 Choosing collagen for FRAP 
Observation of MDMs in FRAP time-sequences led to the finding that some MDMs 
appeared to move across the plane of the coverslip. To determine whether MDMs seeded 
on collagen- or PDL-coated coverslips exhibit a lower level of cell drift, FRAP time-
sequences were analysed using a method that enables any global cell movement to be 
identified as an increase in the mean intensity of the image (Fig. 5.3.2b). MDMs 
embedded in CyGel, which exhibit no movement, were used as negative controls. Results 
showed that MDMs seeded on PDL tended to migrate from their original position (i.e. a 
general increase in intensity per frame) whilst MDMs seeded on collagen were more 
stationary (i.e. intensity fluctuated around zero; Fig. 5.3.2b). Therefore, MDMs seeded on 
collagen had a lower cell drift than those seeded on PDL. Theoretically this means a more 
repeatable recovery will be obtained using collagen as fluctuations occurring due to 
movement of the PM out of the ROIs are reduced. 
5.2.3 Enhancing image signal: noise 
As the fluorescent signal from MDMs was relatively low compared to the background, a 
number of steps were taken to improve the signal:noise ratio. The DyLight and AlexaFluor 
dye series were selected as the fluorochromes of preference since they have suitable 
quantum yields and other properties that make them appropriate for FRAP studies 
(Ishikawa-Ankerhold et al., 2012). In addition, to ensure the LSM780 hardware was 
configured for maximal sensitivity, gallium arsenide phosphide (GaAsP) detectors were 
fitted to side-port (SP) and direct-coupled (DCo) positions sequentially and used to image 
the same field of MC5488-labelled MDMs. When using the DCo configuration enhanced 
detection of the specific fluorescent signal was observed whilst keeping cellular 
autofluorescence low (Fig. 5.4a).  
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Figure 5.4: Enhancement of the signal:noise ratio during FRAP imaging. (a) A field of MDMs 
labelled with DyLight
488
-coupled MC5 (MC5
488
) was imaged with detectors in SP or DCo positions, 
as indicated. (b) A competition binding assay in which increasing concentrations of unlabelled MC5 
were incubated with a constant concentration (15 µg/mL) of MC5
488
 on MDMs from three different 
donors. MDMs were titrated using direct (x MC5
488
 or ▲ Isotype-IgG2a
488
) and indirect (● MC5 or ■ 
Isotype-IgG2a, all followed by Fab
488
) labelling; graphs show data from one donor. (c) Images of 
MDMs labelled with: MC5
488
; MC5 followed by Fab
488
; MC5 followed by a divalent F(ab’)2
488
; or 
matched isotype controls. GaAsP, gallium arsenide phosphide detector; SP, side-port; DCo, direct 
coupled; scale bars, 20 µm. 
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A binding competition assay showed that the binding affinity of MC5 is impaired by 
fluorescent coupling, as a low concentration of unlabelled MC5 can displace a high 
concentration of MC5488 (Fig. 5.4b). Direct and indirect immunolabelling procedures 
(MC5488 and MC5 followed by Fab488, respectively) were compared in parallel by titration 
across MDMs from the same donor (Fig. 5.4b). The indirect immunolabelling procedure 
was clearly advantageous as it gave higher fluorescence intensity above the isotype 
control. In addition, use of the monovalent Fab fragment greatly increased the level of 
fluorescence detectable on MDMs by microscopy but did not alter the uniform staining 
pattern seen with MC5488 (Fig. 5.4c). In contrast, labelling with a divalent F(ab’)2
488 
secondary antibody resulted in a punctuate staining pattern on MDMs. This is important 
as it showed that CCR5 can be cross-linked and that, under these conditions, can be 
brought into close contact with other CCR5 molecules in the plane of the MDM 
membrane. However, in order to enhance the signal:noise ratio whilst maintaining the 
uniform distribution observed with MC5488, the indirect immunolabelling procedure 
employing GAM-Fab488 is preferable. 
5.2.4 Impact of temperature on fluorescence decay 
Accounting for acquisitional photobleaching is an important factor in achieving accurate 
estimations of recovery by FRAP (Zheng et al., 2011). The decay (or reference) ROI 
exists to enumerate the degree of acquisitional photobleaching that occurs over the 
chosen time-course in order for it to be corrected for through the process of double 
normalisation. Ideally the level of decay should not be greater than 10% of the pre-bleach 
signal (Phair et al., 2004). To reduce the level of decay that occurs as a result of 
acquisitional photobleaching but still maintain the ability to resolve any fast recovery that 
occurs immediately post-bleach, all further FRAP was performed by changing the delay 
between image acquisitions from every 3 s to every 10 s at 1 min post-bleach.  
 
From FRAP experiments with MDMs on PEI-coated coverslips it was clear that, despite 
identical FRAP conditions, different levels of decay were possible (Fig. 5.3.1a). To 
investigate whether the experimental design could introduce a decay variable other than 
acquisitional photobleaching, the fluorescence of cells that had been labelled for FRAP 
according to the indirect immunolabelling procedure and then incubated for 0, 15 or 30 
min at either 4°C or 37°C, was measured by flow cytometry. At 4°C little or no loss of 
fluorescence occurred for either CHO-CCR5 or MDMs after 30 min of incubation, relative 
to the fluorescence at 0 min (Fig. 5.5a). However, at 37°C CHO-CCR5 cells showed a 
mean loss of fluorescence of 22% after 30 min, whilst MDMs lost a mean of 78% 
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Figure 5.5: Temperature-dependent dissociation of MC5 contributes to decay. (a) CHO-CCR5 
cells (n = 2), live MDMs (n = 3) or fixed MDMs (n = 2) were labelled with MC5 then Fab
488
, 
according to section 2.4.5, before being incubated for 0, 15 or 30 min at either 4°C or 37°C and the 
level of fluorescence detected by flow cytometry. Fluorescence at 15 or 30 min is expressed as a 
percentage of the start signal (0 min; indicated by the dotted line). Mean ± SD. (b) The same assay 
was performed at 37°C but, after MDMs had been incubated for 15 or 30 min, they were 
transferred to ice and relabelled with Fab
488
 before analysing fluorescence by flow cytometry (n=1). 
(c) Cartoon depicting temperature-dependent dissociation of a fluorescent antibody bound to a cell. 
Transferring a cell labelled with a fluorescent antibody in a solution of medium at a higher 
temperature (e.g. 37 °C) increases the binding on and off rates leading to a more rapid loss of 
fluorescent antibody as the antibody moves towards equilibrium. The overall result is a faster loss 
of cell-associated fluorescence at a higher temperature. 
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fluorescence relative to the initial (0 min) signal (Fig. 5.5a). This showed that CHO-CCR5 
cells retain the majority of their fluorescence after 30 min at 37°C, but the bulk of MDM 
fluorescence is rapidly lost (67% within 15 min). Therefore, photobleaching is not the only 
factor influencing the decay curve. Fixed MDMs were also subjected to the same 
treatment to investigate whether this process may actively involve CCR5 (e.g. 
multimerisation or endocytosis), but as the result was the same as that on live cells this 
hypothesis was rejected (Fig. 5.5a). The loss in fluorescence could be due to dissociation 
of the secondary Fab488 fragment from CCR5-bound MC5. To determine whether this was 
the case, the above assay was modified so that, after the 37°C incubation period, cells 
were re-labelled with Fab488 (Fig. 5.5b). As the loss in fluorescence was not rescued using 
this approach, it indicated that this phenomenon must be caused by the primary antibody 
(MC5) dissociating from MDM CCR5.  
 
The most likely explanation for the observed decrease in fluorescence is the Arrhenius 
nature of antibody-epitope interactions, as first described by Svante Arrhenius over a 
century ago (Arrhenius, 1907). In general this is the principle that outlines how the binding 
kinetics of antibodies may be modified at different temperatures. More recently this 
phenomenon has been applied to describe the binding kinetics of different antibodies 
(Johnstone et al., 1990). As FRAP was performed on cells bound with a high number of 
antibody molecules in comparison to an absence in the surrounding imaging medium, an 
increased off-rate at 37°C combined with diffusion into the medium would explain the loss 
in fluorescence (Fig. 5.5c). The finding that Arrhenius dissociation of MC5 contributes to 
loss in fluorescence means that the decay is multifactorial. Within the first 15-30 min 
Arrhenius dissociation is likely to dominate the apparent decay curve, however, over time 
this factor will become subordinate to the impact of aquisitional photobleaching. Due to 
this result the imaging protocol was modified so that no FRAP curves were acquired for 
the first 20 min after cells had begun incubation at 37°C. Decay ROIs were also chosen to 
match the pre-bleach intensity as closely as possible. Theoretically this limited the 
contribution of Arrhenius dissociation to the bleach curve but still enabled the bleach ROI 
to account for the lower rate of dissociation alongside aquisitional photobleaching over the 
time-frame of FRAP.  
5.2.5 Testing for depths and artefacts of bleaching 
It is common to use FRAP on fixed cells in order to set the bleach depth to > 70% as no 
rapidly mobile fraction is able to lower the perceived bleach level detected in the first 
frame post-bleach (Phair et al., 2004). Different laser powers (4%, 8% and 26%), each 
kept at 50 iterations, were tested for bleach depth achieved on fixed MDMs. Mean ± SD 
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bleach depths of 30 ± 6%, 49 ± 5% and 66 ± 12% were calculated for the 4%, 8% and 
26% laser powers, respectively. As the 26% laser power bleached to an appropriate 
depth, this was chosen as the preferred setting. In addition, FRAP curves on fixed MDMs 
bleached with 26% laser power showed a lower level of decay compared to FRAP with 
lower laser powers (Fig. 5.6.1a). Fixed cells would not be expected to have any true 
recovery as proteins are cross-linked thus FRAP of fixed cells enables the effect of decay 
upon the double normalised recovery to be clearly visualised. Single normalised plots 
show that FRAP with 4% and 8% laser power resulted in high levels of decay but bleach 
recovery values remained close to zero. However, after double normalisation apparent 
recovery of CCR5 occurs solely due to decay, from which mobile fractions of up to 34% 
are calculated from regression (Fig. 5.6.1a). 
A value was calculated to indicate the level of decay. This value, termed ‘1-decay’ was 
defined by calculating the area enclosed between the normalised regression decay curve 
and the fluorescence value of 1 (Fig. 5.6.1b). This area can be compared to the area 
under the mean single normalised recovery curve in order to obtain an idea of whether the 
double normalised recovery is dominated by the bleach, whether bleach is equal to the 
decay (i.e. 1-decay and bleach area values are within ± 10 units of each other), or is 
dominated by the decay. As no true recovery can occur in fixed cells this dataset is able to 
exemplify the utility of the 1-decay value as a confidence indicator for true recovery. A 
high 1-decay value (> 100) indicates that the double normalised recovery is likely to be an 
overestimate, whereas a small 1-decay value (e.g. < 60; such as is the case here for 26% 
laser power) is associated with only small errors introduced by the decay curve. For a 
26% laser power any recovery with a calculated double normalised mobile fraction < 7% 
can effectively be considered as immobile. 
 
To check that the selected bleach condition (26% laser power, 50 iterations) was not 
causing photoinduced cross-linking of proteins via the formation of free-radicals (Ishikawa-
Ankerhold et al., 2012), the recovery rate was checked against FRAP performed with 
lower bleach intensity (8% laser power, 50 iterations). Double normalised recovery curves 
showed that, for each bleach condition, the level of recovery was similar between donors 
(n = 3) (Fig. 5.6.1b). Notice that for FRAP with the 26% laser power there are indications 
of much lower variation, such as smaller SD error bars and tighter 95% prediction bands, 
than FRAP with the 8% laser power or previous FRAP curves acquired under non-
optimised conditions (e.g. PEI, MC5488, etc.; Fig. 5.3.1a & 5.3.2a). The mean FRAP curve 
of all donors bleached at 26% laser power has been overlaid with the mean curve of those 
bleached at 8% in order to aid visual comparison (Fig. 5.6.1b). For the majority of the 
time-course the 8% curve mirrors the 26% curve, the exception being that the 8% curve
  
 
164 
 
0 100 200 300 400
0.0
0.5
1.0
1.5
Time (s)
donor marker
bleach 
power
Area under mean curve t1/2 (s) mobile fraction (%)
R2
1-decay bleach dominance mean lower 95% CI upper 95% CI mean lower 95% CI upper 95% CI
D2012004
CCR5 
(MC5)
8%
101.20 137.90 bleach 21.82 17.69 28.46 62.31 58.98 65.64 0.26
D2013007 78.11 (lin) 127.70 bleach 28.53 19.97 49.88 54.75 48.93 60.56 0.10
D2013008 137.50 92.26 decay 50.37 38.19 73.99 62.94 38.19 73.99 0.22
D2012006
CCR5 
(MC5)
26%
62.17 (lin) 142.90 bleach 72.52 62.87 85.67 68.25 64.48 72.03 0.43
D2013001 47.74 (lin) 180.10 bleach 46.06 40.20 53.93 67.87 65.03 70.72 0.44
D2013002 59.85 156.40 bleach 47.43 42.51 53.64 64.21 61.99 66.42 0.64
s
in
g
le
 n
o
rm
.
d
o
u
b
le
 n
o
rm
.
b
0 100 200 300 400
0.0
0.5
1.0
1.5
D2013001 D2013002D2012006
Time (s)
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
26% laser (Double Norm.)
0 100 200 300 400
-0.2
-0.1
0.0
0.1
0.2
Time (s)
R
e
s
id
u
a
ls
0 100 200 300 400
0.0
0.5
1.0
1.5
D2012004 D2013007 D2013008
Time (s)
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% laser (Double Norm.)
0 100 200 300 400
-0.2
-0.1
0.0
0.1
0.2
Time (s)
R
e
s
id
u
a
ls
DiO (Bleach)
0 50 100 150 200
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
0 50 100 150 200
0.0
0.5
1.0
1.5
D2013005 D2013006 D2013007
Time (s)
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
DiO (Decay)
0 50 100 150 200
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
0 50 100 150 200
0.0
0.5
1.0
1.5
D2013006D2013005 D2013007
Time (s)
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
0 50 100 150 200
0.0
0.5
1.0
1.5
D2013006 D2013007D2013005
Time (s)
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
DiO (Double Norm.)
0 50 100 150 200
-0.2
-0.1
0.0
0.1
0.2
Time (s)
R
e
s
id
u
a
ls
The Effect Bleaching Intensity Upon
Recovery (Double Norm.)
0 100 200 300 400
0.0
0.5
1.0
1.5
8% laser26% laser
Time (s)
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
Individually fitted
1/2 values
26% 8%
1
10
100
1000
ns

1
/2
(s
)
Individually fitted mobile
fraction values
26% 8%
0.0
0.5
1.0
1.5
ns
m
o
b
il
e
 f
ra
c
ti
o
n
0 100 200 300 400
0.0
0.5
1.0
1.5
D2013001 D2013002D2012006
Time (s)
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
26% laser (Double Norm.)
0 100 200 300 400
-0.2
-0.1
0.0
0.1
0.2
Time (s)
R
e
s
id
u
a
ls
0 100 200 300 400
0.0
0.5
1.0
1.5
D2012004 D2013007 D2013008
Time (s)
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% laser (Double Norm.)
0 100 200 300 400
-0.2
-0.1
0.0
0.1
0.2
Time (s)
R
e
s
id
u
a
ls
DiO (Bleach)
0 50 100 150 200
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
0 50 100 150 200
0.0
0.5
1.0
1.5
D2013005 D2013006 D2013007
Time (s)
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
DiO (Decay)
0 50 100 150 200
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
0 50 100 150 200
0.0
0.5
1.0
1.5
D2013006D2013005 D2013007
Time (s)
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
0 50 100 150 200
0.0
0.5
1.0
1.5
D2013006 D2013007D2013005
Time (s)
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
DiO (Double Norm.)
0 50 100 150 200
-0.2
-0.1
0.0
0.1
0.2
Time (s)
R
e
s
id
u
a
ls
The Effect Bleaching Intensity Upon
Recovery (Double Norm.)
0 100 200 300 400
0.0
0.5
1.0
1.5
8% laser26% laser
Time (s)
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
Individually fitted
1/2 values
26% 8%
1
10
100
1000
ns

1
/2
(s
)
Individually fitted mobile
fraction values
26% 8%
0.0
0.5
1.0
1.5
ns
m
o
b
il
e
 f
ra
c
ti
o
n
8% las r 26% laser Overlay of mean 
FRAP curves at 8%
and 26% laser power
a.
4% Bleach
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
-0.5
0.0
0.5
1.0
Time (s)
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% Bleach
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
26% Bleach
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
B
le
a
ch
D
e
c
a
y
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
26% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
4% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
4% Bleach
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
-0.5
0.0
0.5
1.0
Time (s)
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% Bleach
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
26% Bleach
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
B
le
a
ch
D
e
c
a
y
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
26% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
4% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
4% Bleach
0 100 200 300 400
- 1
-
0
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
-0.5
0.0
0.5
1.0
Time (s)
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
100 200 300 400
0.0
0.5
1.0
Ti e (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% Bleach
0 100 200 300 400
- 1
-
0
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
26% Bleach
0 100 200 300 400
- 1
-
0
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
B
le
a
ch
D
e
c
a
y
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
26% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
4% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% laser 26% laser4% laser
4% Bleach
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
-0.5
0.0
0.5
1.0
Time (s)
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% Bleach
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
26% Bleach
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
B
le
a
ch
D
e
c
a
y
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
26% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
4% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
4% Bleach
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
-0.5
0.0
0.5
1.0
Time (s)
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% Bleach
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
26  Bleach
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
B
le
a
ch
D
e
c
a
y
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
26% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
4% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
4% Bleach
0 100 200 300 400
-0.10
-0.05
.0
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
-0.5
0.0
0.5
1.0
Time (s)
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% Bleach
0 100 200 300 400
-0.10
-0.05
.0
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
26% Bleach
0 100 200 300 400
-0.10
-0.05
.0
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
B
le
a
ch
D
e
c
a
y
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
26% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
.1
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
.0
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
4% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
.0
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
4% Bleach
0 100 200 300 400
-0.10
-0.05
0.00
0.05
.
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
-0.5
0.0
0.5
1.0
Time (s)
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% Bleach
0 100 200 300 400
-0.10
-0.05
0.00
0.05
.
Time (s)
R
e
s
id
u
a
ls
26% Bleach
0 100 200 300 400
-0.10
-0.05
0.00
0.05
.
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
B
le
a
ch
D
e
c
a
y
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
26% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
.
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
.
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
4% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
.
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
4% Bleach
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
-0.5
0.0
0.5
1.0
Time (s)
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% Bleach
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
26% Bleach
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
B
le
a
ch
D
e
c
a
y
Tim  (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
26% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
4% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
4% Bleach
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
-0.5
0.0
0.5
1.0
Time (s)
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% Bleach
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
26% Bleach
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
B
le
a
ch
D
e
c
a
y
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
26% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
4% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
4% Bleach
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
-0.5
0.0
0.5
1.0
Time (s)
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% Bleach
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
26% Bleach
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
B
le
a
ch
D
e
c
a
y
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
26% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
4% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
4% Bleach
0 100 200 300 400
- .
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
-0.5
0.0
0.5
1.0
Time (s)
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% Bleach
0 100 200 300 400
- .
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
26% Bleach
0 100 200 300 400
- .
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
B
le
a
ch
D
e
c
a
y
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
26% Bleach (Double Norm.)
0 100 200 300 400
- .
-0.05
.0
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% Bleach (Double Norm.)
0 100 200 300 400
- .
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
4% Bleach (Double Norm.)
0 100 200 300 400
- .
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
4% Bleach
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
-0.5
0.0
0.5
1.0
Time (s)
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% Bleach
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
26% Bleach
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
B
le
a
ch
D
e
c
a
y
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
26% Bl ach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
4% Bleach (Double Norm.)
0 100 200 300 400
-0.10
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
4% Bleach
0 100 200 300 400
- .
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
-0.5
0.0
0.5
1.0
Time (s)
N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% Bleach
0 100 200 300 400
- .
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
26% Bleach
0 100 200 300 400
- .
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
B
le
a
ch
D
e
c
a
y
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
26% Bleach (Double Norm.)
0 100 200 300 400
- .
-0.05
.0
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
8% Bleach (Double Norm.)
0 100 200 300 400
- .
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
4% Bleach (Double Norm.)
0 100 200 300 400
- .
-0.05
0.00
0.05
0.10
Time (s)
R
e
s
id
u
a
ls
100 200 300 400
0.0
0.5
1.0
Time (s)N
o
rm
a
li
s
e
d
 f
lu
o
re
s
c
e
n
c
e
 s
ig
n
a
l
bleach power
bleach depth 
(% ± SD)
# FRAP 
curv s
Area under mean curve t1/2 (s) mobile fraction (%)
R2
1-decay bleach dominance mean low r 95% CI upper 95% CI mean lower 95% CI upper 95% CI
4% 30 ± 6 4 151.10 0.46 decay 50.70 33.80 101.40 18.82 15.99 21.64 0.23
8% 48 ± 5 4 135.90 0.02 decay 219.90 149.10 418.20 33.90 23.48 44.32 0.71
26% 66 ± 12 10 58.45 3.01 decay 56.06 40.70 90.06 6.89 4.16 7.70 0.16
d
o
u
b
le
 n
o
rm
.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6.1: Controlling for bleaching artefacts: decay dominance and photo-induced 
cross-linking. (a) MDMs that had been labelled indirectly with MC5 then fixed were subjected to 
FRAP with bleach laser power at 4%, 8% and 26%. Plots of single normalised data show (●) decay 
ROI curves and (●) bleach ROI curves. The dominance of decay at lower laser power has the 
effect of causing apparent recovery in double normalised plots. FRAP was performed on MDMs 
from two (4%, 8% laser) or three (26% laser) donors but, where fewer than five traces were 
acquired, each replicate is shown, otherwise mean ± SD is plotted. (b) Double normalised recovery 
curves for FRAP on MDMs labelled indirectly with MC5 and bleached at 8% (D2012004, 
D2013007, D2013008) or 26% (D2012006, D2013001, D2013002) laser power. Regression curves 
(solid line), 95% prediction bands (dotted line) and a plot of the mean residuals of the fit for each 
donor (n = 3) are shown. A plot showing the overall mean curves of all donors at 8% and 26% laser 
power is shown for ease of comparison. All graphs show mean ± SD. Tables below the plots show 
the values derived from the single and double normalised FRAP curves for each condition. CI, 
confidence interval; lin, linear regression. 
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appears to show a slightly faster initial phase of recovery. This profile is reflected in the 
values calculated from regression: the mean t1/2 values of the 8% curve are generally 
lower, although most of the 95% CIs overlap with those of the 26% curve; the mean
mobile fractions of both the 8% and 26% laser powers are similar with the majority of 
associated CIs overlapping. In addition, FRAP curves were individually fitted as intra-
donor variation was high (Fig. 5.6.2a). Comparison of t1/2 and mobile fractions from 
individually fitted curves showed no evidence of a statistically significant difference 
between bleaching with the 8% or the 26% laser powers (Fig. 5.6.2b). Thus, there is no 
evidence that the preferred bleach conditions (26% laser power, 50 iterations) cause 
abnormalities in the recovery of CCR5. 
5.2.6 Summary of FRAP technique development 
Testing and minimising sources of error have been critical in being able to extract 
meaningful photometric data at the low fluorescence levels obtained through labelling 
endogenous CCR5 on live MDMs. Many steps have been involved in the development 
process (Fig. 5.7a). Cell drift was minimised through testing with PEI, PDL, collagen and 
CyGel which, ultimately, led to the decision to use collagen-coated coverslips. Microscope 
hardware was optimised and an indirect labelling technique was used to amplify the signal 
from CCR5. Intense ruffling and cell movement made attempts to position the bleach ROI 
on the top face of MDMs futile (supplemental movie 15); therefore the bleach ROI was 
positioned at the side of the cell just above the plane of the coverslip. Different laser 
powers were tested in live and fixed cells, the latter of which enabled appropriate 
bleaching conditions to be determined. Experiments with fixed MDMs also gave insight 
into how the extent of the decay curve can cause apparent recovery. The rapid Arrhenius 
dissociation of MC5 revealed that the decay curve is multifactorial and informed the start 
time of FRAP acquisition post-equilibration. As the final bleach conditions were compared 
to a lower laser power and shown not to cause artefacts in the recovery of CCR5, this final 
set-up (Fig. 5.7b) appears suitable to study the recovery of CCR5 in MDMs. 
5.3 Results 
5.3.1 Mobile and immobile fractions of CCR5 on the MDM membrane 
The fluorescence signal from MDMs labelled indirectly with MC5 Fab488 does not recover 
to the pre-bleach value. Initial indications of this were apparent from the raw FRAP 
images in which fluorescence in the central region of the membrane in the bleach ROI 
after recovery appeared to be less than that of the same region at the start of FRAP     
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Figure 5.6.2: High level of intra-donor variation in FRAP curves necessitates fitting of 
individual FRAP curves. MDMs that had been labelled indirectly with MC5 were subjected to 
FRAP (a) Representative single normalised individual recovery curves of cells from a single donor 
show the variation in (●) decay and (●) bleach ROI curves. (b) FRAP was performed with bleach 
laser powers of 8% or 26%. Each point on the plot shows the t1/2 or mobile fraction value derived 
from an individually fitted double normalised FRAP curve. FRAP curves from three donors were 
fitted and excluded/included according to the criteria detailed in section 5.1.4. Statistical 
comparison was performed using an unpaired Student’s t-test with Welch’s correction. Bars, mean 
± 95% confidence interval; ns, not significant. 
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Figure 5.7: Summary of FRAP technique development leading to final FRAP conditions. (a) 
The flow chart illustrates investigations that have contributed to improvement of the FRAP 
technique. Developments include: efforts to minimise global cell movement whilst maintaining cell 
morphology and unperturbed CCR5 recovery; the effectiveness of different bleach positions and 
higher signal:noise with MC5 Fab
488
 labelling; determining the contributions of decay, the correct 
bleach depth and controlling for effects of photo-induced cross-linking. Key: coverslip coating, red 
boxes; cells used, blue boxes; immunolabelling technique, green boxes; bleach conditions 
explored, grey boxes; it, iterations. (b) Table detailing the final FRAP conditions used specifying 
properties of the total acquisition field and the bleach region. 
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(Fig.5.8a; supplemental movie 16). Indeed, the mean double normalised recovery curve 
of all donors (n = 5) which, unlike the raw images, takes into account the level of decay, 
showed that fluorescence intensity does not recover to the pre-bleach value (Fig. 5.8a). 
This indicated that a small proportion of CCR5 at the PM of MDMs was resident as an 
immobile fraction. Furthermore, even though the profile of recovery curves can vary 
between donors, no double normalised FRAP curves reached the pre-bleach intensity 
(Fig. 5.8b). This shows that the general conclusion of an immobile fraction of CCR5 is not 
drawn from an artefact of calculating the mean of curves that completely recover with 
those that show no recovery. The speed of CCR5 recovery, indicated by the t1/2 values 
derived from regression of double normalised FRAP curves, was highly variant between 
donors (Fig. 5.8b). Even after the exclusion of values from D2012003, in which the decay 
curve was a dominant factor in recovery, MDMs still appeared to fall into two groups 
according to their t1/2 means and CI overlaps ( 73 and 86 s vs. 46 and 47 s). Calculating 
the overall mean of these values would be meaningless as the different speeds of CCR5 
recovery may reflect real differences in the regulation and genetic background between 
donors. In contrast, general trends in the extent of the mobile fraction can be seen, as all 
donors (bar D2012004) have overlapping CIs. The overall average mobile fraction is 73 ± 
10% (mean ± SD) and, therefore, the immobile fraction is estimated to be in the region of 
17 – 37%. The presence of an immobile fraction was also supported by tests on MDMs 
that involved double bleaching. After the initial recovery the original bleach region was 
bleached again; the second recovery curves often returned to ~100% (data not shown). In 
the presence of a true immobile fraction, recovery after the second bleach will always be 
complete or, at the very least, greater than the primary bleach. 
 
Despite the alterations to the FRAP technique that reduced variation, widespread 
differences were still apparent in the recovery curves of individual cells from a particular 
donor (Fig. 5.6.2a). In order to confirm that some level of recovery of CCR5 occurs on 
MDMs, raw data points of the bleach and decay ROIs from the first 30 s post-bleach were 
analysed by linear regression, as detailed in section 2.9.4. The advantage of this method 
of analysis is that raw data can be used and fluorescence decay is minimal over this time-
frame. The runs test was used to determine whether data from the bleach ROI 
significantly deviated from linearity over this time-frame; for MDMs, 93% of all FRAP 
curves fulfilled the assumption of linearity. If CCR5 was not mobile over this initial period 
of time, the gradient of the bleach slope would be expected to be similar to that of the 
decay or to that of the bleach gradients of fixed MDMs. Results showed that the gradients 
from the MDM bleach region were all positive (mean gradient, 1.2), whereas the fixed 
MDM gradients were close to zero and most decay gradients were slightly negative (Fig. 
5.8c). Generally, this indicates an upward trend in fluorescence within the bleached ROI,
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Figure 5.8: An immobile fraction of CCR5 exists on the cell surface of MDMs. MDMs from a 
total of five donors were labelled indirectly with MC5 followed by Fab
488
 and then subjected to 
FRAP under final conditions as detailed in Fig. 5.7b. (a) An example FRAP field and bleach ROI 
fluorescence at the indicated time-points illustrates that CCR5 recovery is not total. The overall 
mean FRAP curve was calculated from the mean of the double normalised recovery curves of all 
donors (n = 5). Graph shows mean ± SD. Scale bar, 20 µm (b) Single normalised bleach and 
decay curves, as well as double normalised recovery curves are presented as the means of all 
curves acquired each donor (2012003, 2012004, 2012006, 2013001, 2013002). Regression curves 
(solid line), 95% prediction bands (dotted line) and a plot of the mean residuals of the fit for each 
donor are shown. Table of values derived from single (area under curve values) and double (t1/2 
and mobile fraction values) normalised FRAP curves. (c) Short time-frame analysis of ROI 
intensities acquired from FRAP of live or fixed MDMs labelled with CCR5 and Fab
488
. Plots show 
the gradients, calculated by linear regression, of raw fluorescence intensity values from bleach and 
decay ROIs acquired over the first 30 s after bleaching, as detailed in section 2.9.4. 
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implying that CCR5 is mobile. Appropriate parametric or non-parametric tests could not be 
performed as the populations of gradients do not satisfy the assumptions of equal 
variance (Bartlett’s test; P<0.0001). However, when re-analysed without the bleach region 
gradients, all other populations showed equal variance by the Bartlett’s test. This indicates 
that the variance of the MDM bleach gradients is greater than the variance of the fixed 
and decay gradients, and highlights how variable the observed recovery is from cell to cell 
even within this short time-frame. 
5.3.2 The recovery of CCR5 compared to DiO 
FRAP was performed (using conditions detailed in Fig. 5.7b) on MDMs that had been 
uniformly labelled with the fluorescent lipid analogue DiO (Fig. 5.9a). The FRAP recovery 
curves illustrate that DiO recovered much faster than CCR5 (Fig. 5.9b). Means of the t1/2 
and mobile fractions extracted from regression (Fig. 5.9b) are 12 ± 3 s and 85 ± 8%, 
respectively. Comparing t1/2 and mobile fraction values from individually fitted DiO FRAP 
curves with those from individually fitted CCR5 FRAP curves showed that DiO recovery 
on MDMs was significantly faster and was associated with a higher mobile fraction than 
CCR5 (Fig. 5.9c). 
5.3.3 Effects of cholesterol depletion on MDM cell surface CCR5 
5.3.3.1 Effects of MβCD, filipin and U18666A on CCR5 cell surface expression  
MDMs were treated with chemical compounds that act to disrupt cholesterol, as detailed 
in section 2.10.1, and then labelled with antibodies to detect the level of cell surface 
CCR5. Histograms show that the level of MDM cell surface CCR5 was reduced by 
treatment with MβCD relative to the levels of CCR5 on control-treated cells (Fig. 5.10.1a). 
A similar decrease in cell surface CCR5 upon MβCD treatment has previously been 
described for mAb clone 45531 in human CD4+ T cells (Berro et al., 2011). In contrast, 
neither filipin nor U18666A treatment caused a decrease in cell surface CCR5 relative to 
respective control-treated samples. On U18666A treatment, a minor decrease in levels of 
the CCR5 epitope detected by mAb clone 45531 was observed for both donors however, 
unlike MβCD, the same decrease could not be detected with either MC5 or 2D7. As 
previously reported, intracellular accumulation of lysobisphosphatidic acid (LBPA) could 
be visualised by immunofluorescence microscopy in U18666A-treated, but not in control-
treated samples (data not shown), thereby showing that treatment was effective 
(Kobayashi et al., 1999). 
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Figure 5.9: Recovery of DiO occurs much faster than CCR5. FRAP was performed on MDMs 
(n=3) labelled with DiO, as detailed in section 2.8.3. (a) Images showing an example FRAP field 
and bleach ROI fluorescence at the indicated time-points. Scale bar, 20 µm. (b) Single normalised 
bleach and decay curves, as well as double normalised recovery curves presented as the means of 
all curves acquired each donor (2013005, 2013006, 2013007). Regression curves (solid line), 95% 
prediction bands (dotted line) and a plot of the mean residuals of the fit for each donor are shown. 
Table of values derived from single (area under curve values) and double (t1/2 and mobile fraction 
values) normalised FRAP curves of DiO-labelled MDMs. Comparative values from FRAP of MC5 
Fab
488
-labelled MDMs are also shown (c) Plots showing t1/2 and mobile fraction values, calculated 
by individually fitting FRAP curves from three donors, from MC5 Fab
488
 and DiO-labelled MDMs 
acquired under identical conditions. t1/2 values were compared using a Mann-Whitney U-test whilst 
mobile fraction values were compared using an unpaired Student’s t-test. Bars, mean ± 95% 
confidence interval; ***, P < 0.001. 
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Figure 5.10.1: MβCD treatment decreases cell surface expression and alters the distribution 
of CCR5. (a) MDMs were treated with 10 mM MβCD, 5 µg/mL filipin, 1 µg/mL U18666A or diluent 
volume-matched controls (PBS, ethanol, and water, respectively). Cells were then labelled with 
MC5, 2D7, 45531 or isotype controls, fixed and then labelled with secondary GAM-PE. Histograms 
show the fluorescence of the cell population gated on in the FSC/SSC dot plot and are 
representative of two donors. Black line, control-treated cells; red line, drug treated cells; grey 
fill, relevant isotype control. (b) MDMs were left untreated or treated with MβCD, filipin, U18666A 
then labelled with MC5 Fab
488
 for FRAP as described in section 2.10.1. Two representative 
fluorescence images, one with the concomitant bright-field (T-PMT) image from a single donor are 
shown for each treatment type. Scale bars, 20 µm. 
MC5 2D7 45531
MβCD
Filipin
U18666A
a
MC5
MC5
T-PMT
MC5
MC5
T-PMT
MC5
MC5
T-PMT
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b MβCD Filipin U18666AUntreated
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Even though MβCD caused a decrease in levels of CCR5, the fluorescence signal 
remained detectable above the isotype control. This lower level of fluorescence was still 
detectable by microscopy, although the distribution of CCR5 no longer appeared with the 
same uniformity seen in untreated MDMs (Fig. 5.10.1b). On many MDMs the majority of 
CCR5 staining appeared to be localised to one or two discrete regions of the PM. Thinner 
lines of fluorescence were also observed in MβCD-treated samples in comparison to 
untreated cells, which may be connected to the observation that wrinkling and ruffling of 
the PM seen in bright-field time-sequences were also reduced (supplemental movies 17 
& 18). By comparison, the U18666A and filipin treated samples exhibited a generally even 
fluorescence labelling with MC5 (Fig. 5.10.1b), very similar to that of the untreated MDMs. 
5.3.3.2 Cholesterol influences the mobile fraction of CCR5 on MDMs 
Following treatment with MβCD, filipin or U18666A, MDMs were labelled with MC5 Fab488 
and FRAP was performed under final conditions (Fig. 5.7b). Double normalised plots 
showed similar levels of recovery with untreated, filipin-treated and U18666A-treated cells 
(Fig. 5.10.2). In fact, despite all drugs affecting cholesterol, only MβCD-treatment 
appeared to have an effect on CCR5 recovery (Fig. 5.10.2). The same relationships 
between treatment and recovery were mirrored in the single normalised bleach recovery 
profiles. The decay curves for all conditions were remarkably similar; indeed, one-way 
ANOVA comparison of the 1-decay values for each treatment yielded no significant 
difference. In contrast the same test revealed a significant difference between areas under 
the bleach ROI curves that Tukey’s post-test showed to be due to the MβCD-treated 
samples (data not shown). This reinforces that the differences in double-normalised 
recovery reflect a real increase observed in the intensity of the bleach ROI rather than 
artefacts that could be introduced from the decay curve.  
 
Mean curves were calculated from all donors for each treatment group. Overlaying each 
curve with the untreated FRAP curve clearly illustrated the decreased recovery of CCR5 
seen with MβCD-treated MDMs (Fig. 5.10.3a). By comparison the recovery curve of 
filipin-treated MDMs appeared to be only slightly lower (Fig. 5.10.3a) and the U18666A-
treated MDMs gave a mean FRAP curve that was very similar to the untreated MDM 
FRAP curve (Fig. 5.10.3a). Individual FRAP curves from each donor for each treatment 
group were fitted and the associated t1/2 and mobile fractions were compared between 
each treatment group. No significant difference was found in the speed (t1/2) of CCR5 
recovery, however the reduction in the overall mobile fraction as seen in the overlaid 
FRAP curves was found to be significant (Fig. 5.10.3b). 
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D2013002 59.85 156.40 bleach 47.43 42.51 53.64 64.21 61.99 66.42 0.64
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MβCD
47.51 67.31 bleach 101.20 78.73 141.70 37.37 33.08 42.38 0.42
D2013002 62.88 56.07 equal 161.30 123.00 234.40 45.13 37.24 53.02 0.57
D2013004 43.40 (lin) 49.41 equal 38.83 30.43 53.63 20.62 19.08 22.17 0.23
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filipin
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U18666A
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D2013007 80.39 134.10 bleach 103.50 88.31 125.10 78.01 72.13 83.89 0.67
D2013008 62.58 (lin) 157.60 bleach 41.58 35.45 50.27 63.70 60.65 66.76 0.45
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Figure 5.10.2: The effect of cholesterol-disrupting drugs on mobility of CCR5 on MDMs. 
MDMs seeded in dishes were left untreated or were treated with 10 mM MβCD, 5 µg/mL filipin or
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1 µg/mL U18666A, then labelled with MC5 and Fab
488
 and subjected to FRAP under identical 
conditions, as described in section 2.10.1. Single normalised bleach and decay curves, as well as 
double normalised recovery curves presented as the means of all curves acquired from each 
donor. Regression curves (solid line), 95% prediction bands (dotted line) and a plot of the mean 
residuals of the fit for each donor (n = 3) are shown. The average normalised fluorescence value at 
the final time-frame is shown on the double normalised recovery plot (mean ± SD). A 
corresponding table of values derived from single (area under curve values) and double (t1/2 and 
mobile fraction values) normalised FRAP curves of untreated, MβCD, filipin and U18666A-treated 
MDMs is shown below. lin, linear fit; amb, ambiguous fit; CI, confidence interval.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10.3: MβCD treatment causes a significant decrease in the mobile fraction of cell 
surface CCR5 on MDMs. (a) The mean FRAP curve of untreated MC5 Fab
488
-labelled MDMs 
overlaid with the mean FRAP curves of MβCD-, filipin- or U18666A-treated MC5 Fab
488
-labelled 
MDMs. Overall mean FRAP curves were calculated from the mean double normalised recovery 
curves of all donors (n = 3). Graphs show mean ± SD. (b) Plots showing t1/2 and mobile fraction 
values, calculated by individually fitting FRAP curves from three donors, according to section 5.1.4, 
of untreated, filipin, U18666A or MβCD-treated MDMs acquired under identical conditions. Values 
were compared using a one-way ANOVA and a Tukey post-test. Bars, mean ± 95% confidence 
interval. ns, non-significant ***, p < 0.001. 
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5.3.4 Recovery of CCR5 on CHO-CCR5 cells vs. MDMs 
FRAP was performed on CHO-CCR5 cells that were labelled indirectly with MC5, as 
described in section 2.8.1. Even though single normalised recovery curves appeared to 
indicate a higher level of recovery of CCR5 than of MDM, the decay curve for CHO-CCR5 
cells was shallower (Fig. 5.11a). Consequently double normalised CCR5 recovery curves 
on CHO-CCR5 cells appeared to be very similar to those of MDMs. Indeed when CHO-
CCR5 FRAP curves were individually fitted, the extracted t1/2 and mobile fractions showed 
no significant difference to those of MDMs (Fig. 5.11b). Visually the similarity was 
illustrated by overlaying CHO-CCR5 and MDM mean CCR5 recovery curves (Fig. 5.11b). 
Note that bleaching at a lower laser power also yielded a similar recovery curve, meaning 
that CCR5 recovery was not perturbed due to photo-induced cross-linking at 26% laser 
power in CHO-CCR5 cells (data not shown). In general, the recovery of CCR5 on MDMs 
was analogous to that of CHO-CCR5 cells, indicating that this cell line suitably models 
CCR5 mobility. 
5.3.5 Recovery of antibody-labelled CCR5 compared to GFP-CCR5  
MDMs were transfected with one of two CCR5-GFP constructs in which GFP was located 
at either the N-terminus (GFP-CCR5) or the C-terminus (CCR5-GFP) of CCR5. As 
expected, successfully transfected MDMs appeared to express CCR5-GFP at the cell 
surface (Fig. 5.12a). FRAP was performed on transfected MDMs in the same way as MC5 
Fab488-labelled MDMs according to the method described in section 2.8.1. Single 
normalised recovery curves of MDMs expressing GFP-CCR5 showed a remarkably quick 
recovery with little or no decay over the course of analysis (Fig. 5.12b). Likewise, FRAP 
curves from MDMs transfected with CCR5-GFP showed a fast recovery, albeit to a lower 
final fluorescence level than seen for the GFP-CCR5 construct (Fig. 5.12b). This was 
reflected by the lower mobile fraction values calculated from regression of the double 
normalised curves for all of the CCR5-GFP FRAP curves, which lie outside of the 95% CIs 
of the higher values associated with GFP-CCR5. Despite this indication of difference, 
neither mobile fraction values nor t1/2 values derived from individually fitted FRAP curves 
of MDMs expressing the two constructs were found to be significantly different (Fig. 
5.12c). Thus, no overall difference between the GFP-CCR5 and the CCR5-GFP 
constructs was evident. As GFP in the latter construct is thought to mask the C-terminal 
PDZ recognition motif, this result demonstrates that this motif may not have any bearing 
on CCR5 mobility in this experimental setting. 
Individually fitted FRAP curve t1/2 values of MDMs expressing GFP-constructs were also 
compared with those of MDMs labelled indirectly with MC5 Fab488. The t1/2 values of both   
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donor cell type marker
Area under mean curve t1/2 (s) mobile fraction (%)
R2
1-decay bleach dominance mean lower 95% CI upper 95% CI mean lower 95% CI upper 95% CI
rpt a
CHO-CCR5
CCR5 
(MC5)
49.23 160.50 bleach 58.25 52.58 65.30 66.04 63.76 68.32 0.58
rpt b 33.74 209.10 bleach 49.78 43.58 58.03 75.26 72.03 78.49 0.61
D2012006
MDM
62.17 (lin) 142.90 bleach 72.52 62.87 85.67 68.25 64.48 72.03 0.43
D2013001 47.74 (lin) 180.10 bl ach 46.06 40.20 53.93 67.87 65.03 70.72 0.44
D2013 02 59.85 156.40 bleach 47.43 42.51 53.64 64.21 61.99 66.42 0.64
Overlay of mean FRAP 
urves in MDMs and 
CHO-CCR5 cells
Values derived from individually           
fitted  FRAP curves
t 1
/2
(s
)
m
o
b
ile
 f
ra
c
ti
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Figure 5.11: CCR5 mobility is similar between CHO-CCR5 cells and MDMs. FRAP was 
performed on CHO-CCR5 cells labelled with MC5 and Fab
488
, as described in section 2.8.1, under 
identical imaging conditions to MDMs. (a) Single normalised bleach and decay curves, as well as 
double normalised recovery curves presented as the means of all FRAP curves acquired for CHO-
CCR5 cells on two separate days (repeat a, repeat b). Data from MDMs are presented in the 
ame format to aid direct compari on (D2012006, D2013001, D2013002). Regression curves (solid 
line), 95% prediction bands (dotted line) and a plot of the mean residuals of the fit for each donor 
are hown. A table of values derived from single (area under curve values) and double (t1/2 and 
obile fraction values) normalised FRAP curves of CHO-CCR5 cells and MDMs is shown below. 
(b) Plots show t1/2 and mobile fraction values calculated by individually fitting FRAP curves from 
MDMs or from CHO-CCR5 cells that were acquired under ide tical conditions. Values were 
compared using an unpaired Student’s t-test. Bars, mean ± 95% CI. Mean (± SD) FRAP curves 
from MC5 Fab
488
 labelled MDMs and CHO-CCR5 cells were calculated from the average double 
normalised recovery curves of all donors (n=3) or days (n=2). CI, confidence interval; ns, non-
significant. 
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Figure 5.12: MDM CCR5-GFP recovers significantly faster than endogenous CCR5 labelled 
with MC5 and Fab
488
. MDMs were transfected with one of two CCR5-GFP constructs in which 
GFP is located at the C-terminus (CCR5-GFP) or the N-terminus (GFP-CCR5) of CCR5. FRAP 
was performed on transfected MDMs under conditions identical to those for MC5 Fab
488
-labelled 
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MDMs, described previously. (a) Three representative fluorescence and bright-field images from 
each donor (n=3) show the PM expression of both constructs. Scale bars, 20 µm. (b) Single 
normalised bleach and decay curves, as well as double normalised recovery curves presented as 
means of all curves acquired for each donor (2013004, 2013005, 2013006) for both GFP-CCR5 
and CCR5-GFP. Regression curves (solid line), 95% prediction bands (dotted line) and a plot of the 
mean residuals of the fit for each donor are shown. The table contains values derived from single 
(area under curve values) and double (t1/2 and mobile fraction values) normalised FRAP curves (c) 
Plots showing t1/2 and mobile fraction values, calculated by individually fitting FRAP curves from 
three donors, according to section 5.1.4, from FRAP of GFP-CCR5 and CCR5-GFP transfected or 
MC5 Fab
488
-labelled MDMs acquired under identical conditions. Values were compared using a 
one-way ANOVA and a Tukey post-test. Bars, mean ± 95% CI. Mean (± SD) FRAP curves 
calculated from the mean double normalised recovery of all donors (n = 3) of MC5 Fab
488
-labelled 
MDMs, GFP-CCR5 MDMs and CCR5-GFP MDMs. **, p < 0.01; ***, p < 0.001. lin, linear fit; amb, 
ambiguous fit; CI, confidence interval; ns, non-significant. 
 
 
 
 
 
CCR5-GFP chimeras were found to be significantly smaller, signifying a faster recovery 
compared with the MC5 Fab488-labelled MDMs (Fig. 5.12c). In addition, the fraction of 
mobile CCR5 molecules on MDMs transfected with the GFP-CCR5 construct was 
significantly greater than that of MC5-labelled MDMs, however the CCR5-GFP mobile 
fraction was not (Fig. 5.12c). Overlay of the mean FRAP curves shows the recovery of 
both GFP constructs to be similar, albeit diverging slightly at later time points (Fig. 5.12c). 
In contrast, the mean FRAP curve of the MC5-labelled MDMs consistently lies below the 
GFP-CCR5 recovery curves for most of the FRAP time course. Together these results 
indicate that the speed of CCR5 mobility in MDMs may be underestimated when using the 
MC5-labelling technique, perhaps as a direct result of antibody binding, or overestimated 
when using GFP-tagged CCR5 constructs. 
5.4 Discussion 
5.4.1 FRAP technique validation 
The levels of endogenous CCR5 expressed on the cell surface of MDMs were known to 
be low at the outset of experimentation. Indeed, a previous report shows that MDMs 
differentiated in human serum and M-CSF have only 40-80 antibody binding sites for the 
prototypical anti-CCR5 mAb 2D7 (Lee et al., 1999b). A low level of fluorescence signal is 
often a problem for FRAP as typical solutions for confocal imaging, such as line averaging 
or increasing the laser power, can result in loss of dynamic information or high aquisitional 
bleaching, respectively, leading to systematic errors in FRAP results (Ishikawa-Ankerhold 
et al., 2012). Therefore other efforts were made to improve the signal. MC5 was found to 
have higher levels of binding and a greater affinity than 2D7 and CTC5 (Fig. 5.2) and was, 
therefore, deemed the most suitable mAb to label endogenous CCR5 on MDMs for FRAP. 
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In addition, MC5 was also a good candidate as it recognises a linear epitope that has 
been mapped to the extreme N-terminus of CCR5 and does not induce oligomerisation as 
evidenced by BRET (Blanpain et al., 2002). Yet use of MC5, which only recognises the 
form of CCR5 susceptible to ligand-induced downmodulation means that the FRAP results 
of the present study only represent one particular antigenic form of CCR5 (Signoret lab, 
unpublished data).  Other forms of endogenous CCR5 may exhibit different mobility. 
 
Conjugating MC5 with a fluorochrome (DyLight488) to a D:P molar ratio of 5.4:1 resulted in 
a ~30-fold lower affinity and rendered fluorescence levels barely detectable above isotype 
control levels (Fig. 5.4b). In contrast, using an indirect immunolabelling procedure to 
detect MC5 with a monovalent Fab488 secondary yielded much higher fluorescence levels 
and did not alter the staining pattern. Thus, indirect immunolabelling for FRAP appears to 
be a useful method to detect low levels of proteins expressed at the cell surface. 
In recent years, with the majority of FRAP studies utilising fluorescent proteins to label the 
molecule of interest, the notion that factors other than aquisitional photobleaching can 
influence the decay curve has become almost foreign. However, when using antibodies to 
study the mobility of a protein by FRAP they must be considered as an element that can 
contribute to the decay because the bound and unbound fractions will tend towards 
equilibrium. The present study showed that MC5 dissociates rapidly at 37°C compared to 
4°C and that this results in a loss of the majority of fluorescence on MDMs after 15 min 
(Fig. 5.5). Thus, FRAP of a labelled sample did not begin until after 20 min at 37°C, after 
which the rate of loss of total fluorescence due to dissociation was expected to be less 
than 1% per minute. This gave greater consistency in decay and ensured that the 
percentage of CCR5 bound with fluorescent antibody was similar for sequential cells 
subjected to FRAP. Ishihara et al. (1987) also described the rate of decay (0.3%/6 s 
recovery) when investigating the mobility of the thymocyte/T-lymphocyte surface 
differentiation antigen (Thy-1) with fluorescently tagged anti-Thy-1 mAbs. They highlighted 
the need for other FRAP studies to state the levels of dissociation, as rapid dissociation 
can lead to artificially slow estimations of the diffusion constant (Ishihara et al., 1987). 
Whilst technological improvements now enable decay ROIs to be acquired simultaneously 
with bleaching, when using antibodies for FRAP care should be taken that a ROI of the 
same fluorescence level as the pre-bleach is used to model the decay. Such an approach 
was taken in the present study because the rate of antibody dissociation was expected to 
be higher in membrane regions of higher fluorescence/antibody concentration.  
To minimise aquisitional photobleaching the image acquisition interval was changed from 
3 s throughout, to 3 s for the first 40 cycles then 10 s for the remaining cycles. Despite this 
theoretical improvement and an appreciation of the MC5 dissociation factor that may 
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influence decay, the overall level of decay over comparable time-frames (316 s post-
bleach) remained similar before (MC5488-labelled MDMs on PEI: 0.74 ± 0.19) and after 
(MC5 Fab488–labelled MDMs on collagen: 0.74 ± 0.16) technique development. This could 
indicate that other unknown factors are also components of the decay curve or that the 
technical improvements in the decay may not be apparent between these experimental 
situations because of the change in the immunolabelling procedure. Indeed, after 
determination of final imaging parameters (Fig. 5.6b) the level of decay was most likely 
due to factors associated with the immunolabelling procedure rather than the imaging 
technique. This is apparent from the lack of decay upon FRAP of CCR5-GFP-transfected 
MDMs (Fig. 5.12b). 
5.4.2 Considerations for fitting CCR5 recovery 
Another major consideration for FRAP is how best to represent the data that have been 
acquired. Variation in FRAP curves between cells from a single donor was evident (Fig. 
5.6.2a), which can be caused by differences in the binding properties of proteins during 
the cell cycle (Phair et al., 2004). To obtain an overview of the mobility of CCR5 within the 
population of MDMs, the mean of the FRAP curves from each donor was calculated but 
SD rather than standard error of the mean (SEM) error bars were shown to provide a 
better representation of variation in the data. Regression of these mean curves, according 
to a simple exponential rise to maximum, yielded t1/2 and mobile fraction values along with 
95% CIs that could be compared between donors and experimental settings. 
The R2 value can be used as a measure of how well the curve describes the data. A value 
of 1.0 indicates that every point will lie along the regression line and a value of 0.0 
indicates that the model fits no better than a horizontal line drawn through the data 
(Motulsky and Christopoulos, 2003). After experiments had been repeated numerous 
times under the final imaging conditions, R2 values of regression for data sets composed 
of ≥10 individual FRAP curves became anticipated to be between 0.4 and 0.6. In 
comparison, under initial FRAP conditions the R2 value for the generated data sets was 
much lower (~0.2; Fig. 5.3.1a). This indicates how improvements in the FRAP technique 
have led to generation of photometric data that can be more accurately described by the 
single exponential rise to maximum model.  
The replicates test for lack of fit indicated that the single exponential rise to maximum 
model (section 2.9.3: Equation 5) was adequate, however, residuals were not found to be 
normally distributed, which is visually reflected by the fact that the majority of mean 
residuals at early time points are positive. This may indicate that the data do not fulfil the 
Gaussian assumptions of regression. To remedy this the data could be fit with a different 
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model, weighting applied, or outliers removed (Motulsky and Christopoulos, 2003). 
However, changing the model to a double exponential did not improve the fit according to 
R2, nor yield normally distributed residuals according to D’Agostino’s test. Further, 
weighting is not appropriate for use with normalised data, which is utilised in the present 
study (Motulsky and Christopoulos, 2003). Outliers can have an effect on fitting because 
of the underestimation of their occurrence by Gaussian distribution (cf. Poisson) (Press, 
2007). Nevertheless, discrimination of outliers using the ROUT method (Motulsky and 
Brown, 2006) and subsequent removal from the data sets did not result in normality of 
residuals after fitting. Given the number of replicates acquired in the present study, other 
methods to identify outliers could be tested (Motulsky and Brown, 2006) in the future to 
provide further evidence as to whether outliers are causing the lack of normality seen in 
residuals. Overall, the least-squares single exponential rise to maximum fit was chosen as 
the replicates test indicated it was not inadequate and none of the alternatives tested 
appeared to solve the problem of lack of normality in residuals. Thus t1/2 and mobile 
fraction parameters derived from regression of averaged data are understood to be rough 
indications rather than absolute values.  
All FRAP curves were also ‘individually fitted’ as described in section 5.4.1. This approach 
was implemented to show the spread of t1/2 and mobile fraction values in order to faithfully 
represent the range of CCR5 mobility in the cells analysed for all donors. One of the 
caveats of this approach was that fitting yielded very low ‘Gamma-Q’ values. These 
values are probabilities derived from the chi-squared (χ2) distribution that can be 
mathematically calculated for the number of degrees of freedom in a particular experiment 
by subtracting the number of adjustable parameters from the number of data points to be 
fitted (Press, 2007). The Q probability is designed to indicate the likelihood that the χ2 
value obtained for the fit should exceed a particular χ2 value by chance (Press, 2007). 
Values of Q > 0.1 indicate a convincing goodness-of-fit of the model but when Q < 0.001 
the validity of the model is brought into question (Press, 2007).  
Several models were applied to the individual FRAP curves, using the FRAPcalc plug-in, 
to determine whether any one fitted better than the other. The fitting procedures applied 
were: (A) single-exponential fit for double normalised data; (B) double-exponential fit for 
double normalised data; (C) single-exponential fit with back multiply normalisation. Details 
of how the fits are performed as well as the pros and cons of these models are 
summarised in Technical Appendix 1a. All fitting procedures gave similar percentages of 
FRAP curves associated with Q < 0.001 (Technical Appendix 1b), which may indicate a 
number of possibilities: (i) that none of the models tested appropriately describe the data; 
(ii) that the plug-in, which calculates χ2 by approximating the SD at each time-point from 
the variance in intensity over the pre-bleach time, may be underestimating the errors; (iii) 
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that Gaussian assumptions of the fitting procedure are inappropriate for these FRAP data 
(Press, 2007). In addition, a number of Q values were found to be very close to 1.0 
indicating a perfect fit, the cause of which is commonly attributed to overestimation of 
error (the opposite of possibility (ii) above) (Press, 2007).  
Given the variability in the individual FRAP curves it is quite likely that χ2 has been 
misrepresented by the program’s estimations. For this reason the related Q value was not 
used as a measure of goodness-of-fit. Instead a single-exponential fit of double 
normalised data was chosen on the basis that this model was not found to be inadequate 
on averaged data. Despite the fact that this may oversimplify the parameters of recovery, 
no current evidence exists that suggests steady state mobility of CCR5 on MDMs is 
multiphasic. Ultimately this approach may not have modelled the data to the best degree 
but it has enabled a relatively unbiased estimation of the mobile fraction, which needs to 
be known to calculate t1/2, so that these values can be used for comparison between drug 
treatments etc. Mobile fraction and t1/2 values from individually fitted FRAP curves, 
therefore, supplement the rough indications given by regression of averaged data. A 
possible direction for future analysis would be to avoid fitting a model altogether and 
simply use the mode fluorescence value in the recovery curve as an estimation of the 
mobile fraction then use this to approximate the t1/2 directly from the unfitted curve.  
5.4.3 Influences of MDM mobility and PM topology 
Cell migration and shape change are well documented phenomena that cause 
undesirable variations in intensity (Klein and Waharte, 2010). Investigations into adhesion 
and movement on different coverslip coatings were carried out in order to minimise these 
problems. MDMs were more spread (flattened shape) on collagen than on PEI (Fig. 
5.3.1b), making the former coating more desirable. In addition, seeding MDMs on 
collagen was shown to be preferable to seeding on PDL which showed a higher cell drift 
(migration) (Fig. 5.3.2b). Therefore the collagen-coating was the best option to limit the 
mobility of MDMs. Even so, many MDMs still exhibited a degree of mobility and change in 
shape over the course of FRAP (supplemental movie 17), which may have contributed 
to variation in the data. Moreover, MDMs have recently been demonstrated to have 
complex, stable (present for over one hour) membrane domains called intracellular 
plasma-membrane connected compartments (IPMCs) (Mlcochova et al., 2013). FRAP of 
MDMs transfected with a GFP-tagged phospholipase Cδ pleckstrin homology domain 
(PH-GFP) showed that the mobility was comparable in the IPMCs and the PM, whilst 
fluorescence loss in photobleaching was used to show that PH-GFP exchanges between 
these compartments (Mlcochova et al., 2013). Combined with the notion that leukocyte 
ruffles are thought to double the spherical surface area of the cell (King, 2004), the 
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presence of IPMCs further convolutes the MDM membrane and, thus, the pathway of PM 
constituents, such as proteins and lipids. Accordingly, microscope measurements of 
CCR5 mobility will be influenced by topological features, particularly if CCR5 does in fact 
exist in clusters on MDM microvilli (Singer et al., 2001) or tetraspanin enrichment in 
IPMCs (Deneka et al., 2007) alters the hydrodynamic friction or trapping effects in these 
compartments. The mobility of soluble GFP in the lumen of the ER was modelled and 
diffusion coefficients were found to vary by up to 2.5 times, depending on the topology of 
the ER (Sbalzarini et al., 2005).  Given the complex shape and mobility of the MDM PM it 
is unlikely that recovery observed in the present study is solely due to lateral CCR5 
mobility in the PM. Ultimately this is the reason why diffusion coefficients were not 
calculated as they would misleadingly imply that the mobility measured in MDMs was 
directly due to CCR5. 
Immobilisation of MDMs was achieved using CyGel (supplemental movie 13). However, 
the recovery of MC5-labelled CCR5 was perturbed in CyGel, therefore it was not deemed 
suitable for use with the labelling technique employed to investigate the mobility of 
endogenous CCR5 on MDMs. Nonetheless the effects of CyGel at the cell:gel interface 
were investigated in CHO-K1 cells transfected with CCR5-GFP constructs (CHO-
K1.CCR5-GFP cells). Similarly to the MDMs, when CHO-K1.CCR5-GFP cells were 
labelled with MC5 the mobility of CCR5 was perturbed in the presence of CyGel 
(Technical Appendix 2a). The gel structure of CyGel allows diffusion of small molecules, 
such as chemokines (8–12 kDa) or cytokines but not of larger macromolecules such as 
antibodies (~150 kDa) (Roy Edwards, personal communication, 27 November, 2012). To 
investigate whether the antibody is responsible for immobilisation of CCR5, the mobility of 
CCR5-GFP or GFP-CCR5 was determined in the presence and absence of CyGel. Both 
GFP constructs showed recovery in both media and CyGel (Technical Appendix 2a), 
indicating that membrane protein mobility was not barred by the action of CyGel. 
Moreover, when FRAP was performed in two channels on dual-labelled cells (MC5650 and 
CCR5-GFP) in the presence and absence of CyGel, the presence of MC5650 in CyGel was 
observed to perturb the recovery of the CCR5-GFP (Technical Appendix 2b). This 
directly shows that the inhibition in recovery is due to trapping of the antibody-bound 
receptor by the CyGel. 
Notice that recovery of CCR5-GFP in the presence of CyGel was slower, to a lower level 
and had less variation than in medium. This could be due to the presence of the gel-
meshwork at the cell interface making the pathway of CCR5 movement from one 
membrane region to the next more tortuous. An interesting alternative hypothesis is that 
the gel immobilises submicron topological features (e.g. ruffles, wrinkles, protrusions, etc.) 
that occur on most cells (King, 2004), which could contribute to non-lateral recovery. 
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Thus, future investigation may show that CyGel has potential use as a tool to distinguish 
between truly lateral and membrane topology-driven recovery in FRAP. 
The mobility of CCR5 on MDMs is slow in comparison to the lipid analogue DiO (Fig. 
5.9c), however the majority of CCR5 exists as a mobile fraction (73 ± 10%) (Fig. 5.8a & 
b). The positive linear gradients fitted to the early time points post-bleach showed the 
mobility of CCR5 to be apparent even in raw uncorrected data. This reinforces that the 
recovery is not simply an artefact of the decay curve. Although the majority of CCR5 
exists in the mobile fraction, a small immobile fraction is apparent. This is consistent with 
a study by Nakata et al. (2010) who showed CCR5 to have a mobile fraction of 84 ± 4.4% 
which, conversely, indicates that a small fraction of CCR5 is immobile. In the present 
study, double bleaching further implied the presence of an immobile fraction (Ishikawa-
Ankerhold et al., 2012), as a second round of bleaching resulted in recovery that was 
higher than recovery after the initial bleach. Still, the term ‘immobile’ only applies to CCR5 
over the FRAP time-frame (7–8 min) as a longer time-frame of analysis may show this 
fraction of CCR5 simply to be slowly exchanging. 
5.4.4 Cholesterol depletion of MDMs appears to reduce PM CCR5 
levels  
Acute cholesterol depletion using MβCD resulted in a reduction in fluorescence levels 
detected by MC5, 2D7 and 45531 compared to controls (Fig. 5.10.1a). A previous study 
has also reported reduction in 2D7 levels after MβCD treatment (Venkatesan et al., 2003), 
whilst other reports have indicated that the 45531 and CTC5 epitopes are reduced after 
hydroxypropyl-β-cyclodextrin (HPCD) treatment (Berro et al., 2011; Nguyen and Taub, 
2002). However, in contrast to Venkatesan et al. (2003) and the present study, Berro et al. 
(2011) did not observe a decrease in the 2D7 epitope upon HPCD treatment. Perhaps this 
relates to the differences between HPCD and MβCD treatment. Kline et al. (2010) directly 
compared the action of MβCD and HPCD on endothelial cells and, at a concentration of 
10 mM, showed a greater level of cholesterol depletion by MβCD but also a higher 
cytoxicity (Kline et al., 2010). Perhaps more severe cholesterol depletion results in 
conformational changes in CCR5 that disrupt epitopes recognised by 2D7 and mask the 
linear MC5 epitope. This hypothesis is consistent with maintained levels of MDM cell 
surface CCR5 expression upon filipin and U18666A treatment, which sequester or reduce 
cholesterol rather than remove it from the membrane like MβCD. In contrast to the present 
study, Venkatesan et al. (2003) showed that filipin treatment reduced cell surface CCR5 
expression on transfected HeLa cells. Perhaps this can be explained by the 
overexpression of CCR5, which may associate with a greater percentage of total PM 
cholesterol than is required by the lower number of CCR5 molecules on MDMs in order to 
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achieve correct conformation. Thus a greater proportion of CCR5 might become 
destabilised upon filipin treatment and unable to bind 2D7 compared to MDMs where 
cholesterol is in excess. An alternative explanation is the longer treatment of filipin at a 
higher concentration (10 µg/mL for 30 min) used by Venkatesan et al. (2003). 
5.4.5 The differential effects of MβCD, filipin and U18666A  
The mobility of CCR5 was significantly reduced upon MβCD treatment of MDMs, 
seemingly implicating a key role of cholesterol in CCR5 lateral mobility (Fig. 5.10.3). Note 
that the reduction in mobility is due to changes in fluorescence in the bleach ROI rather 
than being an artefact of differing fluorescence decay. This was shown by comparison of 
all area under curve values by two-way ANOVA and Tukey post-test, which showed 
significant differences between MβCD and all other treatments, whilst the same 
comparison of area under 1-decay curves yielded no significant difference in the decay 
(data not shown). Previous FRAP studies have described a similar type of decrease in 
CCR5 mobility upon MβCD treatment (Nakata et al., 2010; Steffens and Hope, 2004). 
However, simply concluding that cholesterol mediates CCR5 mobility contradicts why little 
or no reduction in mobility is seen with filipin or U18666A, which also have effects on 
cholesterol. The solution to these enigmatic results may be found by considering the 
mechanism of action of each drug.  
5.4.5.1 MβCD extracts cholesterol from the PM 
MβCD works by directly removing cholesterol from the PM through formation of soluble 
inclusion complexes with cholesterol (Ivanov, 2008). However, MβCD-treatment has also 
been reported to have a number of severe side effects, such as disruption of the cortical 
actin cytoskeleton, of multiple endocytic pathways and activation of Ras (Ivanov, 2008). In 
particular, adverse effects on the cortical cytoskeleton are likely to impact on topological 
features of the PM that would affect the result of FRAP. Through studying membrane 
protrusions, depletion of PM cholesterol content was shown to stiffen the membrane 
relative to higher cholesterol contents. Yet no such difference was observed when F-actin 
was disrupted at the same time (Khatibzadeh et al., 2013). This demonstrates how the 
interplay between the actin cytoskeleton with cholesterol can influence membrane 
topology. In addition, Kwik et al. (2003) reported that a number of mobile receptors (MHC 
class I and epidermal growth factor receptor) demonstrated a lower mobile fraction upon 
cholesterol depletion but they suggested that this was due to cytoskeletal deregulation 
rather than the properties of lipid rafts. Considered together, removal of cholesterol by 
MβCD will disrupt cytoskeletal regulation, increase membrane stiffness and reduce the 
length of membrane protrusions. This may account for the thinner lines of PM 
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fluorescence (Fig. 5.10.1b) and lower degree of membrane wrinkling (supplemental 
movie 18) observed in MβCD-treated MDMs. As MβCD-treatment also lowers the mobile 
fraction for several other receptors (Kwik et al., 2003) it is unlikely that the mobility of 
CCR5 is due to unique interactions with cholesterol. Rather, that PM cholesterol is 
required to maintain the PM dynamics that enable mobility of many membrane 
components.  
5.4.5.2 Filipin sequesters cholesterol in the PM 
Filipin acts mechanically on membranes by forming aggregates (~30 nm as measured by 
freeze-etched electron microscopy (EM) in erythrocyte membranes) that accrue 
cholesterol (Ivanov, 2008; Tillack and Kinsky, 1973). Under the assumption that CCR5 is 
tightly associated with cholesterol and considering that no change in the uniform 
distribution of CCR5 was observed upon filipin treatment, filipin/cholesterol aggregates are 
unlikely to be greater than the diffraction limit (~200 nm) (Ishikawa-Ankerhold et al., 2012). 
Due to the nature of oligomer-induced trapping and the fact that larger complexes will 
experience greater steric hindrance and hydrodynamic frictions (Kusumi et al., 2005) 
CCR5 in these aggregates would be expected to move slower but would not necessarily 
be immobile. Such subtle effects of filipin treatment may be reflected by the overall mean 
recovery curve of CCR5 lying lower than that of untreated MDMs (Fig. 5.10.3a). Equally, 
bundles of cholesterol not associated with CCR5 could slow movement of the receptor. 
Nevertheless, these differences are not significant in this system and would need to be 
investigated in a FRAP technique with much less error (e.g using synchronised cell line, 
GFP-CCR5 and CyGel) or with SPT methods. Note that filipin has also been reported to 
disrupt links with the actin cytoskeleton (Ivanov, 2008) thus SPT would be the favoured 
technique as it could also inform on any changes in PM compartment size as a result of 
drug treatment. 
5.4.5.3 U18666A alters the trafficking of cholesterol  
Unlike the other drugs, U18666A acts indirectly on cholesterol by inhibiting intracellular 
trafficking and exit of cholesterol from lysosomes (Cenedella, 2009). Treatment with 
U18666A has been shown to reduce PM cholesterol levels (Chen et al., 2011; Underwood 
et al., 1998), however other studies have shown no difference in the cholesterol content of 
the PM in U18666A treated cells (Appelqvist et al., 2011; Lange et al., 2000). Attempts 
were made to label U18666A–treated and untreated MDMs with filipin in order to visualise 
cholesterol levels at the PM but these were unsuccessful. Thus, as it is not certain that 
cholesterol is depleted in the PM of MDMs, U18666A treatment cannot inform about 
whether the mobility of CCR5 is dependent upon cholesterol. Nevertheless, as the 
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dynamics of cholesterol trafficking are known to be altered by U18666A (Cenedella, 2009) 
the lack of change in CCR5 recovery in U18666A treated vs. untreated MDMs (Fig. 
5.10.3) shows that the speed of cholesterol replenishment/removal at the PM does not 
appear to impact CCR5 mobility. Even though U18666A treatment can induce autophagy 
and apoptosis as side effects (Cenedella, 2009), it is useful as a tool to study cholesterol 
dependence at the PM. The indirect effects exerted on cholesterol by U18666A make it a 
useful supplement to cholesterol depletion/sequestration by more direct means (e.g. 
filipin, nystatin and MβCD) provided that depletion of PM cholesterol is demonstrated. 
5.4.6 Cholesterol is important in conferring CCR5 mobility in the PM 
Although all three drugs have their side effects, the combined data indicates several 
effects of disrupting cholesterol with regard to endogenous CCR5 on MDMs. Firstly is that 
removal of cholesterol from the PM retards receptor mobility, as has been reported before 
in cell lines (Nakata et al., 2010; Steffens and Hope, 2004) and for other mobile PM 
receptors (Kwik et al., 2003). Secondly, when cholesterol is present at the PM but is 
sequestered, the mobility of CCR5 is not significantly slowed. Together this suggests that 
cholesterol is required to set the stage for CCR5 movement but may not be essential in 
the actual action of movement per se.  
5.4.7 Influences of the labelling method 
GFP-tagged CCR5 has a faster mobility than MC5 Fab488-labelled CCR5 on MDMs (Fig. 
5.12c). This difference in mobility between GFP and antibody -labelled CCR5 was also 
shown in FRAP studies of MC5650-labelled CHO-K1.CCR5-GFP cells. The recovery of the 
GFP and DyLight650 signals after bleaching in the same ROI was found to be different 
despite the fact that both methods distinguish CCR5 (Technical Appendix 1b). This 
phenomenon cannot be explained by MC5 only recognising the ligand-inducible 
downmodulating cell surface pool of CCR5 on MDMs because the same results occur in 
transfected cells, which do not exhibit two pools of CCR5 distinguishable by 
downmodulation (Signoret lab, unpublished data). 
There are a number of technical considerations that may help explain the differences 
observed between GFP and antibody-based CCR5 labelling methods. The simplest 
explanation for slower mobility of antibody-labelled CCR5 would be that MC5 stabilises 
CCR5 dimers and concurrent oligomerisation-induced trapping causes a decrease in 
lateral mobility of the receptor. However, a previous study used BRET to show that MC5 
did not induce receptor dimerization (Blanpain et al., 2002). To confirm the conclusions of 
Blanpain et al. (2002) and rule out this explanation, FRAP could be performed on CHO-
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CCR5 cells labelled with bivalent MC5 or a monovalent MC5 Fab fragment and the speed 
of recovery compared.  
One of the major benefits of the antibody-labelling method is that only the cell surface 
receptors are identified. In contrast, even though the majority of CCR5-GFP fluorescence 
is apparent at the PM (Fig. 5.12a), de novo CCR5-GFP exists in the biosynthetic pathway 
(ER and trafficking vesicles) (Fig. 5.13). Consequently, as long as GFP is folded correctly, 
CCR5-GFP in non-PM organelles and vesicles will contribute to the fluorescence signal 
detected by confocal microscopy. Given that the lipid components of the PM differs vastly 
from that of the ER and other intracellular organelles (van Meer et al., 2008), the mobility 
of receptors is likely to vary between compartments. If such compartments were 
unintentionally included in the bleach ROI this could contribute to the faster recovery of 
CCR5-GFP compared to MC5-labelled CCR5 at the PM.  
Another alternative could be differences in trafficking properties of GFP or antibody-bound 
CCR5. Endogenous CCR5, unlike CXCR4, does not undergo significant levels of 
internalisation in the absence of ligand (Borroni et al., 2010). Nevertheless there is 
potential for the CCR5-GFP chimera to exhibit altered trafficking properties due to the 
masking of a PDZ recognition motif. Indeed, the PDZ-recognition motif of beta-2-
adrenergic receptor (β2AR) was found to be important in association of the receptor with 
actin that mediates an increased cell surface residence time of β2AR in clathrin-coated 
pits (Puthenveedu and von Zastrow, 2006). However since both GFP constructs showed 
faster mobility than antibody-labelled CCR5 in the present study, any possible effects of 
GFP on the PDZ recognition domain cannot explain the increased mobility. With regard to 
ligand induced internalisation, downmodulation in response to autocrine CCL5 would 
affect both antibody and GFP-labelled CCR5, although Gomez-Mouton et al. (2004) noted 
that ligand stimulated CCR5-GFP shows unusually sustained intracellular accumulation. 
Additionally, MC5-bound CCR5 cannot bind CCL3 or CCL4 (Blanpain et al., 2002), 
meaning that any autocrine effects of these chemokines may affect GFP chimeras but not 
antibody-bound CCR5. Overall, differences in chemokine binding and downmodulation 
might influence MC5-labelled and GFP-labelled CCR5 mobility or loss from the PM, 
however the extent of these effects are unclear as the level of CCR5 chemokine secretion 
by MDM during the FRAP procedure is unknown. 
Overall, the main proportion of endogenous cell surface CCR5 appears to be mobile on 
the cell surface of MDMs. The speed of recovery and the mobile percentage of CCR5 on 
MDMs appear to be similar to that of CCR5 on CHO-CCR5 cells, however the complex 
topology of MDMs may mean that the true lateral mobility of CCR5 is underestimated. 
Future work would require single particle techniques (e.g. SPT and SFVI) in combination 
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Figure 5.13: Cartoon summarising how antibody or GFP labelling methods can contribute to 
fluorescence that is perceived to be at the PM. Antibody (indirect labelling with MC5 followed by 
Fab
488
 that is bound to the PM will both associate and dissociate over the duration of FRAP, 
although the extent of dissociation is much greater than the extent of association. MC5 bound 
CCR5 permits binding of CCL5 and ligand-induced internalisation. Similarly the fluorescent signal 
of CCR5-GFP can also be removed from the PM in response to chemokine binding. Unlike 
antibody-associated fluorescence a contribution to apparent PM fluorescence within the bleach 
ROI would also be made from GFP present in the ER. All the indicated events would occur within 
the bleach ROI but, despite fluorescence (and thus CCR5) subsequently being associated with 
different cellular compartments, all events are treated as lateral mobility of CCR5 at the PM. This 
may help explain why GFP-tagged CCR5 can show a faster mobility by FRAP measurements than 
antibody-labelled CCR5. 
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with selective illumination of the sample in the plane of the PM only (e.g. using total 
internal reflection fluorescence microscopy) to supplement this FRAP study and decipher 
the lateral movement of CCR5. The presence of PM cholesterol was found to be important 
to enable CCR5 mobility, although cholesterol may not interact directly with CCR5 to 
facilitate movement. Finally, the labelling method is critical to the measurement of receptor 
mobility at the PM. Technological advances into ligand-directed covalent labelling may 
ultimately lead to stable-binding of fluorochromes to endogenous PM proteins (Fujishima 
et al., 2012). Until such methods become widespread and validated, researchers should 
use fluorescent proteins or antibodies in confocal FRAP studies with a mindfulness that 
these tools may over- or underestimate mobility measurements. 
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Technical Appendix 1: Details of the normalisation and fitting procedures used and the spread of Q probabilities when fitted to individual FRAP curves. (a) 
Table summarising the normalisation and fitting of FRAP data and advantages/disadvantages of each method, see Figure 1 for description of values used. Data 
summarised from FRAPcalc manual. (b) Spread of Q values when individual FRAP curves were fit with each model : A = double norm. single exponential; B = double 
norm. double exponential; C = back multiply single exponential. For each model the percentage (± SD) of FRAP curves giving Q<0.001 is shown in red. 
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Technical Appendix 2: CyGel strongly inhibits the mobility of MC5-bound CCR5. (a) FRAP 
was performed in either medium or CyGel on CHO-K1.CCR5-GFP cells labelled with MC5
650
 or 
CHO-K1.CCR5-GFP cells generating by transfecting in GFP-CCR5 or CCR5-GFP. The 
fluorescence detected during FRAP was that associated with either the MC5
650
 antibody (left 
graph), CCR5-GFP (middle graph) or GFP-CCR5 (right graph). (b) Dual channel FRAP was 
performed by simultaneous bleaching and imaging of the far-red fluorescence of MC5
650
 and the 
green fluorescence of CCR5-GFP when imaging cells in medium or CyGel. Plots show the mean 
recovery of CCR5 as detected by each fluorescent labelling tool. Graphs show mean ± SEM of 
experiments repeated on 2-3 separate days and are overlaid with regression curves (solid line), 
95% prediction bands (dotted line) and a plot of the mean residuals of the fit. A table summarising 
values derived from the FRAP curves is shown below the graphs. lin, linear fit; CI, confidence 
interval. 
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Chapter 6: General Discussion 
The chemokine receptors CCR5 and CXCR4 have been proposed to promote antigen-
dependent cell-cell engagement by localising to the IS. Co-expression of CCR5 and 
CXCR4 occurs on macrophages and on subtypes of CD4+ T cells that primarily circulate 
in peripheral tissues. In these tissues, macrophages and CD4+ T cells can engage in 
dynamic antigen-dependent interactions that may involve IS formation. This thesis has 
considered, for the first time, the formation of an IS between primary human macrophages 
(MDMs) and CD4+ T cells and whether endogenous CCR5 redistributes to the CD4+ T 
cell or the macrophage side of this IS. Live cell calcium imaging and flow cytometry 
techniques were employed to show that sAgs induce the formation of productive MDM-
CD4+ T cell conjugates, and to report on the frequency and signalling profiles of engaged 
CD4+ T cells. A correlative imaging technique identified that MDM-CD4+ T cell IS 
formation, as judged by CD3-capping, accounts for a subset of the productive conjugates. 
The presence or absence of CCR5 accumulation on the CD4+ T cell and MDM sides of 
the synapse, respectively, indicates a difference in the roles of CCR5 on T cells and APCs 
during synapse formation. This thesis also presents an analysis of the mobility of 
endogenous CCR5 at the cell surface of MDMs and the influence of cholesterol on its 
movement, as studied by FRAP. Overall the present study builds upon previous research 
in murine cells and takes us one step further in our understanding of the diverse nature of 
macrophage-CD4+ T cell interactions in human cells and how chemokine receptors may 
contribute to antigen-dependent interactions on either side of this synapse. 
6.1 Investigating MDM-CD4+ T cell IS formation with 
human cells 
6.1.1 Synapses and kinapses form between MDMs and CD4+ T cells  
In chapters 3 and 4, live and fixed cell microscopy showed that IS formation can occur 
between primary human MDMs and CD4+ T cells. When high calcium signals were 
observed they were correlated with CD3 accumulation to the cell-cell interface, which is 
one of the prototypical markers of IS formation (Monks et al., 1998; Revy et al., 2001; 
Yokosuka et al., 2008). Additionally, although T cells appeared to be able to ‘arrest’ 
without demonstrating calcium signalling, the onset of high T cell calcium signalling 
consistently initiated ‘arrest’. T cells that sustained this calcium signalling maintained their 
position within the same cell-sized area, displaying a stable engagement with an MDM 
that is characteristic of IS formation (Dustin, 2009b). Note that in murine systems, stable 
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macrophage-CD4+ T cell interactions were reported at a low frequency in vivo and 
represented only 10% of the antigen-dependent interactions observed in vitro (Egen et al., 
2011; Filipe-Santos et al., 2009; Underhill et al., 1999). In these studies the authors found 
that the vast majority of interactions were transient/dynamic, indicating that kinapses 
rather than synapses were the predominant type of macrophage-CD4+ T cell interactions. 
With regards to the present study, in support of kinapse formation correlative imaging 
suggested that a number of engaged T cells, which exhibited lower calcium signals, were 
lacking TCR clustering at the cell-cell interface (i.e. no CD3-accumulation). Together 
these factors might be indicative of a mobile cell-cell junction such as a kinapse (Azar et 
al., 2010; Beemiller et al., 2012; Kummerow et al., 2009). Typically, cells moving during 
calcium signalling is a sign of kinapses occurring in vivo (Moreau et al., 2012), however in 
the present study calcium signalling in moving cells was generally not detected. Overall 
we provide evidence of IS formation in human macrophage-CD4+ T cell interactions and 
our observations hint that kinapse formation may occur, although the extent of this latter 
type of interaction remains unknown. 
6.1.2 Macrophage-CD4+ T cell interactions: deciding when to be 
stable  
Among productively signalling conjugates, IS formation appears to occur more frequently 
than previously suggested by the limited occurrence of stable macrophage-CD4+ T cell 
interactions observed in mice in vitro or in vivo (Egen et al., 2011; Filipe-Santos et al., 
2009; Underhill et al., 1999). A number of factors may contribute to this disparity. 
Firstly, the in vivo studies found that antigen was presented in limited quantities, unlike the 
excess of sAg used to pulse MDMs in the present study (Egen et al., 2011; Filipe-Santos 
et al., 2009). Not only does a paucity of antigen result in fewer T cells exhibiting 
detectable rises in intracellular calcium (Reay et al., 2000), but lower levels of pMHC have 
also been correlated to an extended period of dynamic contacts between CD8+ T cells 
and DCs in lymph nodes (Henrickson et al., 2008). Thus, the mainly dynamic interactions 
observed in vivo are highly likely to be related to antigen availability. Speculatively this 
may represent a mechanism of immunological control by which CD4+ T cell effector action 
is limited to macrophages that are chronically infected and presenting greater quantities of 
antigen. However a different explanation must apply for the in vitro interaction studied by 
Underhill et al. (1999), where macrophages were pulsed with OVA peptide and so antigen 
is not likely to be limiting. Compared to an antigenic peptide the sAg SEA has previously 
been shown to be far more potent at inducing high T cell calcium signalling (Luxembourg 
and Grey, 2002). When compared to OVA pulsed macrophages, one may predict more 
stable cell-cell interactions in response to sAg considering that higher calcium signals 
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have been shown to be associated with less T cell mobility (Beemiller et al., 2012). Thus 
in the future, by titrating down the amount of sAg and/or switching to a peptide antigen to 
pulse the MDMs a more dynamic CD4+ T cell response repertoire may be achieved. 
Secondly, the activation status of the APC can influence whether the antigen-dependent 
engagement is dynamic or static (Friedl et al., 2005). The IFNγ treatment of macrophages 
carried out by Underhill et al. (1999) was typical of classical activation (M1). In contrast, 
the present study generated MDMs by culture in M-CSF yielding an alternatively activated 
phenotype (M2), in contrast to the GM-CSF/IFNγ/LPS treated MDMs (M1). Perhaps M1 or 
M2 activation might influence the dynamics or formation of the macrophage-CD4+ T cell 
IS. This hypothesis is supported by evidence from chapter 4 in which M1 polarised MDMs 
demonstrated fewer synapses than M2 polarised MDMs. Additionally, a similar 
phenomenon occurs with other APCs; activated B cells or DCs show far more dynamic 
interactions with T cells than their naïve counterparts, which generally demonstrate 
prolonged, stable engagements (Friedl et al., 2005). Further, M1 and M2 polarised MDMs 
exhibit different chemokine receptor expression profiles (Mantovani et al., 2004), which 
may in turn affect the stability of the macrophage-CD4+ T cell interaction according to the 
chemokine hierarchy proposed by Bromley et al. (2000). Specifically, M1 cells show 
increased secretion of CXCL10, which although controversial (Dar and Knechtle, 2007), 
may overcome the TCR ‘stop’ signal and promote mobility (Bromley et al., 2000). In 
contrast, M2 macrophages are not generally associated with CXCL10 secretion but rather 
secrete an array of Th2-linked chemokines (Mantovani et al., 2004). Of these, only the 
action of CCL22 has been considered alongside TCR engagement but was found not to 
promote mobility over the TCR stop signal (Bromley et al., 2000). In this way the differing 
chemokine profiles of M2 versus M1 macrophages may promote more dynamic 
interactions of T cells with M1 macrophages but greater stability with M2 macrophages, a 
possible explanation as to why more synapses were formed with M2 cells. However this 
explanation is likely to be incomplete as M1 macrophages have been reported to 
preferentially secrete CCL3/4/5, which have been suggested to promote stability of the B 
cell-T cell IS (Mantovani et al., 2004; Molon et al., 2005). According to the distraction 
hypothesis, this effect is mediated by CCR5 recruitment to the IS (Molon et al., 2005). As 
chapter 4 suggests, CCR5 can be found to accumulate to the T cell side of the MDM-
CD4+ T cell IS, implying that T cell CCR5 may similarly promote engagement in this 
synapse. Yet it remains unknown whether the recruitment of T cell CCR5 to the MDM-
CD4+ T cell IS is mediated by chemokine secretion or via another mechanism, as was the 
case for TIL-tumour synapses (Franciszkiewicz et al., 2009). Nevertheless the different 
activation status of a macrophage is likely to contribute to whether a more dynamic or 
stable interaction can occur. In the future it would be useful to compare the relative 
  
 
197 
 
influence of M1 versus M2 macrophages on the mobility of the same population of clonal 
T cells in order to determine this relationship directly. 
6.1.3 When would a stable macrophage-CD4+ T cell interaction be 
appropriate? 
Macrophages typically integrate signals from interactions with resting or activated T cells, 
after they have been primed by DCs in lymph nodes (Biswas and Mantovani, 2010; 
Murphy et al., 2011). The different T cell effector functions of a T cell may dictate whether 
a synapse or a kinapse is formed. For example the gasket ring of actin formed in a stable 
IS with CTLs is thought to facilitate targeted secretion of lytic granules (Griffiths et al., 
2010). On this basis a stable IS with an annular arrangement of actin can be imagined to 
assist CD4+ T cells to specifically instruct the activity of macrophages via cytokines such 
as IL-10 or IFNγ, which have been shown to be directionally secreted (Huse et al., 2006; 
Huse et al., 2008). On the other hand, a mobile junction makes teleological sense for 
effector action of other cytokines that show multidirectional secretion patterns such as IL-4 
(Huse et al., 2006).  
6.1.4 Calcium signalling 
Chapter 3 demonstrates that a wide range of T cell intracellular calcium signals are 
induced in response to sAg-pulsed MDMs. This contrasts the fairly consistent, sustained 
calcium responses described for antigen-specific systems using clonal T cells (Wülfing et 
al., 1997), highlighting that the variation in calcium profiles likely comes from the use of a 
polyclonal T cell population being stimulated by a number of sAgs. There is potential that 
these calcium signals can result in selective activation of different transcription factors and 
thus influence the activation status or effector function of the T cells (Acuto et al., 2008; 
Dolmetsch et al., 1997). When calcium profiles were visually classified into groups, those 
that were high and sustained tended to correlate with IS formation which is consistent with 
the fact that stable contact yields sustained calcium signals in vitro (Negulescu et al., 
1996). A recent report suggests that T cells are associated with oscillatory, rather than 
high, sustained calcium responses when contacting APCs (Salles et al., 2013). The T cell 
calcium profiles in the present study do not tend to support this hypothesis but rather 
demonstrate the presence of both high and low, sustained calcium rises, more than 
oscillatory profiles. Perhaps one of the reasons for this disparity is the analysis of naïve T 
cells by Salles et al. (2013), which have previously been demonstrated to undergo 
oscillatory signals that appear contact-independent and are maintained in the background 
of elevated baseline calcium signals even upon stable conjugate formation (Wei et al., 
2007). Nevertheless this highlights that any future automated strategies to group similar 
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calcium profiles may need to be able to describe the oscillations as well as account for the 
general shape of the calcium response. 
6.2 Chemokine receptor distribution at the MDM-CD4+ T 
cell IS 
6.2.1 Factors triggering differential recruitment to the IS 
Chapter 4 shows that endogenous CCR5 does not localise to the MDM side of the MDM-
CD4+ T cell IS, but can localise to the T cell side. Evidently differences may exist in the 
way that CCR5 is regulated on the T cell or APC, which determines whether or not CCR5 
is involved at the IS. Previously, recruitment of CCR5 to the IS has been suggested to be 
mediated by CD103 binding of E-cadherin (Franciszkiewicz et al., 2009), or via APC-
secreted chemokine, possibly acting on a CCR5:CXCR4 heterodimer (Contento et al., 
2008; Molon et al., 2005). Multidirectional secretion of chemokines by the MDM could act 
uniformly in an autocrine fashion on CCR5 present on the MDM cell surface, whilst 
simultaneously imposing a gradient on nearby, interacting T cells expressing CCR5. In the 
presence of a chemokine gradient CCR5 has been suggested to localise to the leading 
edge of T cells (Gomez-Mouton et al., 2004). Additionally, evidence from the B-T cell IS 
shows that if CCL5 or CXCL12 are present in the environment during IS formation then T 
cell CCR5 does not localise to the IS (Contento et al., 2008). This implies that without 
sensing a chemokine gradient CCR5 would not accumulate to the IS. 
Expression of CD103 is not typically associated with macrophages but rather with T 
regulatory cells (Tregs) (Suffia et al., 2005), a subset of DCs in the small intestine 
(Zigmond and Jung, 2013), as well as the TILs identified by Franciszkiewicz et al. (2009). 
Thus the absence of CCR5 localisation to the IS on the MDM side may be related to the 
lack of CD103 expression on macrophages. Notably however, the ligand of CD103, E-
cadherin is known to be a marker of M2 macrophages and so may be expressed by the 
MDMs (Biswas and Mantovani, 2010). Yet neither the expression of E-cadherin on the M2 
MDMs nor CD103 on the CD4+ T cells was assessed in the present study. However 
recruitment of CCR5 to the T cell side of the MDM-CD4+T cell IS, as shown in chapter 4, 
could possibly be mediated by CD103+ Tregs, since staining of MDM-CD4+ T cell 
conjugates for FoxP3 hinted that a number of the synapses formed may involve Tregs 
(data not shown), but other markers would need to be tested to ascertain Treg 
involvement (Corthay, 2009). 
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In order to address why no accumulation of CCR5 was observed on the MDM side of the 
IS, we investigated whether there was an intrinsic inability of CCR5 to move across the 
MDM PM. The FRAP study presented in Chapter 5 demonstrated that the majority of 
endogenous CCR5 is present on MDMs as a mobile fraction in the PM. This is in 
agreement with the findings of previous studies using cell lines transfected with 
fluorescent protein-tagged CCR5 (Nakata et al., 2010; Steffens and Hope, 2004). This 
result implies that the non-accumulation of MDM CCR5 at the IS is not due to pre-existing 
restrictions on the mobility of CCR5 across the PM. Nevertheless, the organisation of 
proteins within the PM of MDMs engaged in the IS may be different to that of MDMs not 
interacting with T cells and this may alter the mobility of CCR5, a possibility that could not 
be tested in the present experimental system. Using the T cell side of the IS as an 
example, organisation within the PM is influenced heavily by the cortical actin 
cytoskeleton. Submicron features such as the dense cortical actin meshwork that 
emanates from TCR clusters have been found to corral proteins and lipids alike (Kusumi 
et al., 2005). CCR5 localised to the contact interface is unlikely to be exempt from F-actin 
mediated corralling and thus the mobility of CCR5 at the IS may be reduced. The 
influence of actin is particularly relevant to CCR5, which has been shown to accumulate in 
actin-rich PM structures and can align along actin filaments (Signoret et al., 2005; Steffens 
and Hope, 2003). It is conceivable that retrograde flow of the cortical actin cytoskeleton at 
the IS, which influences the centripetal movement of TCR (Dustin et al., 2010; Varma et 
al., 2006), might also have an influence on the mobility of CCR5 at the IS. As DCs have 
been reported to accumulate F-actin to the interface upon interaction with CD4+ T cells 
(Riol-Blanco et al., 2009), the cortical actin cytoskeleton may also play a key role in 
regulating membrane protein mobility at the APC-side of the synapse. Overall this implies 
that the mobility of PM CCR5 may differ on MDMs forming an IS, but a system in which 
the frequency of IS formation is much higher than that used in the present study would be 
required to test this hypothesis. Although treating MDMs with drugs that disrupt the 
cytoskeleton is useful to determine contributions of actin to the maintenance of MDM cell 
structures such as IPCMs (Mlcochova et al., 2013), such processes are unlikely to yield 
meaningful CCR5 mobility data by FRAP due to artefacts caused by drug-induced MDM 
detachment. 
Lipid rafts are stabilised at the IS and represent dynamic platforms that are associated 
with actin filaments (Kusumi et al., 2005). It has been proposed that CCR5 associates with 
lipid rafts (Venkatesan et al., 2003). Since lipid rafts have been found to accumulate on 
both the T cell side (Burack et al., 2002) and the B cell side (Hiltbold et al., 2003) of the B-
T cell IS, they potentially represent part of the mechanism by which CCR5 might become 
mobilised to either side of the IS. Chapter 5 shows that depletion but not sequestration of 
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membrane cholesterol, which is a constituent of lipid rafts, modulates the mobility of 
CCR5. The reduction in CCR5 mobility upon cholesterol depletion (using MβCD) 
corroborates the results of previous studies (Nakata et al., 2010; Steffens and Hope, 
2004). However reduced mobility upon cholesterol depletion is common to a number of 
receptors and is thought to be caused by general cytoskeletal dysregulation in the 
absence of cholesterol (Kwik et al., 2003). This situation therefore is not thought to be 
representative of the spatial accumulation of cholesterol that occurs upon synapse 
formation. As CCR5 mobility was not significantly decreased when membrane cholesterol 
was sequestered (using filipin) it implies that the mobility of CCR5 on MDMs does not 
depend upon cholesterol. This suggests that CCR5 is not constitutively associated with 
lipid rafts in the PM of MDMs, perhaps unlike T cells on which CCR5 has been shown to 
cap in a cholesterol-dependent manner upon ligation with CD4-beads (Nguyen et al., 
2005). Determining whether or not cholesterol sequestration affects CCR5 mobility on T 
cells would help to address this issue. However from a technical perspective this is 
unlikely to be possible at 37°C on activated T cells due to their constant mobility on glass. 
Instead the temperature could be lowered or resting T cells used in order to reduce the 
levels of mobility (Negulescu et al., 1996). Nonetheless a direct comparison of CD4+ T 
cell and MDM endogenous CCR5 mobility would be problematic due to differences in the 
PM topology of MDMs and CD4+ T cells, and the influence topological changes can have 
on measures of mobility (Sbalzarini et al., 2005). 
6.2.2 Meaning of chemokine receptor localisation at the IS 
Endogenous CCR5 and CXCR4 can localise to the T cell side of the MDM-CD4+ T cell IS, 
as shown in chapter 4, but what might be their function at this interface? Other studies 
analysing different synapses have suggested the distraction hypothesis, which reasons 
that in this position chemokine receptors are hidden away from chemotactic cues, which 
may otherwise distract from the cell-cell engagement (Contento et al., 2008; 
Franciszkiewicz et al., 2009; Molon et al., 2005). However even when accumulation of 
CCR5 or CXCR4 at the MDM-CD4+ T cell interface does occur, the fluorescence increase 
at the IS is generally not greater than two-fold that of the rest of the T cell. This indicates 
that a significant proportion of chemokine receptors remain distributed around the cell, 
available to distracting chemokines. Perhaps the level of chemokine receptor 
accumulation at the IS acts as a ‘rheostat’ that configures resistance of the T cell to 
distraction by environmental chemokine. Moreover, there is the potential that downstream 
signalling is altered by spatial segregation at the IS as lipid rafts have been shown to 
accumulate to the IS (Burack et al., 2002) and certain G proteins preferentially reside in 
lipid rafts (Oh and Schnitzer, 2001). Gi signalling downstream of chemokine receptors has 
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been implicated in inside-out activation of LFA-1 that leads to mitochondrial recruitment to 
the IS (Contento et al., 2010). However it is unknown whether this may be specific to 
chemokine receptors localised at the IS or globally around the cell. Furthermore, this may 
be an in vitro artefact considering the same effect is also mediated by TCR and that 
shear-flow has been shown to be required for chemokine-mediated integrin activation 
(Contento et al., 2010; Woolf et al., 2007). An additional hypothesis for an active 
functional role of chemokine receptors at the APC-T cell IS is that they may signal via 
G11/q, thereby promoting cell-cell adhesion over chemotaxis (Molon et al., 2005). This is an 
attractive hypothesis given that the type of lipid domains stabilised at the IS contain 
caveolin, which is bound by Gq (Oh and Schnitzer, 2001). However it may not be possible 
to determine the extent of chemokine-receptor induced G11/q signalling using sAg-pulsed 
APC-T cell conjugates since TCR activation of G11 is induced by SEE binding (Bueno et 
al., 2006). Although Bueno et al. (2006) propose that sAgs may use a GPCR as a 
coreceptor during TCR triggering, they rule out CCR5 and CXCR4. This is supported by 
the present study as synapse formation was found to occur irrespective of whether CCR5 
or CXCR4 localised to the interface. Without evidence that CCR5 and CXCR4 enhance 
cell-cell adhesion at the IS, their localisation to the T cell side of the MDM-CD4+ T cell IS 
is assumed to fit the distraction hypothesis as proposed for other synapses 
(Franciszkiewicz et al., 2009; Molon et al., 2005). 
6.2.3 Chemokine receptor localisation in different states of T cell 
activation 
Evidence in chapter 4 hints that T cell CXCR4 may be more faithfully accumulated to the 
MDM-CD4+ T cell IS when T cells are activated with CD3/CD28 beads in comparison to 
PHA/IL-2. As well as having a higher activation status than PHA/IL-2 stimulated CD4+ T 
cells, the lack of detectable cell surface CCR5 expression on CD3/CD28 activated CD4+ 
T cells indicates that CXCR4 accumulation to the IS is not necessarily co-dependent upon 
CCR5. This is in contrast to a previous study, which postulated that the recruitment of 
CXCR4 to the IS requires the presence of and heterodimerisation with CCR5 (Contento et 
al., 2008). However recruitment of endogenous CXCR4 to the T-B cell IS has also been 
shown to be mediated by an actin-binding protein, debrin, in a J77 T cell line (Perez-
Martinez et al., 2010). Although a role for CCR5 cannot be excluded in these cells, the 
parental cell line (Jurkat T cells) has been used as a negative control for CCR5 
expression (Shirvani et al., 2011), and shows no CCR5 expression in our hands. Thus, 
CD4+ T cells may switch to a dectin-dependent mechanism of CXCR4 recruitment to the 
IS after acute TCR stimulation, enabling recruitment independent from CCR5 cell surface 
expression. CXCR4 is thought to associate with the TCR to transduce signals in response 
to CXCL12 binding (Kumar et al., 2006; Patrussi et al., 2007). Specifically, CXCR4 is 
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thought to associate with pre-formed phosphorylated TCR-ZAP-70 complexes for 
signalling (Kumar et al., 2006), which may exist at greater levels in T cells that are 
continuously cultured with TCR stimulating beads and show higher levels of activation 
than the PHA/IL-2 T cells. Unlike classical TCR stimuli ZAP-70 has been reported not to 
be activated by sAg (Bueno et al., 2006; Morgan et al., 2001). This could represent a 
mechanism by which higher, more consistent CXCR4 recruitment to the MDM-CD4+ T cell 
IS occurs with the CD3/CD28 activated T cells. Moreover it is particularly intriguing that 
CXCR4 was found colocalising with debrin in the pSMAC, which is a region enriched in 
TCR-ZAP-70 complexes and actin, both of which CXCR4-TCR signalling depends upon 
(Dustin et al., 2010; Kumar et al., 2006; Perez-Martinez et al., 2010). Nevertheless, more 
repetition will need to be carried out in order to confirm this result. 
In contrast to the CD3/CD28 activated T cells, the PHA/IL-2 activated T cells are thought 
to require co-expression of CXCR4 and CCR5, an MDM-secreted chemokine, or CD103 
in order to mediate recruitment of CXCR4 and CCR5 to the IS (Contento et al., 2008; 
Franciszkiewicz et al., 2009; Molon et al., 2005). A mechanism that triggers recruitment is 
necessary to explain why in our study we observed less than half of the CD4+ T cells 
forming synapses to accumulate CCR5, and only a quarter to accumulate CXCR4. 
However pending future investigation, it is unknown what this trigger mechanism might be. 
6.2.4 Role of the intracellular pool 
In addition to the localisation of CCR5 to the IS on the surface of intact CD4+ T cells, in 
chapter 4 we also observed accumulation of internal CCR5. These internal pools of CCR5 
could be found proximal to the MDM-CD4+ T cell interface even in the absence of IS 
formation. This type of chance distribution at the cell-cell interface in the absence of 
antigen was also demonstrated for the Golgi apparatus in the present study and has been 
reported previously for the MTOC (Meier et al., 2003). In line with previous reports we 
found that the Golgi was preferentially recruited to the cell-cell interface upon IS formation 
(Meier et al., 2003; Stinchcombe et al., 2006). The results of the present study show that 
this also appears to occur for the internal CCR5 pool. Although T cell CCR5 demonstrated 
more consistent polarisation towards the interface upon IS formation it is unclear whether 
the intracellular pool of CCR5 results from surface receptors that get internalised, or new 
CCR5 molecules transported along the biosynthetic pathway towards the cell-cell 
interface, or both. Partial colocalisation with TGN indicates that these pools of CCR5 are 
not the same as those identified by Achour et al. (2009), which were thought to reside in 
the ER. This pool could also result from sustained chemokine stimulation, which has 
previously been reported to cause accumulation of CCR5 in the TGN (Escola et al., 2010). 
However the MDMs are primarily of M2 phenotype, an unlikely source of CCR5 ligands 
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(Mantovani et al., 2004). Thus the origin of the intracellular pool of CCR5 in T cells 
remains unclear. Nevertheless, trafficking of CCR5 from an internal compartment may 
contribute to accumulation of surface CCR5 at the IS, whether this is the TGN, or even 
REs that have been shown to accumulate beneath the plane of the IS and to redirect 
internalised TCR to the cell-cell interface (Das et al., 2004). 
6.3 General limitations of the experimental approach  
6.3.1 Number of signalling MDM-CD4+ T cell conjugates 
The major assay limitations were that conjugates form at an equal frequency in the 
presence and absence of sAg and that the numbers of MDM-CD4+ T cell interactions 
yielding detectable levels of calcium signalling were low. These observations are 
contrasted by previous reports of the high percentage (95%) of antigen-specific T cells 
undergoing calcium signals in the presence of cognate pMHC (Wülfing et al., 1997), or the 
increase in conjugate formation using SEE-pulsed B cells with Jurkat cells expressing 
Vβ8.1, which is recognised by sAg (Morgan et al., 2001). In both of these studies all T 
cells have the potential to productively engage MHC. Since there were no indications that 
the limited frequency of productive conjugate formation was caused by the activation 
status of the CD4+ T cells or the APCs used in the present study, one may postulate that 
the majority of the Vβ-regions of the CD4+ T cells were not recognised by the sAgs 
utilised. However, unless the different T cell activation methods used significantly skewed 
the distribution of the peripheral blood leukocyte Vβ profile (Geursen et al., 1993; 
Ochsenreither et al., 2008) this is unlikely to be the case. Nevertheless in the future, one 
may consider expanding sAg-specific T cells by culturing PBMCs in the presence of sAg 
followed by negative separation of CD4+ T cells and assessing conjugate formation. 
However whether these T cells also express CCR5 is another matter, as SEB expansion 
of CD4+ T cells reveals maximal CCR5 expression after 3 days followed by a rapid 
decline in expression levels (Maier et al., 2000). Ultimately cell-sorting utilising MC5, 
which was shown to rapidly dissociate at 37°C in chapter 5, may be required to isolate 
antigen-specific CCR5+ T cells. 
6.2.2 Measuring arrest 
One of the main difficulties in deciphering which CD4+ T cells were engaged in synapses 
or kinapses was that T cells that had not undergone any detectable rises in intracellular 
calcium were able to undergo ‘arrest’. Initially, the low activation status of PHA/IL-2 T cells 
was thought to cause this phenotype, since activated, but not resting human T cells 
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migrate at 37 °C (Negulescu et al., 1996). However CD3/CD28 activated T cells also 
demonstrated arrest in the absence of any detectable calcium signal (data not shown).  
Thus the cause of premature arrest may be due to the PDL coating of the coverslip used 
to promote attachment of the CFDA-SE labelled MDMs. In future work MDMs should be 
adhered to uncoated glass coverslips to avoid this potential systematic error. Yet as a 
consequence this meant that it was not possible to utilise the level of T cell mobility in 
order to identify kinapses, but rather productive signalling concomitant with a lack of 
molecular clustering (i.e. CD3 capping) was used (Azar et al., 2010). 
So that the initial interactions between MDMs and CD4+ T cells could be observed, T cells 
were injected into the perfusion chamber immediately prior to imaging. Critically this 
enables early signalling events to be captured, as a rise in intracellular calcium occurs 
less than 10 s after TCR engagement (Acuto et al., 2008). However use of controlled rate 
injection, although critical to consistency between assays, means that initially the cells are 
exposed to shear-flow. Although this flow is not maintained the initial wave of T cells may 
be subject to a type of chemokine-mediated integrin-dependent arrest that would not 
normally occur in the tissue environment, thus influencing arrest (Lammermann et al., 
2008; Woolf et al., 2007). To prevent this problem in the future use of a collagen gel would 
be the preferred solution to move towards. A collagen gel represents an appropriate 
model of the 3D solid tissue environments occupied by macrophages, yet still enables the 
early calcium signalling events and migration of infiltrating CD4+ T cells to be imaged 
using human cells (Dustin et al., 2001a). 
6.4 Conclusions 
In summary, the formation of an IS between MDMs and CD4+ T cells and the localisation 
of endogenous CCR5 to either side of the interface, has been explored for the first time 
using primary human cells, with the aim of assessing the impact of the native cellular 
environment of CCR5 on its behaviour. The accumulation of CXCR4 to the T cell side of 
this IS was also examined as an additional reference-point to other types of synapse 
previously studied in vitro. Additionally, the lateral mobility of endogenous CCR5 on 
MDMs was studied to determine whether CCR5 might be stationary within the PM and 
explain the lack of CCR5 interface-accumulation on the MDM side of the synapse. In 
performing this work, I also adapted an arsenal of imaging and cytometry-based 
techniques and developed computational approaches required to analyse large datasets, 
which will serve as a foundation for future in vitro studies of IS formation.  
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Work from this thesis established that a small number of MDM-CD4+ T cell conjugates 
can form in presence and absence of sAg, however the conjugates that form in the 
presence of sAg demonstrate higher T cell intracellular calcium levels. Typically, T cells 
that exhibited high, prolonged intracellular calcium signals were found to accumulate 
TCR-CD3 at the MDM-CD4+ T cell interface, a sign of IS formation. This observation 
would not have been possible using global analysis of the population by flow cytometry, 
thus highlighting the importance of observing calcium signalling at a single-cell level to 
distinguish how minor changes in the calcium profile might correlate with a specific 
outcome like IS formation. Furthermore our observations evidenced that synapse 
formation between human MDMs and CD4+ T cells is more common than might be 
suggested by the infrequent stable macrophage-CD4+ T cell interactions reported in vitro 
for murine cells (Underhill et al., 1999). Results from the present study indicate that a mix 
of both synapse and kinapse interactions can occur between human macrophages and 
CD4+ T cells. Whilst the IS:kinapse balance may change depending on antigen quality 
and abundance, the results presented here evidence that both these modes of antigen-
dependent macrophage-CD4+ T cell engagements previously observed in murine 
systems may also exist in humans. 
The characterisation of MDM-CD4+ T cell IS formation enabled me to establish that 
endogenous CCR5 does not localise to the MDM side of this synapse although can 
localise to the T cell side, as can endogenous CXCR4. Our observations on the T cell side 
are reminiscent of those previously reported by other studies (Contento et al., 2008; 
Franciszkiewicz et al., 2009; Molon et al., 2005; Perez-Martinez et al., 2010). Note that 
none of the studies had considered the macrophage-CD4+ T cell IS, or the APC side of a 
synapse, or the localisation of endogenous chemokine receptors on primary human CD4+ 
T cells. There is a general consensus that T cell CCR5 or CXCR4 localisation to the IS 
contributes to cell-cell engagement, be this by preventing distraction or via more active 
means. Thus localisation of endogenous CCR5 or CXCR4 on the T cell side of the MDM-
CD4+ T cell IS, as shown in the present study, is also expected to contribute to 
engagement. In contrast, because of the lack of accumulation of CCR5 on the MDM side 
one may speculate that macrophage CCR5 may be inert in synapse formation or that the 
engagement of CCR5 is cell-type dependent (supported by: Signoret lab, unpublished 
data). Overall this is the first evidence indicating that the chemokine receptor CCR5 may 
play a different role on the APC compared to the T cell in promoting IS stability. 
In the present study CXCR4 was also found to be able to be recruited to the IS of a highly 
activated (CD3/CD28 stimulated) CD4+ T cells that do not express cell surface CCR5. 
This indicates that co-dependence between CXCR4 and CCR5 for recruitment to the IS 
may not be the only mechanism of chemokine receptor mobilisation to the IS, and this is 
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further supported by the study by Franciszkiewicz et al. (2009) where CXCR4 was not 
recruited to the TIL-tumour IS despite the fact that CCR5 did accumulate to the interface. 
However some form of trigger for chemokine receptor recruitment to the IS appears to be 
required, since many of the CD4+ T cells demonstrating lower levels of activation (PHA/IL-
2 activated) did not show recruitment of CCR5 or CXCR4 to the IS. The requirement for a 
trigger can be envisaged as a mechanism to prevent inappropriate receptor recruitment to 
the IS, which may otherwise render a T cell insensitive to environmental chemokines. 
Pools of CCR5 in CD4+ T cells were identified in the present study and deemed 
intracellular due to partial colocalisation with markers of the TGN. Trafficking via 
intracellular compartments is a mechanism utilised by some components of the IS in order 
to facilitate accumulation to the cell-cell interface (Das et al., 2004; Griffiths et al., 2010). 
Thus the pools of CCR5 which may preferentially accumulate beneath the cell-cell 
interface upon the MDM-CD4+ T cell IS formation potentially represent an additional 
source from which CCR5 may accumulate to the IS upon the correct trigger.  
This thesis demonstrates that endogenous CCR5 is largely present as a mobile fraction in 
the PM of MDMs. Thus, the lack of CCR5 accumulation to the MDM side of the IS does 
not appear to be a consequence of native immobility of CCR5 in the MDM membrane. 
Cholesterol depletion (using MβCD) resulted in inhibition of cell surface CCR5 movement, 
but milder treatment sequestering cholesterol (filipin) did not, which could be explained by 
an extensive loss of membrane cholesterol causing a cytoskeletal dysregulation (Kwik et 
al., 2003). Therefore, cholesterol may not be important for CCR5 mobility. This may 
potentially explain an apparent paradox reported for HIV, where CCR5 mobility is thought 
to be required for infection (Steffens and Hope, 2004; Viard et al., 2002), and HIV was 
shown to preferentially bind a cholesterol-independent form of CCR5. With regard to 
CCR5 behaviour at the IS, lipid rafts may account for the different recruitment of CCR5 on 
the MDM and CD4+ T cell sides of the IS.  
This investigation also highlights the difficulty of working in human cells, as the unknown 
genetic and environmental background of donors can influence a wide range of features, 
from responses to recall antigen and the TCR Vβ profile through to the levels of CCR5 
expressed by leukocytes. Yet these factors must be borne in order to examine the 
influences of the native cellular environment and gather more physiologically relevant 
information.  
Overall this work contributes to our understanding of chemokine receptor cell surface 
function and regulation, and our findings may direct future research into how the 
involvement of chemokine receptors within a tissue can impact the function of 
macrophage-CD4+ T cell interactions in fighting disease.  
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6.5 Future perspectives 
This study shows that CCR5 can localise to the CD4+ T cell side of an antigen-dependent 
junction with macrophages. Avenues of future investigation might explore whether 
chemokines and/or CD103 trigger the localisation of CCR5 at this IS. One exciting 
possibility to explore whether CCR5 localisation on CD4+ T cells at the MDM-CD4+ T cell 
IS might in fact be mediated by CD103, which is present on lymphocytes such as Tregs. 
The role of CD103 in reorganising CCR5 to the TIL-tumour IS (Franciszkiewicz et al., 
2009) may be a mechanism employed to retain CCR5+ T cells in diseases involving CD4+ 
T cell interactions with macrophages, one primary candidate being L. major infection. At 
sites of cutaneous L. major infection Tregs enable the persistence of the pathogen by 
dampening the immune response (Suffia et al., 2005). Treg retention and homing to these 
sites is dependent upon CD103 and CCR5 expression, respectively (Bromley et al., 2008; 
Suffia et al., 2005). Considering that Treg action is antigen specific (Corthay, 2009) there 
might be coordination between CCR5 and CD103 to macrophage-Treg synapses that acts 
to promote retention via a mechanism reminiscent of that shown in TIL-tumour 
interactions (Franciszkiewicz et al., 2009). Additionally through promoting macrophage-
Treg engagement, coordinated CD103 CCR5 action may stabilise the IS so as to facilitate 
targeted secretion of Treg IL-10, a cytokine which has previously been found to be 
directionally secreted (Huse et al., 2006). 
Future studies may also consider a role for the intracellular pool of CCR5 on CD4+ T cells 
as was identified in this study and whether this pool may contribute to CCR5 recruitment 
to the IS. Due to its partial TGN colocalisation the present study considers this pool to 
consist of CCR5 sequestered downstream of receptor internalisation, rather than being 
akin to the pools of CCR5 previously observed earlier in the biosynthetic pathway (Achour 
et al., 2009), however this notion requires confirmation. In the absence of any potential 
chemokine source the intracellular levels of CCR5 would reduce if indeed this pool 
represents recycling receptors in a molecular bottleneck. Irrespective of the origin, a 
potential role of this pool may be examined by determining the levels of CCR5 recruitment 
to the IS with and without inhibitors of exocytosis, such as tetanus toxin, as was previously 
performed for TCR (Das et al., 2004). Additionally the concept of recycling to the IS may 
be examined by analysing the potential directional recovery of MC5488 labelled 
chemokine-treated T cells with and without IS formation by time-lapse microscopy. An 
essential step in order to be able to perform a reliable study of CCR5 receptor trafficking 
at the MDM-CD4+ T cell IS is to improve the frequency of IS formation. Since the type of 
APC was not found to be a limiting factor in the present study, expansion of antigen or 
  
 
208 
 
sAg specific T cells prior to interaction with MDMs may be a starting-point to try and 
achieve an improved frequency of productive MDM-CD4+ T cell conjugates.  
Further investigation into the mobility of CCR5 on MDMs via methods such as SFVI that 
are set up to focus specifically on the PM, may complement the supra-molecular FRAP 
data that is presented here. The improved time-resolution of these single-molecule 
techniques might give a better measurement of the true lateral mobility of CCR5 within the 
membrane in comparison to FRAP, which is likely to be highly influenced by the complex 
topological features of the MDM PM over the extended acquisition period. Nevertheless a 
number of lessons can be learnt from the FRAP study, including potential differences in 
the mobility using GFP-CCR5 and MC5-labelled CCR5, which would be best considered 
using CHO-CCR5 cells first. Single molecule techniques may distinguish differences in the 
mobility of CCR5 on MDMs and CD4+ T cells and when combined with cholesterol 
depletion/sequestration have the potential to correlate mobility to different forms of CCR5 
that exist within the PM. Additionally, planar bilayers could be employed to study whether 
the mobility of CCR5 may differ at the contact interface between a T cell in the presence 
or absence of antigen and the effect chemokine ‘distraction’ might have on CCR5 mobility. 
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Appendix 1 
/******************************************************************************************************** 
plr2.c Piecewise linear regression c-script. 
Author: Dr J. Wilson (University of York, York, UK) 
Positions of input file names are highlighted in red 
********************************************************************************************************/ 
#include <stdlib.h> 
#include <stdio.h> 
#include <math.h> 
#include <string.h> 
#include <ctype.h> 
 
typedef struct dataArray{ 
  char name[1024]; 
  double *vars; 
}SAMPLE; 
 
double getparam(int i, SAMPLE *data, double *y, int length, int c1, int c2, double *slopes, double 
*intercepts, double *jumps, int *nsections); 
 
int main (int argc, char *argv[])  
{     
  int i, j, length;  
  int dtmp, tmp; 
  float ftmp, a; 
  int c1, c2, d; 
   
  double slopes[3]; 
  double bestbeta[3]; 
  double intercepts[3]; 
  double bestalpha[3]; 
  double jumps[2]; 
  double bestjumps[2]; 
  
  char name[1024]; 
  char dir[1024];     
   
  int nsamples; 
  int startlength = 100; 
 
  double y[startlength]; 
  double besty[startlength]; 
   
  FILE *fp = NULL; 
  FILE *fout = NULL; 
  fp = fopen("inputfiles/ 340:380_calcium_data.csv", "r"); 
  tmp = fscanf(fp, "%d\n", &dtmp); 
  nsamples = dtmp;  
  printf("%d\n", nsamples); 
 
  /* initialise array */ 
  SAMPLE *data = NULL; 
  data = (SAMPLE*) malloc (nsamples * sizeof(SAMPLE)); 
  SAMPLE *time = NULL; 
  time = (SAMPLE*) malloc (nsamples * sizeof(SAMPLE)); 
  for (i = 0; i < nsamples; i++) 
  { 
    data[i].vars = (double *) malloc (startlength * sizeof(double)); 
    time[i].vars = (double *) malloc (startlength * sizeof(double)); 
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    for (j = 0; j < startlength; j++) 
    { 
      time[i].vars[j] = 0.0; 
      data[i].vars[j] = 0.0; 
    } 
  } 
 
  for (i = 0; i < nsamples; i++) 
  { 
    /* read in data */ 
    for (j = 0; j < startlength; j++) 
    { 
      tmp = fscanf(fp, "%f,\n", &ftmp); 
      data[i].vars[j] = ftmp; 
 }  
  } 
  fclose(fp); 
 
  fp = fopen("inputfiles/time_data.csv", "r"); 
  /* read in times */ 
  for (i = 0; i < nsamples; i++) 
  { 
    /* read in data */ 
    for (j = 0; j < startlength; j++) 
    { 
      tmp = fscanf(fp, "%d,\n", &dtmp); 
      time[i].vars[j] = (float)dtmp; 
 }  
  } 
  fclose(fp); 
 
  fp = fopen("segmentinfoNoAg", "w"); 
  fout = fopen("test", "w"); 
  double rsq, maxrsq; 
  int bestc1, bestc2, nsections, bestn; 
  for (i = 0; i < nsamples; i++) 
  { 
    for (j = 0; j < startlength; j++) 
    { 
      besty[j] = 0.0; 
    } 
    /* find real length for this sample */ 
    length = startlength-1; 
    while ((data[i].vars[length] == 0.0) && (length > 0)) length--; 
    bestc1 = 0; 
    bestc2 = 0; 
    maxrsq = 0.0; 
    d = 0; 
    bestn = 0; 
    if (length > 3) 
    { 
      for (c1 = 0; c1 < length; c1++) 
      { 
        for (c2 = c1; c2 < length; c2++) 
        { 
           rsq = getparam(i, data, y, length, c1, c2, slopes, intercepts, jumps, &nsections);   
          if (rsq > maxrsq) 
          { 
            maxrsq = rsq; 
            bestc1 = c1; 
            bestc2 = c2; 
            d = c2 - c1; 
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            bestn = nsections; 
            for (j = 0; j < length; j++) 
            { 
              besty[j] = y[j]; 
            } 
            for (j = 0; j < 3; j++) 
            { 
              bestbeta[j] = slopes[j]; 
              bestalpha[j] = intercepts[j]; 
            } 
            for (j = 0; j < 2; j++) 
            { 
              bestjumps[j] = jumps[j]; 
            } 
          } 
        } 
      } 
    } 
    else  
    { 
      for (j = 0; j < 3; j++) 
      { 
        bestbeta[j] = 0.0; 
        bestalpha[j] = 0.0; 
      } 
      jumps[0] = 0.0; 
      jumps[1] = 0.0;       
    } 
    for (j = 0; j < startlength; j++) 
    {  
      fprintf(fout, "%f ", besty[j]); 
    } 
    fprintf(fout, "\n"); 
    printf("%d %d %d %d %d %d %0.3f %0.3f %0.3f %0.3f %0.3f %0.3f %0.3f %0.3f %0.3f %0.3f 
%0.3f %0.3f %0.3f\n", i, bestc1, bestc2, d, length, bestn, maxrsq, time[i].vars[0], 
time[i].vars[bestc1], time[i].vars[bestc2], time[i].vars[length-1], bestbeta[0], jumps[0], bestbeta[1], 
jumps[1], bestbeta[2], bestalpha[0], bestalpha[1], bestalpha[2]); 
    fprintf(fp, "%d %d %d %d %d %0.3f %0.3f %0.3f %0.3f %0.3f %0.3f %0.3f %0.3f %0.3f %0.3f 
%0.3f %0.3f %0.3f\n", bestc1, bestc2, d, length, bestn, maxrsq, time[i].vars[0], time[i].vars[bestc1], 
time[i].vars[bestc2], time[i].vars[length-1], bestbeta[0], jumps[0], bestbeta[1], jumps[1], bestbeta[2], 
bestalpha[0], bestalpha[1], bestalpha[2]); 
  } 
  fclose(fp); 
         
  for (i = 0; i < nsamples; i++) 
  { 
    free(data[i].vars); 
    free(time[i].vars); 
  }   
  free (data); 
  free (time); 
  
  return 0; 
} 
 
/************************************************************************************************************* 
Procedure:  slope 
finds the slope from linear regression 
**********************************************************************************************************/ 
double slope(int n, double *data, int length) 
{ 
  int j; 
  
 
212 
 
  double sx, sy, sxx, sxy; 
  double beta; 
   
  sx = 0.0; 
  sxx = 0.0; 
  sy = 0.0; 
  sxy = 0.0; 
  for (j = 0; j < length; j++) 
  { 
    sx += (n+j+1); 
    sxx += (n+j+1)*(n+j+1); 
    sy += data[j]; 
    sxy += data[j]*(n+j+1); 
  } 
  sxx = sxx - (sx*sx/(float)length); 
  sxy = sxy - (sx*sy/(float)length); 
  beta = sxy/sxx; 
  
  return(beta); 
} 
 
/************************************************************************************************************* 
Procedure:  intercept 
finds the intercept from linear regression 
**********************************************************************************************************/ 
double intercept(int n, double *data, int length, double beta) 
{ 
  int j; 
  double alpha; 
  double sx, sy; 
  sx = 0.0; 
  sy = 0.0; 
  for (j = 0; j < length; j++) 
  { 
    sx += (n+j+1); 
    sy += data[j]; 
  } 
  alpha = (sy -beta*sx)/(float)length; 
  return(alpha); 
}      
 
 
/************************************************************************************************************* 
Procedure:  getparam 
finds the 3 alphas and betas for a pair of breakpoints c1 and c2 
**********************************************************************************************************/ 
double getparam(int i, SAMPLE *data, double *y, int length, int c1, int c2, double *betas, double 
*alphas, double *jumps, int *nsec) 
{   
  int j; 
  double alpha1, beta1, alpha2, beta2, alpha3, beta3; 
  int length1, length2, length3; 
  int nsections = 3;    
   
  if (c1 == 0) 
  { 
    c1 = c2; 
  } 
  if (c1 == c2) 
  { 
    c2 = length -1; 
    nsections = 2; 
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  } 
  if (c1 == length -1) 
  { 
    nsections = 1; 
  } 
 
  length1 = c1; 
  length2 = c2 - c1; 
  length3 = length - c2; 
 
  beta1 = 0.0; 
  alpha1 = 0.0; 
  beta2 = 0.0; 
  alpha2 = 0.0; 
  beta3 = 0.0; 
  alpha3 = 0.0; 
 
  double section1[length1]; 
  for (j = 0; j < c1; j++) 
  { 
    section1[j] = data[i].vars[j]; 
  } 
  beta1 = slope(0, section1, length1); 
  alpha1 = intercept(0, section1, length1, beta1); 
 
  if (nsections > 1) 
  { 
    double section2[length2]; 
    for (j = c1; j < c2; j++) 
    { 
      section2[j-c1] = data[i].vars[j]; 
    } 
    beta2 = slope(c1, section2, length2); 
    alpha2 = intercept(c1, section2, length2, beta2); 
   
    if (nsections > 2) 
    { 
      double section3[length3]; 
      for (j = c2; j < length; j++) 
      { 
        section3[j-c2] = data[i].vars[j]; 
      } 
      beta3 = slope(c2, section3, length3); 
      alpha3 = intercept(c2, section3, length3, beta3); 
   } 
 } 
   
  int n = 0; 
  if (c1 != 0) 
  { 
    for (j = 0; j < c1; j++) 
    { 
      y[n] = alpha1 + beta1*(j+1); 
      n++; 
    } 
  } 
  if (c2 != c1) 
  { 
    for (j = c1; j < c2; j++) 
    { 
      y[n] = alpha2 + beta2*(j+1); 
      n++; 
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    } 
  } 
  if (c2 != length -1) 
  { 
    for (j = c2; j < length; j++) 
    { 
      y[n] = alpha3 + beta3*(j+1); 
      n++; 
    } 
  }     
  jumps[0] = y[c1] - y[c1-1]; 
  jumps[1] = y[c2] - y[c2-1]; 
   
  alphas[0] = alpha1; 
  betas[0] = beta1; 
  alphas[1] = alpha2; 
  betas[1] = beta2; 
  alphas[2] = alpha3; 
  betas[2] = beta3; 
   
  /* get sst */ 
  double sst = 0.0; 
  double sy = 0.0; 
  double syy = 0.0; 
  double sse = 0.0; 
  for (j = 0; j < length; j++) 
  { 
    sy += data[i].vars[j]; 
    syy += data[i].vars[j]*data[i].vars[j]; 
    sse += (y[j]-data[i].vars[j])*(y[j]-data[i].vars[j]); 
  } 
  sst = syy - (sy*sy/(float)length); 
  /* get R-squared */ 
  double rsq = 1.0 - sse/sst; 
  double adjrsq = 1.0 - nsections*(1.0 - rsq)/3.0; 
  *nsec = nsections; 
 
  return (adjrsq);   
} 
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Definitions 
β2AR   Beta-2-adrenergic receptor 
µg   Microgram 
µL   Microlitre 
µM   Micromolar 
7TM   Seven transmembrane 
AC   Adenylate cyclase 
Ag   Antigen 
ANOVA  Analysis of variance 
APC   Antigen-presenting cell 
BM   Binding media 
BRET   Bioluminescence resonance energy transfer 
CD   Cluster of differentiation  
CFDA-SE   Carboxyfluorescein diacetate N-succinimidyl ester 
CHO   Chinese hamster ovary 
CI   Confidence interval 
CO2   Carbon dioxide 
co-IP   Co-immunoprecipitation 
CRAC   Calcium release activated channel 
cSMAC  Central supramolecular activation cluster 
CTL   Cytotoxic T lymphocyte 
DAG   Diacylglycerol 
DAPI   4',6-diamidino-2-phenylindole 
DC   Dendritic cell 
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DCo   Direct coupled   
DMSO   Dimethyl sulphoxide 
DNA   Deoxyribonucleic acid 
D:P   Dye:protein 
dSMAC  Distal supramolecular activation cluster 
DTP   Diptheria, tetanus and poliomyelitis 
EBV   Epstein-Barr virus 
ECL   Extracellular loop 
ECM   Extracellular matrix 
EDTA   Ethylenediaminetetraacetic acid 
EM   Electron microscopy 
ER   Endoplasmic reticulum 
Fab   Monovalent antigen-binding fragment 
FcR   Receptor for the Fc antibody region 
FCS   Foetal calf serum 
FoxP3   Forkhead box P3 
FRAP   Fluorescence recovery after photobleaching 
g   Gram 
GaAsP  Gallium arsenide phosphide 
GAG   Glycosaminoglycans 
GAM   Goat anti-mouse 
GDP   Guanosine diphosphate 
GFP   Green fluorescent protein 
GM-CSF  Granulocyte-macrophage colony-stimulating factor 
GPCR   G protein coupled receptor 
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GRK    G protein receptor kinase 
GTP   Guanosine triphosphate 
HEK   Human embryonic kidney 
HeLa   Henrietta Lacks human epithelial cell line 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV   Human immunodeficiency virus 
HLA-DR  Human leukocyte antigen-DR 
HOS   Human osteosarcoma 
HPCD   Hydroxypropyl-β-cyclodextrin 
ICAM1   Intercellular adhesion molecule 1 
ICL   Intracellular loop 
IFNγ   Interferon gamma 
IgG   Immunoglobulin G 
IL   Interleukin 
IPMCs   Intracellular plasma-membrane connected compartments 
IP3   Inositol-1,4,5-triphosphate 
IS   Immunological synapse 
ITAM   Immunoreceptor tyrosine-based activation motif 
kDa   Kilodaltons 
LAT   Linker for activation of T cells 
LBPA   Lysobisphosphatidic acid 
Lck   Lymphocyte-specific protein tyrosine kinase 
LFA   Lymphocyte function-associated antigen 
Lf U   Limit of flocculation unit 
LN   Lymph node 
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LPS   Lipopolysaccharide 
LUT   Look-up table 
Ly6C+   Lymphocyte antigen 6C 
mAb   Monoclonal antibody  
MAGI   HeLa-CD4-LTR-beta-gal cell line 
MßCD   Methyl-ß cyclodextrin 
M-CSF   Macrophage colony-stimulating factor 
MDM   Monocyte-derived macrophage 
MEM   Minimum essential medium 
MFI   Median fluorescence intensity 
MHC   Major histocompatibility complex 
mg   Milligram 
mL   Millilitre 
mM   Millimolar 
mRNA   Messenger ribonucleic acid 
MTOC   Microtubule-organizing centre 
NFAT   Nuclear factor of activated T cells 
ng   Nanogram 
nm   Nanometre 
nM   Nanomolar 
ns   Non-significant 
nsRPMI  RPMI without serum 
OVA   Ovalbumin    
PBL   Peripheral blood lymphocyte 
PBMC   Peripheral blood mononuclear cell 
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PBS   Phosphate buffered saline 
PC-12   Cell line derived from a pheochromocytoma (rat) 
PCA   Principal component analysis 
PDL   Poly-D-lysine 
PDZ Post synaptic density protein (PSD95), Drosophilia disc large 
tumour Suppressor (D1g1), and zonula occludens-1 protein (zo-1) 
 
PE   R-phycoerythrin 
PEI   Polyethylenimine 
PFA   Paraformaldehyde 
PH   Pleckstrin homology domain 
PHA   Phytohaemagglutinin-M 
PI3K    Phosphatidylinositol 3-kinase 
PIP2   Phosphatidylinositol-4,5-bisphosphate 
PIP3    Phosphatidylinositol-3,4,5,-trisphosphate 
pMHC   Peptide-major histocompatibility complex 
PKB    Protein kinase B 
PKC   Protein kinase C 
PLC   Phospholipase C 
PM   Plasma membrane 
PSC    Nα-(n-nonanoyl)-des-Ser1-[l-thioproline2, l-α-cyclohexyl-glycine3]  
RANTES 
pSMAC  Peripheral supramolecular activation cluster 
PTX   Pertussis toxin 
PW   Pulse width 
px   Pixels 
RANTES  Regulated and normal T cell expressed and secreted 
  
 
220 
 
RE    Recycling endosome 
ROI   Region of interest 
rpm   Rotations per minute 
RPMI   Roswell Park Memorial Institute 
RT   Room temperature 
sAg   Superantigen 
SD   Standard deviation 
SEA   Staphylococcal enterotoxin A 
SEB   Staphylococcal enterotoxin B 
SEE   Staphylococcal enterotoxin E 
SEM   Standard error of the mean 
SFVI   Single fluorescent molecule video imaging 
SMAC   Supramolecular activation cluster 
SP   Side-port 
SPT   Single particle tracking 
SSC   Side-scattered light 
STIM1   Stromal interaction molecule 1 
t   Timepoint 
Treg   Regulatory T cell 
TCR   T cell receptor 
TCM   T central memory 
TEM   T effector memory 
TfR   Transferrin receptor 
TGN    trans-Golgi network 
Th   T helper 
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Thy-1   Thymocyte/ T-lymphocyte surface differentiation antigen 
TIL   Tumour-infiltrating lymphocyte 
TT   Tetanus toxoid 
WASp   Wiskott-Aldrich syndrome protein 
YFP   Yellow fluorescent protein 
ZAP-70  ζ-chain-associated protein kinase of 70 kDa 
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